{"docstore/data": {"9a5bfc13-a550-4f45-94fe-773f02876989": {"__data__": {"id_": "9a5bfc13-a550-4f45-94fe-773f02876989", "embedding": null, "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event. ", "original_text": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1c42720-5ab7-423d-a8af-06ebf80c6e56", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "original_text": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc. "}, "hash": "a71e4e97e7ac8da129457b0bd9a595b1eac276bb9292d11b0b72cd66ace01157", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1c42720-5ab7-423d-a8af-06ebf80c6e56": {"__data__": {"id_": "b1c42720-5ab7-423d-a8af-06ebf80c6e56", "embedding": null, "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "original_text": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a5bfc13-a550-4f45-94fe-773f02876989", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event. ", "original_text": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b73ef69f341afc64f4a5c7da6f08df34129bfab217d576fdbf84438e8380c722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef3b19a9-af26-4e0e-81e2-f7913d636b31", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "original_text": "Earnings \nConference Call. "}, "hash": "fd55e7b7d792c01d2aac34f4ed323a8b6b73b4421b4a7014e04d6da941e55958", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc. ", "start_char_idx": 48, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef3b19a9-af26-4e0e-81e2-f7913d636b31": {"__data__": {"id_": "ef3b19a9-af26-4e0e-81e2-f7913d636b31", "embedding": null, "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "original_text": "Earnings \nConference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1c42720-5ab7-423d-a8af-06ebf80c6e56", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "original_text": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e1e5e32b31c4246bbea476463903220e3733feef749143cf4d93709a1c27ef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d2e4d8c-fd83-4481-bc99-e7b505394daf", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "original_text": "My name is George, and I will be your coordinator for today's event. "}, "hash": "6e51c721db5aff5bcab6dc7ddb5ac83fb98493dcf257d77873ccb8c7d9ab2f27", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call. ", "start_char_idx": 195, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d2e4d8c-fd83-4481-bc99-e7b505394daf": {"__data__": {"id_": "9d2e4d8c-fd83-4481-bc99-e7b505394daf", "embedding": null, "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "original_text": "My name is George, and I will be your coordinator for today's event. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef3b19a9-af26-4e0e-81e2-f7913d636b31", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "original_text": "Earnings \nConference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4af52ccbb42ef7394d6d9b68a49a75f57603931128a49eef9cc1ea8e38c01b8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "original_text": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. "}, "hash": "bcc7c8f50f9de26584dbd69d7b755f8b68b0de0bd38263ddad4e2620dd1fd94b", "class_name": "RelatedNodeInfo"}}, "text": "My name is George, and I will be your coordinator for today's event. ", "start_char_idx": 222, "end_char_idx": 291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9": {"__data__": {"id_": "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "original_text": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d2e4d8c-fd83-4481-bc99-e7b505394daf", "node_type": "1", "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "original_text": "My name is George, and I will be your coordinator for today's event. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "194407c69db189dee1aa0718bb610a2f2e4f95262658384a1703c4fb1f5ab791", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38a67711-a796-45bb-bad7-2e0fe0bf214b", "node_type": "1", "metadata": {"window": "Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "original_text": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. "}, "hash": "e55a7f7b7161d512989016d42d58dcb13a4877eb4ddfff95c37375f9dd5d0a77", "class_name": "RelatedNodeInfo"}}, "text": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "start_char_idx": 291, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38a67711-a796-45bb-bad7-2e0fe0bf214b": {"__data__": {"id_": "38a67711-a796-45bb-bad7-2e0fe0bf214b", "embedding": null, "metadata": {"window": "Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "original_text": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "original_text": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bd1300196d27b284a9889d775c46fcd65b05d0763d96dbbe5d5183df9eb12d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a677db83-a6bd-403d-8149-a5a453bc09c9", "node_type": "1", "metadata": {"window": "My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n", "original_text": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. "}, "hash": "513f1ab6bb8a9274660160d289f4693a494eb30c6f26735a125289ee443da0d1", "class_name": "RelatedNodeInfo"}}, "text": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "start_char_idx": 418, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a677db83-a6bd-403d-8149-a5a453bc09c9": {"__data__": {"id_": "a677db83-a6bd-403d-8149-a5a453bc09c9", "embedding": null, "metadata": {"window": "My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n", "original_text": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38a67711-a796-45bb-bad7-2e0fe0bf214b", "node_type": "1", "metadata": {"window": "Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "original_text": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c6c993817b30245e8f0a4ed9a22c4dfae3bc0bfdc1b604d91cd700a86323c8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f6380c1-31cf-4593-87ba-1d552394c1ff", "node_type": "1", "metadata": {"window": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. "}, "hash": "fc0f767e41a8dc2b4900c70d3e8fc7854b1150984adf4eb65af15af4c95673d9", "class_name": "RelatedNodeInfo"}}, "text": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "start_char_idx": 600, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f6380c1-31cf-4593-87ba-1d552394c1ff": {"__data__": {"id_": "3f6380c1-31cf-4593-87ba-1d552394c1ff", "embedding": null, "metadata": {"window": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a677db83-a6bd-403d-8149-a5a453bc09c9", "node_type": "1", "metadata": {"window": "My name is George, and I will be your coordinator for today's event.  Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n", "original_text": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb16fee5a356e1e5de5cd9278ce841af841dbc54d43c6f193cb9290dfee5b6cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30e55fa5-bc77-4078-943e-4bd3f005261a", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. "}, "hash": "a7237a9d8e010416338504b2e09eca610f61e298756acc651b14f1429f1440ca", "class_name": "RelatedNodeInfo"}}, "text": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "start_char_idx": 728, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30e55fa5-bc77-4078-943e-4bd3f005261a": {"__data__": {"id_": "30e55fa5-bc77-4078-943e-4bd3f005261a", "embedding": null, "metadata": {"window": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f6380c1-31cf-4593-87ba-1d552394c1ff", "node_type": "1", "metadata": {"window": "Please note \nthis conference is being recorded and for the duration of the call your line s will be in the listen -only \nmode.  However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d21b378868237597df1c96a7bb884ce84a36dbf8e291782517554ec70413c00f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23797e91-34df-4149-a806-090d1b7be757", "node_type": "1", "metadata": {"window": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "original_text": "Please go -ahead , sir. \n \n"}, "hash": "f8effe267ea5f3ae0a79e68bc3c530136982480cdbdbb57fb8beab7d3db6c834", "class_name": "RelatedNodeInfo"}}, "text": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "start_char_idx": 838, "end_char_idx": 940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23797e91-34df-4149-a806-090d1b7be757": {"__data__": {"id_": "23797e91-34df-4149-a806-090d1b7be757", "embedding": null, "metadata": {"window": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "original_text": "Please go -ahead , sir. \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30e55fa5-bc77-4078-943e-4bd3f005261a", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask a question at the end of the presentation , and \nthis can be done by pressing star  one on your telephone keypad  to ask your question.  We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e25503774b58adee226715b628eb14bd405a9112365533049ce2abc33f0f2ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23a5a8b6-900c-4f56-9bc6-0860ac2ee545", "node_type": "1", "metadata": {"window": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. "}, "hash": "7faf99c5ce14e4551723963e9621355d5ab75f52fca2666374db3b14f81fe210", "class_name": "RelatedNodeInfo"}}, "text": "Please go -ahead , sir. \n \n", "start_char_idx": 940, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23a5a8b6-900c-4f56-9bc6-0860ac2ee545": {"__data__": {"id_": "23a5a8b6-900c-4f56-9bc6-0860ac2ee545", "embedding": null, "metadata": {"window": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23797e91-34df-4149-a806-090d1b7be757", "node_type": "1", "metadata": {"window": "We ask also \nthat you limit yourselves to on e question per person to allow the maximum number of attendees to \nask a question.  If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "original_text": "Please go -ahead , sir. \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62140c6459132cfde655e4d6852768848ca74511c82f3f2c05362046ffaa5ddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb7e4d90-0130-484f-b826-e25b6120bf8b", "node_type": "1", "metadata": {"window": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n"}, "hash": "88404b0211c427a6b99f131cfe2ea8bb77605368281f292275d36dd648ad3c64", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "start_char_idx": 967, "end_char_idx": 1105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb7e4d90-0130-484f-b826-e25b6120bf8b": {"__data__": {"id_": "bb7e4d90-0130-484f-b826-e25b6120bf8b", "embedding": null, "metadata": {"window": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23a5a8b6-900c-4f56-9bc6-0860ac2ee545", "node_type": "1", "metadata": {"window": "If you require any assistance at any point, please press star zero and you will be \nconnected to an operator.  I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28089f856cf7c25507276f0ee4e3982c5f919f5a8d02bb0ebf3fc9ee834a4a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e45ccb65-d227-46bb-ab43-9079195f1ad6", "node_type": "1", "metadata": {"window": "Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "original_text": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . "}, "hash": "6a282954cdea4155721e7bda64e68386de7650e5a28efb806365c9a668a743ea", "class_name": "RelatedNodeInfo"}}, "text": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "start_char_idx": 1105, "end_char_idx": 1188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e45ccb65-d227-46bb-ab43-9079195f1ad6": {"__data__": {"id_": "e45ccb65-d227-46bb-ab43-9079195f1ad6", "embedding": null, "metadata": {"window": "Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "original_text": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb7e4d90-0130-484f-b826-e25b6120bf8b", "node_type": "1", "metadata": {"window": "I would like to turn the call over to your host today, Matt Sims, Vice \nPresident Investor Relations.  Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45ba26464a2c280b1dae4c5547d21efd0eb34b6f45b6d393faca55ae83a23f6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c62db472-466d-4e68-9d18-f394660aa2bd", "node_type": "1", "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "original_text": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n"}, "hash": "11a919ddaf4fca97f2e8a37dbd475bee22acbd6df9a258a18b660f921ffa4bf4", "class_name": "RelatedNodeInfo"}}, "text": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "start_char_idx": 1188, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c62db472-466d-4e68-9d18-f394660aa2bd": {"__data__": {"id_": "c62db472-466d-4e68-9d18-f394660aa2bd", "embedding": null, "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "original_text": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e45ccb65-d227-46bb-ab43-9079195f1ad6", "node_type": "1", "metadata": {"window": "Please go -ahead , sir. \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "original_text": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fc0b32f31d345aec16a494edccb31c3a4d2df023093b3d882dacf7f052d5aea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fb961db-2a53-4816-9f4d-54527b404e9f", "node_type": "1", "metadata": {"window": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n"}, "hash": "d9ee144471c1daab2ce417e6eeb119ff12c2c32457e427241cf591840e9cc2e9", "class_name": "RelatedNodeInfo"}}, "text": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "start_char_idx": 1342, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fb961db-2a53-4816-9f4d-54527b404e9f": {"__data__": {"id_": "1fb961db-2a53-4816-9f4d-54527b404e9f", "embedding": null, "metadata": {"window": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c62db472-466d-4e68-9d18-f394660aa2bd", "node_type": "1", "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Third -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "original_text": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a64b63a66d378b42719e3a6d5381d85fbc37b5ea805f3b51fc2fca52bf39f878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e904f9-8569-4646-9f3d-645b139ee6bf", "node_type": "1", "metadata": {"window": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  "}, "hash": "cc6205fa4b4df1d40ffcc5f419fc8eb98692e58169b53f331c1f2e11530e2ed2", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "start_char_idx": 1593, "end_char_idx": 1760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e904f9-8569-4646-9f3d-645b139ee6bf": {"__data__": {"id_": "37e904f9-8569-4646-9f3d-645b139ee6bf", "embedding": null, "metadata": {"window": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fb961db-2a53-4816-9f4d-54527b404e9f", "node_type": "1", "metadata": {"window": "With me today are Cardinal Health CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e9d70d4ba1c59ca6776eaad42cc4c70fc24d86bcd8b5ac1c7da49fd39cafe6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6647f02c-e1ae-4569-bb13-ef8f2a43622b", "node_type": "1", "metadata": {"window": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n"}, "hash": "fc8124b6652655b749432ac83850d3ec4ce393c51105c4cdc93c79ff35fa621b", "class_name": "RelatedNodeInfo"}}, "text": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "start_char_idx": 1760, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6647f02c-e1ae-4569-bb13-ef8f2a43622b": {"__data__": {"id_": "6647f02c-e1ae-4569-bb13-ef8f2a43622b", "embedding": null, "metadata": {"window": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e904f9-8569-4646-9f3d-645b139ee6bf", "node_type": "1", "metadata": {"window": "You can find this morning\u2019s earnings press release and investor presentation on the investor relations \nsection of our website at ir.cardinalhealth.com .  Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e2dcaa7bfa807908fa57a34f704a9ec2c906c48687ccffc5a41a26cd82545fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d794dc99-5299-48bc-8d5d-38fb8fe1409b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n"}, "hash": "912c035c7f2efd801a86cdcd172ca71d90323b6a01b3593ac6f506878451c5ee", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "start_char_idx": 1891, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d794dc99-5299-48bc-8d5d-38fb8fe1409b": {"__data__": {"id_": "d794dc99-5299-48bc-8d5d-38fb8fe1409b", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6647f02c-e1ae-4569-bb13-ef8f2a43622b", "node_type": "1", "metadata": {"window": "Since we will be making forward -looking statements \ntoday, let me remind you that the matters addressed in the statements are subject to risks and \nuncertainties that could cause actual results to differ materially from those projected or implied.  \n Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdd9876514b438947288dfc5a5cb6cfd4e94cd024ad17c054847fdfbcef857ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71af6e9c-190c-4b87-bc77-7ca43a60a978", "node_type": "1", "metadata": {"window": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n"}, "hash": "379ef63e52d124f81da2c5e0d1f8f9595ea070983da839bb9dd5b470af1b95fc", "class_name": "RelatedNodeInfo"}}, "text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "start_char_idx": 2027, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71af6e9c-190c-4b87-bc77-7ca43a60a978": {"__data__": {"id_": "71af6e9c-190c-4b87-bc77-7ca43a60a978", "embedding": null, "metadata": {"window": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d794dc99-5299-48bc-8d5d-38fb8fe1409b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f68fa4984ba9fa4c922ab2fb5abf46868d8e28fbc940e1441d4faec5e471342e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n"}, "hash": "9ccb5597a33761010e3a4eaa350470243d87406452f02fd41337338c12afb2e1", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Jason.  \n \n", "start_char_idx": 2185, "end_char_idx": 2240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e": {"__data__": {"id_": "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71af6e9c-190c-4b87-bc77-7ca43a60a978", "node_type": "1", "metadata": {"window": "Please note, that during our discussion today, the comments will be on a non -GAAP basis unless \nspecifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfc24b4a483bee400bb83a4ae2f49410d31f8e19958dfb7cb13abb4bc829b866", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df258f3c-bc80-4255-a215-e1d642d788f4", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n", "original_text": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. "}, "hash": "79e643ea602e5cf96b5164efd6e3229b8f73983a9dab361ce98d7e566a5cf752", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Good morning, everyone.  \n \n", "start_char_idx": 2240, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df258f3c-bc80-4255-a215-e1d642d788f4": {"__data__": {"id_": "df258f3c-bc80-4255-a215-e1d642d788f4", "embedding": null, "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n", "original_text": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da95a152e0506ca585762d62a7ff5541c4d15437601e0fcfee0026cb1c838fc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94709e04-121b-495f-9794-cf5ce3f86b4d", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "original_text": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. "}, "hash": "42261e1ace586a9a96657d24c4dc824415885bb11d9de168aaa15c4cfeab33e7", "class_name": "RelatedNodeInfo"}}, "text": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "start_char_idx": 2284, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94709e04-121b-495f-9794-cf5ce3f86b4d": {"__data__": {"id_": "94709e04-121b-495f-9794-cf5ce3f86b4d", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "original_text": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df258f3c-bc80-4255-a215-e1d642d788f4", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  \n \n With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n", "original_text": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "299259250265926f033d2d11c9ffaf9dbab27f4d82f6c220a6c7c8453ed2c87a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af1ef664-7954-41e5-b314-cc0d8d737da7", "node_type": "1", "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n"}, "hash": "a7e444dcd9d33a1de7100b593594c1ff7c81aa15392015670c914be3400fa594", "class_name": "RelatedNodeInfo"}}, "text": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "start_char_idx": 2371, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af1ef664-7954-41e5-b314-cc0d8d737da7": {"__data__": {"id_": "af1ef664-7954-41e5-b314-cc0d8d737da7", "embedding": null, "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94709e04-121b-495f-9794-cf5ce3f86b4d", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "original_text": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9665099acc8ff5885d8aa8ed4ca4465b8932a7d42e197590cf3d5a83cfad1613", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b22ec311-a27c-420f-89d9-a970dc85faa9", "node_type": "1", "metadata": {"window": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "At the same time, I was open about some of the opportunities in front of us as an organization. \n"}, "hash": "9f81af56db6b193711e22ecb89f93e8765edb00f80b7f2607ff1e14c4b009039", "class_name": "RelatedNodeInfo"}}, "text": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "start_char_idx": 2454, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b22ec311-a27c-420f-89d9-a970dc85faa9": {"__data__": {"id_": "b22ec311-a27c-420f-89d9-a970dc85faa9", "embedding": null, "metadata": {"window": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "At the same time, I was open about some of the opportunities in front of us as an organization. \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af1ef664-7954-41e5-b314-cc0d8d737da7", "node_type": "1", "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bf64993c4a5d7be4f83654f5fdd8a3559fd4183b63d5e81b9688087e6a6a195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b107d7e3-f80f-4401-81c9-9dff1914b365", "node_type": "1", "metadata": {"window": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. "}, "hash": "9d7eeb3271b8e24fc3da5b3cf1485bfe95422737bdabb9778f21c5bbaed5a124", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, I was open about some of the opportunities in front of us as an organization. \n", "start_char_idx": 2659, "end_char_idx": 2756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b107d7e3-f80f-4401-81c9-9dff1914b365": {"__data__": {"id_": "b107d7e3-f80f-4401-81c9-9dff1914b365", "embedding": null, "metadata": {"window": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b22ec311-a27c-420f-89d9-a970dc85faa9", "node_type": "1", "metadata": {"window": "A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health.  Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "At the same time, I was open about some of the opportunities in front of us as an organization. \n", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f63e863bbf38b5abd4eeafc163d8ce622fdaa13655a0bd7901c6af511daafb27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9d64cee-3a4e-4f42-885f-6526f8cdb280", "node_type": "1", "metadata": {"window": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "All the time, prioritizing our core business to em erge as a stronger, more resilient company.  "}, "hash": "835c7e3e5d079712cdcd7d282c7ec7ecdb10fe8b7f9216a1f255f6d586796130", "class_name": "RelatedNodeInfo"}}, "text": "Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "start_char_idx": 2756, "end_char_idx": 2867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9d64cee-3a4e-4f42-885f-6526f8cdb280": {"__data__": {"id_": "c9d64cee-3a4e-4f42-885f-6526f8cdb280", "embedding": null, "metadata": {"window": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a12502e-cc47-4649-8477-68f012a15051", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eece5156a8d8066eeeb40bb775af250ee291a879ce2a6f22785793c8ee306e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b107d7e3-f80f-4401-81c9-9dff1914b365", "node_type": "1", "metadata": {"window": "Our strong \nculture, values,  and mission to be healthcare\u2019s most trusted partner.  How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "600ebf6dd2e7b74d4a81ceebef55807870fd6b8bdf4e538916e439768521b7ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbc645c6-d232-4967-b743-525e9dd02342", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "original_text": " \nPage 2 of 20 \n \nAnd we have a recent proof point.  "}, "hash": "98d5dba674ce814857358fbe90b23630db332bdb37a44bd5bccdd16572a96a08", "class_name": "RelatedNodeInfo"}}, "text": "All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "start_char_idx": 2867, "end_char_idx": 2963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbc645c6-d232-4967-b743-525e9dd02342": {"__data__": {"id_": "dbc645c6-d232-4967-b743-525e9dd02342", "embedding": null, "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "original_text": " \nPage 2 of 20 \n \nAnd we have a recent proof point.  ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9d64cee-3a4e-4f42-885f-6526f8cdb280", "node_type": "1", "metadata": {"window": "How the company was uniquely \npositioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and \nserve the needs of customers, manufacturers, and ultimately, patients.  \n \n At the same time, I was open about some of the opportunities in front of us as an organization. \n Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to \nwork.  All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "original_text": "All the time, prioritizing our core business to em erge as a stronger, more resilient company.  ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "787c6652a72cc9327ce8bc46202e951be134de09f420769341e9b421d4eed584", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b8ab74d-be62-4525-86cb-a573e2454337", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "original_text": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825. "}, "hash": "1f683b25558a6152d4706f0800d632cbecaf3b32f242fa2fa1df63c65b2abbfd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 20 \n \nAnd we have a recent proof point.  ", "start_char_idx": 0, "end_char_idx": 53, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b8ab74d-be62-4525-86cb-a573e2454337": {"__data__": {"id_": "6b8ab74d-be62-4525-86cb-a573e2454337", "embedding": null, "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "original_text": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbc645c6-d232-4967-b743-525e9dd02342", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "original_text": " \nPage 2 of 20 \n \nAnd we have a recent proof point.  ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ad42e342b96c206a58f392f08932a83a9897fdcf7158e937b370337480e7f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3630c16b-8855-42d3-878a-df76f95ba4d0", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "original_text": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n"}, "hash": "4afb5bf9c3051281ea77d354cbf939d6bcf2d8d4278fd7a98b0cd24a4a6eb138", "class_name": "RelatedNodeInfo"}}, "text": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825. ", "start_char_idx": 53, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3630c16b-8855-42d3-878a-df76f95ba4d0": {"__data__": {"id_": "3630c16b-8855-42d3-878a-df76f95ba4d0", "embedding": null, "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "original_text": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b8ab74d-be62-4525-86cb-a573e2454337", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "original_text": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "843823e101c03c31c2d1938f0913e8dde34a6f35122ca8d2be08d1a82e5b718a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c4cad97-1dd8-4d67-984f-5df263df8a59", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "original_text": "As we look ahead, the current quarter\u2019s results reinforce our confidence. "}, "hash": "b6381e687d598d0fbff5b499554b3931a57daf3e84a477f980754f3b199b1653", "class_name": "RelatedNodeInfo"}}, "text": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n", "start_char_idx": 342, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c4cad97-1dd8-4d67-984f-5df263df8a59": {"__data__": {"id_": "5c4cad97-1dd8-4d67-984f-5df263df8a59", "embedding": null, "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "original_text": "As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3630c16b-8855-42d3-878a-df76f95ba4d0", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "original_text": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ba43106fbab061df7758b74330016ad7a87bb04f2b7e9659407ab23c3b79c1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf63221-b039-478e-9cd2-e5ba5c95b976", "node_type": "1", "metadata": {"window": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "original_text": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n"}, "hash": "b7e4de140ed6a2aab4f26ba35caab9cd7228824aeefe74d2c34ab23510539283", "class_name": "RelatedNodeInfo"}}, "text": "As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "start_char_idx": 661, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf63221-b039-478e-9cd2-e5ba5c95b976": {"__data__": {"id_": "6cf63221-b039-478e-9cd2-e5ba5c95b976", "embedding": null, "metadata": {"window": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "original_text": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c4cad97-1dd8-4d67-984f-5df263df8a59", "node_type": "1", "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "original_text": "As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cbc53afdef5596f3ecfd91a5ff12afeacb339e8ca57edac77b3f4aa5e10a63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4129cfad-1e8b-4d36-823a-bed84ce33343", "node_type": "1", "metadata": {"window": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "original_text": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n"}, "hash": "ee8d9f71c1863bb6f83f075d15ffd21d0ab0366ac860b53eeb5602c47f9ebde8", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "start_char_idx": 735, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4129cfad-1e8b-4d36-823a-bed84ce33343": {"__data__": {"id_": "4129cfad-1e8b-4d36-823a-bed84ce33343", "embedding": null, "metadata": {"window": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "original_text": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf63221-b039-478e-9cd2-e5ba5c95b976", "node_type": "1", "metadata": {"window": "Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "original_text": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b7f72fe71df8b64c180e6deeb7396da536117823c6ef11674d1b97b9adc8d68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5e4076c-c571-461c-9063-2f707a014b09", "node_type": "1", "metadata": {"window": "As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "original_text": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. "}, "hash": "696e2aa5114f63ecc9e8f071c7b7a64974320b974908cab18347ed8b60e03839", "class_name": "RelatedNodeInfo"}}, "text": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "start_char_idx": 866, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5e4076c-c571-461c-9063-2f707a014b09": {"__data__": {"id_": "c5e4076c-c571-461c-9063-2f707a014b09", "embedding": null, "metadata": {"window": "As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "original_text": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4129cfad-1e8b-4d36-823a-bed84ce33343", "node_type": "1", "metadata": {"window": "By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "original_text": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1e076781089d43808f38f6438decf0f9391544dd8fe7f7bb2b7d431ed3d3c2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d007017-a8bc-474d-bff6-2ec97cc70709", "node_type": "1", "metadata": {"window": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "original_text": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n"}, "hash": "35e9933f05dc282f899a7c8416016c3f84637ea823ee2d41792aa54b6565da41", "class_name": "RelatedNodeInfo"}}, "text": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "start_char_idx": 1182, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d007017-a8bc-474d-bff6-2ec97cc70709": {"__data__": {"id_": "5d007017-a8bc-474d-bff6-2ec97cc70709", "embedding": null, "metadata": {"window": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "original_text": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5e4076c-c571-461c-9063-2f707a014b09", "node_type": "1", "metadata": {"window": "As we look ahead, the current quarter\u2019s results reinforce our confidence.  We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "original_text": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "089111b662c0cefe99c2e17be98f7c2fcd56bf25521f5ab040921392135278d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68125a42-6bfd-4e71-9c03-282526ed937d", "node_type": "1", "metadata": {"window": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "original_text": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. "}, "hash": "8b1c80875f6bbdfe8f4c0de076c5fff99232f3b873037bbbeeaaa92d932714d9", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "start_char_idx": 1361, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68125a42-6bfd-4e71-9c03-282526ed937d": {"__data__": {"id_": "68125a42-6bfd-4e71-9c03-282526ed937d", "embedding": null, "metadata": {"window": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "original_text": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d007017-a8bc-474d-bff6-2ec97cc70709", "node_type": "1", "metadata": {"window": "We\u2019re operating from a \nposition of growing strength and resiliency, with industry trends that remain stable and in our favor.  \n \n In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "original_text": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc2791e364619ae069e142a4af8771c6866cbfe51e07dd824b066347f047fcb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "416ccc70-010a-462a-9dc7-7d1495172504", "node_type": "1", "metadata": {"window": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "original_text": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n"}, "hash": "22bede050dfa43745568a7b5e5a17d4849dc771c33ec42ed968a1985fff5c382", "class_name": "RelatedNodeInfo"}}, "text": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "start_char_idx": 1655, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "416ccc70-010a-462a-9dc7-7d1495172504": {"__data__": {"id_": "416ccc70-010a-462a-9dc7-7d1495172504", "embedding": null, "metadata": {"window": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "original_text": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68125a42-6bfd-4e71-9c03-282526ed937d", "node_type": "1", "metadata": {"window": "In Q3, we delivered broad -based growth, while executing on our 4 strategic priorities: building upon \nthe growth and resiliency of Pharmaceutical and Specialty Solutions, executing our GMPD \nImprovement Plan, accelerating growth in key areas, and maintaining  a relentless focus on \nshareholder value creation.  \n \n In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "original_text": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5da2843041da75c00d4a34bd9a6ee9e05222b7231a1372a0185e330eea8fbd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6da3b17-0111-4d18-a7bc-7f838010b43a", "node_type": "1", "metadata": {"window": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "original_text": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. "}, "hash": "d7626a85a7922a516df6fe4a9a22a8da1203a9140e07997e25c284395e5d80f2", "class_name": "RelatedNodeInfo"}}, "text": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "start_char_idx": 1837, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6da3b17-0111-4d18-a7bc-7f838010b43a": {"__data__": {"id_": "c6da3b17-0111-4d18-a7bc-7f838010b43a", "embedding": null, "metadata": {"window": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "original_text": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "416ccc70-010a-462a-9dc7-7d1495172504", "node_type": "1", "metadata": {"window": "In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit \ngrowth, on top of a difficult comparison to last year\u2019s strong performance.  We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "original_text": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d19285274e3f4dfd1042caa1d94de33c174449a4fa0abd15a3944c752c1a423a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1590b2e6-4b37-4f17-a382-be5c4021c75d", "node_type": "1", "metadata": {"window": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "original_text": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n"}, "hash": "0731d80aa347bff46ad49500a3378ef5522f38d0a441fa4488f09f8f18dde472", "class_name": "RelatedNodeInfo"}}, "text": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "start_char_idx": 1976, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1590b2e6-4b37-4f17-a382-be5c4021c75d": {"__data__": {"id_": "1590b2e6-4b37-4f17-a382-be5c4021c75d", "embedding": null, "metadata": {"window": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "original_text": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6da3b17-0111-4d18-a7bc-7f838010b43a", "node_type": "1", "metadata": {"window": "We\u2019ve seen ongoing \nstability in pharmaceutical demand, consistent market dynam ics in our generics program and strong \nperformance in Specialty, both downstream and upstream , all of which enables us to raise our fiscal  \n\u201824 profit outlook for the segment to a mid -point of 9% growth .   \n \n In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "original_text": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth. ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3115ecc9631a452a08364ddef848c14f8037e9bd975b3157ef292ea6a29f5185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586d942d-e8b0-491d-b61d-667e3768f538", "node_type": "1", "metadata": {"window": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n"}, "hash": "f287a9f86a75836c55297c25f657f334f6bb57fee739147d67cf2284e32ae537", "class_name": "RelatedNodeInfo"}}, "text": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "start_char_idx": 2151, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586d942d-e8b0-491d-b61d-667e3768f538": {"__data__": {"id_": "586d942d-e8b0-491d-b61d-667e3768f538", "embedding": null, "metadata": {"window": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1590b2e6-4b37-4f17-a382-be5c4021c75d", "node_type": "1", "metadata": {"window": "In GMPD, we were pleased to see the strong top -line and bottom -line performance, with an \nacceleration in growth reflecting further progress against the business\u2019 turnaround plan.  GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "original_text": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae9a90d25ce5180829f6d1ce7f556b65347bb9db642abe93c178e835394da46e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b08638b-ae2d-412b-9de3-5b33af7fa8a8", "node_type": "1", "metadata": {"window": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n"}, "hash": "d2e0f5a82372f15009d67fab105febc85da1573de2baa8be73562a272364dc1c", "class_name": "RelatedNodeInfo"}}, "text": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "start_char_idx": 2376, "end_char_idx": 2522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b08638b-ae2d-412b-9de3-5b33af7fa8a8": {"__data__": {"id_": "2b08638b-ae2d-412b-9de3-5b33af7fa8a8", "embedding": null, "metadata": {"window": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586d942d-e8b0-491d-b61d-667e3768f538", "node_type": "1", "metadata": {"window": "GMPD\u2019s \nquarter was overall consistent with our expectations and the team is a lready working hard on the \ncontinued ramp -up in Q4 .   \n \n Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d606adad09f46ebf556a12ae1b6fdf089f07e5274c35c10e8b0366cf381b250", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac05931b-808a-4641-808d-fcd241bb84a4", "node_type": "1", "metadata": {"window": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n"}, "hash": "5d684d6d05c488d120c1cdb8bd36df42e84a767e550b2705cc709ebd638518b2", "class_name": "RelatedNodeInfo"}}, "text": "Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "start_char_idx": 2522, "end_char_idx": 2820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac05931b-808a-4641-808d-fcd241bb84a4": {"__data__": {"id_": "ac05931b-808a-4641-808d-fcd241bb84a4", "embedding": null, "metadata": {"window": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b08638b-ae2d-412b-9de3-5b33af7fa8a8", "node_type": "1", "metadata": {"window": "Among our Other operating businesses, our new reporting structure implemented at the start of Q3 is \nreinforcing our focus on performance and purposeful investment in growth.  The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a78cdb8d9ad0aa3242e232cc801d95d15b6a3921100ea078f2ca0aca2dbc4d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73", "node_type": "1", "metadata": {"window": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n "}, "hash": "ad54ff430ecb71b8f24515593124b13abc3d60a47410d31ed965162bf2c86461", "class_name": "RelatedNodeInfo"}}, "text": "Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "start_char_idx": 2820, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73": {"__data__": {"id_": "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73", "embedding": null, "metadata": {"window": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2946cdda47e7afa5198f3453f7ca5b261217061e7060f48a70c28892b550da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac05931b-808a-4641-808d-fcd241bb84a4", "node_type": "1", "metadata": {"window": "The strong demand we \nare seeing across Nuclear, at -Home Solutions and OptiFreight\u00ae , fueled by favorable industry trends, \nexcites us about the long -term potential as these markets and businesses continue to develop .  \n \n And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f70dd59db50e21d18bb632464905aad3300f69fe55b39332212a774a0c9fa46b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "732a36ea-b175-46c0-b755-cf756e7957a6", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "original_text": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n"}, "hash": "5bf9d2026db65f2a05430e365f13e7633bbe5905b56f36f65b34b60aaa04ee2b", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "start_char_idx": 2997, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "732a36ea-b175-46c0-b755-cf756e7957a6": {"__data__": {"id_": "732a36ea-b175-46c0-b755-cf756e7957a6", "embedding": null, "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "original_text": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73", "node_type": "1", "metadata": {"window": "And, as we\u2019ve optimized the financial strength of the broader enterprise, we\u2019ve seen meaningful \nbenefits below the operating line this year.  \n \n Putting it all together, we\u2019re pleased to be in a position to raise our fiscal  \u201824 EPS outlook , provide \npreliminary guidance for fiscal  \u201825 of profit growth in each of Pharma, GMPD and Other, as well as \noverall EPS , and reiterate our long -term targets for our businesses and enterprise.  \n \n Our strategy and long -term outlook are unaltered, and our team remains focused on executing our \nplan, as we serve our customers and continue to drive our company forward.  \n \n With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "original_text": "With that, let me turn it over to Aaron to review our Q3 results, fiscal  \u201824 guidance and early fiscal  \u201825 \noutlook in more detail.  \n ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c99b6bae5d69e4e0cbd70a064cf795c2070e210a06b0f7b17e8c62715453a9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bc0a095-c41e-4d15-8295-dac9975f7ff0", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "original_text": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3. "}, "hash": "99a66a0157f6b0412b50f845f0f6e5c70fb7f34884f4088c775c14eabcdce6fb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n", "start_char_idx": 0, "end_char_idx": 53, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bc0a095-c41e-4d15-8295-dac9975f7ff0": {"__data__": {"id_": "7bc0a095-c41e-4d15-8295-dac9975f7ff0", "embedding": null, "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "original_text": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "732a36ea-b175-46c0-b755-cf756e7957a6", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "original_text": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b0ab46512bd333b297d02034f2ee7c766cb534eec599ccc3d618a44adf8b41e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aa50260-fc64-4d96-98ca-c1f4a200e312", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "original_text": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other. "}, "hash": "779715ca90d3029ee7347a5960730ac09e59eff09e4142037a8e5bd5626260f4", "class_name": "RelatedNodeInfo"}}, "text": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3. ", "start_char_idx": 53, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aa50260-fc64-4d96-98ca-c1f4a200e312": {"__data__": {"id_": "3aa50260-fc64-4d96-98ca-c1f4a200e312", "embedding": null, "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "original_text": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bc0a095-c41e-4d15-8295-dac9975f7ff0", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "original_text": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e371f0c7169a0dbce758bda1e5f8e68e094ea0fe3c3057b2d313fbc009810548", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca2a1648-dbbb-4f72-9953-47569d4d981f", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "original_text": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n"}, "hash": "e12c18d6a6afe96176730bc187524932c13e1dbec3f19a29b3b64264c62cf55d", "class_name": "RelatedNodeInfo"}}, "text": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other. ", "start_char_idx": 195, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca2a1648-dbbb-4f72-9953-47569d4d981f": {"__data__": {"id_": "ca2a1648-dbbb-4f72-9953-47569d4d981f", "embedding": null, "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "original_text": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aa50260-fc64-4d96-98ca-c1f4a200e312", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "original_text": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c49295eb586f7a2d3385c9187d17ba493bc0207743451f2d429376a79ffd5ee8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b12b0de-4e64-4238-919c-9d1cc9c3b172", "node_type": "1", "metadata": {"window": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n", "original_text": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n"}, "hash": "a376def11297e6923a21d0ccc7c153fbfe762d1ce1db464cf3a3dd42481ff503", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "start_char_idx": 465, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b12b0de-4e64-4238-919c-9d1cc9c3b172": {"__data__": {"id_": "7b12b0de-4e64-4238-919c-9d1cc9c3b172", "embedding": null, "metadata": {"window": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n", "original_text": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca2a1648-dbbb-4f72-9953-47569d4d981f", "node_type": "1", "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "original_text": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4bde111191f2a2d8016bb2f03301c8eaa26892481f884cc6bb1a39979ed50d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ec884c6-7679-422c-9ed2-5848759cde4e", "node_type": "1", "metadata": {"window": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "original_text": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n"}, "hash": "f8817c1dccfe7e3618e55cc108e2ed88419e0a77d3baf73184f80d95a735898b", "class_name": "RelatedNodeInfo"}}, "text": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "start_char_idx": 657, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ec884c6-7679-422c-9ed2-5848759cde4e": {"__data__": {"id_": "6ec884c6-7679-422c-9ed2-5848759cde4e", "embedding": null, "metadata": {"window": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "original_text": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b12b0de-4e64-4238-919c-9d1cc9c3b172", "node_type": "1", "metadata": {"window": "This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n", "original_text": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8882aa2a6449136f361814f1aeef8af25a5bda2f9ba7d12777653555708e2a2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee78718-3392-4f37-9030-71988e4249e3", "node_type": "1", "metadata": {"window": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "original_text": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. "}, "hash": "abeb07b356bfef3396a3b64dc8aa52e47ad4c044137074587436a376d956a1b7", "class_name": "RelatedNodeInfo"}}, "text": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "start_char_idx": 758, "end_char_idx": 930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee78718-3392-4f37-9030-71988e4249e3": {"__data__": {"id_": "8ee78718-3392-4f37-9030-71988e4249e3", "embedding": null, "metadata": {"window": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "original_text": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ec884c6-7679-422c-9ed2-5848759cde4e", "node_type": "1", "metadata": {"window": "To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "original_text": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88d6822ac23a8a110185f6bcd861118ae3eada528e73fd9ac481811ce04ed170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a615a80-733d-4a7a-87c7-2da5f0f681a1", "node_type": "1", "metadata": {"window": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion. ", "original_text": "More on that shortly.  \n \n"}, "hash": "444f01797a33bf762020c2a267a19a4d1c852e12942acea7eab072940877456e", "class_name": "RelatedNodeInfo"}}, "text": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "start_char_idx": 930, "end_char_idx": 1085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a615a80-733d-4a7a-87c7-2da5f0f681a1": {"__data__": {"id_": "6a615a80-733d-4a7a-87c7-2da5f0f681a1", "embedding": null, "metadata": {"window": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion. ", "original_text": "More on that shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee78718-3392-4f37-9030-71988e4249e3", "node_type": "1", "metadata": {"window": "As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "original_text": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb67a5e896b186edf9b03e63b069d5883d0fde7bb9a98e54bc525fbe806aed59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4577259-debc-4fd9-be21-95f0fba06b4d", "node_type": "1", "metadata": {"window": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. "}, "hash": "fe01963583c5e7befed372201b7b489b0c0303ec91b44890c514b2e74ac9835f", "class_name": "RelatedNodeInfo"}}, "text": "More on that shortly.  \n \n", "start_char_idx": 1085, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4577259-debc-4fd9-be21-95f0fba06b4d": {"__data__": {"id_": "f4577259-debc-4fd9-be21-95f0fba06b4d", "embedding": null, "metadata": {"window": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a615a80-733d-4a7a-87c7-2da5f0f681a1", "node_type": "1", "metadata": {"window": "Overall, Q3 was a strong quarter, with double -digit operating earnings growth and 20% EPS growth.  \n We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion. ", "original_text": "More on that shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "583453bab9a6985a4019a92d76e9f27492c055b133d48f9ed9b838e05d15eb1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17853fb0-d9f1-4025-967a-5480290e20c9", "node_type": "1", "metadata": {"window": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "original_text": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n"}, "hash": "e96099bf0afe17871187f01ce9a1fa7d607f900b13c15b6d08fc6615c40c88b4", "class_name": "RelatedNodeInfo"}}, "text": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "start_char_idx": 1111, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17853fb0-d9f1-4025-967a-5480290e20c9": {"__data__": {"id_": "17853fb0-d9f1-4025-967a-5480290e20c9", "embedding": null, "metadata": {"window": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "original_text": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4577259-debc-4fd9-be21-95f0fba06b4d", "node_type": "1", "metadata": {"window": "We accomplished that growth while at the same time leaning in and making significant investments of \ntime, expense and capital against our longer -term strategic plan.  \n \n With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6707231d20d6ca8129ab7a345e3b9dc9de243ee471cc5482376e52d5425e06a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ee45c5-567e-410e-86a1-608fbda190a2", "node_type": "1", "metadata": {"window": "More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "original_text": "We are also pleased that gross margin increased 9% to $1.9 billion. "}, "hash": "da4257b677e452e07eed1e2cadf9d8d7296886b1a4f6814bcd57b5823c633daa", "class_name": "RelatedNodeInfo"}}, "text": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "start_char_idx": 1329, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ee45c5-567e-410e-86a1-608fbda190a2": {"__data__": {"id_": "78ee45c5-567e-410e-86a1-608fbda190a2", "embedding": null, "metadata": {"window": "More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "original_text": "We are also pleased that gross margin increased 9% to $1.9 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17853fb0-d9f1-4025-967a-5480290e20c9", "node_type": "1", "metadata": {"window": "With both continued confidence in our strategies, and a resilient business and team, we are pleased \nto again raise our EPS guidance for fiscal  year \u201824.  More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "original_text": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c022f5465fd69ec73f726ab7d91571707727c78f67b4fdddfb43245ce11df032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3e131b-1d2e-4ad7-92b1-870b443ea672", "node_type": "1", "metadata": {"window": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "original_text": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n"}, "hash": "30cb9e9494334411b6057b5572bbfe3d86df0363989b4c00acc7c5b846c87a24", "class_name": "RelatedNodeInfo"}}, "text": "We are also pleased that gross margin increased 9% to $1.9 billion. ", "start_char_idx": 1435, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3e131b-1d2e-4ad7-92b1-870b443ea672": {"__data__": {"id_": "4a3e131b-1d2e-4ad7-92b1-870b443ea672", "embedding": null, "metadata": {"window": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "original_text": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78ee45c5-567e-410e-86a1-608fbda190a2", "node_type": "1", "metadata": {"window": "More on that shortly.  \n \n As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "original_text": "We are also pleased that gross margin increased 9% to $1.9 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62058005ac731ab2759ae8ba137ab7734b4c330901936038b7474d6bb90ae3a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b11fb997-d842-43e8-be43-032f11098eaf", "node_type": "1", "metadata": {"window": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "original_text": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n"}, "hash": "958b3fc450a8991b956dc2087a7c6fbc6870871a7f28ef121e7961044335ee37", "class_name": "RelatedNodeInfo"}}, "text": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "start_char_idx": 1503, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b11fb997-d842-43e8-be43-032f11098eaf": {"__data__": {"id_": "b11fb997-d842-43e8-be43-032f11098eaf", "embedding": null, "metadata": {"window": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "original_text": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3e131b-1d2e-4ad7-92b1-870b443ea672", "node_type": "1", "metadata": {"window": "As seen on slide 4 , total company revenue increased 9% to $55 billion, reflecting revenue growth in \nthe Pharmaceutical and Specialty Solutions segment, the GMPD segment and in all of the \nbusinesses making up Other.  We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "original_text": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50e537f1d7c29e5cc7f1f7ba8e42faa8c7224260c04bd18547165b761b015c9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1", "node_type": "1", "metadata": {"window": "We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "original_text": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n"}, "hash": "07e342d23b0b4a2f94a7a15d62ead25d899a76007d8b5072aa9a0c6fcbe2c0bf", "class_name": "RelatedNodeInfo"}}, "text": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "start_char_idx": 1747, "end_char_idx": 1868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1": {"__data__": {"id_": "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1", "embedding": null, "metadata": {"window": "We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "original_text": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b11fb997-d842-43e8-be43-032f11098eaf", "node_type": "1", "metadata": {"window": "We were particularly pleased to see the second consecutive quarter of \nrevenue growth in GMPD, at 4%.  \n \n We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "original_text": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef6253e59d68f158e710c583bb54ae7b2c6b4e3ea3ecf36fcefef65eab14161a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41125bc1-47ef-4b32-8517-7f435580b3ce", "node_type": "1", "metadata": {"window": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "original_text": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n"}, "hash": "e1840623144925390b3b7f2a38b3bb582cab594db239432b776403455271e46d", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "start_char_idx": 1868, "end_char_idx": 1973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41125bc1-47ef-4b32-8517-7f435580b3ce": {"__data__": {"id_": "41125bc1-47ef-4b32-8517-7f435580b3ce", "embedding": null, "metadata": {"window": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "original_text": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1", "node_type": "1", "metadata": {"window": "We are also pleased that gross margin increased 9% to $1.9 billion.  While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "original_text": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a6bcb76043d79acb12f9a3d886b8ea605a906943c09ab997680d62d6ea5ec5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e654f313-60a6-4acc-a0d7-a603329ac594", "node_type": "1", "metadata": {"window": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "original_text": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n"}, "hash": "a666712435cf327b1c21aabf12442c38ae2abdeb972e13262ebbd4d49f18f854", "class_name": "RelatedNodeInfo"}}, "text": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "start_char_idx": 1973, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e654f313-60a6-4acc-a0d7-a603329ac594": {"__data__": {"id_": "e654f313-60a6-4acc-a0d7-a603329ac594", "embedding": null, "metadata": {"window": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "original_text": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41125bc1-47ef-4b32-8517-7f435580b3ce", "node_type": "1", "metadata": {"window": "While consolidated SG&A also \nincreased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and \nother purposeful investments against the future of the bus iness and higher costs to support sales \ngrowth.  \n \n With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "original_text": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a13ebd73cc7b3505ec12af4ea68b7cec31e87c8e30d6a19928929a47de375003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa7d385-d3eb-41f2-830a-cffd9f9970a7", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "original_text": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n"}, "hash": "a1f01a434b467f1c879c9950a686032b4e6fb95af614ae8b1555194453100b68", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "start_char_idx": 2090, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa7d385-d3eb-41f2-830a-cffd9f9970a7": {"__data__": {"id_": "0aa7d385-d3eb-41f2-830a-cffd9f9970a7", "embedding": null, "metadata": {"window": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "original_text": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e654f313-60a6-4acc-a0d7-a603329ac594", "node_type": "1", "metadata": {"window": "With strong broad -based profit growth, we delivered operating earnings of $666 million, 10% higher \nthan last year.  \n \n Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "original_text": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80c84d87bde1a6a5b3288b46f9fb62d9d520312bb0bc8ef1edb9699bfdd039d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71db3aec-bd16-4901-b566-ab567c47b3a8", "node_type": "1", "metadata": {"window": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n"}, "hash": "328078393451c22ac8a423ef8a4808611b3188bdc328e9caa9f3a5958cf36c97", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "start_char_idx": 2221, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71db3aec-bd16-4901-b566-ab567c47b3a8": {"__data__": {"id_": "71db3aec-bd16-4901-b566-ab567c47b3a8", "embedding": null, "metadata": {"window": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa7d385-d3eb-41f2-830a-cffd9f9970a7", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other was generally consistent with the prior year at $26 million . \n And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "original_text": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b5bf23fcca928f4d7b58c70a804a4eb3a295bf4fdd4a5c0df4b058ae7096087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207ede5a-f11a-4ee5-ae30-1b01a8681552", "node_type": "1", "metadata": {"window": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. "}, "hash": "feb69e0498fb858be854662d207f67b8696f7cdf184aafd63674bce621943805", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "start_char_idx": 2315, "end_char_idx": 2415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207ede5a-f11a-4ee5-ae30-1b01a8681552": {"__data__": {"id_": "207ede5a-f11a-4ee5-ae30-1b01a8681552", "embedding": null, "metadata": {"window": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71db3aec-bd16-4901-b566-ab567c47b3a8", "node_type": "1", "metadata": {"window": "And o ur third quarter effective tax rate of 20.4 % was better than we expected due to positive discrete \nitems.  \n \n As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e24394ac8891fb4e1457f1453e6d41d72d6a1ba65051514cd83614a2fbcc1949", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8c2e92d-e61a-4789-a95a-29d7c9b48b03", "node_type": "1", "metadata": {"window": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. "}, "hash": "c4c9677e43385debd724254c91ef0f07c23647959d4f7dd1a2781ab738beebe2", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "start_char_idx": 2415, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8c2e92d-e61a-4789-a95a-29d7c9b48b03": {"__data__": {"id_": "b8c2e92d-e61a-4789-a95a-29d7c9b48b03", "embedding": null, "metadata": {"window": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207ede5a-f11a-4ee5-ae30-1b01a8681552", "node_type": "1", "metadata": {"window": "As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, \n5% lower than a year ago.  \n \n As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e53f2fb017c458fa4a61dec60b32bb5fd593c7c1304cad6bca7ead914589f688", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cca9215-b782-4af3-a3b0-f4cac7779d1a", "node_type": "1", "metadata": {"window": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  "}, "hash": "eebb2cba4b0297ad1f8f597c6b1aa12f3c228edf53e998b17f3b33fc7b82842c", "class_name": "RelatedNodeInfo"}}, "text": "We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "start_char_idx": 2528, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cca9215-b782-4af3-a3b0-f4cac7779d1a": {"__data__": {"id_": "1cca9215-b782-4af3-a3b0-f4cac7779d1a", "embedding": null, "metadata": {"window": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58273310-5952-4a1f-8284-f79597ed94b9", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f48a7484d5ff940bba79d7ac30f5e32429dcf11235708a371181b0f299ae4ef3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8c2e92d-e61a-4789-a95a-29d7c9b48b03", "node_type": "1", "metadata": {"window": "As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%.  \n \n Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers. ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee8d0eb04e1008a910f16922cf4f47a9ef9d8c80e7425edb44b8dbc44c65cf3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feabcdc9-7aa2-446f-a541-13eff393462d", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "original_text": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.  "}, "hash": "463f2d25d922b04da987fd70e81fff8ce18147a31d397ed91b832cee4d5849cf", "class_name": "RelatedNodeInfo"}}, "text": "While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "start_char_idx": 2686, "end_char_idx": 2912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feabcdc9-7aa2-446f-a541-13eff393462d": {"__data__": {"id_": "feabcdc9-7aa2-446f-a541-13eff393462d", "embedding": null, "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "original_text": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.  ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cca9215-b782-4af3-a3b0-f4cac7779d1a", "node_type": "1", "metadata": {"window": "Now, turning to the segments, beginning with Pharmaceutical and Specialty Solutions on slide 5 . \n \n Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical \nsales growth.  We continued to see strong pharmaceutical demand across product categories: brand, \nspecialty, consumer health and generics, and from our largest  customers.  While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "original_text": "While we again saw robust \ndemand for GLP -1 medications, recall that we had guided that the revenue growth rate would \nmoderate this quarter, as it did, given the acceleration that we started to realize last year during Q3.  ", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0069560114ad411902ebb48de60a85267abb4e2d8b2b2564299eba13433ef9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc18428-b404-43d8-8133-28b68bf067c3", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "original_text": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n"}, "hash": "ec9cacc8c31df4e6d7038d39345c6fff1ef13682536a5fcf5f1a7f0c9cfbf76d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.  ", "start_char_idx": 0, "end_char_idx": 88, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc18428-b404-43d8-8133-28b68bf067c3": {"__data__": {"id_": "4cc18428-b404-43d8-8133-28b68bf067c3", "embedding": null, "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "original_text": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feabcdc9-7aa2-446f-a541-13eff393462d", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "original_text": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.  ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74fe1533e1b8ab0ff79dd116a9b08c3e9dc747733b21a8b48017dcb3bffafc4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c35a8e5-f257-40d3-9f48-a495814fd852", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "original_text": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance. "}, "hash": "2010bfad8986b124a25c401d1c0f71250f0cdf8ed8948194762196c7c12ed9ff", "class_name": "RelatedNodeInfo"}}, "text": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n", "start_char_idx": 88, "end_char_idx": 184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c35a8e5-f257-40d3-9f48-a495814fd852": {"__data__": {"id_": "5c35a8e5-f257-40d3-9f48-a495814fd852", "embedding": null, "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "original_text": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc18428-b404-43d8-8133-28b68bf067c3", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "original_text": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e132a5bd4d7bc9c9cdcc98b03ee30678eddf40bbfca0b68ccb5fb73e9c97e2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a868d88f-e667-485a-b3f4-6ef3d428779a", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "original_text": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n"}, "hash": "e013bc867fd8464d6d6091ecef8c52f021b193968cffd91127e9d6d447aa81f5", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance. ", "start_char_idx": 184, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a868d88f-e667-485a-b3f4-6ef3d428779a": {"__data__": {"id_": "a868d88f-e667-485a-b3f4-6ef3d428779a", "embedding": null, "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "original_text": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c35a8e5-f257-40d3-9f48-a495814fd852", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "original_text": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e7863f950c382a002a957f55d71ed7f5e9b54c249f4ff1e706e1223643f518e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "315bd1e5-6a04-425c-b169-52344da8166c", "node_type": "1", "metadata": {"window": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n", "original_text": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n"}, "hash": "cc94211413d34e8a05f2a958195f5d4dd617fb733e90b1efd6b2ce154b539929", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "start_char_idx": 300, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "315bd1e5-6a04-425c-b169-52344da8166c": {"__data__": {"id_": "315bd1e5-6a04-425c-b169-52344da8166c", "embedding": null, "metadata": {"window": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n", "original_text": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a868d88f-e667-485a-b3f4-6ef3d428779a", "node_type": "1", "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "original_text": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a63b53d1aafa52d580392e41feb512fb545a451fc119030a99834a52df67d86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0199404-c498-4b4b-8047-991601f3a5fd", "node_type": "1", "metadata": {"window": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "original_text": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n"}, "hash": "9e2bff0991ae288ab08b688296720a3871efba94ae829e2df258eeb0bd19209f", "class_name": "RelatedNodeInfo"}}, "text": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "start_char_idx": 394, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0199404-c498-4b4b-8047-991601f3a5fd": {"__data__": {"id_": "d0199404-c498-4b4b-8047-991601f3a5fd", "embedding": null, "metadata": {"window": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "original_text": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "315bd1e5-6a04-425c-b169-52344da8166c", "node_type": "1", "metadata": {"window": "As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n", "original_text": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52a40d5a4eb06c16064c3d0792035ac295354060a24ed272de6a9c7864bc61a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db39e1b3-e5b7-460c-bc60-4ace0800ad17", "node_type": "1", "metadata": {"window": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n", "original_text": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n"}, "hash": "5689fce72a4c3c63e877da99052652a31f28e7876e5d1dcd58e1c1c558f04f8e", "class_name": "RelatedNodeInfo"}}, "text": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "start_char_idx": 554, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db39e1b3-e5b7-460c-bc60-4ace0800ad17": {"__data__": {"id_": "db39e1b3-e5b7-460c-bc60-4ace0800ad17", "embedding": null, "metadata": {"window": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n", "original_text": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0199404-c498-4b4b-8047-991601f3a5fd", "node_type": "1", "metadata": {"window": "Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "original_text": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f6e4b773154eb72ad676bbe34c54e55725d5b27f17f80cb3c125941dbb91ba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5059cf2-793d-48cd-886e-e099f189cad6", "node_type": "1", "metadata": {"window": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "original_text": "Turning to the GMPD segment on slide 6.  \n \n"}, "hash": "e8cb377cd33e2c4d368ea48e48aad61566eca5456bfaf3fb653c3b063761174b", "class_name": "RelatedNodeInfo"}}, "text": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "start_char_idx": 693, "end_char_idx": 887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5059cf2-793d-48cd-886e-e099f189cad6": {"__data__": {"id_": "c5059cf2-793d-48cd-886e-e099f189cad6", "embedding": null, "metadata": {"window": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "original_text": "Turning to the GMPD segment on slide 6.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db39e1b3-e5b7-460c-bc60-4ace0800ad17", "node_type": "1", "metadata": {"window": "Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n", "original_text": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57196ba21025cf5ae2a51e03179236881de41c86f9eec3b6401ecb9ef086d3fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58324abb-c5fd-4ddc-a526-3c4b7019c6a1", "node_type": "1", "metadata": {"window": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "original_text": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. "}, "hash": "c9da0e512942feb8d7608cb1b86a5072194b6b6f769e2a9ed782b6577ff38f3c", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the GMPD segment on slide 6.  \n \n", "start_char_idx": 887, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58324abb-c5fd-4ddc-a526-3c4b7019c6a1": {"__data__": {"id_": "58324abb-c5fd-4ddc-a526-3c4b7019c6a1", "embedding": null, "metadata": {"window": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "original_text": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5059cf2-793d-48cd-886e-e099f189cad6", "node_type": "1", "metadata": {"window": "Within our brand and specialty products, demand for COVID -19 vaccines in the quarter was, \nconsistent with our expectations, not a meaningful contributor.  \n \n As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "original_text": "Turning to the GMPD segment on slide 6.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "948daf5b692f5e8767595a2f34af76e16872e0d0b48864401c902f6673ca3e87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea17d7b7-4479-47a7-8719-cd6bdab65604", "node_type": "1", "metadata": {"window": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "original_text": "This increase was driven \nby volume growth from existing customers.  \n \n"}, "hash": "44de483af4b5d858def8b5b67820bfb3d07e30fba5b9342d65fb2a96cdefe666", "class_name": "RelatedNodeInfo"}}, "text": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "start_char_idx": 931, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea17d7b7-4479-47a7-8719-cd6bdab65604": {"__data__": {"id_": "ea17d7b7-4479-47a7-8719-cd6bdab65604", "embedding": null, "metadata": {"window": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "original_text": "This increase was driven \nby volume growth from existing customers.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58324abb-c5fd-4ddc-a526-3c4b7019c6a1", "node_type": "1", "metadata": {"window": "As anticipated and guided, lower branded inflation than last year\u2019s relative high -point was a year -\nover-year drag on profit growth.  \n \n So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "original_text": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1144d29b62012bfa309f46696f3bb410103a2a26715993bd10c01637ece6e8c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4105315b-17fa-4a78-b3a8-ad523dc12fbd", "node_type": "1", "metadata": {"window": "Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "original_text": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. "}, "hash": "cc9407414b74152b76292792a8e796fdc7380b80fdbc726d42a10fd93225314a", "class_name": "RelatedNodeInfo"}}, "text": "This increase was driven \nby volume growth from existing customers.  \n \n", "start_char_idx": 1007, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4105315b-17fa-4a78-b3a8-ad523dc12fbd": {"__data__": {"id_": "4105315b-17fa-4a78-b3a8-ad523dc12fbd", "embedding": null, "metadata": {"window": "Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "original_text": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea17d7b7-4479-47a7-8719-cd6bdab65604", "node_type": "1", "metadata": {"window": "So overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty \nSolutions, solid growth on top of an exceptionally strong quarter a year ago which grew 23%.  \n \n Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "original_text": "This increase was driven \nby volume growth from existing customers.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb7ffda8e443dd8d24ac102d275739e4054aa41abe6b802c62e638194349cb4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff4ac06c-bba4-456f-9d64-f1dae9dda735", "node_type": "1", "metadata": {"window": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "original_text": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n"}, "hash": "1bceba34ad27795c94fee225c8e904d279dd59778f5f9dfea142e8140cfb5822", "class_name": "RelatedNodeInfo"}}, "text": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "start_char_idx": 1079, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff4ac06c-bba4-456f-9d64-f1dae9dda735": {"__data__": {"id_": "ff4ac06c-bba4-456f-9d64-f1dae9dda735", "embedding": null, "metadata": {"window": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "original_text": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4105315b-17fa-4a78-b3a8-ad523dc12fbd", "node_type": "1", "metadata": {"window": "Turning to the GMPD segment on slide 6.  \n \n Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "original_text": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fb3516c88938f7212144964833d1e88bb6f719dd6a36631603d032ddb219715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe209236-5956-4ef9-b26d-aa5cda78f348", "node_type": "1", "metadata": {"window": "This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "original_text": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. "}, "hash": "1773059a48292dcbf7faf2562ed15eb21bc34fce68102429abe7bbef83d4eaed", "class_name": "RelatedNodeInfo"}}, "text": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "start_char_idx": 1270, "end_char_idx": 1404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe209236-5956-4ef9-b26d-aa5cda78f348": {"__data__": {"id_": "fe209236-5956-4ef9-b26d-aa5cda78f348", "embedding": null, "metadata": {"window": "This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "original_text": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff4ac06c-bba4-456f-9d64-f1dae9dda735", "node_type": "1", "metadata": {"window": "Revenue grew for the second quarter in a row, by 4% in Q3, to $3.1 billion.  This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "original_text": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "642a884472b7e5d1a393970f43c128156c495cf47e5619618dbdac0541a78ff0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92b1fdb2-3924-4245-b8ab-4569101d835c", "node_type": "1", "metadata": {"window": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "original_text": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n"}, "hash": "db4f502e1e5e39fce506f619b57383a34b89bbdf3eb75a9b646aad58ae394734", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "start_char_idx": 1404, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92b1fdb2-3924-4245-b8ab-4569101d835c": {"__data__": {"id_": "92b1fdb2-3924-4245-b8ab-4569101d835c", "embedding": null, "metadata": {"window": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "original_text": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe209236-5956-4ef9-b26d-aa5cda78f348", "node_type": "1", "metadata": {"window": "This increase was driven \nby volume growth from existing customers.  \n \n The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "original_text": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan. ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "423d5a07d78193f25dc7426388366166bd325e797bf5e05376084531925c0e3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c015cdb-bc48-4df7-8418-e8e1dc77b42f", "node_type": "1", "metadata": {"window": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "original_text": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n"}, "hash": "9de5431b926d8f5d1716de45a6098e143aa48f84853c74fcfa6a2fcd23211c82", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "start_char_idx": 1546, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c015cdb-bc48-4df7-8418-e8e1dc77b42f": {"__data__": {"id_": "8c015cdb-bc48-4df7-8418-e8e1dc77b42f", "embedding": null, "metadata": {"window": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "original_text": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92b1fdb2-3924-4245-b8ab-4569101d835c", "node_type": "1", "metadata": {"window": "The GMPD segment delivered segment profit of $20 million, a $66 million year -over-year increase, \ndriven by an improvement in net inflationary impacts, including our mitigation initiatives.  GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "original_text": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e02de53afd7a04b9f786ed59629e206a56db416508e637ed0c31b68e9da238b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae99f1b9-2674-43c4-b1cd-6dfef15105c3", "node_type": "1", "metadata": {"window": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n"}, "hash": "bc650730f12dd19f9ee1bc126f34360eaafd5147a6a05cd1990e6e099d525aa4", "class_name": "RelatedNodeInfo"}}, "text": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "start_char_idx": 1695, "end_char_idx": 1930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae99f1b9-2674-43c4-b1cd-6dfef15105c3": {"__data__": {"id_": "ae99f1b9-2674-43c4-b1cd-6dfef15105c3", "embedding": null, "metadata": {"window": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c015cdb-bc48-4df7-8418-e8e1dc77b42f", "node_type": "1", "metadata": {"window": "GMPD \ncontinued its strong turnaround trajectory, achieving its high est level of quarterly profitability in the last \n2.5 years.  \n \n We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "original_text": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06dc0c47da48f80b9efc35aa658823d96dad71ce8df2b53b38f93463b1edc499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ae7708-1b7c-4cce-9ffd-417bf99502e4", "node_type": "1", "metadata": {"window": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n"}, "hash": "3ffef2004fb1309cdeee39de24d5242b9aded0964f2895a2c3f4258adeb1c132", "class_name": "RelatedNodeInfo"}}, "text": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "start_char_idx": 1930, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ae7708-1b7c-4cce-9ffd-417bf99502e4": {"__data__": {"id_": "78ae7708-1b7c-4cce-9ffd-417bf99502e4", "embedding": null, "metadata": {"window": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae99f1b9-2674-43c4-b1cd-6dfef15105c3", "node_type": "1", "metadata": {"window": "We continue to be encouraged by the underlying improvements in the business, driven by the team\u2019s \nefforts against the GMPD Improvement Plan.  As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdfb27502dec188f0807db9e29e91c8f8c5e4d6eb76682a84adbd6fe5f0a2de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc", "node_type": "1", "metadata": {"window": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n"}, "hash": "ee033a0475d3e309bbaf9873fd16919a1876a28c3c5f8c9947c9302f9ecadae8", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "start_char_idx": 2011, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc": {"__data__": {"id_": "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc", "embedding": null, "metadata": {"window": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78ae7708-1b7c-4cce-9ffd-417bf99502e4", "node_type": "1", "metadata": {"window": "As a reminder, the components of the former Medical \nImprovement Plan are now split between GMPD and Other, and the plan continues to be on track.  \n The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ced975a7f6e392767cf09f3926dad6cd4d027fac6ab0687868517649f18ec42e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66769955-cca4-4289-9a29-fa0915d0f675", "node_type": "1", "metadata": {"window": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n "}, "hash": "a6338bc5b518c8267d4835b77b631f2f78dd6e43c3f74812a31315b83d1de36d", "class_name": "RelatedNodeInfo"}}, "text": "Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "start_char_idx": 2199, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66769955-cca4-4289-9a29-fa0915d0f675": {"__data__": {"id_": "66769955-cca4-4289-9a29-fa0915d0f675", "embedding": null, "metadata": {"window": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70227763e0a8e086a58c0565000b206d6935a03b00f1525bdd3fdf46d2e6bc90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc", "node_type": "1", "metadata": {"window": "The team achieved notable progress on inflation mitigation in the quarter, and we again saw year -\nover-year improvement and growth in Cardinal Health Brand volumes, providing continued fuel for the \nbusiness\u2019 ongoing turnaround .  \n \n Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8a8fcbb32510d303ad41f38c0f19aad5712acbd9e61dd7b58f995f7408e3379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db135c83-7f9b-423b-9fb7-138511825223", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "original_text": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n"}, "hash": "7735a89830c489e0a55fda0491aa9c10e4d31e0f8d98222b7771ee07a80df725", "class_name": "RelatedNodeInfo"}}, "text": "Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "start_char_idx": 2442, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db135c83-7f9b-423b-9fb7-138511825223": {"__data__": {"id_": "db135c83-7f9b-423b-9fb7-138511825223", "embedding": null, "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "original_text": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66769955-cca4-4289-9a29-fa0915d0f675", "node_type": "1", "metadata": {"window": "Finishing with the businesses that aggregate into Other as seen on slide 7 .  \n \n Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses , at-\nHome Solutions, Nuclear and Precision Health Solutions and OptiFreight\u00ae  Logistics.  \n \n Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight\u00ae  Logistics \nshowing particular strength as we worked during the quarter to create the foundations for future profit \ngrowth in all of the businesses.  \n \n Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "original_text": "Jason will further discuss our excitement around these businesses and some of the recent trends \nmomentarily.  \n ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd346187faf0c9b2db1d95897ba24c7d7d537b058878b9fc01ff9dd707dc5372", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f77c13-898f-40ed-b198-d4fe87f76551", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "original_text": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n"}, "hash": "a4efde9403c0e4e993d93392ccb0cb6d6ab467f1ac686bc839f824ff04819818", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n", "start_char_idx": 0, "end_char_idx": 57, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f77c13-898f-40ed-b198-d4fe87f76551": {"__data__": {"id_": "74f77c13-898f-40ed-b198-d4fe87f76551", "embedding": null, "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "original_text": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db135c83-7f9b-423b-9fb7-138511825223", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "original_text": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8328525023b971218386f8a2104096159eb64e3346b6f919c67587d6626e3daf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fff023f-8974-43cf-8ddf-e62d98034246", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "original_text": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n"}, "hash": "b97847bece466a670ed0621dda3fb992c0c43a04bd15c1ca2ab3a9f4582ce9e7", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n", "start_char_idx": 57, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fff023f-8974-43cf-8ddf-e62d98034246": {"__data__": {"id_": "8fff023f-8974-43cf-8ddf-e62d98034246", "embedding": null, "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "original_text": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f77c13-898f-40ed-b198-d4fe87f76551", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "original_text": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6edfee08a901ed464f84040d76c3e7ba458454cf3c52515c99088d92c9d1b140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db89ec8e-3e39-4614-8fbf-9ce1b11a081c", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "original_text": "Over the past several years we\u2019ve made tremendous progress with our balance sheet. "}, "hash": "d25ecfcdb230b9c82a1f0d556e2e5278996a481292fda6bfcac03988526804ae", "class_name": "RelatedNodeInfo"}}, "text": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n", "start_char_idx": 178, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db89ec8e-3e39-4614-8fbf-9ce1b11a081c": {"__data__": {"id_": "db89ec8e-3e39-4614-8fbf-9ce1b11a081c", "embedding": null, "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "original_text": "Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fff023f-8974-43cf-8ddf-e62d98034246", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "original_text": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "556617bc82b9d389f818ca660a9b4ab95bf5e64388aa389ffe12ba2163cd9a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42f85b46-fac7-4771-9110-299a31136a97", "node_type": "1", "metadata": {"window": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "original_text": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. "}, "hash": "a87667f9d7e5d3b4a31c44f86402314b70399544740181710f124bca2f2b81f4", "class_name": "RelatedNodeInfo"}}, "text": "Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "start_char_idx": 525, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42f85b46-fac7-4771-9110-299a31136a97": {"__data__": {"id_": "42f85b46-fac7-4771-9110-299a31136a97", "embedding": null, "metadata": {"window": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "original_text": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db89ec8e-3e39-4614-8fbf-9ce1b11a081c", "node_type": "1", "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "original_text": "Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "117812c6082f757293cd62fcaca27f808bc5c1052e45fcfcddb1df7d2cb0af56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "408dd544-ec4b-499e-9ce5-c8ba914627b6", "node_type": "1", "metadata": {"window": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "original_text": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. "}, "hash": "5a0b813e5ec775070bde8814a2b9ce9569ad209e79aef098cde7b5f803db31dc", "class_name": "RelatedNodeInfo"}}, "text": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "start_char_idx": 608, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "408dd544-ec4b-499e-9ce5-c8ba914627b6": {"__data__": {"id_": "408dd544-ec4b-499e-9ce5-c8ba914627b6", "embedding": null, "metadata": {"window": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "original_text": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42f85b46-fac7-4771-9110-299a31136a97", "node_type": "1", "metadata": {"window": "We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "original_text": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab2561105ddf671f00df5daf9ba58fe526742db304aac824591437d4d1681afa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "419f8d0a-ca0d-445c-957f-40fee49e7835", "node_type": "1", "metadata": {"window": "Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "original_text": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. "}, "hash": "aa2bc3c8b61cf7eb2051996e602151931fa47df736a6b9423fe4f614af3c61a7", "class_name": "RelatedNodeInfo"}}, "text": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "start_char_idx": 735, "end_char_idx": 854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "419f8d0a-ca0d-445c-957f-40fee49e7835": {"__data__": {"id_": "419f8d0a-ca0d-445c-957f-40fee49e7835", "embedding": null, "metadata": {"window": "Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "original_text": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "408dd544-ec4b-499e-9ce5-c8ba914627b6", "node_type": "1", "metadata": {"window": "Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "original_text": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "653e6eac1834560011bc16ff28dc2157793f75abb68941b8d62e424bd5ddb2d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6404f772-0a1b-429c-987e-4d6905f0e222", "node_type": "1", "metadata": {"window": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "original_text": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. "}, "hash": "ccc2451d7e0c7c53b138a240455d2419b443d6f52490f49afd0285cf2d4a6e03", "class_name": "RelatedNodeInfo"}}, "text": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "start_char_idx": 854, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6404f772-0a1b-429c-987e-4d6905f0e222": {"__data__": {"id_": "6404f772-0a1b-429c-987e-4d6905f0e222", "embedding": null, "metadata": {"window": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "original_text": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "419f8d0a-ca0d-445c-957f-40fee49e7835", "node_type": "1", "metadata": {"window": "Over the past several years we\u2019ve made tremendous progress with our balance sheet.  At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "original_text": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d292eb0ddc61d75625e0d94b478fdb8eceb75b23b6a4e50ecd981eb27b3b475", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17b627d9-f0e9-4360-81f4-4bb360292dab", "node_type": "1", "metadata": {"window": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "original_text": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n"}, "hash": "54f69f2493a6ebfbd4e02d3164623b6f97a8c3748165004ffaea7325b23b1fd6", "class_name": "RelatedNodeInfo"}}, "text": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "start_char_idx": 956, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17b627d9-f0e9-4360-81f4-4bb360292dab": {"__data__": {"id_": "17b627d9-f0e9-4360-81f4-4bb360292dab", "embedding": null, "metadata": {"window": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "original_text": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6404f772-0a1b-429c-987e-4d6905f0e222", "node_type": "1", "metadata": {"window": "At the end of \nthe quarter, we received a further update to our ratings outlook, with Moody\u2019s moving our outlook to \npositive.  We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "original_text": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f684b196e82913b32a6ffb282e3a15fa75468d6ba1e03fda9b066d1beb028632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6add21ee-14d5-4c87-8cb5-7cb5172f89c8", "node_type": "1", "metadata": {"window": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "original_text": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n"}, "hash": "d3521ee7e3032f088836df82132edbf73cd947a3aa4dd8d4eabeea94c2c01a45", "class_name": "RelatedNodeInfo"}}, "text": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "start_char_idx": 1093, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6add21ee-14d5-4c87-8cb5-7cb5172f89c8": {"__data__": {"id_": "6add21ee-14d5-4c87-8cb5-7cb5172f89c8", "embedding": null, "metadata": {"window": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "original_text": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17b627d9-f0e9-4360-81f4-4bb360292dab", "node_type": "1", "metadata": {"window": "We issued $1.15 billion  in new notes during the quarter to refinance our upcoming June and \nNovember debt maturities.  We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "original_text": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0616d9fe027f33edac8a1084fcd9b14eec1a4d4632b87284887fc2e2c9855c19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df744f32-4e83-420b-8170-b89488717cf5", "node_type": "1", "metadata": {"window": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "original_text": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. "}, "hash": "144e4eabb311f89af50a2afef2b45e97515448171d6a3663a7c67355c859705a", "class_name": "RelatedNodeInfo"}}, "text": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "start_char_idx": 1191, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df744f32-4e83-420b-8170-b89488717cf5": {"__data__": {"id_": "df744f32-4e83-420b-8170-b89488717cf5", "embedding": null, "metadata": {"window": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "original_text": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6add21ee-14d5-4c87-8cb5-7cb5172f89c8", "node_type": "1", "metadata": {"window": "We plan to hold the cash proceeds in time deposits until the calendar year  \n\u201824 maturities come due.  I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "original_text": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abb3540addc045ae798c4b7078c72fd7402e06e05bfc513d69d64d11708c8489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f92f51c1-c27c-4e56-ab11-df020c1a0326", "node_type": "1", "metadata": {"window": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "original_text": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. "}, "hash": "75828db2269e9fc2332cc3ba221c7b7d2f3a0ea98ba79ca363d7ea876e1559b7", "class_name": "RelatedNodeInfo"}}, "text": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "start_char_idx": 1544, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f92f51c1-c27c-4e56-ab11-df020c1a0326": {"__data__": {"id_": "f92f51c1-c27c-4e56-ab11-df020c1a0326", "embedding": null, "metadata": {"window": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "original_text": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df744f32-4e83-420b-8170-b89488717cf5", "node_type": "1", "metadata": {"window": "I\u2019ll note due to the nature of these contracts, only about half of the total cash \nrecei ved is reflected in our Q3 ending cash balance.  The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "original_text": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8ad386aedf9aa51d71132749c06fad929cf8db88ec53fbf998a803edc99bb42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0faef01-7b6e-418a-8c11-e18d7db5a6f6", "node_type": "1", "metadata": {"window": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "original_text": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n"}, "hash": "0fc8c62d75a5f0b4cd6587e720d50bec0fc99d666062190bf8e786f69c4e5eb3", "class_name": "RelatedNodeInfo"}}, "text": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "start_char_idx": 1617, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0faef01-7b6e-418a-8c11-e18d7db5a6f6": {"__data__": {"id_": "f0faef01-7b6e-418a-8c11-e18d7db5a6f6", "embedding": null, "metadata": {"window": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "original_text": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f92f51c1-c27c-4e56-ab11-df020c1a0326", "node_type": "1", "metadata": {"window": "The remaining $550  million  is recorded in \nPrepaid Expenses and Other on the balance sheet.  \n \n We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "original_text": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06d75c842ff0387c9797f42c53b0bc75a466b75abab3dcc3006939eeb7c112e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46be63d5-483c-48a9-8460-de1f0bd369f6", "node_type": "1", "metadata": {"window": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "original_text": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n"}, "hash": "f722aad4e57cda658d0e188746e2a8bf604c067df2a0dd275d5391573d02067b", "class_name": "RelatedNodeInfo"}}, "text": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "start_char_idx": 1719, "end_char_idx": 1846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46be63d5-483c-48a9-8460-de1f0bd369f6": {"__data__": {"id_": "46be63d5-483c-48a9-8460-de1f0bd369f6", "embedding": null, "metadata": {"window": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "original_text": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0faef01-7b6e-418a-8c11-e18d7db5a6f6", "node_type": "1", "metadata": {"window": "We have returned over $1 billion total to shareholders year -to-date, which includes approximately \n$375  million  of quarterly dividend payments and $750 million in share repurchases, which is in excess \nof our committed baseline repurchases of $500 millio n.  \n \nNow, for our updated fiscal \u201824 guidance on slide 9, beginning with the enterprise.  \n \n We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "original_text": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c6d2af99e18257769002e84da1463d7b87851c0b96bd165337d67eaab7c0ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "271a596f-37c9-42ab-ac2a-6d998ebcdf46", "node_type": "1", "metadata": {"window": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "original_text": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. "}, "hash": "3c4e832bf0ec999ff3752a385281b7b26534726ac3e523695ec3d6eacf021cda", "class_name": "RelatedNodeInfo"}}, "text": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "start_char_idx": 1846, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "271a596f-37c9-42ab-ac2a-6d998ebcdf46": {"__data__": {"id_": "271a596f-37c9-42ab-ac2a-6d998ebcdf46", "embedding": null, "metadata": {"window": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "original_text": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46be63d5-483c-48a9-8460-de1f0bd369f6", "node_type": "1", "metadata": {"window": "We are raising and narrowing our fiscal year \u201824 non -GAAP EPS guidance.  Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "original_text": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff661eb6ead942a82f18ae2ee103a6a0193fbc703306540a7cebc30493a94956", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf8cac38-0cb6-472f-9305-8f77fbf906d9", "node_type": "1", "metadata": {"window": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "original_text": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n"}, "hash": "caa9eca3ca2b07defd65d62727da7a46e4a74afd5aef3c8e88d3cd93740788de", "class_name": "RelatedNodeInfo"}}, "text": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "start_char_idx": 1928, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf8cac38-0cb6-472f-9305-8f77fbf906d9": {"__data__": {"id_": "bf8cac38-0cb6-472f-9305-8f77fbf906d9", "embedding": null, "metadata": {"window": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "original_text": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "271a596f-37c9-42ab-ac2a-6d998ebcdf46", "node_type": "1", "metadata": {"window": "Our new range of $7.30 \nto $7.40 reflects a mid -point which is 27% above our fiscal \u201823 EPS results.  We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "original_text": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%. ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "666e71bc50f0f234eccf9dff7a34c2c2c7edc9ef79367e6368a5bea0d49db959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cec9cbb-9345-4dd8-a656-097d02496f7d", "node_type": "1", "metadata": {"window": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n"}, "hash": "6b3bc5a21e7166c68b498a073594088ba1ae12b32c5baf525775160ed56a6ae4", "class_name": "RelatedNodeInfo"}}, "text": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "start_char_idx": 2055, "end_char_idx": 2378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cec9cbb-9345-4dd8-a656-097d02496f7d": {"__data__": {"id_": "9cec9cbb-9345-4dd8-a656-097d02496f7d", "embedding": null, "metadata": {"window": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf8cac38-0cb6-472f-9305-8f77fbf906d9", "node_type": "1", "metadata": {"window": "We started the year \nworking to deliver our guidance of 14% EPS growth at the mid -point , what a year it has been so far.  \n \n Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "original_text": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26df6552e9002a42b3283c2871925c29fa22aaf90fa2dc86241d9392ce4192a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d4785d-4ff2-48fb-889a-59d88272f011", "node_type": "1", "metadata": {"window": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n"}, "hash": "7aed34adfeae652cf7b8da9eb4405c9c02ab3463ba2cc0e105fc7c6975d26ea5", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "start_char_idx": 2378, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d4785d-4ff2-48fb-889a-59d88272f011": {"__data__": {"id_": "23d4785d-4ff2-48fb-889a-59d88272f011", "embedding": null, "metadata": {"window": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cec9cbb-9345-4dd8-a656-097d02496f7d", "node_type": "1", "metadata": {"window": "Before we turn to the segments, a few comments on our enterprise assumptions.  \n \n With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14e76272e7fd14f4141f94f1fac2ba605476e95a6aa89091032d03444c037cbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "791555bf-732f-4b82-b0b6-1adf7cc3b53d", "node_type": "1", "metadata": {"window": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n"}, "hash": "18a48f33157d3171a19208cb9b3a4be65714ccf2f93a940e8136b392e4f2c4c9", "class_name": "RelatedNodeInfo"}}, "text": "With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "start_char_idx": 2482, "end_char_idx": 2760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "791555bf-732f-4b82-b0b6-1adf7cc3b53d": {"__data__": {"id_": "791555bf-732f-4b82-b0b6-1adf7cc3b53d", "embedding": null, "metadata": {"window": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d4785d-4ff2-48fb-889a-59d88272f011", "node_type": "1", "metadata": {"window": "With the year -to-date results, we are improving our fiscal \u201824 effective tax rate guidance to an updated \nrange of 22% - 23%.  And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0082f4a2c7ab0ea9512891a107a97c2d795af73a5cb52b2e7e33bb157f2da6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a4c211-3152-4f87-b004-3ae882fb9542", "node_type": "1", "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued "}, "hash": "be8f657e7fa2d1e2984293b7e0fd03ee4c7f089b0ca8034c14a7b74fca06dd14", "class_name": "RelatedNodeInfo"}}, "text": "We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "start_char_idx": 2760, "end_char_idx": 2866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a4c211-3152-4f87-b004-3ae882fb9542": {"__data__": {"id_": "a6a4c211-3152-4f87-b004-3ae882fb9542", "embedding": null, "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67435a7d-4b18-4711-a325-95e98b72f911", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38c1429f780a14c50fe7550d56838e878019e527d9bb3d682151011dfce332f4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "791555bf-732f-4b82-b0b6-1adf7cc3b53d", "node_type": "1", "metadata": {"window": "And we are reiterating our fiscal \u201824 expectations for adjusted free cash flow of \napproximately $2.5 billion, capex of around $500 million, diluted shares of approximately 247 million \nand share repurchases of $750 millio n, which consistent with our framework, does not assume further \nrepurchase activity this year.  \n \n Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6882866aa45c4b25266e4d64f789a0aa879c08d6619b7bab9c21d08c8c6943f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c7d40d7-1a2b-413c-9515-74362c3bffbf", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "original_text": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n"}, "hash": "0bb6ccb43d4b49f9026af8875222e3a2fbc4e6f6e4cb2e58662b8f7d8231d0d4", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "start_char_idx": 2866, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c7d40d7-1a2b-413c-9515-74362c3bffbf": {"__data__": {"id_": "8c7d40d7-1a2b-413c-9515-74362c3bffbf", "embedding": null, "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "original_text": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a4c211-3152-4f87-b004-3ae882fb9542", "node_type": "1", "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our new segment reporting structure as seen on slide 10.  \n \n With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing \nour segment profit guidance for the full year to 8.5% to 9.5% growth, which at the mid -point, implies \ncontinued mid -single digit profit growth in the fourt h quarter .   \n \n We are reiterating our guide for GMPD segment profit of approximately $65  million for fiscal year \u2018 24. \n We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "original_text": "We continue to expect to address the impact of inflation as we exit fiscal \u201824, along with continued ", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a5925ba2505bd3d6dbd79a1a1c7026986d14514f8a2e86b5d21167f6ab11f1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a2bd04e-d428-4d1f-a28d-0e025da74204", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "original_text": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n"}, "hash": "b75eea6e9a01d218f64cb2f68a1aeb5646916ac57f7619a5744399f5d1d49526", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n", "start_char_idx": 0, "end_char_idx": 113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2bd04e-d428-4d1f-a28d-0e025da74204": {"__data__": {"id_": "1a2bd04e-d428-4d1f-a28d-0e025da74204", "embedding": null, "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "original_text": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c7d40d7-1a2b-413c-9515-74362c3bffbf", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "original_text": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94edbd56392c48b430887fc99cfe165550e6fd2307fa22a8aaf55bb070cf95d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9772a33-98de-44c0-ad55-65c065a4bdbc", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "original_text": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses. "}, "hash": "b3d7025b266b3f9b573f22532cba5012513e425ff5054771b3907ecc8910bed4", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n", "start_char_idx": 113, "end_char_idx": 202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9772a33-98de-44c0-ad55-65c065a4bdbc": {"__data__": {"id_": "c9772a33-98de-44c0-ad55-65c065a4bdbc", "embedding": null, "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "original_text": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a2bd04e-d428-4d1f-a28d-0e025da74204", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "original_text": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63ae2d89859f5f9748414138229de5b121c3f2c0f019ae3f2dd111ca1af92184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "084bfaae-5b24-4a50-914e-dfa2fa11dabf", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "original_text": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n"}, "hash": "d49713a8430ee91389d437ead8949e0418c3d664f82fb1befe338c14e4aae06f", "class_name": "RelatedNodeInfo"}}, "text": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses. ", "start_char_idx": 202, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "084bfaae-5b24-4a50-914e-dfa2fa11dabf": {"__data__": {"id_": "084bfaae-5b24-4a50-914e-dfa2fa11dabf", "embedding": null, "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "original_text": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9772a33-98de-44c0-ad55-65c065a4bdbc", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "original_text": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "854aecd76877d3357e27a90db00dbb1ea26bdcacec3e0d5b71444e152db89a2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d", "node_type": "1", "metadata": {"window": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "original_text": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. "}, "hash": "2c77c528f3676a39f2dfb7392c74a24d48266b76e543ea78d2ba25ff5eddd353", "class_name": "RelatedNodeInfo"}}, "text": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "start_char_idx": 384, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d": {"__data__": {"id_": "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d", "embedding": null, "metadata": {"window": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "original_text": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "084bfaae-5b24-4a50-914e-dfa2fa11dabf", "node_type": "1", "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "original_text": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f955edbe415bde7982b1c6fd3f22c85af4e4b9a7a48e483a652dc3f58544ab1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3240e164-cdca-455a-a089-19d5f6cbf1b9", "node_type": "1", "metadata": {"window": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "original_text": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. "}, "hash": "eb2ed5b0979b663e5f99eabc6822434497f664d05806784b9151f9c1594615db", "class_name": "RelatedNodeInfo"}}, "text": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "start_char_idx": 473, "end_char_idx": 571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3240e164-cdca-455a-a089-19d5f6cbf1b9": {"__data__": {"id_": "3240e164-cdca-455a-a089-19d5f6cbf1b9", "embedding": null, "metadata": {"window": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "original_text": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d", "node_type": "1", "metadata": {"window": "Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "original_text": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84ca2c5070367489235b2854c6aeee010d1c893807bbee7d70ddb37613d6b043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b038af58-0867-46ac-b97f-1dfd61547b10", "node_type": "1", "metadata": {"window": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "original_text": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. "}, "hash": "c33af16eeeded0545a442dcab8932efb1aa6aa59337971069656b59d920b2fce", "class_name": "RelatedNodeInfo"}}, "text": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "start_char_idx": 571, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b038af58-0867-46ac-b97f-1dfd61547b10": {"__data__": {"id_": "b038af58-0867-46ac-b97f-1dfd61547b10", "embedding": null, "metadata": {"window": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "original_text": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3240e164-cdca-455a-a089-19d5f6cbf1b9", "node_type": "1", "metadata": {"window": "We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "original_text": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ee65be28bff0df433fb21f2a617c89084ea3ddfb4776a390b79053b9f4c9f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "def7626f-0dbd-402e-8c76-7d30a40f674e", "node_type": "1", "metadata": {"window": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "original_text": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n"}, "hash": "610272df21b2eb56168420e43db72047400e36e889141f2057544daf7d2aba0d", "class_name": "RelatedNodeInfo"}}, "text": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "start_char_idx": 661, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "def7626f-0dbd-402e-8c76-7d30a40f674e": {"__data__": {"id_": "def7626f-0dbd-402e-8c76-7d30a40f674e", "embedding": null, "metadata": {"window": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "original_text": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b038af58-0867-46ac-b97f-1dfd61547b10", "node_type": "1", "metadata": {"window": "On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "original_text": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "635b6d9f8161619e2c18239c4163859d5d067b30628b3b71ec2ce73f47d94232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cefd68e2-7155-4206-b898-26e8ed9ad6dc", "node_type": "1", "metadata": {"window": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "original_text": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n"}, "hash": "08b04c85e89b1c012f6e092d0140fa55631220c89874c3230e5a30c68dbc0d82", "class_name": "RelatedNodeInfo"}}, "text": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "start_char_idx": 764, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cefd68e2-7155-4206-b898-26e8ed9ad6dc": {"__data__": {"id_": "cefd68e2-7155-4206-b898-26e8ed9ad6dc", "embedding": null, "metadata": {"window": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "original_text": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "def7626f-0dbd-402e-8c76-7d30a40f674e", "node_type": "1", "metadata": {"window": "So, as I highlighted earlier, we are raising our guidance for fiscal year \u2018 24 to $7.30 to $7.40.  Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "original_text": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4239b22b10330dd117054c0ef6a1e728a1b1c9219701c31d7912f26ca296ebfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8811e18-2fda-44c6-b485-594c9749364a", "node_type": "1", "metadata": {"window": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "original_text": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. "}, "hash": "2bd9a5a039bacab43ed5959c940ad21a8eba35b4210e2237a7a7d23f514fc3f4", "class_name": "RelatedNodeInfo"}}, "text": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "start_char_idx": 952, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8811e18-2fda-44c6-b485-594c9749364a": {"__data__": {"id_": "a8811e18-2fda-44c6-b485-594c9749364a", "embedding": null, "metadata": {"window": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "original_text": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cefd68e2-7155-4206-b898-26e8ed9ad6dc", "node_type": "1", "metadata": {"window": "Finally, \nlet me conclude my remarks by providing a guidance preview of fiscal year \u2018 25.  We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "original_text": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3521fe539553984e8dbb58a880787efea5db67ed634e433761e8e091052c8db8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a1c9c04-3591-41e1-9eff-003674591109", "node_type": "1", "metadata": {"window": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "original_text": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. "}, "hash": "1e8edb4643922a797a173cd894128785c6bc3acf8e08db49a840318d26c94a70", "class_name": "RelatedNodeInfo"}}, "text": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "start_char_idx": 1252, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a1c9c04-3591-41e1-9eff-003674591109": {"__data__": {"id_": "5a1c9c04-3591-41e1-9eff-003674591109", "embedding": null, "metadata": {"window": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "original_text": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8811e18-2fda-44c6-b485-594c9749364a", "node_type": "1", "metadata": {"window": "We will provide formal \nfiscal year \u2018 25 guidance during our Q4 and full year earnings call in August.  However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "original_text": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9223e32a0a9ffa4bde78e30879c14c94be50cd6f3f080f5e31dd7341596fc134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "241e7537-60a3-465d-8e87-d60cb98adbaf", "node_type": "1", "metadata": {"window": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "original_text": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. "}, "hash": "9ae087ac221e530e89d00c3686822ea270d970857b07391901323569d053f7fb", "class_name": "RelatedNodeInfo"}}, "text": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "start_char_idx": 1383, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "241e7537-60a3-465d-8e87-d60cb98adbaf": {"__data__": {"id_": "241e7537-60a3-465d-8e87-d60cb98adbaf", "embedding": null, "metadata": {"window": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "original_text": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a1c9c04-3591-41e1-9eff-003674591109", "node_type": "1", "metadata": {"window": "However, with the benefit \nof our raised fiscal year \u201824 expectations and the action plans already underway in response to recent \nmarket changes, here is our preliminary perspective.  \n \n For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "original_text": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82edbbed4be0d257a0b53a2db53e96bec2d79179732c3ae352b1a912fc12e01a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3", "node_type": "1", "metadata": {"window": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "original_text": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n"}, "hash": "39ed0ce240eb87f1935a651caf002f1d2b80938b152d659fcc5a664893621a0d", "class_name": "RelatedNodeInfo"}}, "text": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "start_char_idx": 1534, "end_char_idx": 1675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3": {"__data__": {"id_": "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3", "embedding": null, "metadata": {"window": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "original_text": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "241e7537-60a3-465d-8e87-d60cb98adbaf", "node_type": "1", "metadata": {"window": "For our largest business,  Pharmaceutical and Specialty Solutions, while revenue will reset in the year \nas we offset a recent customer nonrenewal, we notably expect to deliver at least 1% segment profit \ngrowth in fiscal year \u2018 25, before returning to more normalized growth in fiscal year \u2018 26. \n \n Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "original_text": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd53a3904038caeb5b706ca0b692cc40c72ff1c8e867da1cd3713e90cb4efdc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e93f2485-46cf-45e9-8a20-f30a1b10c68b", "node_type": "1", "metadata": {"window": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "original_text": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. "}, "hash": "bae59295fd558bd31c830e00d9a02da0331c2fe8e25ca5b857cea55a0410211c", "class_name": "RelatedNodeInfo"}}, "text": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "start_char_idx": 1675, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e93f2485-46cf-45e9-8a20-f30a1b10c68b": {"__data__": {"id_": "e93f2485-46cf-45e9-8a20-f30a1b10c68b", "embedding": null, "metadata": {"window": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "original_text": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3", "node_type": "1", "metadata": {"window": "Looking forward, our commercial and operational teams have been busy, and our value proposition is \nresonating in the marketplace.  Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "original_text": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fecf132601776b1f973371e0cc99dd399a0ac09383bab4969fb51173a71fe9c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e2041e1-3fe2-4688-846d-d03c7b6d7980", "node_type": "1", "metadata": {"window": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "original_text": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. "}, "hash": "e030f774d0c7eef0dc4cd4c658476231eb69abc403f1c8b37f153a1121f3f6df", "class_name": "RelatedNodeInfo"}}, "text": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "start_char_idx": 1782, "end_char_idx": 1899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e2041e1-3fe2-4688-846d-d03c7b6d7980": {"__data__": {"id_": "5e2041e1-3fe2-4688-846d-d03c7b6d7980", "embedding": null, "metadata": {"window": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "original_text": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e93f2485-46cf-45e9-8a20-f30a1b10c68b", "node_type": "1", "metadata": {"window": "Over the past several months, we have had some attractive wins with \nnew customers and also existing customers expanding their own footprints with us.  Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "original_text": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d2877a2d42b0e9cdf16b2d1e48ef78472f6123592f9a57d4bc6ae59b5394b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77315319-49a3-4973-8f1d-5ec011a81e04", "node_type": "1", "metadata": {"window": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "original_text": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n"}, "hash": "38b1c1b5eb116bb97ff6c93c1ce7e042acb74dcca803a31fada10ee852dd3a66", "class_name": "RelatedNodeInfo"}}, "text": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "start_char_idx": 1899, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77315319-49a3-4973-8f1d-5ec011a81e04": {"__data__": {"id_": "77315319-49a3-4973-8f1d-5ec011a81e04", "embedding": null, "metadata": {"window": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "original_text": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e2041e1-3fe2-4688-846d-d03c7b6d7980", "node_type": "1", "metadata": {"window": "Some of these \nare already under contract and ordering, and others are scheduled for implementation in the second \nhalf of next fiscal year.  So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "original_text": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f968daa187da10b352efd169b683ea22128e5d5b9ac7912e7464f25f6a0a58da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a", "node_type": "1", "metadata": {"window": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "original_text": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. "}, "hash": "b30877bf3fd7fb3faa74694d589c7587d0bab5db387c277d71bb512fd82ec152", "class_name": "RelatedNodeInfo"}}, "text": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "start_char_idx": 2035, "end_char_idx": 2241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a": {"__data__": {"id_": "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a", "embedding": null, "metadata": {"window": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "original_text": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77315319-49a3-4973-8f1d-5ec011a81e04", "node_type": "1", "metadata": {"window": "So, over the course of the upcoming year, we expect new volume coming our \nway at sustainable margins.  \n \n We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "original_text": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e601d06f1409c0c72767982be91f8492240f8dc3c66b12db940600202edf501", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a29e9b8b-c45b-4902-9060-2faccf130b6a", "node_type": "1", "metadata": {"window": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "original_text": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n"}, "hash": "ed45b429b44279af1c4a3cd79c3f5d4b2d39c774dcbb9b4862fb25b2bd11e33a", "class_name": "RelatedNodeInfo"}}, "text": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "start_char_idx": 2241, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a29e9b8b-c45b-4902-9060-2faccf130b6a": {"__data__": {"id_": "a29e9b8b-c45b-4902-9060-2faccf130b6a", "embedding": null, "metadata": {"window": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "original_text": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a", "node_type": "1", "metadata": {"window": "We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal \nyear \u2018 25.  Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "original_text": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aacad4f0a7c056360e91e0dd788aeb0464a0622c60cb8608e8e77904c9e6d5da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "616c81aa-9826-4299-a6d3-71bb514f5931", "node_type": "1", "metadata": {"window": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. "}, "hash": "596b03755cc07ce070902be3a2c93655b23b26e62a284c3fa918e95cc615a137", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "start_char_idx": 2544, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "616c81aa-9826-4299-a6d3-71bb514f5931": {"__data__": {"id_": "616c81aa-9826-4299-a6d3-71bb514f5931", "embedding": null, "metadata": {"window": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a29e9b8b-c45b-4902-9060-2faccf130b6a", "node_type": "1", "metadata": {"window": "Separately, we have turned a further eye to optimizing our cost structure across the \nPharmaceutical and Specialty Solutions portfolio.  Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "original_text": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecb0ff6551c9d0a95dce6737c214c57e54680b03ece532d8a3d1b6ae433f99ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9471167b-282c-4ef8-b001-9dd0c4112a2e", "node_type": "1", "metadata": {"window": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n"}, "hash": "edc542d1522cf4b5e3dcbb71594de173141a35f969beb5dcf5d16549303c909c", "class_name": "RelatedNodeInfo"}}, "text": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "start_char_idx": 2631, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9471167b-282c-4ef8-b001-9dd0c4112a2e": {"__data__": {"id_": "9471167b-282c-4ef8-b001-9dd0c4112a2e", "embedding": null, "metadata": {"window": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "616c81aa-9826-4299-a6d3-71bb514f5931", "node_type": "1", "metadata": {"window": "Regarding some environmental factors, we are \nexpecting brand inflation to be roughly equivalent to fiscal year \u2018 24 levels while we remain watchful \nrelative to the contribution of COVID -19 vaccines.  \n \n For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue. ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "787ec0f88b065a55d03b6d7829bc05002c61d02b7455ca527d93100dc4093392", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "473c2869-bbcf-4f0a-96e2-ad1270a03ccf", "node_type": "1", "metadata": {"window": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n"}, "hash": "75126f27e9416c7ad068be0862e7999968c70abc216397835ba84e5ac3521da6", "class_name": "RelatedNodeInfo"}}, "text": "With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "start_char_idx": 2750, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "473c2869-bbcf-4f0a-96e2-ad1270a03ccf": {"__data__": {"id_": "473c2869-bbcf-4f0a-96e2-ad1270a03ccf", "embedding": null, "metadata": {"window": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9471167b-282c-4ef8-b001-9dd0c4112a2e", "node_type": "1", "metadata": {"window": "For the GMPD segment, we expect continued growth in fiscal year \u20182 5 on our path to approximately \n$300  million  in segment profit by fiscal year \u2018 26, driven by the annualization of inflation mitigation, \nprogress with Cardinal Health Brand growth, and continued simplification and cost optimization.  We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e40ff7cb179b4b36d2608bdf82b84965f5009449494423ccdcb186fe944144e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89818386-719a-48a4-8951-c83b941d7617", "node_type": "1", "metadata": {"window": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n "}, "hash": "5accd265330ba758c00af669a54ff08c98f34a219a26b0e0953c052948f4f6c6", "class_name": "RelatedNodeInfo"}}, "text": "During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "start_char_idx": 2958, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89818386-719a-48a4-8951-c83b941d7617": {"__data__": {"id_": "89818386-719a-48a4-8951-c83b941d7617", "embedding": null, "metadata": {"window": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1695c05-c36e-480f-b39b-a2911516c999", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9607fedcbf6c54f75840f819b061abe406fa04721c932b9ea0d504ba154c131d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "473c2869-bbcf-4f0a-96e2-ad1270a03ccf", "node_type": "1", "metadata": {"window": "We \nexpect approximately $175  million  in GMPD segment profit in fiscal year \u2018 25. \n \n And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6d5579896c0f27160afdc8d38e41a64c4a73f915550e6c6c8641f71c43129b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54ea95ee-6290-4a41-b763-018eae909936", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "original_text": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n"}, "hash": "53424851ec8c8fc6f26c788bff814601ac5c11ea0379a086a4249207c8637b8c", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "start_char_idx": 3262, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54ea95ee-6290-4a41-b763-018eae909936": {"__data__": {"id_": "54ea95ee-6290-4a41-b763-018eae909936", "embedding": null, "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "original_text": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89818386-719a-48a4-8951-c83b941d7617", "node_type": "1", "metadata": {"window": "And for the businesses included in Other, we expect the strong demand we\u2019ve seen across these \nbusinesses to continue.  With positive industry trends and the strength of our competitive positioning, \nwe expect collective segment profit growth in fiscal year \u2018 25 at the top end of our long -term target, \napproximately 10%.  \n \n During fiscal \u2018 25 we will be investing across all of our businesses, with key examples being new \nfacilities like our Consumer Health Logistics Center, at -Home Solutions facilities in Texas and South \nCarolina, and further geographic reach of our Nuclear and Precisions Hea lth Solutions PET network. \n We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "original_text": "We\u2019ll also continue our build -out of Navista \u2122 and investments in GMPD supply chain resiliency.  \n ", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16e1fbe29507c9795a582c5b50c87fdeaf12aa9eb5617bd9f82834de2916a640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d5e5fc-565c-4601-b7c7-c0b9d536c215", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "original_text": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal. "}, "hash": "ba50eb3a241035c5885f9f1eaae300a99af0bb8b4aed5ac53b3e39a7345e43f6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n", "start_char_idx": 0, "end_char_idx": 86, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d5e5fc-565c-4601-b7c7-c0b9d536c215": {"__data__": {"id_": "b3d5e5fc-565c-4601-b7c7-c0b9d536c215", "embedding": null, "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "original_text": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54ea95ee-6290-4a41-b763-018eae909936", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "original_text": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "094a9b947ab6da05d477a2fdfd3e3c25fe95c4f4bfab655b8bb25f2d9c9b2014", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "300e5319-f677-44d5-a173-d40e3876a86a", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "original_text": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n"}, "hash": "4e44cbf64ae876a90970a8ff33a7f626e6e0c148f2030e27923100676af956cf", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal. ", "start_char_idx": 86, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "300e5319-f677-44d5-a173-d40e3876a86a": {"__data__": {"id_": "300e5319-f677-44d5-a173-d40e3876a86a", "embedding": null, "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "original_text": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d5e5fc-565c-4601-b7c7-c0b9d536c215", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "original_text": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0ea8feed1645ca700bc249fc5fe38385707178963016148b275adb0b90d54b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year. ", "original_text": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n"}, "hash": "e0055f470eaad099f13ab5278cfc37768fe0a4848bac12c0fa04d14a14600bd6", "class_name": "RelatedNodeInfo"}}, "text": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n", "start_char_idx": 364, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a": {"__data__": {"id_": "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a", "embedding": null, "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year. ", "original_text": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "300e5319-f677-44d5-a173-d40e3876a86a", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "original_text": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2648ed35924eddaac27942adafe87efc3c915ae15e88e3446b4d2b91a6b1efe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c58840f8-6c70-4dae-880a-05ec218c719b", "node_type": "1", "metadata": {"window": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "original_text": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n"}, "hash": "f8ec831eb258b8acbab54671cf05d3ed4da01b54b9dbea089f345f05c49a9d24", "class_name": "RelatedNodeInfo"}}, "text": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "start_char_idx": 623, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c58840f8-6c70-4dae-880a-05ec218c719b": {"__data__": {"id_": "c58840f8-6c70-4dae-880a-05ec218c719b", "embedding": null, "metadata": {"window": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "original_text": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a", "node_type": "1", "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year. ", "original_text": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cee188c2ad137e06636200dec3b9cf21aac3dfd830b063cffbc9effb561a8000", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e2e12bf-d2d2-48a8-b001-da9bb3af1631", "node_type": "1", "metadata": {"window": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead. ", "original_text": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. "}, "hash": "394e78a8e4808580f93b14e0afd2309e95e34459af67408d63bebe73b94a9a3c", "class_name": "RelatedNodeInfo"}}, "text": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "start_char_idx": 793, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e2e12bf-d2d2-48a8-b001-da9bb3af1631": {"__data__": {"id_": "7e2e12bf-d2d2-48a8-b001-da9bb3af1631", "embedding": null, "metadata": {"window": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead. ", "original_text": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c58840f8-6c70-4dae-880a-05ec218c719b", "node_type": "1", "metadata": {"window": "We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "original_text": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5569ca716b8718e809107228b5c397dfe2a355f5e15477f90dfae5a3488e354", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f", "node_type": "1", "metadata": {"window": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "original_text": "These dynamics will significantly influence our cash flow in Q1 of next year. "}, "hash": "fac143512ec8e6bc7c4d8f86a39a4dbece681ba7dcaa8a9829e0effa998ed079", "class_name": "RelatedNodeInfo"}}, "text": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "start_char_idx": 994, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f": {"__data__": {"id_": "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f", "embedding": null, "metadata": {"window": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "original_text": "These dynamics will significantly influence our cash flow in Q1 of next year. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e2e12bf-d2d2-48a8-b001-da9bb3af1631", "node_type": "1", "metadata": {"window": "We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead. ", "original_text": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3154b07c5403d4e54c02d5be6028a3b08d3e55f723260910ab2f50de58ad36a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8be3412-25c8-466d-ac5d-c3b16e7650dd", "node_type": "1", "metadata": {"window": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n", "original_text": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n"}, "hash": "92111418a14c6f8883073a01000b050f0b51d4d23abc46fd9468c30736c730f4", "class_name": "RelatedNodeInfo"}}, "text": "These dynamics will significantly influence our cash flow in Q1 of next year. ", "start_char_idx": 1314, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8be3412-25c8-466d-ac5d-c3b16e7650dd": {"__data__": {"id_": "c8be3412-25c8-466d-ac5d-c3b16e7650dd", "embedding": null, "metadata": {"window": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n", "original_text": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f", "node_type": "1", "metadata": {"window": "We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "original_text": "These dynamics will significantly influence our cash flow in Q1 of next year. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f47ff6a88ece989e2b476a705ac5e73b1cd691a160463d0795902e5a37f0806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ad6423-7260-47a2-b9fa-d0211b809ef0", "node_type": "1", "metadata": {"window": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "With respect to the long term, it is full speed ahead. "}, "hash": "17ae4d670383c441548afa9f31ad92f6462538eecaca7152a7e590c16c4a0749", "class_name": "RelatedNodeInfo"}}, "text": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "start_char_idx": 1392, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ad6423-7260-47a2-b9fa-d0211b809ef0": {"__data__": {"id_": "34ad6423-7260-47a2-b9fa-d0211b809ef0", "embedding": null, "metadata": {"window": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "With respect to the long term, it is full speed ahead. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8be3412-25c8-466d-ac5d-c3b16e7650dd", "node_type": "1", "metadata": {"window": "Partially offsetting these impacts, we would expect a lower share count, between 244  million  and 245  \nmillion , due to the $500 million  of baseline share repurchases we\u2019ve previously outlined.  \n \n Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n", "original_text": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dde943e27ec61f607fe9b05c712bd75dd06551e210a9f5dbc3a658e6c8ab03d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850afa52-2d1e-480a-893c-0b4732779109", "node_type": "1", "metadata": {"window": "These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "original_text": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n"}, "hash": "3b82c75c35b47993d1decb84b14b2b678822a74e14cd93da399005c9591dd214", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the long term, it is full speed ahead. ", "start_char_idx": 1505, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "850afa52-2d1e-480a-893c-0b4732779109": {"__data__": {"id_": "850afa52-2d1e-480a-893c-0b4732779109", "embedding": null, "metadata": {"window": "These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "original_text": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ad6423-7260-47a2-b9fa-d0211b809ef0", "node_type": "1", "metadata": {"window": "Finally, while we continue to expect to generate adjusted free cash flow of approximately $2  billion  on \naverage from fiscal 2024 to \u201826, we think it\u2019s important to call out that fiscal 2025 will be lower than \nthat average, primarily due to the large contract unwind, as well as quarter -end day of the week \ntiming.  These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "With respect to the long term, it is full speed ahead. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96749af0fedfa81885f65d8cda9650522c681143ee884b27a0edba5b95c3542a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d597be4-aad0-4258-9258-55c5780cd3a5", "node_type": "1", "metadata": {"window": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "original_text": "With that, I will turn it back over to Jason.  \n \n"}, "hash": "9fc8c99ec3641d2160ff122b1cd4f5ef34d3a8c28dd423b818e7399840d02dcf", "class_name": "RelatedNodeInfo"}}, "text": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "start_char_idx": 1560, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d597be4-aad0-4258-9258-55c5780cd3a5": {"__data__": {"id_": "1d597be4-aad0-4258-9258-55c5780cd3a5", "embedding": null, "metadata": {"window": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "original_text": "With that, I will turn it back over to Jason.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "850afa52-2d1e-480a-893c-0b4732779109", "node_type": "1", "metadata": {"window": "These dynamics will significantly influence our cash flow in Q1 of next year.  However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "original_text": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a07d33d651b6032a15bff9e740f95f10f9990bbede06a66fb0983f5ebe0c012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d03e3a09-b941-46f6-97c6-9a72e68279cf", "node_type": "1", "metadata": {"window": "With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "original_text": "Jason Hollar:  Thanks, Aaron. "}, "hash": "03c2ad0891439d4a3f9b8690058c4b451a6425748be758498e49c06dca4dbaa6", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will turn it back over to Jason.  \n \n", "start_char_idx": 1798, "end_char_idx": 1848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d03e3a09-b941-46f6-97c6-9a72e68279cf": {"__data__": {"id_": "d03e3a09-b941-46f6-97c6-9a72e68279cf", "embedding": null, "metadata": {"window": "With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "original_text": "Jason Hollar:  Thanks, Aaron. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d597be4-aad0-4258-9258-55c5780cd3a5", "node_type": "1", "metadata": {"window": "However, o ur \nstrong investment grade balance sheet positions us well to manage through these fluctuations.  \n \n With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "original_text": "With that, I will turn it back over to Jason.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc8dc0f887ec58938467874e492dbce27d29211620795126986e023566aa3375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35501589-1cbc-4b5a-96f8-627d66653f11", "node_type": "1", "metadata": {"window": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "original_text": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n"}, "hash": "e82019bd217962be71051b39d38b5d13c910b71d4079b2b2ad14cc3c971e55aa", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Aaron. ", "start_char_idx": 1848, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35501589-1cbc-4b5a-96f8-627d66653f11": {"__data__": {"id_": "35501589-1cbc-4b5a-96f8-627d66653f11", "embedding": null, "metadata": {"window": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "original_text": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d03e3a09-b941-46f6-97c6-9a72e68279cf", "node_type": "1", "metadata": {"window": "With respect to the long term, it is full speed ahead.  We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "original_text": "Jason Hollar:  Thanks, Aaron. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "897b040e05e5c17eee364314698bc50bf10976b4a2d81d45ffa12a1f5645f571", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f547df87-f536-41e3-9f53-eb2532f90c35", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "original_text": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. "}, "hash": "180aa3d4bde2b67c26d2c275c00d1c1260b0a6a63bb53f36500826efa720ac57", "class_name": "RelatedNodeInfo"}}, "text": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "start_char_idx": 1878, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f547df87-f536-41e3-9f53-eb2532f90c35": {"__data__": {"id_": "f547df87-f536-41e3-9f53-eb2532f90c35", "embedding": null, "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "original_text": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35501589-1cbc-4b5a-96f8-627d66653f11", "node_type": "1", "metadata": {"window": "We are reiterating our fiscal year \u2019 24 to \u201826 \ntargets for the enterprise and segments and  expect to deliver at least $7.50 of non -GAAP EPS in \nfiscal year \u2018 25, which reflects at least 30% total EPS growth on a two -year basis .   \n \n With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "original_text": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d73dbbf1e03a83d12a8d351962837164eca4583ec9b39fdfd1a7c5627883ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1b1324f-25cd-4510-a722-8181b0625359", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n"}, "hash": "b060cefee0998b8282a460a039d4948b186001577510a79fd1775ef581261f68", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "start_char_idx": 2079, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b1324f-25cd-4510-a722-8181b0625359": {"__data__": {"id_": "b1b1324f-25cd-4510-a722-8181b0625359", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f547df87-f536-41e3-9f53-eb2532f90c35", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "original_text": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b251864fa45ca9b592f4b8f83cf885d5b27536207ca1db0de6b391257d89c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ab7ad1a-73ff-4f18-8554-c4c276062e0a", "node_type": "1", "metadata": {"window": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. "}, "hash": "208d49f7a551da9fc3724f8be437cd23bb419a46dc02cf0d02b67fb04647cbec", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "start_char_idx": 2213, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ab7ad1a-73ff-4f18-8554-c4c276062e0a": {"__data__": {"id_": "7ab7ad1a-73ff-4f18-8554-c4c276062e0a", "embedding": null, "metadata": {"window": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1b1324f-25cd-4510-a722-8181b0625359", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f44c1c760d67977a9934d0d40dcf70fb38f6ae758676f531c7e5c11396b72659", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a2f9760-9bca-437e-8fdc-6e9dca3f4066", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. "}, "hash": "fbd2cef3ab312a677f957f38ed3bb9835c23bd594d0b282315cd00e3ce76adba", "class_name": "RelatedNodeInfo"}}, "text": "As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "start_char_idx": 2399, "end_char_idx": 2753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a2f9760-9bca-437e-8fdc-6e9dca3f4066": {"__data__": {"id_": "6a2f9760-9bca-437e-8fdc-6e9dca3f4066", "embedding": null, "metadata": {"window": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ab7ad1a-73ff-4f18-8554-c4c276062e0a", "node_type": "1", "metadata": {"window": "Now, for some additional perspective on our businesses, beginning \nwith Pharma ceutical and Specialty Solutions, where our focus remains executing in the core to build \nupon our strong foundation.  \n \n We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50239e054d57117489a1362a2115605a3004924871f6d2a77070255e0fcd1e7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6607325-9e23-4aad-96a4-9f0df0437758", "node_type": "1", "metadata": {"window": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n "}, "hash": "aad84caa9729ff222a28584c77e8a6109e0e5847e4bcd601c587607d0fbc631a", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "start_char_idx": 2753, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6607325-9e23-4aad-96a4-9f0df0437758": {"__data__": {"id_": "b6607325-9e23-4aad-96a4-9f0df0437758", "embedding": null, "metadata": {"window": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3133095d-d419-4f68-b29a-47abc408b487", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45f2fa05fd8da72a2568f57d8e6238f725ee74818518455c7965971d0fe91cb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a2f9760-9bca-437e-8fdc-6e9dca3f4066", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in our core business to drive operational efficiency and provide improved \ncustomer -focused capabilities.  At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies. ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41ba46001ac0566e75e9e58e62702667b9a8cf06fe1b3a441d52de7ab99ef048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f7c4eb-c377-492c-9a39-ed3e439a8bf2", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "original_text": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace. "}, "hash": "d981d273041fd0979fd372149a4fd390ae857c850bc0162f173fbfe453777c75", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "start_char_idx": 2933, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f7c4eb-c377-492c-9a39-ed3e439a8bf2": {"__data__": {"id_": "95f7c4eb-c377-492c-9a39-ed3e439a8bf2", "embedding": null, "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "original_text": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6607325-9e23-4aad-96a4-9f0df0437758", "node_type": "1", "metadata": {"window": "At the same time, we have been evolving our commercial engagement \nstrategies to get closer to the customer, better understan d their complex needs and provide proactive \nsolutions.  \n \n As an example, we\u2019ve highlighted our first -to-market clinically integrated supply chain, the Cardinal \nHealth InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry \nplatform to analyze real -time clinical and purchasing data t o help providers reduce costs, optimize \ndrug inventories, and streamline medication supply.  We\u2019ve also developed the Cardinal Health Atrix \u2122 \nElements offering, which is a suite of hospital reimbursement services that help improve hospitals\u2019 \nworkflows and ef ficiencies.  We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "original_text": "We\u2019ve driven tremendous progress in our services for health systems, \nleading to the successful onboarding of a new key customer and additional new health system \nbusiness coming in fiscal \u2018 25.  \n ", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32b1878b0f7ea2897c4fd1da181ab232dea15425ba9d225b9775e56d2f2305da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "222e43de-71ae-4ba3-ab72-ccf1ae192a45", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "original_text": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies. "}, "hash": "917ed0b9c6afb578df4eae28c9933dc83679b2434e6784a9ab94d3370d446203", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace. ", "start_char_idx": 0, "end_char_idx": 176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "222e43de-71ae-4ba3-ab72-ccf1ae192a45": {"__data__": {"id_": "222e43de-71ae-4ba3-ab72-ccf1ae192a45", "embedding": null, "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "original_text": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f7c4eb-c377-492c-9a39-ed3e439a8bf2", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "original_text": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d33e810fa86d3fc68bddf2c6096ca65c86a09d503a4a6de481585b7a65a7aa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2376659f-44d4-47b6-a167-00819593aacf", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "original_text": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n"}, "hash": "d216150293fc2efebfcc46977aa15dcc4826c75fe81291b38fbeb2995768c7ff", "class_name": "RelatedNodeInfo"}}, "text": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies. ", "start_char_idx": 176, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2376659f-44d4-47b6-a167-00819593aacf": {"__data__": {"id_": "2376659f-44d4-47b6-a167-00819593aacf", "embedding": null, "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "original_text": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "222e43de-71ae-4ba3-ab72-ccf1ae192a45", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "original_text": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fe042e0362fbd4178606a70f22d5051466d31559102c742ee14e1384b8d3c30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a3bc2a9-6473-4755-a9f0-a41f84fa9083", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "original_text": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. "}, "hash": "f45152ab00f6470bfe4993de6391220ea2b0bc4e5572953276f358a134079e7d", "class_name": "RelatedNodeInfo"}}, "text": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n", "start_char_idx": 435, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a3bc2a9-6473-4755-a9f0-a41f84fa9083": {"__data__": {"id_": "6a3bc2a9-6473-4755-a9f0-a41f84fa9083", "embedding": null, "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "original_text": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2376659f-44d4-47b6-a167-00819593aacf", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "original_text": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a121320efa4ad771902f013b191420e3c54ba5a479cf63cc2b500ec8def251c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc347c1e-2d9a-486a-b1f1-9a22676e13b8", "node_type": "1", "metadata": {"window": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "original_text": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n"}, "hash": "76ad8d6beb3ee893ac409fe5f981f3f0364c0870be35b10d34002f31e9b30c17", "class_name": "RelatedNodeInfo"}}, "text": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "start_char_idx": 718, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc347c1e-2d9a-486a-b1f1-9a22676e13b8": {"__data__": {"id_": "fc347c1e-2d9a-486a-b1f1-9a22676e13b8", "embedding": null, "metadata": {"window": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "original_text": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a3bc2a9-6473-4755-a9f0-a41f84fa9083", "node_type": "1", "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "original_text": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df4ca51fcddf62f21f7af9dcacaeba36a5160bc723f2885b72d3a5017e395025", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e956fdb-8f3c-41aa-b5b0-6de59385d869", "node_type": "1", "metadata": {"window": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "original_text": "Turning to Specialty, where we have and will continue to invest to accelerate our growth. "}, "hash": "baa3bbd6be2e531a91f9e44281bd985ac246be6aff371e7a4b1f476985dff707", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "start_char_idx": 828, "end_char_idx": 1016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e956fdb-8f3c-41aa-b5b0-6de59385d869": {"__data__": {"id_": "9e956fdb-8f3c-41aa-b5b0-6de59385d869", "embedding": null, "metadata": {"window": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "original_text": "Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc347c1e-2d9a-486a-b1f1-9a22676e13b8", "node_type": "1", "metadata": {"window": "Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "original_text": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "026ea0aa9bd19d04e16d232ab218804a5782a0e30ff077f1a9273d699ad072b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c55c3d-6c7f-457b-896a-9447d2f25ae5", "node_type": "1", "metadata": {"window": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "original_text": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n"}, "hash": "c09e41dbe910f9bb35a185e5d6648cfd5ea77c2f3d64b8aad7cc29b28adee939", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "start_char_idx": 1016, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c55c3d-6c7f-457b-896a-9447d2f25ae5": {"__data__": {"id_": "27c55c3d-6c7f-457b-896a-9447d2f25ae5", "embedding": null, "metadata": {"window": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "original_text": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e956fdb-8f3c-41aa-b5b0-6de59385d869", "node_type": "1", "metadata": {"window": "With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "original_text": "Turning to Specialty, where we have and will continue to invest to accelerate our growth. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6de241ac654fc39a8e74b5cece2ba07f7a0aa1bbe7750fe033a599887163bced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "794437ce-a716-47de-b591-e1c0364dd82d", "node_type": "1", "metadata": {"window": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "original_text": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. "}, "hash": "3e4947383e7ddc49cf220ce301b792925559b90baeed07c4611687e243f76dde", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "start_char_idx": 1106, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "794437ce-a716-47de-b591-e1c0364dd82d": {"__data__": {"id_": "794437ce-a716-47de-b591-e1c0364dd82d", "embedding": null, "metadata": {"window": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "original_text": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c55c3d-6c7f-457b-896a-9447d2f25ae5", "node_type": "1", "metadata": {"window": "We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business.  During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "original_text": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86793d651f631facc29bcad23c0a952a66887d18a09722c5b32088d6455030d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ea50913-7025-4840-8cb8-871c82d05377", "node_type": "1", "metadata": {"window": "Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "original_text": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n"}, "hash": "73f2798bb8102701b0785802b62f2a867d85d770c55d10a2ac155bb5c5b50cb6", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "start_char_idx": 1294, "end_char_idx": 1533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ea50913-7025-4840-8cb8-871c82d05377": {"__data__": {"id_": "1ea50913-7025-4840-8cb8-871c82d05377", "embedding": null, "metadata": {"window": "Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "original_text": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "794437ce-a716-47de-b591-e1c0364dd82d", "node_type": "1", "metadata": {"window": "During the quarter we deployed new sortation systems in a number of our distribution \ncenters, with a continual focus on employee safety, customer s ervice and operational efficiency.  \n \n Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "original_text": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a61ae274a79e58f4dbc214bd56f1e42cdc5b0679d00706fb20dd9f079a07e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df8b3c92-af93-4945-9839-f41198116245", "node_type": "1", "metadata": {"window": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "original_text": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. "}, "hash": "6fb36d50115038a07ce7a35392f823efe8344f9dc5e1d8b7f7cf0ce9146e4530", "class_name": "RelatedNodeInfo"}}, "text": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "start_char_idx": 1533, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df8b3c92-af93-4945-9839-f41198116245": {"__data__": {"id_": "df8b3c92-af93-4945-9839-f41198116245", "embedding": null, "metadata": {"window": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "original_text": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea50913-7025-4840-8cb8-871c82d05377", "node_type": "1", "metadata": {"window": "Turning to Specialty, where we have and will continue to invest to accelerate our growth.  As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "original_text": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09d4abde0c0fb16c5dcda698c85966a7cee7dabec388cd313b3a04f933afa5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee5fb38-c077-41b3-a62b-7ae517a51e9d", "node_type": "1", "metadata": {"window": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "original_text": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n"}, "hash": "21a65e9c42ae5d3e9eddfc802e69c3b7901b8b86fac9d6642f675303c00c82ef", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "start_char_idx": 1786, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee5fb38-c077-41b3-a62b-7ae517a51e9d": {"__data__": {"id_": "bee5fb38-c077-41b3-a62b-7ae517a51e9d", "embedding": null, "metadata": {"window": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "original_text": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df8b3c92-af93-4945-9839-f41198116245", "node_type": "1", "metadata": {"window": "As Aaron \nnoted, our integration of Specialty Networks is underway and the reaction from the providers we \nserve and the energy from our new teammates has been extremel y encouraging.  \n \n Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "original_text": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31c5a515571bd7ae378821982bb8009b47de9ffbee1c185145bb72aef3251c7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d0ba463-4f0b-424d-87b5-f65942ce447e", "node_type": "1", "metadata": {"window": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "original_text": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. "}, "hash": "1c081538578342595d62e4a7f3b2c9d4b520764c20fecae55ab9bb3c75e8090d", "class_name": "RelatedNodeInfo"}}, "text": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "start_char_idx": 2055, "end_char_idx": 2228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d0ba463-4f0b-424d-87b5-f65942ce447e": {"__data__": {"id_": "6d0ba463-4f0b-424d-87b5-f65942ce447e", "embedding": null, "metadata": {"window": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "original_text": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee5fb38-c077-41b3-a62b-7ae517a51e9d", "node_type": "1", "metadata": {"window": "Specialty Networks\u2019 mission as part of Cardinal Health remains creating clinical and economic value \nfor independent physicians by lowering costs, operating more efficiently, and helping them deliver \nbest-in-class care to their patients.  We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "original_text": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4847cecb1e9d29d3ed676d692223c9ffb5d4a4ac94ebf562d535d66704ee119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa048122-b246-4b02-8a57-9f6a5f06cbba", "node_type": "1", "metadata": {"window": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "original_text": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. "}, "hash": "4e5425389e98b11fcfc9331d549160e500fe858bb67f2250eda9da59ba3363fb", "class_name": "RelatedNodeInfo"}}, "text": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "start_char_idx": 2228, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa048122-b246-4b02-8a57-9f6a5f06cbba": {"__data__": {"id_": "fa048122-b246-4b02-8a57-9f6a5f06cbba", "embedding": null, "metadata": {"window": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "original_text": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d0ba463-4f0b-424d-87b5-f65942ce447e", "node_type": "1", "metadata": {"window": "We see greater oppo rtunities together, with the business\u2019 multi -\nspecialty platform, proprietary technology and deep clinical expertise being a natural extension of \nCardinal Health\u2019s suite of solutions for specialty practices across the country.  \n \n Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "original_text": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5561cb9db7665e73b50c828a377dd1854675f6e6ae6ace517ebe480a98c749b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a3341b5-cc37-4011-886d-422b31a2e354", "node_type": "1", "metadata": {"window": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "original_text": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n"}, "hash": "72ee8a6b2ac447bbb01602e0ffa7db63c5e5a7664dcc14ee27661ebdd4118ee0", "class_name": "RelatedNodeInfo"}}, "text": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "start_char_idx": 2409, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a3341b5-cc37-4011-886d-422b31a2e354": {"__data__": {"id_": "6a3341b5-cc37-4011-886d-422b31a2e354", "embedding": null, "metadata": {"window": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "original_text": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa048122-b246-4b02-8a57-9f6a5f06cbba", "node_type": "1", "metadata": {"window": "Specialty Networks expands our offerings with physicians in the areas of urology, GI, and \nrheumatology, while providing a proven platform in PPS Analytics that we\u2019ll further invest into in fiscal \n\u201825 and look to extend into other therapeutic areas, such as oncology.  The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "original_text": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a49d941ab0bfaf017c142ad170a134bb5017f7d768691a1566f8a1d5d875467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5", "node_type": "1", "metadata": {"window": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "original_text": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. "}, "hash": "b35232028edff10ea7f2e000a84c676ba7e2d2ceb82a32d6eb6aec3405d2cc56", "class_name": "RelatedNodeInfo"}}, "text": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "start_char_idx": 2557, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5": {"__data__": {"id_": "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5", "embedding": null, "metadata": {"window": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "original_text": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a3341b5-cc37-4011-886d-422b31a2e354", "node_type": "1", "metadata": {"window": "The platform\u2019s insight \ngeneration capabilities for clinicians are robust, which accelerates our upstream data and research \nopportunities with biopharma manufacturers.  \n \n We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "original_text": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f63135acf0a72bfdc0ef79dd27c73c6f05f5a7feeb98df18fb8ae3987a1c2055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3751aa-e286-446d-a10e-b6794921fd72", "node_type": "1", "metadata": {"window": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n"}, "hash": "c37efa16afec8298504a092a77bd442353c041cd77404623501fb1c6262ef884", "class_name": "RelatedNodeInfo"}}, "text": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "start_char_idx": 2718, "end_char_idx": 2833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3751aa-e286-446d-a10e-b6794921fd72": {"__data__": {"id_": "3d3751aa-e286-446d-a10e-b6794921fd72", "embedding": null, "metadata": {"window": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5", "node_type": "1", "metadata": {"window": "We see these and other capabilities as supporting our ongoing build -out of Navista \u2122, our clinician \ndesigned oncology practice alliance offering advanced services and technology.  Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "original_text": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d2abf686be5d57f199666658c0b89fb9577f692d80c8472911bb735ddb58661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86af24c0-9854-4dc5-b1b4-61893da9ee2c", "node_type": "1", "metadata": {"window": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n"}, "hash": "a10102c475d47c8bf7c0753544b16797b12fba6eb5085ea56785765b81fd7311", "class_name": "RelatedNodeInfo"}}, "text": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "start_char_idx": 2833, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86af24c0-9854-4dc5-b1b4-61893da9ee2c": {"__data__": {"id_": "86af24c0-9854-4dc5-b1b4-61893da9ee2c", "embedding": null, "metadata": {"window": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3751aa-e286-446d-a10e-b6794921fd72", "node_type": "1", "metadata": {"window": "Navista \u2019s\u2122 mission \nis to unlock the power of community oncologists to secure their independence and revolutionize \npatient -centered cancer care.  This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "500dd8c93173b05add4732017c158fe8ac040d3a296de5c06c9f91cf35cd18de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c76fe5e1-151f-4467-b207-cf5c83d4301b", "node_type": "1", "metadata": {"window": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. "}, "hash": "2a39317caa55cf4e41a4da8009a2eef83b4a0ee3e87511466d9f2e1f5377d625", "class_name": "RelatedNodeInfo"}}, "text": "Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "start_char_idx": 3043, "end_char_idx": 3247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c76fe5e1-151f-4467-b207-cf5c83d4301b": {"__data__": {"id_": "c76fe5e1-151f-4467-b207-cf5c83d4301b", "embedding": null, "metadata": {"window": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86af24c0-9854-4dc5-b1b4-61893da9ee2c", "node_type": "1", "metadata": {"window": "This build -out continues to progress according to plan, as we actively \npilot next generation technologies and capabilities with select oncology practices.  \n \n Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb7cd13f3a7b66ec7cae97e5475b1277917fe7db99ee9d5ff666b0cf77fb45a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5f20e95-c79b-4d43-91f0-ad6108697057", "node_type": "1", "metadata": {"window": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "And we\u2019ve seen our "}, "hash": "27d630c94cc41a7b42e92f283b677c125b0c9900def1ecd9b2f5531430cec95a", "class_name": "RelatedNodeInfo"}}, "text": "Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "start_char_idx": 3247, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5f20e95-c79b-4d43-91f0-ad6108697057": {"__data__": {"id_": "b5f20e95-c79b-4d43-91f0-ad6108697057", "embedding": null, "metadata": {"window": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "And we\u2019ve seen our ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79bdd048f5498d111911edc3712a4c34439af06b9b7916d6953a268f9229243", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c76fe5e1-151f-4467-b207-cf5c83d4301b", "node_type": "1", "metadata": {"window": "Upstream with manufacturers, we saw strong performance  from our Biopharma Solutions business \nduring the quarter.  With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aca7d0322b4fe7e6cee13b1514fadea80ee5ec1ca23f95b957e72c25d0b6638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c9aeddd-72ac-4580-9924-6a539e7fecc5", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "original_text": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n"}, "hash": "3bd2bcaa74ff2e856577fbb941d90f3f8af4ce20a719ccb601099c8519d6f684", "class_name": "RelatedNodeInfo"}}, "text": "And we\u2019ve seen our ", "start_char_idx": 3420, "end_char_idx": 3439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c9aeddd-72ac-4580-9924-6a539e7fecc5": {"__data__": {"id_": "0c9aeddd-72ac-4580-9924-6a539e7fecc5", "embedding": null, "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "original_text": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5f20e95-c79b-4d43-91f0-ad6108697057", "node_type": "1", "metadata": {"window": "With scaled assets, differentiated solutions and a tenured team of experts, our \nleading Specialty 3PL has supported 23 launches year -to-date through March, with more anticipated \nin the coming quart ers.  \n \n Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR -\nT cell and gene therapies years ago, and we continue to bring innovative services to the market.  \n \n Opening in May, our Advanced Therapy Innovation Center that features a deep -frozen storage suite \nwill support the complex storage requirements of cell and gene therapies.  And we\u2019ve seen our ", "original_text": "And we\u2019ve seen our ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0264d739b86a7021b2c774ba56c059085cdda664c876a2bbfe59eea1d19e817d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8331b69-13ef-43ab-90d5-627b4dafac56", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "original_text": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n"}, "hash": "1d242d43ee534fc2e0ffa02c974cd5adc83f4ccf215af66e00cb4be2408869c6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n", "start_char_idx": 0, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8331b69-13ef-43ab-90d5-627b4dafac56": {"__data__": {"id_": "f8331b69-13ef-43ab-90d5-627b4dafac56", "embedding": null, "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "original_text": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c9aeddd-72ac-4580-9924-6a539e7fecc5", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "original_text": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5cebfd4b1d6230fb9b718012470c9148f61ea692418550daa17e3e91abdf92b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85953dc3-664e-4b9e-a034-b43e66645a0a", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "original_text": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n"}, "hash": "f47fd11a7673e7ad5d66da684f5e18554ae7634f78614fdf9e056d5975b9cff8", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n", "start_char_idx": 174, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85953dc3-664e-4b9e-a034-b43e66645a0a": {"__data__": {"id_": "85953dc3-664e-4b9e-a034-b43e66645a0a", "embedding": null, "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "original_text": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8331b69-13ef-43ab-90d5-627b4dafac56", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "original_text": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b20f2db9aaa4b495d858ac6e8e7ef38c21c86e812890db8da06e8a9895c1bd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "009295a0-dc92-477d-bcd7-9ee08765c687", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "original_text": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n"}, "hash": "6485610306c03f38faa959fc4d3e29b7fc37f2b820a12aba8c17b8a2d486edde", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n", "start_char_idx": 410, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "009295a0-dc92-477d-bcd7-9ee08765c687": {"__data__": {"id_": "009295a0-dc92-477d-bcd7-9ee08765c687", "embedding": null, "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "original_text": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85953dc3-664e-4b9e-a034-b43e66645a0a", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "original_text": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83455e6371d9a2e077cfc92f4851e64a6cfcce46d9d8b9328b5c4b3d251939f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "617bb2d2-a0f2-4519-97d7-363f6c59b18d", "node_type": "1", "metadata": {"window": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S. ", "original_text": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. "}, "hash": "59f806de4613a6029b69b5a8c65e9d8e1332a81044b501080a5180619aee2c3b", "class_name": "RelatedNodeInfo"}}, "text": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "start_char_idx": 505, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "617bb2d2-a0f2-4519-97d7-363f6c59b18d": {"__data__": {"id_": "617bb2d2-a0f2-4519-97d7-363f6c59b18d", "embedding": null, "metadata": {"window": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S. ", "original_text": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "009295a0-dc92-477d-bcd7-9ee08765c687", "node_type": "1", "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "original_text": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "253d3a8f06ab2e30db747466062bb45845185718f05980a61afd10648ebcd731", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec864a2-8d76-4657-a6c2-e11a77359a7f", "node_type": "1", "metadata": {"window": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "original_text": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n"}, "hash": "3a9f5c0ff32ecd6e3d4433b6b12ef8f29d6bf670d0affa77f8099338da89ca58", "class_name": "RelatedNodeInfo"}}, "text": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "start_char_idx": 758, "end_char_idx": 869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec864a2-8d76-4657-a6c2-e11a77359a7f": {"__data__": {"id_": "5ec864a2-8d76-4657-a6c2-e11a77359a7f", "embedding": null, "metadata": {"window": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "original_text": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "617bb2d2-a0f2-4519-97d7-363f6c59b18d", "node_type": "1", "metadata": {"window": "Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S. ", "original_text": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98a7c228edbc876b1420d6d86a92d5b34a36f8af41c6691d8aa5b2a20fb1791e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd5bd418-d396-460c-833c-4659020ac4d0", "node_type": "1", "metadata": {"window": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "original_text": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. "}, "hash": "3dbc3b6d8f4dfc969ec660da866f020ac49ff145f17736033f1112e67a761d2d", "class_name": "RelatedNodeInfo"}}, "text": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "start_char_idx": 869, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd5bd418-d396-460c-833c-4659020ac4d0": {"__data__": {"id_": "dd5bd418-d396-460c-833c-4659020ac4d0", "embedding": null, "metadata": {"window": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "original_text": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec864a2-8d76-4657-a6c2-e11a77359a7f", "node_type": "1", "metadata": {"window": "During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "original_text": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c9e804a6670b3b6b39e9db569b0e2044ca27375665f76d8dfd964cf3810f64c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e", "node_type": "1", "metadata": {"window": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "original_text": "Our customer loyalty index score for U.S. "}, "hash": "06234ac11b537d3a93db8f39b4a30939e777c213370e6dbc4aaac1dd4a17f68b", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "start_char_idx": 990, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e": {"__data__": {"id_": "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e", "embedding": null, "metadata": {"window": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "original_text": "Our customer loyalty index score for U.S. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd5bd418-d396-460c-833c-4659020ac4d0", "node_type": "1", "metadata": {"window": "Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "original_text": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1550ef2c006432859a87053f4545c5721b3e8e5c77d228e46443d5d945cd6e49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94beb6dd-f233-4c08-9b88-790fe46726bb", "node_type": "1", "metadata": {"window": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "original_text": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. "}, "hash": "283c9a7126130f8f293b4192a96e0fe8c1dbc79b877a584b29b4f8ebce01a600", "class_name": "RelatedNodeInfo"}}, "text": "Our customer loyalty index score for U.S. ", "start_char_idx": 1133, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94beb6dd-f233-4c08-9b88-790fe46726bb": {"__data__": {"id_": "94beb6dd-f233-4c08-9b88-790fe46726bb", "embedding": null, "metadata": {"window": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "original_text": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e", "node_type": "1", "metadata": {"window": "We were pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our \nbusiness.  We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "original_text": "Our customer loyalty index score for U.S. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2c95a43c739ac5f8ef511e41a2084f642bb899ee3157a3c4865aad3bfc5c249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e5753f3-3888-4bcf-affa-95ebdb229e8a", "node_type": "1", "metadata": {"window": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "original_text": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n"}, "hash": "d17b283b00b0c646706956030f856188fb8b0d3ffc640a34d2b58bca0b7b46ea", "class_name": "RelatedNodeInfo"}}, "text": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "start_char_idx": 1175, "end_char_idx": 1304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e5753f3-3888-4bcf-affa-95ebdb229e8a": {"__data__": {"id_": "1e5753f3-3888-4bcf-affa-95ebdb229e8a", "embedding": null, "metadata": {"window": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "original_text": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94beb6dd-f233-4c08-9b88-790fe46726bb", "node_type": "1", "metadata": {"window": "We saw growth across Cardinal Health Brand and core distribution, and in our domestic \nand international businesses.  \n \n Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "original_text": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d441f7563b0fa482a8d163dae4822fc821475c09a6d3aa014133370eda74c7c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30", "node_type": "1", "metadata": {"window": "Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "original_text": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n"}, "hash": "baa105cfdf356844373de36e4969303831d3c6871c85739e3ae7b00308d196d7", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "start_char_idx": 1304, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30": {"__data__": {"id_": "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30", "embedding": null, "metadata": {"window": "Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "original_text": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e5753f3-3888-4bcf-affa-95ebdb229e8a", "node_type": "1", "metadata": {"window": "Specifically, our five -point plan to grow Cardinal Health Brand volumes continues to show positive \ntrends across the key leading indicators.  Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "original_text": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3caefb457b0dbe8710bd7a0381fb88456fe0634fe5d64c98f17e94d1f82a666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba511882-e2a3-46e4-b338-f5cbf3a98396", "node_type": "1", "metadata": {"window": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "original_text": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. "}, "hash": "0d49f5d55522c0cd3c656470c4cc34c87d268768a16366b9b8a58a7ee38e5c7a", "class_name": "RelatedNodeInfo"}}, "text": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "start_char_idx": 1452, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba511882-e2a3-46e4-b338-f5cbf3a98396": {"__data__": {"id_": "ba511882-e2a3-46e4-b338-f5cbf3a98396", "embedding": null, "metadata": {"window": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "original_text": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30", "node_type": "1", "metadata": {"window": "Our customer loyalty index score for U.S.  Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "original_text": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "049cb5e7b1c9eec73178b85c3853fa16aaf3bb7c5ac8b56f5c8ca988d550248e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f00f3da-fc11-43d3-9395-dd90e2419e12", "node_type": "1", "metadata": {"window": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "original_text": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n"}, "hash": "8074bda10e8ab31581ea0b27c2f645b763e4cb811044cfb7832e548c4b73ad43", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "start_char_idx": 1667, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f00f3da-fc11-43d3-9395-dd90e2419e12": {"__data__": {"id_": "5f00f3da-fc11-43d3-9395-dd90e2419e12", "embedding": null, "metadata": {"window": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "original_text": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba511882-e2a3-46e4-b338-f5cbf3a98396", "node_type": "1", "metadata": {"window": "Distribution has \nincreased by 14 points in the past two years and is up o ver 20 points from its pandemic low a few \nyears ago.  We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "original_text": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62189cbb3b122c68acbf3f0391d35175ab84836567b2daf0ddcc5d26fb985371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c712732-ce3e-468c-9bcc-051f3efa0188", "node_type": "1", "metadata": {"window": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "original_text": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n"}, "hash": "90854b7c62ef1b5ad1c93d0ece57eb69d1f48ad6cc6f30291d844d9f145c8185", "class_name": "RelatedNodeInfo"}}, "text": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "start_char_idx": 1767, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c712732-ce3e-468c-9bcc-051f3efa0188": {"__data__": {"id_": "9c712732-ce3e-468c-9bcc-051f3efa0188", "embedding": null, "metadata": {"window": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "original_text": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f00f3da-fc11-43d3-9395-dd90e2419e12", "node_type": "1", "metadata": {"window": "We\u2019ve successfully retained key distribution customers, and the team is gearing up for \nsome new customer implementations in the months ahead.  \n  \n Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "original_text": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b55b6e44835d022e956d46502fd85cf83dabd2eabf2c4df87404298af676a71f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1c2c702-ce00-4234-9edf-627e0ac96958", "node_type": "1", "metadata": {"window": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. "}, "hash": "32c4b8cdde4f7217db29458f148b17943c683dafe123f0f4df5b8a08e8b56be0", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "start_char_idx": 1983, "end_char_idx": 2165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1c2c702-ce00-4234-9edf-627e0ac96958": {"__data__": {"id_": "a1c2c702-ce00-4234-9edf-627e0ac96958", "embedding": null, "metadata": {"window": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c712732-ce3e-468c-9bcc-051f3efa0188", "node_type": "1", "metadata": {"window": "Our product backorders remain  near multi -year lows, and we\u2019ve continued to develop and \ncommercialize new products such as our Kendall Pediatric Sleeve to prevent deep vein thrombosis \nrisk in young patients.  \n \n We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "original_text": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e6676cef69aa1cbeba8809a4dbfdab4e486c4e13d9ea5cbb096e8f8c011c4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e100d9-95e5-45ed-9c09-c1908740d54f", "node_type": "1", "metadata": {"window": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "original_text": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n"}, "hash": "676237093cb555c4044e4bcd7f763b3319db456e587675be5c00bbb3219efc6a", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "start_char_idx": 2165, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e100d9-95e5-45ed-9c09-c1908740d54f": {"__data__": {"id_": "79e100d9-95e5-45ed-9c09-c1908740d54f", "embedding": null, "metadata": {"window": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "original_text": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1c2c702-ce00-4234-9edf-627e0ac96958", "node_type": "1", "metadata": {"window": "We\u2019ve  noted our investments in the resiliency of our supply chain to better service our customers.  In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5ea9c8cc2a0481a31938b303b17bf1e3c0000593d98da92f847e86b777926d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182ebc49-b649-433a-9aed-0a8c3d633331", "node_type": "1", "metadata": {"window": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. "}, "hash": "1eeb2b6f08bc4128691f6d1b7139fc9b9d033bb1b806976c67763654d50486ce", "class_name": "RelatedNodeInfo"}}, "text": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "start_char_idx": 2362, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182ebc49-b649-433a-9aed-0a8c3d633331": {"__data__": {"id_": "182ebc49-b649-433a-9aed-0a8c3d633331", "embedding": null, "metadata": {"window": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e100d9-95e5-45ed-9c09-c1908740d54f", "node_type": "1", "metadata": {"window": "In \nQ3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare \nIndustry Resiliency Collaborative\u2019s Resiliency Badge progr am, a key industry benchmark of our \nprogress.  \n \n Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "original_text": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e20f6117b2f098545fe4eb40f37d487e0a1726de88f7f966be6bcf8cd946d940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6735cac7-d542-48ea-b2ea-534afcfd718e", "node_type": "1", "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. "}, "hash": "418fe7f1e2fbf9806902c71216661228d5ba6fcf9a6bdefd570f2874d0c6eadc", "class_name": "RelatedNodeInfo"}}, "text": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "start_char_idx": 2600, "end_char_idx": 2715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6735cac7-d542-48ea-b2ea-534afcfd718e": {"__data__": {"id_": "6735cac7-d542-48ea-b2ea-534afcfd718e", "embedding": null, "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182ebc49-b649-433a-9aed-0a8c3d633331", "node_type": "1", "metadata": {"window": "Finally, we are executing our simplification initiatives across our business, with a continued focus on \noptimizing our cost structure and global manufacturing and supply chain.  \n \n In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00fa25c2c947d94d267c3b44664cb58bb74664bd06f214873b3a2d180cb4fb9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f073d2d0-09e0-4c39-b761-38cf89681956", "node_type": "1", "metadata": {"window": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. "}, "hash": "c8fa564a3e96260c48a5ce325fa2a1f84107a0a3ff5b8c789782ab238475a10f", "class_name": "RelatedNodeInfo"}}, "text": "The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "start_char_idx": 2715, "end_char_idx": 2914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f073d2d0-09e0-4c39-b761-38cf89681956": {"__data__": {"id_": "f073d2d0-09e0-4c39-b761-38cf89681956", "embedding": null, "metadata": {"window": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6735cac7-d542-48ea-b2ea-534afcfd718e", "node_type": "1", "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re realizing continued double -digit growth in \ntheranostics, driven by the successful launch execution of new and advanced theranostics in \noncology.  For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b2c17c9f58c65340d552775b164b1b870b4c409647237339e2002a7f4e94abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cee9ad58-e9d8-46b5-a9cc-ee89112cd301", "node_type": "1", "metadata": {"window": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As we look into the future, when you consider the strength of the "}, "hash": "b6577c1a17ee461e568051e0657db9186ff7f8b6b61d2acb48aa8f54abf8232e", "class_name": "RelatedNodeInfo"}}, "text": "As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "start_char_idx": 2914, "end_char_idx": 3040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cee9ad58-e9d8-46b5-a9cc-ee89112cd301": {"__data__": {"id_": "cee9ad58-e9d8-46b5-a9cc-ee89112cd301", "embedding": null, "metadata": {"window": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As we look into the future, when you consider the strength of the ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d153a6de4cbfc152a60249ffefefd7c4c1d896d163036b65e666bb8170418db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f073d2d0-09e0-4c39-b761-38cf89681956", "node_type": "1", "metadata": {"window": "For example, we have realized meaningful growth in fiscal \u2018 24 from the adoption and \ngrowing demand of prostate cancer radiodiagnostics, which are an important tool for healthcare \nproviders to assess and properly treat the disease.  \n \n We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25. ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3daec311133b5c07ca6f248db475cabf3d62d3246c21390cae3a07d7c077881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27deab52-26cc-42bf-912e-e4bffcff5d31", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "original_text": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n"}, "hash": "2506a96afbdb405804e868292fcb1eaf5cc3e2e65d597e5363d5a9737a3e4cba", "class_name": "RelatedNodeInfo"}}, "text": "As we look into the future, when you consider the strength of the ", "start_char_idx": 3040, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27deab52-26cc-42bf-912e-e4bffcff5d31": {"__data__": {"id_": "27deab52-26cc-42bf-912e-e4bffcff5d31", "embedding": null, "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "original_text": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cee9ad58-e9d8-46b5-a9cc-ee89112cd301", "node_type": "1", "metadata": {"window": "We see a large, growing and diversified pipeline, positioning our business to deliver value long into \nthe future.  The pipeline consists of more than 60 opportunities across oncology, cardiology and \nneurology that are either contracted, in negotiations, or being actively explored with pharmaceutical \ncompanies.  As an example, in oncology, we look forward to expanding our support of novel prostate \nradioligand therapies in fiscal \u2018 25.  As we look into the future, when you consider the strength of the ", "original_text": "As we look into the future, when you consider the strength of the ", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e473f2bf69198302bd4509d3f58c44511baba7b5e5cea99cac032f70a66af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7106b6a3-4404-4375-91b0-953321878261", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "original_text": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home. "}, "hash": "c1d3cb34d16d66557c2fe080f6032dadcced6fa0b0c2a144cc4562f1d1cacfba", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n", "start_char_idx": 0, "end_char_idx": 161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7106b6a3-4404-4375-91b0-953321878261": {"__data__": {"id_": "7106b6a3-4404-4375-91b0-953321878261", "embedding": null, "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "original_text": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27deab52-26cc-42bf-912e-e4bffcff5d31", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "original_text": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddcf1b7334b7c07fa4208162372d43efbaac5207f8f287697b987b8d683d98fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d593740d-98ae-4539-afab-f6ed36a05a9d", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "original_text": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today. "}, "hash": "94c3a13acad4835602dac1929745e84c32b9c7122a3335dfb35762dee953ca04", "class_name": "RelatedNodeInfo"}}, "text": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home. ", "start_char_idx": 161, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d593740d-98ae-4539-afab-f6ed36a05a9d": {"__data__": {"id_": "d593740d-98ae-4539-afab-f6ed36a05a9d", "embedding": null, "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "original_text": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7106b6a3-4404-4375-91b0-953321878261", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "original_text": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caca3097ceed48c795af4bc3043da2667c73651b52ad948d8f463f716f94576c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a0e986d-b9a9-4810-87f6-67d1830017bc", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "original_text": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. "}, "hash": "110420622c778d377d6ebafcb9e2d886710f331348c361f9eb378af452df100a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today. ", "start_char_idx": 325, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a0e986d-b9a9-4810-87f6-67d1830017bc": {"__data__": {"id_": "1a0e986d-b9a9-4810-87f6-67d1830017bc", "embedding": null, "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "original_text": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d593740d-98ae-4539-afab-f6ed36a05a9d", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "original_text": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea237872ada753e7bb366004b715b52ca0d69cbe7b4ac758241ea930dc072b22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed5457ff-ab0c-4a34-846b-6a5739473b55", "node_type": "1", "metadata": {"window": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "original_text": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n"}, "hash": "7b537c2dbdc4c9820508b3d916d375e11b7e574b9cac110d3f63b179107ba828", "class_name": "RelatedNodeInfo"}}, "text": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "start_char_idx": 497, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed5457ff-ab0c-4a34-846b-6a5739473b55": {"__data__": {"id_": "ed5457ff-ab0c-4a34-846b-6a5739473b55", "embedding": null, "metadata": {"window": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "original_text": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0e986d-b9a9-4810-87f6-67d1830017bc", "node_type": "1", "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "original_text": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd2d2a1b572e2c5bd9368bcf5769b3b6014d60c03be2be86751cc48eb92d3d3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a470aee8-fb88-49e7-b5b0-13ac32088639", "node_type": "1", "metadata": {"window": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "original_text": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n"}, "hash": "fa4e58186e6a11dac5cdde6a428dce93f86d169f0d44886893a4056e0ff88fd7", "class_name": "RelatedNodeInfo"}}, "text": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "start_char_idx": 679, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a470aee8-fb88-49e7-b5b0-13ac32088639": {"__data__": {"id_": "a470aee8-fb88-49e7-b5b0-13ac32088639", "embedding": null, "metadata": {"window": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "original_text": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed5457ff-ab0c-4a34-846b-6a5739473b55", "node_type": "1", "metadata": {"window": "Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "original_text": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40384d66a382de500055a298910ccb46d5abe283511e7131e457b838cbc53fe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd98777-422a-4102-8336-d023acaeef87", "node_type": "1", "metadata": {"window": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n", "original_text": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. "}, "hash": "75461b2d555888f1aecc873a899b54e04d1afa8e19d809f385dc1ee11e953b6e", "class_name": "RelatedNodeInfo"}}, "text": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "start_char_idx": 890, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd98777-422a-4102-8336-d023acaeef87": {"__data__": {"id_": "bbd98777-422a-4102-8336-d023acaeef87", "embedding": null, "metadata": {"window": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n", "original_text": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a470aee8-fb88-49e7-b5b0-13ac32088639", "node_type": "1", "metadata": {"window": "We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "original_text": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50e66f6b068460b59582ba7b0d733f3c4189fc443cd73604df56ba32c0f85685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982", "node_type": "1", "metadata": {"window": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "original_text": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. "}, "hash": "70109f2e5da48aaf842e369a87899773853a8b9abc67bda5d2ebe304277a4cf4", "class_name": "RelatedNodeInfo"}}, "text": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "start_char_idx": 1093, "end_char_idx": 1203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982": {"__data__": {"id_": "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982", "embedding": null, "metadata": {"window": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "original_text": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd98777-422a-4102-8336-d023acaeef87", "node_type": "1", "metadata": {"window": "Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology.  W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n", "original_text": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "235c8666dd300128c5ec1b8d3c5de8e54f218b18a7a8736e9ade3bc45ee10805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f2961c8-df8a-40ce-91ee-a790d20f7199", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "original_text": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n"}, "hash": "793c888329eee9d7e210d49209ead084696c4b9384182d30e4dbf9074a0713dc", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "start_char_idx": 1203, "end_char_idx": 1350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f2961c8-df8a-40ce-91ee-a790d20f7199": {"__data__": {"id_": "6f2961c8-df8a-40ce-91ee-a790d20f7199", "embedding": null, "metadata": {"window": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "original_text": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982", "node_type": "1", "metadata": {"window": "W e\u2019re excited that our new distribution center being built in South Carolina, \nfeaturing the fastest order fulfillment system per square foot in the market, is scheduled to open by \nearly next fiscal year.  \n \n In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "original_text": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc5cbd457450ebffb8213404657c5654f4242c8e257551e1643a4c844250042f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3046171a-cae0-4f38-8577-70d15dc747ec", "node_type": "1", "metadata": {"window": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "original_text": "Across our businesses, opportunities are everywhere we look.  \n \n"}, "hash": "7792d131a81757283848bc5b746690f35d727c42538e3f8f09b251cf8e8e11df", "class_name": "RelatedNodeInfo"}}, "text": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "start_char_idx": 1350, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3046171a-cae0-4f38-8577-70d15dc747ec": {"__data__": {"id_": "3046171a-cae0-4f38-8577-70d15dc747ec", "embedding": null, "metadata": {"window": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "original_text": "Across our businesses, opportunities are everywhere we look.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f2961c8-df8a-40ce-91ee-a790d20f7199", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae Logistics, we continue to hear from our customers the value our TotalVue \u2122 Insights \ntechnology platform is providing as they seek to control their shipping spend and drive performance. \n Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "original_text": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d780aac498acc201db34f92550cddc9d02f75acac804f8ae1f2f40fed7bd163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc036459-de3b-4e1a-83dd-d300a7cb9b7c", "node_type": "1", "metadata": {"window": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "original_text": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n"}, "hash": "5a95f637d204fee75e1eafcc433dc2d0543f38fd21d98cc477d27362c38bb886", "class_name": "RelatedNodeInfo"}}, "text": "Across our businesses, opportunities are everywhere we look.  \n \n", "start_char_idx": 1520, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc036459-de3b-4e1a-83dd-d300a7cb9b7c": {"__data__": {"id_": "dc036459-de3b-4e1a-83dd-d300a7cb9b7c", "embedding": null, "metadata": {"window": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "original_text": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3046171a-cae0-4f38-8577-70d15dc747ec", "node_type": "1", "metadata": {"window": "Our technology provides action -driving analytics and benchmarks, with shipping status and delay \nvisibility.  We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "original_text": "Across our businesses, opportunities are everywhere we look.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77e81a24efbc888ce6817900d2bd46c4ff0eb09cbbd85a0ed47ac9143fc2292d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fe8d05e-364c-432c-ac5f-d72147fc9ccb", "node_type": "1", "metadata": {"window": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "original_text": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. "}, "hash": "7685e011b9ed31a11a955b591fcf68b468a68d1b3b3f03ff201a698d2f7e034e", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "start_char_idx": 1585, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fe8d05e-364c-432c-ac5f-d72147fc9ccb": {"__data__": {"id_": "2fe8d05e-364c-432c-ac5f-d72147fc9ccb", "embedding": null, "metadata": {"window": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "original_text": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc036459-de3b-4e1a-83dd-d300a7cb9b7c", "node_type": "1", "metadata": {"window": "We continue to invest in new technolo gy-driven solutions, and true to our commitment to \ninnovation, we collaborate side -by-side with customers.  For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "original_text": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ab612ffa6a97f029ea48a4facf25d59690eeb5fcc08e84c554250d8bf3a5f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0388045-3752-4621-81d8-326efe251625", "node_type": "1", "metadata": {"window": "Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "original_text": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n"}, "hash": "35887889f8dc0d48d5fb851215ca3e85b3beff90f6685e1115603649f97f29cc", "class_name": "RelatedNodeInfo"}}, "text": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "start_char_idx": 1823, "end_char_idx": 1930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0388045-3752-4621-81d8-326efe251625": {"__data__": {"id_": "e0388045-3752-4621-81d8-326efe251625", "embedding": null, "metadata": {"window": "Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "original_text": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fe8d05e-364c-432c-ac5f-d72147fc9ccb", "node_type": "1", "metadata": {"window": "For example, this quarter, we successfully \nco-developed and introduced a tailored pharmacy shipping solution with a strategic customer, across \nmultiple facilities.  \n \n Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "original_text": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "384ef4151bcc8750d586fef20fe5bd56bb2367aa31400a8b529eefc32b71f8e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4730ecc1-2271-44f5-85b4-5e221e1aeb78", "node_type": "1", "metadata": {"window": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n", "original_text": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. "}, "hash": "86d4a1d7eac13cf6d1ddfaa0f09538f8e253c0222a7eb36dbaa61e4e72f4309c", "class_name": "RelatedNodeInfo"}}, "text": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "start_char_idx": 1930, "end_char_idx": 2070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4730ecc1-2271-44f5-85b4-5e221e1aeb78": {"__data__": {"id_": "4730ecc1-2271-44f5-85b4-5e221e1aeb78", "embedding": null, "metadata": {"window": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n", "original_text": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0388045-3752-4621-81d8-326efe251625", "node_type": "1", "metadata": {"window": "Across our businesses, opportunities are everywhere we look.  \n \n We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "original_text": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fb0139a845f9ded073e3ae2b3f49ec6fee67dfab0dba6d68566b56e20c6456e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1edf9823-401e-433b-990b-695bbfcf92e8", "node_type": "1", "metadata": {"window": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "original_text": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n"}, "hash": "014fc9c70101352aa28e7632ce9179c1637e3dccc46f201fc298cb62480eee1e", "class_name": "RelatedNodeInfo"}}, "text": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "start_char_idx": 2070, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1edf9823-401e-433b-990b-695bbfcf92e8": {"__data__": {"id_": "1edf9823-401e-433b-990b-695bbfcf92e8", "embedding": null, "metadata": {"window": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "original_text": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4730ecc1-2271-44f5-85b4-5e221e1aeb78", "node_type": "1", "metadata": {"window": "We\u2019ve affirmed our long -term targets for the enterprise and segments, which reflects Cardinal \nHealth\u2019s ability to achieve sustained growth and deliver attractive returns for shareholders through an \nongoing focus on value creation.  \n \n We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n", "original_text": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ebf2054114e1831b6ca66a30d295534c4e4369a04bdd10fa28d8b95bc5ef00f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08437907-3f20-4bba-b9db-d366264380ac", "node_type": "1", "metadata": {"window": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "original_text": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. "}, "hash": "07a6553b8ac337c367ee33aad4dec5bb6b551afc5af780adba94fcf7cb9e2bec", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "start_char_idx": 2234, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08437907-3f20-4bba-b9db-d366264380ac": {"__data__": {"id_": "08437907-3f20-4bba-b9db-d366264380ac", "embedding": null, "metadata": {"window": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "original_text": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1edf9823-401e-433b-990b-695bbfcf92e8", "node_type": "1", "metadata": {"window": "We continue to prioritize the prudent management of our balance sheet and responsible capital \nallocation.  We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "original_text": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acfe42901af9d2a34cbb2b5eaf381ebc69e585f93f109cac4e2d0b2d235cd2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "383e2741-3615-4522-8986-0935295cef03", "node_type": "1", "metadata": {"window": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "original_text": "We have no further updates to share today, but plan to keep you apprised of our progress. \n"}, "hash": "3e85d92d6f7cb25471868227831f65fb956bb13178b558c2b1e24a63bfac6ffb", "class_name": "RelatedNodeInfo"}}, "text": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "start_char_idx": 2405, "end_char_idx": 2507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "383e2741-3615-4522-8986-0935295cef03": {"__data__": {"id_": "383e2741-3615-4522-8986-0935295cef03", "embedding": null, "metadata": {"window": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "original_text": "We have no further updates to share today, but plan to keep you apprised of our progress. \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08437907-3f20-4bba-b9db-d366264380ac", "node_type": "1", "metadata": {"window": "We remain well -positioned with the financial flexibility to continue investing in our business \nand returning capital to shareholders.  \n \n As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "original_text": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "547b10e91d5d621477822450f45a6753e7d742cb5657dd710a07a69d565cbd4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1", "node_type": "1", "metadata": {"window": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n"}, "hash": "45d9e346c46e63ceb8c671f9435eb6b1fe43ea5777012b46e71794f05fb304c6", "class_name": "RelatedNodeInfo"}}, "text": "We have no further updates to share today, but plan to keep you apprised of our progress. \n", "start_char_idx": 2507, "end_char_idx": 2598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1": {"__data__": {"id_": "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1", "embedding": null, "metadata": {"window": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "383e2741-3615-4522-8986-0935295cef03", "node_type": "1", "metadata": {"window": "As part of our simplification journey, we are taking proactive actions to optimize our future cost \nstructure and enhance our ability to grow well into the future.  During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "original_text": "We have no further updates to share today, but plan to keep you apprised of our progress. \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9293e42ed286117059728fb217a0c051eb94f7c1e159f74136da8c335b107e57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e790cd7-3cbc-4854-bdb4-6da8030ff200", "node_type": "1", "metadata": {"window": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. "}, "hash": "d7d0d72a491f4ec254acd1c310715bfff626b28d1ea7601acc23d6db303a8288", "class_name": "RelatedNodeInfo"}}, "text": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "start_char_idx": 2598, "end_char_idx": 2708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e790cd7-3cbc-4854-bdb4-6da8030ff200": {"__data__": {"id_": "1e790cd7-3cbc-4854-bdb4-6da8030ff200", "embedding": null, "metadata": {"window": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1", "node_type": "1", "metadata": {"window": "During the quarter, we took substantial \nsteps to reduce our corporate real estate footprint a nd reorganized certain teams for greater \nefficiency and effectiveness.  \n \n Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaf6cafbded725d6b71035903585f080d12d3d109e0bbefcf7e7e3be941e99b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc49eee-38ae-464a-b1da-cda2e861acf9", "node_type": "1", "metadata": {"window": "We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. "}, "hash": "0b49e27dc5ba266dd7e6089f59ec7a1ee9ad8f44018276620072bd1c5df89598", "class_name": "RelatedNodeInfo"}}, "text": "To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "start_char_idx": 2708, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc49eee-38ae-464a-b1da-cda2e861acf9": {"__data__": {"id_": "8fc49eee-38ae-464a-b1da-cda2e861acf9", "embedding": null, "metadata": {"window": "We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e790cd7-3cbc-4854-bdb4-6da8030ff200", "node_type": "1", "metadata": {"window": "Our Business Review Committee continues to make progress on our ongoing review of the GMPD \nbusiness.  We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a28795d8c516802332ca9907fb48f7bb38eee27f4cf50f95fd0267c81670d0a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "997b7368-b697-4809-950a-3ee34b4ed5e1", "node_type": "1", "metadata": {"window": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  "}, "hash": "2800d5aac4a756dfbc654664c39aed0888aaa0a83ded584145c158ae8591ba31", "class_name": "RelatedNodeInfo"}}, "text": "Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "start_char_idx": 2818, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "997b7368-b697-4809-950a-3ee34b4ed5e1": {"__data__": {"id_": "997b7368-b697-4809-950a-3ee34b4ed5e1", "embedding": null, "metadata": {"window": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96113e461878eec0159f9b3674ef2ac785f35747617bdfa31bbeaaf538f01f25", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc49eee-38ae-464a-b1da-cda2e861acf9", "node_type": "1", "metadata": {"window": "We have no further updates to share today, but plan to keep you apprised of our progress. \n Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders. ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d1d86b8c1cab39d92970bd7244f0af66e4c72aec1c73404646481b3cf51cc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5470e70c-642c-4cb1-88ca-5943c32d0f29", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] . ", "original_text": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n"}, "hash": "43e3a544726da67a01436f6e0f9e725408003e984fbb5f530dabe39a4ed12996", "class_name": "RelatedNodeInfo"}}, "text": "None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "start_char_idx": 2949, "end_char_idx": 3152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5470e70c-642c-4cb1-88ca-5943c32d0f29": {"__data__": {"id_": "5470e70c-642c-4cb1-88ca-5943c32d0f29", "embedding": null, "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] . ", "original_text": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "997b7368-b697-4809-950a-3ee34b4ed5e1", "node_type": "1", "metadata": {"window": "Driving the improvement plan remains the near -term priority, and the team is making excellent \nprogress.  \n \n To close, we\u2019ve had a strong first three quarters of the year and are focused on sprinting through the \ntape.  Plans are in place to deliver growth in fiscal \u2018 25 and beyond, and we\u2019re eager to continue \ndelivering for our many stakeholders.  None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "original_text": "None of this would be possible without our highly -engaged and \ntalented team, who continues to lean in, drive our company forward, and fulfill our critical role as \nhealthcare\u2019s  most trusted partner.  ", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19e3fb71d217674fdeb0f5a873b5aba3947a408ed7a8c8e62f93a1576a0c599b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "921a49cd-35b0-4bca-8cf9-d37c94c413e7", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each. ", "original_text": "Operator :  Thank you very much, sir. "}, "hash": "f3c638a8ac5242bb480f809a94486ad878666275eb20d8474d4cf22ddc834502", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n", "start_char_idx": 0, "end_char_idx": 63, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "921a49cd-35b0-4bca-8cf9-d37c94c413e7": {"__data__": {"id_": "921a49cd-35b0-4bca-8cf9-d37c94c413e7", "embedding": null, "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each. ", "original_text": "Operator :  Thank you very much, sir. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5470e70c-642c-4cb1-88ca-5943c32d0f29", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] . ", "original_text": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d2b14cb984c270a3ae75f86fb843f3a7313745daa088bd3962ac5098ed54d89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8efd33c-cb68-4112-9c5e-25356959428d", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you. ", "original_text": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.  "}, "hash": "6a55f1006321a13b673b1445fb8317eb158f60ac1d537f286ba1a0a5e7caf7e2", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you very much, sir. ", "start_char_idx": 63, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8efd33c-cb68-4112-9c5e-25356959428d": {"__data__": {"id_": "f8efd33c-cb68-4112-9c5e-25356959428d", "embedding": null, "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you. ", "original_text": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "921a49cd-35b0-4bca-8cf9-d37c94c413e7", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each. ", "original_text": "Operator :  Thank you very much, sir. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "101014af8084c97a2a3ed5fbcf7d8439ecc61b384856a4d8bf8e75ca79eb2a74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbab93c6-d465-48f5-bc9f-b99e2c29e50b", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "original_text": "Please also  [indiscernible] . "}, "hash": "59b72bc8709556cdc6a297feef375e126cc3459ed0756b49b71de538abe75013", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.  ", "start_char_idx": 101, "end_char_idx": 225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbab93c6-d465-48f5-bc9f-b99e2c29e50b": {"__data__": {"id_": "fbab93c6-d465-48f5-bc9f-b99e2c29e50b", "embedding": null, "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "original_text": "Please also  [indiscernible] . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8efd33c-cb68-4112-9c5e-25356959428d", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you. ", "original_text": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25935bb804010165544de278b748e7cde9db2c5cc727638862fc34b4ea616fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20aa6438-f6bc-49c2-8999-c2072cd80a11", "node_type": "1", "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n", "original_text": "Also, please \nlimit yourselves to one question each. "}, "hash": "7f5fdc52800c5f52efe1ba97e4eb7b221f5911099d6daf0401050d61b343bfd6", "class_name": "RelatedNodeInfo"}}, "text": "Please also  [indiscernible] . ", "start_char_idx": 225, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20aa6438-f6bc-49c2-8999-c2072cd80a11": {"__data__": {"id_": "20aa6438-f6bc-49c2-8999-c2072cd80a11", "embedding": null, "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n", "original_text": "Also, please \nlimit yourselves to one question each. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbab93c6-d465-48f5-bc9f-b99e2c29e50b", "node_type": "1", "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "original_text": "Please also  [indiscernible] . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee07b59d50d054e5740851912191be4c83c035bd4b7278ec478e08a910d8d83a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8ee40fa-9851-4f44-bba4-be5365547431", "node_type": "1", "metadata": {"window": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "original_text": "Thank you. "}, "hash": "7e684b1ac177d79989688466b9f847889f11f7c25118359b0c5987e233df3f6e", "class_name": "RelatedNodeInfo"}}, "text": "Also, please \nlimit yourselves to one question each. ", "start_char_idx": 256, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8ee40fa-9851-4f44-bba4-be5365547431": {"__data__": {"id_": "e8ee40fa-9851-4f44-bba4-be5365547431", "embedding": null, "metadata": {"window": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "original_text": "Thank you. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20aa6438-f6bc-49c2-8999-c2072cd80a11", "node_type": "1", "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n", "original_text": "Also, please \nlimit yourselves to one question each. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1053dbad19ebaad7e0b7a74ca211c092d72957b301e6b1ed93e6706669ca093b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d77b58b5-998d-4e7e-8638-88a4ecbd77bf", "node_type": "1", "metadata": {"window": "Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "original_text": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. "}, "hash": "b6afcffe5d92701e4e662499105823ead6bf88453c49c0c53b92409c43de4166", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 309, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d77b58b5-998d-4e7e-8638-88a4ecbd77bf": {"__data__": {"id_": "d77b58b5-998d-4e7e-8638-88a4ecbd77bf", "embedding": null, "metadata": {"window": "Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "original_text": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8ee40fa-9851-4f44-bba4-be5365547431", "node_type": "1", "metadata": {"window": "Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "original_text": "Thank you. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d0640e7136056ff98aa19106e52886168529e7f8955425f20f913b50594e8dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de0577c8-d770-450c-9dac-3b7fbe5a248c", "node_type": "1", "metadata": {"window": "Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "original_text": "Please go ahead.  \n \n"}, "hash": "373b8dd23e86cea3bb09f4015ad41865ec5cdc749601d6dcb164d993638e3c80", "class_name": "RelatedNodeInfo"}}, "text": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "start_char_idx": 320, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de0577c8-d770-450c-9dac-3b7fbe5a248c": {"__data__": {"id_": "de0577c8-d770-450c-9dac-3b7fbe5a248c", "embedding": null, "metadata": {"window": "Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d77b58b5-998d-4e7e-8638-88a4ecbd77bf", "node_type": "1", "metadata": {"window": "Please also  [indiscernible] .  Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "original_text": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c0f91ca4e3edcade8846231ce284426183a73629cbcc9a6e02d088fd7b1320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a60ccbe1-14a1-4178-a042-4fab7c71d269", "node_type": "1", "metadata": {"window": "Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "original_text": "Lisa Gill:  Hi, good morning , and thanks for taking my question. "}, "hash": "c27730eb939a1c4ec4b6091b6b49872afdf266699d2808ef4f281bbd52257626", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 396, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a60ccbe1-14a1-4178-a042-4fab7c71d269": {"__data__": {"id_": "a60ccbe1-14a1-4178-a042-4fab7c71d269", "embedding": null, "metadata": {"window": "Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "original_text": "Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de0577c8-d770-450c-9dac-3b7fbe5a248c", "node_type": "1", "metadata": {"window": "Also, please \nlimit yourselves to one question each.  Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d0a6c3f0e6b5c7d18cfe29d360b2d038a875d666cea8766773e5ef6b41a542d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d517919-cecb-43ff-b9d7-9aee444c3859", "node_type": "1", "metadata": {"window": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n", "original_text": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n"}, "hash": "3f34a8efc08633ca602f6f341f8273a606cd6c179ccf2b565f7aabe3063ce4b4", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "start_char_idx": 417, "end_char_idx": 483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d517919-cecb-43ff-b9d7-9aee444c3859": {"__data__": {"id_": "5d517919-cecb-43ff-b9d7-9aee444c3859", "embedding": null, "metadata": {"window": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n", "original_text": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a60ccbe1-14a1-4178-a042-4fab7c71d269", "node_type": "1", "metadata": {"window": "Thank you.  Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "original_text": "Lisa Gill:  Hi, good morning , and thanks for taking my question. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1daf4bab67e9b52d22f50b8b5d591bad7f381a16f0fa0827112196b6baa925c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03fe5b46-34ac-43b0-b875-e5a8a6c2493d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning. ", "original_text": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n"}, "hash": "824e68f8022cc29eaa6aab878664e0aac1c047a29bf1934f047906ab5bf9ad51", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "start_char_idx": 483, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03fe5b46-34ac-43b0-b875-e5a8a6c2493d": {"__data__": {"id_": "03fe5b46-34ac-43b0-b875-e5a8a6c2493d", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning. ", "original_text": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d517919-cecb-43ff-b9d7-9aee444c3859", "node_type": "1", "metadata": {"window": "Our first question today is coming from Lisa Gill, \ncoming from JP  Morgan.  Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n", "original_text": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4196f7852d41413f214498d4049e99966b30bf8fed3407afb2de99b1f677503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50eba34b-a560-4f86-97f9-6800ac39d603", "node_type": "1", "metadata": {"window": "Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop . ", "original_text": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  "}, "hash": "1d585ece42d8933179d4f5249869b66595b73bdafef3eebddae4cf6338c8192c", "class_name": "RelatedNodeInfo"}}, "text": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "start_char_idx": 624, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50eba34b-a560-4f86-97f9-6800ac39d603": {"__data__": {"id_": "50eba34b-a560-4f86-97f9-6800ac39d603", "embedding": null, "metadata": {"window": "Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop . ", "original_text": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03fe5b46-34ac-43b0-b875-e5a8a6c2493d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning. ", "original_text": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c23d079fff7014c5865d7997f46fc4ce6542cf96dbc2395cf4204e4c78ba03fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5d42be9-6c6e-4650-8f23-3043129490b6", "node_type": "1", "metadata": {"window": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "original_text": "Please go ahead.  \n \n"}, "hash": "d9720f28ba1c6903d0f23932f8f36234cdc5e9533fafcd7dfe433eb330d33853", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "start_char_idx": 764, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5d42be9-6c6e-4650-8f23-3043129490b6": {"__data__": {"id_": "a5d42be9-6c6e-4650-8f23-3043129490b6", "embedding": null, "metadata": {"window": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50eba34b-a560-4f86-97f9-6800ac39d603", "node_type": "1", "metadata": {"window": "Lisa Gill:  Hi, good morning , and thanks for taking my question.  Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop . ", "original_text": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "249fae8ec944239d26485fea660406ae7f32c0981c0d90fd0dc0efa11e96df5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e40de8-2635-4c94-977a-d7dd640e7aed", "node_type": "1", "metadata": {"window": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "original_text": "Michael Cherny:   Good morning. "}, "hash": "5c11de0b235c63c1ebc930bb0de8d0eddb27287db1be0a1c97abd381e719d7a7", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 396, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e40de8-2635-4c94-977a-d7dd640e7aed": {"__data__": {"id_": "f3e40de8-2635-4c94-977a-d7dd640e7aed", "embedding": null, "metadata": {"window": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "original_text": "Michael Cherny:   Good morning. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5d42be9-6c6e-4650-8f23-3043129490b6", "node_type": "1", "metadata": {"window": "Jason, I just really want to dig into the \n2025 guidance that you have given, especially when we think about the Rx and specialty business. \n We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7df1e4dbf80f97220f731817d3f070da06afe99f50e40304b95e365b356e9db2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "437f1f7d-060e-4492-998a-9d63dadf3c77", "node_type": "1", "metadata": {"window": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "original_text": "Hopefully my line won\u2019t drop . "}, "hash": "50cd02f8b1ee1cc4c3ee249991f58cb96e71f940f64ab9f373f4f725af435085", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:   Good morning. ", "start_char_idx": 975, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "437f1f7d-060e-4492-998a-9d63dadf3c77": {"__data__": {"id_": "437f1f7d-060e-4492-998a-9d63dadf3c77", "embedding": null, "metadata": {"window": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "original_text": "Hopefully my line won\u2019t drop . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e40de8-2635-4c94-977a-d7dd640e7aed", "node_type": "1", "metadata": {"window": "We clearly know that revenue will be down, because of the change Rx , I am sorry because of the \nOptumRx contract, but [indiscernible].  \n \n Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "original_text": "Michael Cherny:   Good morning. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59183e6efe0296093ab5a240f51c837d014fded29c291d5e3a054459f660960b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "original_text": "I probably  have a similar question to \nLisa, so hopefully you can address this directly. "}, "hash": "103e5080a2ad9ddf3fcc80792f3172885ecf700e701de00ea07d36517fd1de97", "class_name": "RelatedNodeInfo"}}, "text": "Hopefully my line won\u2019t drop . ", "start_char_idx": 1007, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7": {"__data__": {"id_": "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "original_text": "I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "437f1f7d-060e-4492-998a-9d63dadf3c77", "node_type": "1", "metadata": {"window": "Operator:   Very sorry about that  gentlemen, her line appears just a drop suddenl y, so she could just \ndial back in I will put her back in a queue but now we will move to Michael Cherny.   Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "original_text": "Hopefully my line won\u2019t drop . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a71c84a190191c1e3b20cc372fa46a73f9e4f23d698568c33610873615c9b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb14811-9660-4649-8f8e-7d9975b9a207", "node_type": "1", "metadata": {"window": "Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "original_text": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. "}, "hash": "f62aa136ad2a1eb2264db612f1c10315e1fd20cd4024aa63a1239c5bdb7ac2dc", "class_name": "RelatedNodeInfo"}}, "text": "I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "start_char_idx": 1038, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb14811-9660-4649-8f8e-7d9975b9a207": {"__data__": {"id_": "bdb14811-9660-4649-8f8e-7d9975b9a207", "embedding": null, "metadata": {"window": "Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "original_text": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "original_text": "I probably  have a similar question to \nLisa, so hopefully you can address this directly. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ac341759acad14b622980949a572db39317ade06e7d27ace8188120b449d9f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99df7daf-a983-4282-8a92-11fe17841adb", "node_type": "1", "metadata": {"window": "Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n", "original_text": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? "}, "hash": "071581b43bee61592b2e46ec8a4af2788d36fef933261610e961893424b79e83", "class_name": "RelatedNodeInfo"}}, "text": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "start_char_idx": 1128, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99df7daf-a983-4282-8a92-11fe17841adb": {"__data__": {"id_": "99df7daf-a983-4282-8a92-11fe17841adb", "embedding": null, "metadata": {"window": "Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n", "original_text": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb14811-9660-4649-8f8e-7d9975b9a207", "node_type": "1", "metadata": {"window": "Michael Cherny:   Good morning.  Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "original_text": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8363d3cd449e8c331677cb1d1422adfb9ab16c081a0c6fa821ceb53ac0bc25b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25f592ec-eca8-4e9b-8f26-7092439a7341", "node_type": "1", "metadata": {"window": "I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure. ", "original_text": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? "}, "hash": "b6d3fdca39964ddde9c96f202177a0ac581822b295db93e887d4457da10dfe0c", "class_name": "RelatedNodeInfo"}}, "text": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "start_char_idx": 1239, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25f592ec-eca8-4e9b-8f26-7092439a7341": {"__data__": {"id_": "25f592ec-eca8-4e9b-8f26-7092439a7341", "embedding": null, "metadata": {"window": "I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure. ", "original_text": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99df7daf-a983-4282-8a92-11fe17841adb", "node_type": "1", "metadata": {"window": "Hopefully my line won\u2019t drop .  I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n", "original_text": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum? ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10e105f0cdd3f4c4f4ed25e8cb50cf3216dfcd02983f6bc188228903fbd95b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a744de-b972-47da-81ae-83b11540136c", "node_type": "1", "metadata": {"window": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron. ", "original_text": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. "}, "hash": "a27a8d15fee8cf79f0e04c8d1b7543c83354e1f4cedd8c33d58106e78992eaac", "class_name": "RelatedNodeInfo"}}, "text": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "start_char_idx": 1329, "end_char_idx": 1518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a744de-b972-47da-81ae-83b11540136c": {"__data__": {"id_": "64a744de-b972-47da-81ae-83b11540136c", "embedding": null, "metadata": {"window": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron. ", "original_text": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25f592ec-eca8-4e9b-8f26-7092439a7341", "node_type": "1", "metadata": {"window": "I probably  have a similar question to \nLisa, so hopefully you can address this directly.  Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure. ", "original_text": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers? ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f51bbeaad614fea67e8555ac6e7376dd2815cd77f8dfaa94c9f49404941ecb2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c513df0-bfc0-4850-bec7-9618ebcaf723", "node_type": "1", "metadata": {"window": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context. ", "original_text": "Thanks so much.  \n \n"}, "hash": "d0af2b2214341a94b7183e68dcf19f8fc8766a4793d3b44c45d7b39a15261adf", "class_name": "RelatedNodeInfo"}}, "text": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "start_char_idx": 1518, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c513df0-bfc0-4850-bec7-9618ebcaf723": {"__data__": {"id_": "1c513df0-bfc0-4850-bec7-9618ebcaf723", "embedding": null, "metadata": {"window": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context. ", "original_text": "Thanks so much.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a744de-b972-47da-81ae-83b11540136c", "node_type": "1", "metadata": {"window": "Relative to the \u201825 segment EBIT, as you think about \nthe moving pieces here, maybe it's a two -part question.  First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron. ", "original_text": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "139148bf0ae8912b03d2309ae8abe01a6b2479c2b867e396d913df9cbb6e1f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2", "node_type": "1", "metadata": {"window": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "original_text": "Aaron Alt:  Sure. "}, "hash": "da24a435c1a40bd98614b612e8bfeae8b6494033f17a8723adc62880eee92b0e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much.  \n \n", "start_char_idx": 1644, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2": {"__data__": {"id_": "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2", "embedding": null, "metadata": {"window": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "original_text": "Aaron Alt:  Sure. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c513df0-bfc0-4850-bec7-9618ebcaf723", "node_type": "1", "metadata": {"window": "First, is there any way you can give us \nunderlying growth rate beyond the loss of Optum?  And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context. ", "original_text": "Thanks so much.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc6f15c5ac8b41ae98ea8266c20a91a34f0c271f0c5519aae8dc2a46320c0e65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c117f52c-e778-4774-bc1d-f1ef617c34cc", "node_type": "1", "metadata": {"window": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "original_text": "Good morning, this is Aaron. "}, "hash": "0b7059340922b678039f97b07831ea40e4d8b229c01972c0ed3a50e7a0f94c6f", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Sure. ", "start_char_idx": 1664, "end_char_idx": 1682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c117f52c-e778-4774-bc1d-f1ef617c34cc": {"__data__": {"id_": "c117f52c-e778-4774-bc1d-f1ef617c34cc", "embedding": null, "metadata": {"window": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "original_text": "Good morning, this is Aaron. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2", "node_type": "1", "metadata": {"window": "And then second , as you think about the at least \n1% segment performance, can you give us just a further breakdown on how much of that is volume \ngrowth versus mix , versus new customers?  Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "original_text": "Aaron Alt:  Sure. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "687d6128ce924df989861026f95ebe47117adbf902ddab8d1ebc3cb42498aedd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da625ffa-b093-4a04-9570-071f8bfc45d3", "node_type": "1", "metadata": {"window": "Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "original_text": "I appreciate the question and happy to provide a little \nmore context. "}, "hash": "40e5b63f7dd99869146075884c5b1331213b66fd75e5e5c110a2c12e0e5db623", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, this is Aaron. ", "start_char_idx": 1682, "end_char_idx": 1711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da625ffa-b093-4a04-9570-071f8bfc45d3": {"__data__": {"id_": "da625ffa-b093-4a04-9570-071f8bfc45d3", "embedding": null, "metadata": {"window": "Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "original_text": "I appreciate the question and happy to provide a little \nmore context. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c117f52c-e778-4774-bc1d-f1ef617c34cc", "node_type": "1", "metadata": {"window": "Any more color you can provide on that as we think about \nthe jumping off point and how that factors into \u201826 would be great.  Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "original_text": "Good morning, this is Aaron. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e8078a6193956e116cf257814199d58161c1e864c44e437e7c00999c94845ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942", "node_type": "1", "metadata": {"window": "Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "original_text": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. "}, "hash": "949fbf92fa7fb8cf3e85682ff212e84a2015fac8827b3ac3ac1d58146419f348", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the question and happy to provide a little \nmore context. ", "start_char_idx": 1711, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942": {"__data__": {"id_": "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942", "embedding": null, "metadata": {"window": "Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "original_text": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da625ffa-b093-4a04-9570-071f8bfc45d3", "node_type": "1", "metadata": {"window": "Thanks so much.  \n \n Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "original_text": "I appreciate the question and happy to provide a little \nmore context. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c4654c3f929f8406731bbe76b613b11536ed0dbc72e7dea131b7eeeb109ddc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1d27382-74b7-4a24-b3aa-b42acc5aa150", "node_type": "1", "metadata": {"window": "Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "original_text": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. "}, "hash": "472020e06d50d1a6399a4c79e72a80b8671eae2fdf7082536ad4e302e2a922a2", "class_name": "RelatedNodeInfo"}}, "text": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "start_char_idx": 1782, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d27382-74b7-4a24-b3aa-b42acc5aa150": {"__data__": {"id_": "e1d27382-74b7-4a24-b3aa-b42acc5aa150", "embedding": null, "metadata": {"window": "Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "original_text": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942", "node_type": "1", "metadata": {"window": "Aaron Alt:  Sure.  Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "original_text": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6415615e54990e3b16ae3c9f522e6daaac809451b6ab963bb153681b88c69eb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33c37d34-8624-43d4-9cca-16fe0062bb45", "node_type": "1", "metadata": {"window": "I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "original_text": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  "}, "hash": "a34e69a4e15e1204a6131f75dbf4d7aa1851aebdbca0151e09a19ee43ddb0e9e", "class_name": "RelatedNodeInfo"}}, "text": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "start_char_idx": 1928, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33c37d34-8624-43d4-9cca-16fe0062bb45": {"__data__": {"id_": "33c37d34-8624-43d4-9cca-16fe0062bb45", "embedding": null, "metadata": {"window": "I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "original_text": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1d27382-74b7-4a24-b3aa-b42acc5aa150", "node_type": "1", "metadata": {"window": "Good morning, this is Aaron.  I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "original_text": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11a8d7ed41943450425e2f84306200e69b51c7736753d6c52d8ed87ef5a832bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0effd95-6959-4d11-8f36-956cea4b4ade", "node_type": "1", "metadata": {"window": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n", "original_text": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . "}, "hash": "6644862600a367638a95651563f982b394030c3ad0bf80d5219d1efb37689a2f", "class_name": "RelatedNodeInfo"}}, "text": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "start_char_idx": 2001, "end_char_idx": 2128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0effd95-6959-4d11-8f36-956cea4b4ade": {"__data__": {"id_": "d0effd95-6959-4d11-8f36-956cea4b4ade", "embedding": null, "metadata": {"window": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n", "original_text": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33c37d34-8624-43d4-9cca-16fe0062bb45", "node_type": "1", "metadata": {"window": "I appreciate the question and happy to provide a little \nmore context.  I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "original_text": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.  ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb585c1692a09451c6e232d8b58460dfa4bdbaba0cebcf3688c3eca5f9b46bb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aea0186-6c3b-4956-8ba9-27c259bf900b", "node_type": "1", "metadata": {"window": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "original_text": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. "}, "hash": "6d401e2a7f8251f96ba652d07fcd72e025d51849d70e35b9923ecaf97c47176c", "class_name": "RelatedNodeInfo"}}, "text": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "start_char_idx": 2128, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aea0186-6c3b-4956-8ba9-27c259bf900b": {"__data__": {"id_": "9aea0186-6c3b-4956-8ba9-27c259bf900b", "embedding": null, "metadata": {"window": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "original_text": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0effd95-6959-4d11-8f36-956cea4b4ade", "node_type": "1", "metadata": {"window": "I want to start by observing that the PS&S team have strong plans for \u201825 as they \ncontinue to deliver against what was a very strong fiscal \u201824.  We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n", "original_text": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business . ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c08f7534e7d994fc7475d11c2e44fef8ea1bea05210442762d97a40d8e263b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "022840a3-6e70-4365-9bab-ec26d957a20d", "node_type": "1", "metadata": {"window": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "original_text": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. "}, "hash": "85e7dfb933c32c743b12b9a0c9b25bda9ed36767130eb6f45af862a389982485", "class_name": "RelatedNodeInfo"}}, "text": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "start_char_idx": 2261, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "022840a3-6e70-4365-9bab-ec26d957a20d": {"__data__": {"id_": "022840a3-6e70-4365-9bab-ec26d957a20d", "embedding": null, "metadata": {"window": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "original_text": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aea0186-6c3b-4956-8ba9-27c259bf900b", "node_type": "1", "metadata": {"window": "We had provided long -term guidance for \nPS&S of 4  to 6% profit growth.  As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "original_text": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c72bc96a9ed0fb9a92909f7bb3ce62efae2c12be015cb18bb416ea1f5df044d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0", "node_type": "1", "metadata": {"window": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "original_text": "So , that's the profit guide I would \ngive you.  \n \n"}, "hash": "1d19b125aa89238e9be75b8a36e51357256335160d4d58731f1a6192f6129b2b", "class_name": "RelatedNodeInfo"}}, "text": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "start_char_idx": 2402, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0": {"__data__": {"id_": "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0", "embedding": null, "metadata": {"window": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "original_text": "So , that's the profit guide I would \ngive you.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "022840a3-6e70-4365-9bab-ec26d957a20d", "node_type": "1", "metadata": {"window": "As we now think about that in comparison to the guidance we \nprovided today of at least 1% profit growth within that segment.   The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "original_text": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb3059517a5cd4dca7fc1d8dfb65e8b4fc513590ddd7c5e671b494224ccbcb7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c04543e4-0815-4668-970f-0f82adfa7e4a", "node_type": "1", "metadata": {"window": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "original_text": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. "}, "hash": "2b570f9fbc39fb2bd130f0bec97bca882119930f20928a71f72002a18d06ce8c", "class_name": "RelatedNodeInfo"}}, "text": "So , that's the profit guide I would \ngive you.  \n \n", "start_char_idx": 2547, "end_char_idx": 2599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c04543e4-0815-4668-970f-0f82adfa7e4a": {"__data__": {"id_": "c04543e4-0815-4668-970f-0f82adfa7e4a", "embedding": null, "metadata": {"window": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "original_text": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0", "node_type": "1", "metadata": {"window": "The delta you should think about it is \nreally the impact of profit, net i mpact of profit so fa r, relative to the Optum business .  And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "original_text": "So , that's the profit guide I would \ngive you.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58d6942925de7fc37a94c2c6d48be97107e04be8e0d573bb08e0d26daa9eb154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8596fd5-1e35-450c-8d85-e566d4370911", "node_type": "1", "metadata": {"window": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "original_text": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. "}, "hash": "3b466617dbbae2e90ae582834917019e5dc798d16c98090a309a467d1458d5cc", "class_name": "RelatedNodeInfo"}}, "text": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "start_char_idx": 2599, "end_char_idx": 2724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8596fd5-1e35-450c-8d85-e566d4370911": {"__data__": {"id_": "d8596fd5-1e35-450c-8d85-e566d4370911", "embedding": null, "metadata": {"window": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "original_text": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c04543e4-0815-4668-970f-0f82adfa7e4a", "node_type": "1", "metadata": {"window": "And the simple \nmath I do is if you take the midpoint of our long -term guidance, the 5%, each percentage point is \nworth about $20 million.  If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "original_text": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cd1981847db44dadc56d12f38f68bbc6eaf3052e48d20cf0e21a3bfa3b6c347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7251315-be09-41bd-a4df-ac8b79c02bd5", "node_type": "1", "metadata": {"window": "So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "original_text": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n"}, "hash": "796358c798245f86eb256f17fba6256f398ac97904ac0ba93867c3b53b16d9ed", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "start_char_idx": 2724, "end_char_idx": 2824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7251315-be09-41bd-a4df-ac8b79c02bd5": {"__data__": {"id_": "e7251315-be09-41bd-a4df-ac8b79c02bd5", "embedding": null, "metadata": {"window": "So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "original_text": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8596fd5-1e35-450c-8d85-e566d4370911", "node_type": "1", "metadata": {"window": "If you take it down to the 1% , the at least 1% that we have guided, that's \nabout an $80 million net impact so far that we are working through.  So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "original_text": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b410915d2b734c74a303b9072a10726e359d3d9f43438b35c7a2899391f556c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f3cd1e-d36e-4777-aae4-f83b403a21e4", "node_type": "1", "metadata": {"window": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. "}, "hash": "63248cf3174469e98387c5986e0cc8f6643eea8e8a0db39f51bc1d5bd1d47a0c", "class_name": "RelatedNodeInfo"}}, "text": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "start_char_idx": 2824, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f3cd1e-d36e-4777-aae4-f83b403a21e4": {"__data__": {"id_": "e1f3cd1e-d36e-4777-aae4-f83b403a21e4", "embedding": null, "metadata": {"window": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7251315-be09-41bd-a4df-ac8b79c02bd5", "node_type": "1", "metadata": {"window": "So , that's the profit guide I would \ngive you.  \n \n On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "original_text": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08af49191d428e3b836adfc5792a78b412cd2ee9cf5b3f19fcb515a224dcd75d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c88ca13-86f6-4c68-9773-a9d2a9987f10", "node_type": "1", "metadata": {"window": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. "}, "hash": "9324656a32393969e7c077756f073283a48423f627315b1737a3a06a4700af2a", "class_name": "RelatedNodeInfo"}}, "text": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "start_char_idx": 2925, "end_char_idx": 3114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c88ca13-86f6-4c68-9773-a9d2a9987f10": {"__data__": {"id_": "1c88ca13-86f6-4c68-9773-a9d2a9987f10", "embedding": null, "metadata": {"window": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f3cd1e-d36e-4777-aae4-f83b403a21e4", "node_type": "1", "metadata": {"window": "On the revenue side, I would observe that we have already provided the impact that fiscal \u201823 was \nabout 16% of our revenue.  Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "872a0b9e5e28fdfa58715871d5acc08ef5e03d23fda5b74a66f9e69ef20a25e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b17baed-9cac-4079-bb6e-156e6d6ebec4", "node_type": "1", "metadata": {"window": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. "}, "hash": "6e1f426d6867071a4049402f6b47179245bb08be92e496554b6d8257a2d065d7", "class_name": "RelatedNodeInfo"}}, "text": "It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "start_char_idx": 3114, "end_char_idx": 3258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b17baed-9cac-4079-bb6e-156e6d6ebec4": {"__data__": {"id_": "8b17baed-9cac-4079-bb6e-156e6d6ebec4", "embedding": null, "metadata": {"window": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c88ca13-86f6-4c68-9773-a9d2a9987f10", "node_type": "1", "metadata": {"window": "Fiscal \u201924 is not yet done, we will land somewhere between $35 million \nand $40 billion of revenue.  Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46f00d688e8293f3a3aca6fdd5bb6ae1780b81f2da9dfe6ebfeb28808ac768a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71", "node_type": "1", "metadata": {"window": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "J ason, do you want to add?  \n "}, "hash": "0162cceb36a3c1c8c180f121abf84cd2cc581c93b14941925a9a4c7e97158174", "class_name": "RelatedNodeInfo"}}, "text": "But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "start_char_idx": 3258, "end_char_idx": 3394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71": {"__data__": {"id_": "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71", "embedding": null, "metadata": {"window": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "J ason, do you want to add?  \n ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18435f0ac0dd869e3d32eaa442049dd1624c39fa2782ddb638c754d0845ff2f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b17baed-9cac-4079-bb6e-156e6d6ebec4", "node_type": "1", "metadata": {"window": "Back that out but  recognizing that the portfolio is still growing 10% or so, \nas we push ahead.  \n \n And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place. ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96d95b0543b62371c240c22266884ff287b63d0571a9460bf5d6ffd671440e51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8826952-e754-4120-9038-d0076b11008a", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that. ", "original_text": " \nPage 12 of 20 \n \nJason Hollar:  Yes. "}, "hash": "a67afc45ed2de39dd5b986720b2823dabd7a2bceb8e492701c8fd91c1bc2db59", "class_name": "RelatedNodeInfo"}}, "text": "J ason, do you want to add?  \n ", "start_char_idx": 3394, "end_char_idx": 3425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8826952-e754-4120-9038-d0076b11008a": {"__data__": {"id_": "b8826952-e754-4120-9038-d0076b11008a", "embedding": null, "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that. ", "original_text": " \nPage 12 of 20 \n \nJason Hollar:  Yes. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71", "node_type": "1", "metadata": {"window": "And then lastly on the cash flow side of the house, I hope you noted my comments that we are \nholding to our average of $2 billion of adjusted cash flow each year in the \u201824 to \u201826 period.  It will be \nlower in \u201825 as we work through the negative working capital position from that non -renew contract \nand a days of the week impact.  But this is manageable, and I hope you take away from the fact we're \ncalling growth as we push ahead for PS&S, we have plans in place.  J ason, do you want to add?  \n ", "original_text": "J ason, do you want to add?  \n ", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76619d3b00e00a5d674be384b01d5601122a05cf300f6d591b3ef46d4195485c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78baffd8-025f-4008-9774-74ff783d9cf0", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.  ", "original_text": "Just I'll build out a little bit further the puts and takes for \u201825. "}, "hash": "8d9441f3b0fc25e3eca4ce79186bb99644388ac40464af89df609f89bfdb9b73", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 20 \n \nJason Hollar:  Yes. ", "start_char_idx": 0, "end_char_idx": 39, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78baffd8-025f-4008-9774-74ff783d9cf0": {"__data__": {"id_": "78baffd8-025f-4008-9774-74ff783d9cf0", "embedding": null, "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.  ", "original_text": "Just I'll build out a little bit further the puts and takes for \u201825. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8826952-e754-4120-9038-d0076b11008a", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that. ", "original_text": " \nPage 12 of 20 \n \nJason Hollar:  Yes. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b440a65bfe681f904392da1be0566ec787fbc4902fdee59c7fc54fe6bdd41209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4c0caf-2f53-4f87-826e-da650d00e0e9", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had. ", "original_text": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints. "}, "hash": "e24661235a94f461f6ffc2587ae6f1c39111af124154e4d2a0606f7ef850f4cb", "class_name": "RelatedNodeInfo"}}, "text": "Just I'll build out a little bit further the puts and takes for \u201825. ", "start_char_idx": 39, "end_char_idx": 108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4c0caf-2f53-4f87-826e-da650d00e0e9": {"__data__": {"id_": "bf4c0caf-2f53-4f87-826e-da650d00e0e9", "embedding": null, "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had. ", "original_text": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78baffd8-025f-4008-9774-74ff783d9cf0", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.  ", "original_text": "Just I'll build out a little bit further the puts and takes for \u201825. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ad59c586bb9aa3b55094d0dde26a0e188f2af9c2096833eb88c0eb0f8ee7649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "768deaeb-3435-4bfc-9c90-15883b95acf8", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "original_text": "So , that obviously implies an Optum impact of something greater than that. "}, "hash": "992da25f5e28bb9ad205721733f229884ea9c8fabd210ef25e5a264b8e4f0108", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints. ", "start_char_idx": 108, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "768deaeb-3435-4bfc-9c90-15883b95acf8": {"__data__": {"id_": "768deaeb-3435-4bfc-9c90-15883b95acf8", "embedding": null, "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "original_text": "So , that obviously implies an Optum impact of something greater than that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4c0caf-2f53-4f87-826e-da650d00e0e9", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had. ", "original_text": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09308b90f203591b6df620794764312d3609d6aa31accd5518e5d0896cae047a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9df38c7e-48cc-48b8-9d2c-ce022106c713", "node_type": "1", "metadata": {"window": "Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "original_text": "That's being \npartially mitigated through several different items that we have called out.  "}, "hash": "48aba8db3c001815fc9c8bee966f5bff33ebf93d68cde66ae9c18fc2bbd17862", "class_name": "RelatedNodeInfo"}}, "text": "So , that obviously implies an Optum impact of something greater than that. ", "start_char_idx": 242, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9df38c7e-48cc-48b8-9d2c-ce022106c713": {"__data__": {"id_": "9df38c7e-48cc-48b8-9d2c-ce022106c713", "embedding": null, "metadata": {"window": "Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "original_text": "That's being \npartially mitigated through several different items that we have called out.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "768deaeb-3435-4bfc-9c90-15883b95acf8", "node_type": "1", "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "original_text": "So , that obviously implies an Optum impact of something greater than that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67e72084e08fa38cb873078a7affb1ccebd959ff94276e3299b4f213861d9a69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb974195-4233-4808-8153-bb1e16f2fc85", "node_type": "1", "metadata": {"window": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "original_text": "One is the other customer \nprogress that we have had. "}, "hash": "f222eb996151fa494a148c99dfbf8db972538e91daa5e9cd11d96e2ced111a46", "class_name": "RelatedNodeInfo"}}, "text": "That's being \npartially mitigated through several different items that we have called out.  ", "start_char_idx": 318, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb974195-4233-4808-8153-bb1e16f2fc85": {"__data__": {"id_": "eb974195-4233-4808-8153-bb1e16f2fc85", "embedding": null, "metadata": {"window": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "original_text": "One is the other customer \nprogress that we have had. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9df38c7e-48cc-48b8-9d2c-ce022106c713", "node_type": "1", "metadata": {"window": "Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "original_text": "That's being \npartially mitigated through several different items that we have called out.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2bf0392a66eecd7fbd941ff2761267fe526ec68d864c45e0e617b12bee0716d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dce6cf34-b013-4449-a8a0-e2a994ae47b5", "node_type": "1", "metadata": {"window": "So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "original_text": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. "}, "hash": "e8680e6a63337db1977b8549094c472371bd2f30943e863bdffd1d7a09bd9e49", "class_name": "RelatedNodeInfo"}}, "text": "One is the other customer \nprogress that we have had. ", "start_char_idx": 410, "end_char_idx": 464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dce6cf34-b013-4449-a8a0-e2a994ae47b5": {"__data__": {"id_": "dce6cf34-b013-4449-a8a0-e2a994ae47b5", "embedding": null, "metadata": {"window": "So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "original_text": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb974195-4233-4808-8153-bb1e16f2fc85", "node_type": "1", "metadata": {"window": "As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "original_text": "One is the other customer \nprogress that we have had. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b88874f86481e9dfa9a5549e5c14dd619af41c9a4763cdf49a9cc73eecb33ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc5b596e-8213-43eb-8f25-fcc152f991b7", "node_type": "1", "metadata": {"window": "That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "original_text": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  "}, "hash": "b6399a04b421fb9d0824d7517e8188f25cde75d20e4b27f96184bae473642870", "class_name": "RelatedNodeInfo"}}, "text": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "start_char_idx": 464, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc5b596e-8213-43eb-8f25-fcc152f991b7": {"__data__": {"id_": "dc5b596e-8213-43eb-8f25-fcc152f991b7", "embedding": null, "metadata": {"window": "That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "original_text": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dce6cf34-b013-4449-a8a0-e2a994ae47b5", "node_type": "1", "metadata": {"window": "So , that obviously implies an Optum impact of something greater than that.  That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "original_text": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90ab18a473d550c776dad30569035f1ad2d0d428f2899618238b5d5dd75a0e64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55d1f3cd-77a7-4ea9-9ccf-de430eac2005", "node_type": "1", "metadata": {"window": "One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "original_text": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . "}, "hash": "f08b8d187eac538924e928fa1f45b2aaf9836b7db4fe8f6e90315e756d96343f", "class_name": "RelatedNodeInfo"}}, "text": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "start_char_idx": 663, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55d1f3cd-77a7-4ea9-9ccf-de430eac2005": {"__data__": {"id_": "55d1f3cd-77a7-4ea9-9ccf-de430eac2005", "embedding": null, "metadata": {"window": "One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "original_text": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc5b596e-8213-43eb-8f25-fcc152f991b7", "node_type": "1", "metadata": {"window": "That's being \npartially mitigated through several different items that we have called out.   One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "original_text": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc3e944c5ce5a5a60d1e0375731b407b9457d319212ca9a23e5919c8799ef2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d25143b7-f86c-47c3-8b8d-671a5b2a1b76", "node_type": "1", "metadata": {"window": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n", "original_text": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. "}, "hash": "bccb2822e6c56435e86b93ad4c815bfd24d2acb0ef5ea5dbeadb186dc611e709", "class_name": "RelatedNodeInfo"}}, "text": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "start_char_idx": 755, "end_char_idx": 902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d25143b7-f86c-47c3-8b8d-671a5b2a1b76": {"__data__": {"id_": "d25143b7-f86c-47c3-8b8d-671a5b2a1b76", "embedding": null, "metadata": {"window": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n", "original_text": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55d1f3cd-77a7-4ea9-9ccf-de430eac2005", "node_type": "1", "metadata": {"window": "One is the other customer \nprogress that we have had.  So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "original_text": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month . ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b59658ae25f86179dfc36a8477beb7373693ec2fb467ef7ff8795246befe8ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22f1f4b-b412-4719-9e02-ba4becc7a7b0", "node_type": "1", "metadata": {"window": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir. ", "original_text": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . "}, "hash": "1f486df315945403bc997a40b808f70ef00afff7193931c3123cd7b998d9fb47", "class_name": "RelatedNodeInfo"}}, "text": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "start_char_idx": 902, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22f1f4b-b412-4719-9e02-ba4becc7a7b0": {"__data__": {"id_": "d22f1f4b-b412-4719-9e02-ba4becc7a7b0", "embedding": null, "metadata": {"window": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir. ", "original_text": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d25143b7-f86c-47c3-8b8d-671a5b2a1b76", "node_type": "1", "metadata": {"window": "So , there's value proposition is definitely resonating well with our \ncustomers, and so we have had good win rates in other areas, so that would allow us some \nopportunity to partially offset that.  That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n", "original_text": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3c9556f3ba564505580ed264d13ec156593725c0e59a51fe0eff59b7a9757b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b4ebcee-2f56-49fd-bf7d-93a77925b711", "node_type": "1", "metadata": {"window": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank. ", "original_text": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n"}, "hash": "2e39b41342ba274c0c1f1927a87c3a30ed6e3a333cf4e1ae58ee26bde8a30f45", "class_name": "RelatedNodeInfo"}}, "text": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "start_char_idx": 1066, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b4ebcee-2f56-49fd-bf7d-93a77925b711": {"__data__": {"id_": "6b4ebcee-2f56-49fd-bf7d-93a77925b711", "embedding": null, "metadata": {"window": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank. ", "original_text": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22f1f4b-b412-4719-9e02-ba4becc7a7b0", "node_type": "1", "metadata": {"window": "That's included in that net $80 million , as well as the inclusion of \nSpecialty Networks.   So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir. ", "original_text": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further . ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66bfc8b9e447d7040612c1b0bba845f78b2895b2153461dad80f406d47296767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c4bd27d-506a-48c7-9f71-6ed5e1d67626", "node_type": "1", "metadata": {"window": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead. ", "original_text": "Matt Sims: Next question, please.  \n \n"}, "hash": "65add7a5b812907b0994f3f35c1936e792baf7481c0d96e02eeb6629971af43e", "class_name": "RelatedNodeInfo"}}, "text": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "start_char_idx": 1197, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c4bd27d-506a-48c7-9f71-6ed5e1d67626": {"__data__": {"id_": "8c4bd27d-506a-48c7-9f71-6ed5e1d67626", "embedding": null, "metadata": {"window": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b4ebcee-2f56-49fd-bf7d-93a77925b711", "node_type": "1", "metadata": {"window": "So overall , Specialty growth we expect to continue  to be strong  and then  we \nhave  the Specialty Networks acquisition that closed last month .  So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank. ", "original_text": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61d47de2fff5498646444570763456502f966fd5da3cd8b1b583c4024edb2f7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097e9b38-c952-4afd-8669-283707661457", "node_type": "1", "metadata": {"window": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n", "original_text": "Operator:  Thank you, sir. "}, "hash": "5dd2ed67456153008c37b3149273db6edabc74dfd1a08956eb81ed9b7615f992", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims: Next question, please.  \n \n", "start_char_idx": 1343, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097e9b38-c952-4afd-8669-283707661457": {"__data__": {"id_": "097e9b38-c952-4afd-8669-283707661457", "embedding": null, "metadata": {"window": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n", "original_text": "Operator:  Thank you, sir. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c4bd27d-506a-48c7-9f71-6ed5e1d67626", "node_type": "1", "metadata": {"window": "So, we'll get kind of  get a three -\nquarter type of year -over-year benefit because we'll have it in our fourth quarter as well and the \nongoing growth with that.  And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "611708bb182316ae5f2cc659c6e61ab0c18324045d9b61b258da1e100976a55d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beb68fbd-1116-45a2-90f8-8aac0fe4d227", "node_type": "1", "metadata": {"window": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes. ", "original_text": "We will now move to George Hill of Deutsche Bank. "}, "hash": "00368ab7df33721e70ef9f9824d45bc6b6cc8d929982abd0f54d16b17d60edf2", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you, sir. ", "start_char_idx": 1381, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beb68fbd-1116-45a2-90f8-8aac0fe4d227": {"__data__": {"id_": "beb68fbd-1116-45a2-90f8-8aac0fe4d227", "embedding": null, "metadata": {"window": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes. ", "original_text": "We will now move to George Hill of Deutsche Bank. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097e9b38-c952-4afd-8669-283707661457", "node_type": "1", "metadata": {"window": "And then there's some opportunity to further reduce costs by streamlining \nour processe s even further, simplifying even further .  So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n", "original_text": "Operator:  Thank you, sir. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bc56d04f06d8dd1fa6013a4b078a363885e37cc74437410315e628cf0861fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05142a04-edb6-48b1-9600-7342a31d43e7", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys. ", "original_text": "Please go ahead. "}, "hash": "c3509e4f94b0bd40b71f23d2204749a4356883c332144ce8ae6ef70937ce49b9", "class_name": "RelatedNodeInfo"}}, "text": "We will now move to George Hill of Deutsche Bank. ", "start_char_idx": 1408, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05142a04-edb6-48b1-9600-7342a31d43e7": {"__data__": {"id_": "05142a04-edb6-48b1-9600-7342a31d43e7", "embedding": null, "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys. ", "original_text": "Please go ahead. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beb68fbd-1116-45a2-90f8-8aac0fe4d227", "node_type": "1", "metadata": {"window": "So overall,  we feel really good about those \noffsets, and that gets us to that net about 4 percentage points that we're calling out right now.  \n Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes. ", "original_text": "We will now move to George Hill of Deutsche Bank. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "200ced68d3a606dc854d51ddb5737af0138fd59f1e6f32a4aca46e50d4a985f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e44ffaef-8585-4360-af94-9493be5ad3ca", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "original_text": "Your \nline is open.  \n \n"}, "hash": "90535365e06bc490f04003ef21c95a8317c0f7ba014118d1ae452706af18a557", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead. ", "start_char_idx": 1458, "end_char_idx": 1475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e44ffaef-8585-4360-af94-9493be5ad3ca": {"__data__": {"id_": "e44ffaef-8585-4360-af94-9493be5ad3ca", "embedding": null, "metadata": {"window": "Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "original_text": "Your \nline is open.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05142a04-edb6-48b1-9600-7342a31d43e7", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys. ", "original_text": "Please go ahead. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "556654f902f86239835077e717a9becbe515e278716736ea5144d2daa35cd799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef760c53-017e-4061-b9ab-a07c50602b4b", "node_type": "1", "metadata": {"window": "We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "original_text": "George Hill:  Yes. "}, "hash": "cb2b039ae1ab006600098713e9c2a98c39b6dc19aa956d7be7939e2245a91e6c", "class_name": "RelatedNodeInfo"}}, "text": "Your \nline is open.  \n \n", "start_char_idx": 1475, "end_char_idx": 1499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef760c53-017e-4061-b9ab-a07c50602b4b": {"__data__": {"id_": "ef760c53-017e-4061-b9ab-a07c50602b4b", "embedding": null, "metadata": {"window": "We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "original_text": "George Hill:  Yes. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e44ffaef-8585-4360-af94-9493be5ad3ca", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "original_text": "Your \nline is open.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d03103ba8f460c3b8dbe97fd648a58cf8c1c7d2a42294e1eeaeaf2cb9eb5c15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8", "node_type": "1", "metadata": {"window": "Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "original_text": "Good morning, guys. "}, "hash": "5ede9062631e9bdd72d58d91989f0c9456ad536cab83ad0f5cb2f57381d798ba", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Yes. ", "start_char_idx": 1499, "end_char_idx": 1518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8": {"__data__": {"id_": "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8", "embedding": null, "metadata": {"window": "Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "original_text": "Good morning, guys. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef760c53-017e-4061-b9ab-a07c50602b4b", "node_type": "1", "metadata": {"window": "We will now move to George Hill of Deutsche Bank.  Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "original_text": "George Hill:  Yes. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b90bca6f3ed6bffb19bc95be69a46a52368e680b52fdb731f0a9b5577956e102", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6164f303-6034-468e-8c3d-9985f85ccb91", "node_type": "1", "metadata": {"window": "Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "original_text": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. "}, "hash": "5c86a5ea6bb8b90b27036b6ce07ddf0f9e169586b9366bc0717e0cd68e544ae9", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys. ", "start_char_idx": 1518, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6164f303-6034-468e-8c3d-9985f85ccb91": {"__data__": {"id_": "6164f303-6034-468e-8c3d-9985f85ccb91", "embedding": null, "metadata": {"window": "Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "original_text": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8", "node_type": "1", "metadata": {"window": "Please go ahead.  Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "original_text": "Good morning, guys. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa4a8bd7e43cc149d27bf67e6e8c8ff01af828032b0721f45da1d15e24782fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cca79382-7d43-4f82-b774-5d2ac106a84d", "node_type": "1", "metadata": {"window": "George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "original_text": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. "}, "hash": "cb55fd39863136be68591ea02860735eadb025ab2a391d9fe05ed909cf6dace0", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "start_char_idx": 1538, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cca79382-7d43-4f82-b774-5d2ac106a84d": {"__data__": {"id_": "cca79382-7d43-4f82-b774-5d2ac106a84d", "embedding": null, "metadata": {"window": "George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "original_text": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6164f303-6034-468e-8c3d-9985f85ccb91", "node_type": "1", "metadata": {"window": "Your \nline is open.  \n \n George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "original_text": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d7da5d9a36a5a766c7af12021f7da384cd95d6ae4a128f7ed47e0a1a65ca89a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90be1458-674b-4b7b-8808-9350e5983248", "node_type": "1", "metadata": {"window": "Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question. ", "original_text": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? "}, "hash": "2cfd6f8010ea0c15f5713c22690bb46b85cba89fa5a528195443cfcd155dbd8e", "class_name": "RelatedNodeInfo"}}, "text": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "start_char_idx": 1633, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90be1458-674b-4b7b-8808-9350e5983248": {"__data__": {"id_": "90be1458-674b-4b7b-8808-9350e5983248", "embedding": null, "metadata": {"window": "Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question. ", "original_text": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cca79382-7d43-4f82-b774-5d2ac106a84d", "node_type": "1", "metadata": {"window": "George Hill:  Yes.  Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "original_text": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7131f5105f4eb9c132a3043a53bc43c0624b75b2a7e7cd20292040779e595034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a348348c-b27a-4d68-8265-1af4a1f29674", "node_type": "1", "metadata": {"window": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "original_text": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n"}, "hash": "0235add6a10cd192adafeb23328798eee14b73f3e29e82f5c19ca708fc8788a4", "class_name": "RelatedNodeInfo"}}, "text": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "start_char_idx": 1777, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a348348c-b27a-4d68-8265-1af4a1f29674": {"__data__": {"id_": "a348348c-b27a-4d68-8265-1af4a1f29674", "embedding": null, "metadata": {"window": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "original_text": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90be1458-674b-4b7b-8808-9350e5983248", "node_type": "1", "metadata": {"window": "Good morning, guys.  Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question. ", "original_text": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ? ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b050a81d70aff3f3225f54bba93d7a76f989a6eed9a066799c57e3bc392bd014", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e14055a-0394-4da2-8502-e824f196a682", "node_type": "1", "metadata": {"window": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it. ", "original_text": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. "}, "hash": "34262e284a00c405d9117ee689aebc3ab386d6c7d8d4d3eec990a69512cd01d0", "class_name": "RelatedNodeInfo"}}, "text": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "start_char_idx": 2079, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e14055a-0394-4da2-8502-e824f196a682": {"__data__": {"id_": "1e14055a-0394-4da2-8502-e824f196a682", "embedding": null, "metadata": {"window": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it. ", "original_text": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a348348c-b27a-4d68-8265-1af4a1f29674", "node_type": "1", "metadata": {"window": "Jason, I have a question around the intersection of the \ncompetitive environment in Specialty.  The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "original_text": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8446afd9f4889cbc6ef3555f8e32eb47ac08b941b344fc782f809461c9b4e740", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d0014ee-2613-47a0-ac36-669a5157b2de", "node_type": "1", "metadata": {"window": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands. ", "original_text": "First of all, thanks for \nthe question. "}, "hash": "4db369c51a4c4576c0256c954ce6741ed42bc135d9f0e57de9176c39b354410c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "start_char_idx": 2227, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d0014ee-2613-47a0-ac36-669a5157b2de": {"__data__": {"id_": "6d0014ee-2613-47a0-ac36-669a5157b2de", "embedding": null, "metadata": {"window": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands. ", "original_text": "First of all, thanks for \nthe question. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e14055a-0394-4da2-8502-e824f196a682", "node_type": "1", "metadata": {"window": "The industry's been pretty stable  without any large contract \nswitches for a while, though we saw two kinds  of in the last handful of months.  And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it. ", "original_text": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be00a05bf9a2135a96bd1374ba9aad9e57a6ea8009e9dfff01e637f18aebaaad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b40063-df13-4df1-942a-325f659153b1", "node_type": "1", "metadata": {"window": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal. ", "original_text": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. "}, "hash": "d4c37c12a17f799a4bc910068f6257844b154559d21623da0557f78c2e44ec9d", "class_name": "RelatedNodeInfo"}}, "text": "First of all, thanks for \nthe question. ", "start_char_idx": 2310, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b40063-df13-4df1-942a-325f659153b1": {"__data__": {"id_": "d8b40063-df13-4df1-942a-325f659153b1", "embedding": null, "metadata": {"window": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal. ", "original_text": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d0014ee-2613-47a0-ac36-669a5157b2de", "node_type": "1", "metadata": {"window": "And my question is \nlike given the composition of assets in the Pharmaceutical business right now, are you seeing more of \na demand for what I would call like cross -functional service where people want to see core \npharmaceutical distribution with other parts of specialty as it relates to oncology ?  And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands. ", "original_text": "First of all, thanks for \nthe question. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dd067ac6ad320a056c2b7b07aca666905715c1c4f01817d6f118eddf3ded43f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things. ", "original_text": "We continue to be very thoughtful and disciplined \nin how we participate within it. "}, "hash": "66cb2d36b7b50ccd65af9f8a97aaecbbf5fba67c159a8f06ee8bb9d443936f20", "class_name": "RelatedNodeInfo"}}, "text": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "start_char_idx": 2350, "end_char_idx": 2586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd": {"__data__": {"id_": "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd", "embedding": null, "metadata": {"window": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things. ", "original_text": "We continue to be very thoughtful and disciplined \nin how we participate within it. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b40063-df13-4df1-942a-325f659153b1", "node_type": "1", "metadata": {"window": "And just trying to \nfigure out like how do you guys feel with the breadth of solutions that you offer as the  competitive \nenvironment evolves?  \n \n Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal. ", "original_text": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae8267148cb721ee7e18402df2ab169cc0a298d5b9d6765b7ff0eb7485c8fd3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b", "node_type": "1", "metadata": {"window": "First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "original_text": "And it's the exception of those contracts changing hands. "}, "hash": "cf17b1c9e9cdb2fe5f422fdaf81e98595c27e61244643f19575476c647bb6315", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be very thoughtful and disciplined \nin how we participate within it. ", "start_char_idx": 2586, "end_char_idx": 2670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b": {"__data__": {"id_": "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b", "embedding": null, "metadata": {"window": "First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "original_text": "And it's the exception of those contracts changing hands. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Y eah, t here's a couple of things I think about with this, George.  First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things. ", "original_text": "We continue to be very thoughtful and disciplined \nin how we participate within it. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2daff8ce9023006ce7d3448c2f0fcf99dceb3d71c7cbe1eb6b4f07f192149c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5b599d2-f238-4eca-9005-78dc165575d7", "node_type": "1", "metadata": {"window": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.  ", "original_text": "The vast \nmajority of contracts don't change hands as they come up for renewal. "}, "hash": "8cbd0e037b6ffb8210a882b401799cbd8993b9c789d78826565c1e88417fb4a9", "class_name": "RelatedNodeInfo"}}, "text": "And it's the exception of those contracts changing hands. ", "start_char_idx": 2670, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5b599d2-f238-4eca-9005-78dc165575d7": {"__data__": {"id_": "e5b599d2-f238-4eca-9005-78dc165575d7", "embedding": null, "metadata": {"window": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.  ", "original_text": "The vast \nmajority of contracts don't change hands as they come up for renewal. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b", "node_type": "1", "metadata": {"window": "First of all, thanks for \nthe question.  As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "original_text": "And it's the exception of those contracts changing hands. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8c23e9e7940c694fec667a748aee29d8d275446d5700739721dd46f9215c798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2db330d-df36-46db-bf87-75ee0a5b8818", "node_type": "1", "metadata": {"window": "We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n", "original_text": "So, I don't think that , that  \nchanges things. "}, "hash": "dd97938d25e83ef6d8110578f61c7aa794f92bb144a7aae3223d3a27ce7d85ee", "class_name": "RelatedNodeInfo"}}, "text": "The vast \nmajority of contracts don't change hands as they come up for renewal. ", "start_char_idx": 2728, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2db330d-df36-46db-bf87-75ee0a5b8818": {"__data__": {"id_": "a2db330d-df36-46db-bf87-75ee0a5b8818", "embedding": null, "metadata": {"window": "We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n", "original_text": "So, I don't think that , that  \nchanges things. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5b599d2-f238-4eca-9005-78dc165575d7", "node_type": "1", "metadata": {"window": "As I step back and think about just the backdrop of your question on the competitive \nenvironment, while there are a couple of changing hands, as you highlight ed, I think the overall \nmarket continues to behave in a very rational way.  We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.  ", "original_text": "The vast \nmajority of contracts don't change hands as they come up for renewal. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4f03616d6509f75d4dc7895b5c470146f00fc04a5c9524399e61da402e3fb23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "913230bc-7001-4cd0-979f-f2e28fc13c6c", "node_type": "1", "metadata": {"window": "And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services. ", "original_text": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. "}, "hash": "a591920d399810fe53ddaf2c56204457afaf19d770f38f68acff7f7f675b7b27", "class_name": "RelatedNodeInfo"}}, "text": "So, I don't think that , that  \nchanges things. ", "start_char_idx": 2808, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "913230bc-7001-4cd0-979f-f2e28fc13c6c": {"__data__": {"id_": "913230bc-7001-4cd0-979f-f2e28fc13c6c", "embedding": null, "metadata": {"window": "And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services. ", "original_text": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2db330d-df36-46db-bf87-75ee0a5b8818", "node_type": "1", "metadata": {"window": "We continue to be very thoughtful and disciplined \nin how we participate within it.  And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n", "original_text": "So, I don't think that , that  \nchanges things. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d19d6b10e9cd777a05682b640bafce4d232334dea5accb12453c67378075190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54d58bbc-186e-4ca7-87e8-69d46a882ce1", "node_type": "1", "metadata": {"window": "The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further. ", "original_text": "That \nhasn't changed.  "}, "hash": "3857d63407c13c4be43526df6c17f9719179ca09835f72475a5c048ead73eb39", "class_name": "RelatedNodeInfo"}}, "text": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "start_char_idx": 2856, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54d58bbc-186e-4ca7-87e8-69d46a882ce1": {"__data__": {"id_": "54d58bbc-186e-4ca7-87e8-69d46a882ce1", "embedding": null, "metadata": {"window": "The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further. ", "original_text": "That \nhasn't changed.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "913230bc-7001-4cd0-979f-f2e28fc13c6c", "node_type": "1", "metadata": {"window": "And it's the exception of those contracts changing hands.  The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services. ", "original_text": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503a38d92568ce8bb04852fe5811035d20c14c4eaa9d981a09f31fcbeff7b573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb", "node_type": "1", "metadata": {"window": "So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "original_text": "Now I think your question is, are there other elements that make that evolve further? \n"}, "hash": "0cc0d8154e176f6aa47f2a72209213de34f775eae3d0c852c45f934a65fe6b50", "class_name": "RelatedNodeInfo"}}, "text": "That \nhasn't changed.  ", "start_char_idx": 3041, "end_char_idx": 3064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb": {"__data__": {"id_": "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb", "embedding": null, "metadata": {"window": "So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "original_text": "Now I think your question is, are there other elements that make that evolve further? \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54d58bbc-186e-4ca7-87e8-69d46a882ce1", "node_type": "1", "metadata": {"window": "The vast \nmajority of contracts don't change hands as they come up for renewal.  So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further. ", "original_text": "That \nhasn't changed.  ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab4d7d4ae42c75bb630b9934423e47e799d788b6c87c58669226427806648d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "266eb1d3-7163-4e0a-b2c9-f7c99322c833", "node_type": "1", "metadata": {"window": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused. ", "original_text": "Hey, we've got the full suite of services. "}, "hash": "333554b9c80779d4887b060d863d0357e98dd841df30ac0bb026f816046e5338", "class_name": "RelatedNodeInfo"}}, "text": "Now I think your question is, are there other elements that make that evolve further? \n", "start_char_idx": 3064, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "266eb1d3-7163-4e0a-b2c9-f7c99322c833": {"__data__": {"id_": "266eb1d3-7163-4e0a-b2c9-f7c99322c833", "embedding": null, "metadata": {"window": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused. ", "original_text": "Hey, we've got the full suite of services. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb", "node_type": "1", "metadata": {"window": "So, I don't think that , that  \nchanges things.  And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "original_text": "Now I think your question is, are there other elements that make that evolve further? \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a864206ee215938f7bee3f03c1cdd702f65be7727f9a3d639a8130f0502a3cce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792fb1bd-bed7-483f-b0fc-ff21ae2accfb", "node_type": "1", "metadata": {"window": "That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from. ", "original_text": "We are building those out further. "}, "hash": "cfee6d784a677847c247f3109ed2dd7b84eba58cc94e5ea03c424e7c8d8a4672", "class_name": "RelatedNodeInfo"}}, "text": "Hey, we've got the full suite of services. ", "start_char_idx": 3151, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792fb1bd-bed7-483f-b0fc-ff21ae2accfb": {"__data__": {"id_": "792fb1bd-bed7-483f-b0fc-ff21ae2accfb", "embedding": null, "metadata": {"window": "That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from. ", "original_text": "We are building those out further. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "266eb1d3-7163-4e0a-b2c9-f7c99322c833", "node_type": "1", "metadata": {"window": "And while you're still stepping back from everything, our role, ultimately, on the \ndistribution side is to safely, securely , and efficiently deliver these products for our customers.  That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused. ", "original_text": "Hey, we've got the full suite of services. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa243a11fce1a5b8cfa6c23a6690ab1b92cadb95c265e3fbe11798ee89b25238", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8ab1445-7e03-45de-b72e-be2b8a93b3c1", "node_type": "1", "metadata": {"window": "Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n", "original_text": "I think our customers \nalways are looki ng for opportunities where we can add additional value. "}, "hash": "4d3fdd62af52670280cb2d2595dec16a431587debeca832a4cb06340e2676dd3", "class_name": "RelatedNodeInfo"}}, "text": "We are building those out further. ", "start_char_idx": 3194, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8ab1445-7e03-45de-b72e-be2b8a93b3c1": {"__data__": {"id_": "f8ab1445-7e03-45de-b72e-be2b8a93b3c1", "embedding": null, "metadata": {"window": "Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n", "original_text": "I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792fb1bd-bed7-483f-b0fc-ff21ae2accfb", "node_type": "1", "metadata": {"window": "That \nhasn't changed.   Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from. ", "original_text": "We are building those out further. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "653eb5461ab0108ca967d07d9b51416cf5bf9fd62784c837e3e863be20981622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b50939a-147e-4501-869a-f2d229e020b6", "node_type": "1", "metadata": {"window": "Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "That hasn't changed either, it \njust evolves as to where they are most focused. "}, "hash": "523df4977e2df47f469184f217c0c96a3a47d703fb0f74aa78306bb3497e09af", "class_name": "RelatedNodeInfo"}}, "text": "I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "start_char_idx": 3229, "end_char_idx": 3325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b50939a-147e-4501-869a-f2d229e020b6": {"__data__": {"id_": "7b50939a-147e-4501-869a-f2d229e020b6", "embedding": null, "metadata": {"window": "Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "That hasn't changed either, it \njust evolves as to where they are most focused. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8ab1445-7e03-45de-b72e-be2b8a93b3c1", "node_type": "1", "metadata": {"window": "Now I think your question is, are there other elements that make that evolve further? \n Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n", "original_text": "I think our customers \nalways are looki ng for opportunities where we can add additional value. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc2af32fd0e6e345952dd6fce4fda7499a71f5b5db1db2ca07e5ddf424aa0ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20a477e8-e235-42cd-8288-57711b64738a", "node_type": "1", "metadata": {"window": "We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And each customer has a little bit different value \nproposition from which to build from. "}, "hash": "1eb91056f895b7ca5c6d9276ab0c9c9e27cdb4e2a03cc94a3ef6439889a60b25", "class_name": "RelatedNodeInfo"}}, "text": "That hasn't changed either, it \njust evolves as to where they are most focused. ", "start_char_idx": 3325, "end_char_idx": 3405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20a477e8-e235-42cd-8288-57711b64738a": {"__data__": {"id_": "20a477e8-e235-42cd-8288-57711b64738a", "embedding": null, "metadata": {"window": "We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And each customer has a little bit different value \nproposition from which to build from. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b50939a-147e-4501-869a-f2d229e020b6", "node_type": "1", "metadata": {"window": "Hey, we've got the full suite of services.  We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "That hasn't changed either, it \njust evolves as to where they are most focused. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c0382e3a7bf857735449a033ed847c8ea79a3f7cd7b2342db5e646b76e7f82e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8663a03-caa7-4683-b01e-1a836bf3675a", "node_type": "1", "metadata": {"window": "I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "So that will resonate better wit h some customers than others. \n"}, "hash": "db6f14b7b85f015acc2fceb8a6b7113e38178018ba1ed979a9961b6d6c61f184", "class_name": "RelatedNodeInfo"}}, "text": "And each customer has a little bit different value \nproposition from which to build from. ", "start_char_idx": 3405, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8663a03-caa7-4683-b01e-1a836bf3675a": {"__data__": {"id_": "f8663a03-caa7-4683-b01e-1a836bf3675a", "embedding": null, "metadata": {"window": "I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "So that will resonate better wit h some customers than others. \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20a477e8-e235-42cd-8288-57711b64738a", "node_type": "1", "metadata": {"window": "We are building those out further.  I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And each customer has a little bit different value \nproposition from which to build from. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e7f2a3c1f16bb2c9eff18d913a25bcac332ee40e14542b11fea746e4abf1eb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f5c1589-07b8-4f17-802d-eaa8b931507d", "node_type": "1", "metadata": {"window": "That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n "}, "hash": "1541c0ddbcf7333c2143f39cc746a3ec64063bd66e943b9e188f8ab52086d136", "class_name": "RelatedNodeInfo"}}, "text": "So that will resonate better wit h some customers than others. \n", "start_char_idx": 3495, "end_char_idx": 3559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f5c1589-07b8-4f17-802d-eaa8b931507d": {"__data__": {"id_": "0f5c1589-07b8-4f17-802d-eaa8b931507d", "embedding": null, "metadata": {"window": "That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390808cdce1e7940eda5362bbc196769a2debc0d11e283a05e4720c508594aeb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8663a03-caa7-4683-b01e-1a836bf3675a", "node_type": "1", "metadata": {"window": "I think our customers \nalways are looki ng for opportunities where we can add additional value.  That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "So that will resonate better wit h some customers than others. \n", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a514da8afc5fc8ff74ca92a5c794577357f508ed75ad9cb1abc3599fe1ea76e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bfc3cd9-7962-4efa-bd9b-7a7e07c18046", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan. ", "original_text": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks . "}, "hash": "e8d6e62c3201dcdc1d7e4ecfb6be889beac4fab271314a9fee34a7a84c124259", "class_name": "RelatedNodeInfo"}}, "text": "And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "start_char_idx": 3559, "end_char_idx": 3774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bfc3cd9-7962-4efa-bd9b-7a7e07c18046": {"__data__": {"id_": "6bfc3cd9-7962-4efa-bd9b-7a7e07c18046", "embedding": null, "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan. ", "original_text": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks . ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f5c1589-07b8-4f17-802d-eaa8b931507d", "node_type": "1", "metadata": {"window": "That hasn't changed either, it \njust evolves as to where they are most focused.  And each customer has a little bit different value \nproposition from which to build from.  So that will resonate better wit h some customers than others. \n And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "original_text": "And our objective is to continue to build out those capabilities, both upstream and downstream, so \nthat we can be that full -service supplier and partner to ensure that we can help them to grow their \nbusiness.  \n ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "283f26677b112ae808a4d4ee9577b65e2e657ebae77e06b11ad5d7bfb5e41029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27fe7f73-2202-4bcc-b948-a93339f65b53", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks. ", "original_text": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n"}, "hash": "4e8b352c3e6481126669988327ffa75ffbd3ac15730c641cd85b30760a5762c8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks . ", "start_char_idx": 0, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27fe7f73-2202-4bcc-b948-a93339f65b53": {"__data__": {"id_": "27fe7f73-2202-4bcc-b948-a93339f65b53", "embedding": null, "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks. ", "original_text": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bfc3cd9-7962-4efa-bd9b-7a7e07c18046", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan. ", "original_text": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks . ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "884176f7e17ac0b6e2b1fa2c4983529b623ee543e7e60f82d9b3f6248331c12a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a090a661-572b-4de5-8c75-91151545025c", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n", "original_text": "Operator:  Thank you. "}, "hash": "3471712ba98ad8863888e19e7807099c031b96ea4faadae472f5b27f9cd94142", "class_name": "RelatedNodeInfo"}}, "text": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n", "start_char_idx": 155, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a090a661-572b-4de5-8c75-91151545025c": {"__data__": {"id_": "a090a661-572b-4de5-8c75-91151545025c", "embedding": null, "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n", "original_text": "Operator:  Thank you. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27fe7f73-2202-4bcc-b948-a93339f65b53", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks. ", "original_text": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e97177c45df803c9f5d9e0e81df6676700d39781db25502fe43535fcfd6f1291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3500c88-ba41-4663-b711-ec92ade04afe", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you. ", "original_text": "We now move to Lisa Gill of JP  Morgan. "}, "hash": "ff9fbcc7f47f2e1397bbfa4bb0341c3461536c71230d52992834f30276b797d3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 324, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3500c88-ba41-4663-b711-ec92ade04afe": {"__data__": {"id_": "e3500c88-ba41-4663-b711-ec92ade04afe", "embedding": null, "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you. ", "original_text": "We now move to Lisa Gill of JP  Morgan. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a090a661-572b-4de5-8c75-91151545025c", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n", "original_text": "Operator:  Thank you. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9f76acb1f066e75d29393730c39054ec6f8cde9900db3208866dd9dd7316925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7812593-0215-496e-af1c-be6aa35503fe", "node_type": "1", "metadata": {"window": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work. ", "original_text": "Thanks. "}, "hash": "a42dba1599835f4c869281e396636ce9b461520956d6d0959a01de39f966f982", "class_name": "RelatedNodeInfo"}}, "text": "We now move to Lisa Gill of JP  Morgan. ", "start_char_idx": 346, "end_char_idx": 386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7812593-0215-496e-af1c-be6aa35503fe": {"__data__": {"id_": "c7812593-0215-496e-af1c-be6aa35503fe", "embedding": null, "metadata": {"window": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3500c88-ba41-4663-b711-ec92ade04afe", "node_type": "1", "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you. ", "original_text": "We now move to Lisa Gill of JP  Morgan. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d50dffdd1132cd018e6c5f675dc13acf6af4ea53c2c7425cdd33328be21121b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14c7607d-1b06-4d3f-aef6-ae304138d057", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "original_text": "Please go ahead again , \nma'am.  \n \n"}, "hash": "81af0a8cdc2b7bd7dec460516d21ecc214d8e2c9664088085a1e0a69a1617d0a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 386, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14c7607d-1b06-4d3f-aef6-ae304138d057": {"__data__": {"id_": "14c7607d-1b06-4d3f-aef6-ae304138d057", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "original_text": "Please go ahead again , \nma'am.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7812593-0215-496e-af1c-be6aa35503fe", "node_type": "1", "metadata": {"window": "Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1acc9325a49d6eb6e2bd443bd4e0233d6aec766176d5f5b262ac3d0f5898a51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa4ddced-2236-4a44-9666-def27c5c5966", "node_type": "1", "metadata": {"window": "We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025? ", "original_text": "Lisa Gill:  Good morning  and thank you. "}, "hash": "69053a0023c29783ce793bd6eb1bc0afd0411806d6f568439aabdd75257cb168", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead again , \nma'am.  \n \n", "start_char_idx": 394, "end_char_idx": 430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa4ddced-2236-4a44-9666-def27c5c5966": {"__data__": {"id_": "aa4ddced-2236-4a44-9666-def27c5c5966", "embedding": null, "metadata": {"window": "We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025? ", "original_text": "Lisa Gill:  Good morning  and thank you. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14c7607d-1b06-4d3f-aef6-ae304138d057", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "original_text": "Please go ahead again , \nma'am.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f26f1f8f73664aceb63dd0cda6f66e4f34e431d878a8fa9bafaad6023d9b9e68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec6cfd84-18d4-40ec-9cba-aafd702c6053", "node_type": "1", "metadata": {"window": "Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "original_text": "And hopefully, this time it will work. "}, "hash": "bf28ecaca7c7c8b9d3bda0255ed5b828a4509ce09aa2abf9b9b4c787ee07a125", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Good morning  and thank you. ", "start_char_idx": 430, "end_char_idx": 471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec6cfd84-18d4-40ec-9cba-aafd702c6053": {"__data__": {"id_": "ec6cfd84-18d4-40ec-9cba-aafd702c6053", "embedding": null, "metadata": {"window": "Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "original_text": "And hopefully, this time it will work. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa4ddced-2236-4a44-9666-def27c5c5966", "node_type": "1", "metadata": {"window": "We now move to Lisa Gill of JP  Morgan.  Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025? ", "original_text": "Lisa Gill:  Good morning  and thank you. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e83080d26dfea39ba4cf18f73514ec186e3524bb5d80a5528776299984c30ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7", "node_type": "1", "metadata": {"window": "Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay. ", "original_text": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. "}, "hash": "05aa03d3a723dc47d3c57f7e6171121ffc13b6354d098db24e98ca294f6959c6", "class_name": "RelatedNodeInfo"}}, "text": "And hopefully, this time it will work. ", "start_char_idx": 471, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7": {"__data__": {"id_": "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7", "embedding": null, "metadata": {"window": "Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay. ", "original_text": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec6cfd84-18d4-40ec-9cba-aafd702c6053", "node_type": "1", "metadata": {"window": "Thanks.  Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "original_text": "And hopefully, this time it will work. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887bfa9182e1c72d82723f8906cd2c6e5b4c6dc8f1c5b3ba1bcd268fa0a9a7f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc9dc170-2e15-4dd6-9385-b3a7b21782c3", "node_type": "1", "metadata": {"window": "Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that. ", "original_text": "As I think about the cadence for \n2025? "}, "hash": "6f464c8057b17140778f48c55c8e3decee282d85d4a03e97ff03d2040b6be5b6", "class_name": "RelatedNodeInfo"}}, "text": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "start_char_idx": 510, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc9dc170-2e15-4dd6-9385-b3a7b21782c3": {"__data__": {"id_": "fc9dc170-2e15-4dd6-9385-b3a7b21782c3", "embedding": null, "metadata": {"window": "Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that. ", "original_text": "As I think about the cadence for \n2025? ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7", "node_type": "1", "metadata": {"window": "Please go ahead again , \nma'am.  \n \n Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay. ", "original_text": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd6c72941b7e6f3319e6463c99d87593e8925e14f7f6590a4b25d38a6e67e732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41f20d92-95c4-4237-8884-051e2034775a", "node_type": "1", "metadata": {"window": "And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n", "original_text": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n"}, "hash": "1ac0962a8fbc80833f2d2d37dea5b02450e58b96fdd4070ab9a1a7e31a0b8adb", "class_name": "RelatedNodeInfo"}}, "text": "As I think about the cadence for \n2025? ", "start_char_idx": 607, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41f20d92-95c4-4237-8884-051e2034775a": {"__data__": {"id_": "41f20d92-95c4-4237-8884-051e2034775a", "embedding": null, "metadata": {"window": "And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n", "original_text": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc9dc170-2e15-4dd6-9385-b3a7b21782c3", "node_type": "1", "metadata": {"window": "Lisa Gill:  Good morning  and thank you.  And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that. ", "original_text": "As I think about the cadence for \n2025? ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6ea92309f434336c27c8a635a092368d7f62064d85393957318c8c899a4ff21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4", "node_type": "1", "metadata": {"window": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "original_text": "Operator:  Okay. "}, "hash": "f8e2a429d59c81b3cb39e29a8c8f85734c74b40d7cb4a18f5985a6fcc0f4b4ca", "class_name": "RelatedNodeInfo"}}, "text": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "start_char_idx": 647, "end_char_idx": 846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4": {"__data__": {"id_": "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4", "embedding": null, "metadata": {"window": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "original_text": "Operator:  Okay. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41f20d92-95c4-4237-8884-051e2034775a", "node_type": "1", "metadata": {"window": "And hopefully, this time it will work.  So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n", "original_text": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3563c4ff8739d99cba7339a00a3716625a241e7bc460811fe3b35517c7baadc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8de2a458-2ffe-4827-b952-43c42d8272a9", "node_type": "1", "metadata": {"window": "As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "original_text": "Very sorry about that. "}, "hash": "08b9a23869bf6a94efb14f8d0912d051643b3d8eb3d7c44e0c0cef1163d2ecec", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Okay. ", "start_char_idx": 846, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8de2a458-2ffe-4827-b952-43c42d8272a9": {"__data__": {"id_": "8de2a458-2ffe-4827-b952-43c42d8272a9", "embedding": null, "metadata": {"window": "As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "original_text": "Very sorry about that. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4", "node_type": "1", "metadata": {"window": "So , my question was \nactually asked, but I want to just really dig in just a little bit deeper.  As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "original_text": "Operator:  Okay. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cb5e654cb0fbbc64c8e0c18672b21f831c2dcc1903c130e8455b119fd9ad931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49f8c2e-1991-4705-8d06-5c8b74bbb151", "node_type": "1", "metadata": {"window": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "original_text": "It would appear I'm very sorry [indiscernible].  \n"}, "hash": "cd1b4eba02d9a6bb7e714e734dec722c3393373f9063c02915d2be1a0e2ccc93", "class_name": "RelatedNodeInfo"}}, "text": "Very sorry about that. ", "start_char_idx": 863, "end_char_idx": 886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b49f8c2e-1991-4705-8d06-5c8b74bbb151": {"__data__": {"id_": "b49f8c2e-1991-4705-8d06-5c8b74bbb151", "embedding": null, "metadata": {"window": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "original_text": "It would appear I'm very sorry [indiscernible].  \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8de2a458-2ffe-4827-b952-43c42d8272a9", "node_type": "1", "metadata": {"window": "As I think about the cadence for \n2025?  I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "original_text": "Very sorry about that. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2e0f1375bd456f251b448be23e378ee2f3fa193923694de35725276883d3476", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb785eeb-7989-4c58-8aa8-67ff22696e5b", "node_type": "1", "metadata": {"window": "Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "original_text": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. "}, "hash": "5cb604da2c0555d85ddf20ad9c452faa46aa5e7a0a3bf97153ca7110c411d933", "class_name": "RelatedNodeInfo"}}, "text": "It would appear I'm very sorry [indiscernible].  \n", "start_char_idx": 886, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb785eeb-7989-4c58-8aa8-67ff22696e5b": {"__data__": {"id_": "bb785eeb-7989-4c58-8aa8-67ff22696e5b", "embedding": null, "metadata": {"window": "Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "original_text": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49f8c2e-1991-4705-8d06-5c8b74bbb151", "node_type": "1", "metadata": {"window": "I know you're not giving specific guidance, but maybe even first half, second half as we think \nabout some of the comments you  made, for example, simplifying costs, right, that [indiscernible].  \n \n Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "original_text": "It would appear I'm very sorry [indiscernible].  \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0827a8168af7fd931878805505cbb1253713ee68c4334380c1c08065bfd1d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "893ef4ad-12c6-4ae9-8945-28af4836b472", "node_type": "1", "metadata": {"window": "Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "original_text": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. "}, "hash": "32886f0c57ef6a494af7eec24ce673bc4f442676ea038f97ed0f912f547bb4a7", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "start_char_idx": 936, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "893ef4ad-12c6-4ae9-8945-28af4836b472": {"__data__": {"id_": "893ef4ad-12c6-4ae9-8945-28af4836b472", "embedding": null, "metadata": {"window": "Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "original_text": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb785eeb-7989-4c58-8aa8-67ff22696e5b", "node_type": "1", "metadata": {"window": "Operator:  Okay.  Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "original_text": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aa9357f195f64f93f1ab719c9e3a914818cf5ccf9bb580fcbd056c15b1329fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78568140-0523-47ae-b948-d5cfdee20109", "node_type": "1", "metadata": {"window": "It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in. ", "original_text": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. "}, "hash": "d8b63a0e4ce9450446705a3ae130c2a8ec951c878ad44a7f35167e412e5082eb", "class_name": "RelatedNodeInfo"}}, "text": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "start_char_idx": 1066, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78568140-0523-47ae-b948-d5cfdee20109": {"__data__": {"id_": "78568140-0523-47ae-b948-d5cfdee20109", "embedding": null, "metadata": {"window": "It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in. ", "original_text": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "893ef4ad-12c6-4ae9-8945-28af4836b472", "node_type": "1", "metadata": {"window": "Very sorry about that.  It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "original_text": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f72aa17216aa96dd9e60539f614b1c2fe934e911cf2b22e459ba527def965b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3920b587-72af-4337-b0e9-c6b19cdbbc85", "node_type": "1", "metadata": {"window": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "original_text": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year. "}, "hash": "fb79e32d7e65c0c647b5ebd37926e9c6ad9f29f49392c1450cc1788e48eb2851", "class_name": "RelatedNodeInfo"}}, "text": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "start_char_idx": 1175, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3920b587-72af-4337-b0e9-c6b19cdbbc85": {"__data__": {"id_": "3920b587-72af-4337-b0e9-c6b19cdbbc85", "embedding": null, "metadata": {"window": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "original_text": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78568140-0523-47ae-b948-d5cfdee20109", "node_type": "1", "metadata": {"window": "It would appear I'm very sorry [indiscernible].  \n Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in. ", "original_text": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c3cfc44d75c21ec4028ad9c53136f6ca18e249f4ae93af94d6c596e407ac88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b55c6268-43cd-4784-8063-93d0208951e1", "node_type": "1", "metadata": {"window": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "original_text": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously. "}, "hash": "12ba262d13e17ccad504a3e42e2860da0e46135221be0fa73fbf4c44f3169377", "class_name": "RelatedNodeInfo"}}, "text": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "start_char_idx": 1269, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b55c6268-43cd-4784-8063-93d0208951e1": {"__data__": {"id_": "b55c6268-43cd-4784-8063-93d0208951e1", "embedding": null, "metadata": {"window": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "original_text": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3920b587-72af-4337-b0e9-c6b19cdbbc85", "node_type": "1", "metadata": {"window": "Jason Hollar:  I think we can understand where she was going with trying to build out further for first \nhalf versus second half.  So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "original_text": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "970eda905382b152feaf237b7e1bebd2a517c579e55433814c1d0bfda4d627bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4189cc94-0d19-4b0b-97a5-bbb6c4a88020", "node_type": "1", "metadata": {"window": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "original_text": "And then the other business that we've \nwon, some of it is already feathering in. "}, "hash": "c04dc27bcc37acde3a431988210211b434f1cab628ed8bf684f4eff797bbdee0", "class_name": "RelatedNodeInfo"}}, "text": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "start_char_idx": 1347, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4189cc94-0d19-4b0b-97a5-bbb6c4a88020": {"__data__": {"id_": "4189cc94-0d19-4b0b-97a5-bbb6c4a88020", "embedding": null, "metadata": {"window": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "original_text": "And then the other business that we've \nwon, some of it is already feathering in. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b55c6268-43cd-4784-8063-93d0208951e1", "node_type": "1", "metadata": {"window": "So, the one thing I would stress, let's talk about the puts and takes and the \ntiming of the puts and takes.  So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "original_text": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c5a5258ebc71ba4a38a061fe3d260a8088375c166db27336cd67e7338f0f954", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd", "node_type": "1", "metadata": {"window": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter. ", "original_text": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. "}, "hash": "a7c5875726dbcabbae55c9bc9580b9c997a408c2c4e4d569e330384622c12ac2", "class_name": "RelatedNodeInfo"}}, "text": "And then the other business that we've \nwon, some of it is already feathering in. ", "start_char_idx": 1424, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd": {"__data__": {"id_": "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd", "embedding": null, "metadata": {"window": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter. ", "original_text": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4189cc94-0d19-4b0b-97a5-bbb6c4a88020", "node_type": "1", "metadata": {"window": "So, this customer migration will be somewhat of a cliff event at the end \nof the fiscal year.  So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "original_text": "And then the other business that we've \nwon, some of it is already feathering in. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d9f705e9d409e91e38ea2212daa0b31dc7bb01d60752ddf42f81556f3f843eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "735aa3a4-bb8c-45b0-a18b-1664970d188d", "node_type": "1", "metadata": {"window": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "original_text": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . "}, "hash": "b24a8e9348c291be6ac3c9fbd02b8230b58a2ba9b38c30474aaba13e47b44b9c", "class_name": "RelatedNodeInfo"}}, "text": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "start_char_idx": 1506, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "735aa3a4-bb8c-45b0-a18b-1664970d188d": {"__data__": {"id_": "735aa3a4-bb8c-45b0-a18b-1664970d188d", "embedding": null, "metadata": {"window": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "original_text": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd", "node_type": "1", "metadata": {"window": "So, the June 30 to July 1, which is exactly the beginning of the fiscal year.  So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter. ", "original_text": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b902f5417aa640150fbe91bbeea07da909332a3f95996ad384ae44ab15d3692", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7a5db69-170c-4c81-9dc0-dbab01869369", "node_type": "1", "metadata": {"window": "And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied. ", "original_text": "I \nreferenced that is a nice tailwind that is going to start benefiting us. "}, "hash": "8697464ef29795f40a161e571ff94c60bd87a496d00046e8d3d5476c174d9e4d", "class_name": "RelatedNodeInfo"}}, "text": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "start_char_idx": 1657, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7a5db69-170c-4c81-9dc0-dbab01869369": {"__data__": {"id_": "c7a5db69-170c-4c81-9dc0-dbab01869369", "embedding": null, "metadata": {"window": "And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied. ", "original_text": "I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "735aa3a4-bb8c-45b0-a18b-1664970d188d", "node_type": "1", "metadata": {"window": "So that \nfirst quarter, we'll see that volume drop off fairly precipitously.  And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "original_text": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks . ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0aaf5209b48c548acca98ea3c8bce3f3f926b2e927c234a382e61b2ee5d5b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f98e191e-cef7-4710-832b-56bd8aeedff0", "node_type": "1", "metadata": {"window": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time. ", "original_text": "It's included in our guidance for \nthe fourth quarter. "}, "hash": "8584893789560aeb3b7d09c98ab79bb74d3682205a7b6989a766ec99407186a1", "class_name": "RelatedNodeInfo"}}, "text": "I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "start_char_idx": 1781, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f98e191e-cef7-4710-832b-56bd8aeedff0": {"__data__": {"id_": "f98e191e-cef7-4710-832b-56bd8aeedff0", "embedding": null, "metadata": {"window": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time. ", "original_text": "It's included in our guidance for \nthe fourth quarter. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7a5db69-170c-4c81-9dc0-dbab01869369", "node_type": "1", "metadata": {"window": "And then the other business that we've \nwon, some of it is already feathering in.  Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied. ", "original_text": "I \nreferenced that is a nice tailwind that is going to start benefiting us. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fc4234cddd318110d7d44794d84bfe92a2efd35bd5e926085fb9ab7cc383adc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eea1d7ba-fd18-4e03-aaaf-a43b7de23042", "node_type": "1", "metadata": {"window": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n", "original_text": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  "}, "hash": "3fb5fe84c600674eef306a3ef2ff296a16c3368797bd5db564999831add55fe4", "class_name": "RelatedNodeInfo"}}, "text": "It's included in our guidance for \nthe fourth quarter. ", "start_char_idx": 1857, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eea1d7ba-fd18-4e03-aaaf-a43b7de23042": {"__data__": {"id_": "eea1d7ba-fd18-4e03-aaaf-a43b7de23042", "embedding": null, "metadata": {"window": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n", "original_text": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f98e191e-cef7-4710-832b-56bd8aeedff0", "node_type": "1", "metadata": {"window": "Some of that will contin ue over the course of the year, and \nwe've highlighted in our comments, a lot of it will be in the second half of fiscal '25.  So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time. ", "original_text": "It's included in our guidance for \nthe fourth quarter. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b28ed483a39dcf136c93aef1e7ae54cfc41abb9c05aac7318f406f1762afed0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d", "node_type": "1", "metadata": {"window": "I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume. ", "original_text": "The other cost actions will be varied. "}, "hash": "ee4d24266133929f205dee2313160b4146c8b5c0c1588cd3c9be727d13132f4a", "class_name": "RelatedNodeInfo"}}, "text": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "start_char_idx": 1912, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d": {"__data__": {"id_": "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d", "embedding": null, "metadata": {"window": "I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume. ", "original_text": "The other cost actions will be varied. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eea1d7ba-fd18-4e03-aaaf-a43b7de23042", "node_type": "1", "metadata": {"window": "So, the timing of \nthat piece of the pu ts and takes will be a little bit more second half weighted , especially networks .  I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n", "original_text": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.  ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80bbe2b19b5141a48f5fa89bcf5007c07ce9b4aa950bed8b50209ba4ffb0549d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a8a019f-f6a6-4e94-86d6-6603492afc02", "node_type": "1", "metadata": {"window": "It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "original_text": "There are some things we've been planning for \nthis for quite some  time. "}, "hash": "f63ffe86ecc29523dc20231e43d2cd2ff5ba303c09521f3ebb719457b0c39d5e", "class_name": "RelatedNodeInfo"}}, "text": "The other cost actions will be varied. ", "start_char_idx": 2114, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a8a019f-f6a6-4e94-86d6-6603492afc02": {"__data__": {"id_": "7a8a019f-f6a6-4e94-86d6-6603492afc02", "embedding": null, "metadata": {"window": "It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "original_text": "There are some things we've been planning for \nthis for quite some  time. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d", "node_type": "1", "metadata": {"window": "I \nreferenced that is a nice tailwind that is going to start benefiting us.  It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume. ", "original_text": "The other cost actions will be varied. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12c9ad8806f4d6d150ef2749838bb8e613acb821b936c751e99093a189da98ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d24dfe06-220f-4805-9f3c-fe4c07f41de4", "node_type": "1", "metadata": {"window": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "original_text": "And so, some of those cost actions will be in place by the end of the year. \n"}, "hash": "1308082acd105e3e3ec43a150815f1287b0607fa2e1d99efa62cbdad100a4af8", "class_name": "RelatedNodeInfo"}}, "text": "There are some things we've been planning for \nthis for quite some  time. ", "start_char_idx": 2153, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d24dfe06-220f-4805-9f3c-fe4c07f41de4": {"__data__": {"id_": "d24dfe06-220f-4805-9f3c-fe4c07f41de4", "embedding": null, "metadata": {"window": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "original_text": "And so, some of those cost actions will be in place by the end of the year. \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a8a019f-f6a6-4e94-86d6-6603492afc02", "node_type": "1", "metadata": {"window": "It's included in our guidance for \nthe fourth quarter.  But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "original_text": "There are some things we've been planning for \nthis for quite some  time. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a04b30f5ca2ad7b0a0df2fb3129f875545983b58d87cf0b4428cc58dde22952", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "805d523d-5610-460b-846a-3e1b4600863e", "node_type": "1", "metadata": {"window": "The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "original_text": "Some of those will need to take time to allow our operations to settle with that lower volume. "}, "hash": "34e3b3486a70f224d2af89c55e72025fa038b683fd5239472fff41ca3fe89033", "class_name": "RelatedNodeInfo"}}, "text": "And so, some of those cost actions will be in place by the end of the year. \n", "start_char_idx": 2227, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "805d523d-5610-460b-846a-3e1b4600863e": {"__data__": {"id_": "805d523d-5610-460b-846a-3e1b4600863e", "embedding": null, "metadata": {"window": "The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "original_text": "Some of those will need to take time to allow our operations to settle with that lower volume. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d24dfe06-220f-4805-9f3c-fe4c07f41de4", "node_type": "1", "metadata": {"window": "But we'll have 3 quarters of year -over-year performance driven by that business \nbeing added in and continued just overall growt h of utilization over the course of next year that we \nexpect as well.   The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "original_text": "And so, some of those cost actions will be in place by the end of the year. \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3389ca86912982d0ddeb8cc0b3979c352e4f4bf3c6eec8b9a0d652d7c8b0623c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5a630cf-cb88-429a-ba77-9724db53b5c8", "node_type": "1", "metadata": {"window": "There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "original_text": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  "}, "hash": "b1bb36c7cad2d8a53b4d31efda3f59059d89e6af42bc0b3bb746cdee89fa11ff", "class_name": "RelatedNodeInfo"}}, "text": "Some of those will need to take time to allow our operations to settle with that lower volume. ", "start_char_idx": 2304, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5a630cf-cb88-429a-ba77-9724db53b5c8": {"__data__": {"id_": "d5a630cf-cb88-429a-ba77-9724db53b5c8", "embedding": null, "metadata": {"window": "There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "original_text": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "805d523d-5610-460b-846a-3e1b4600863e", "node_type": "1", "metadata": {"window": "The other cost actions will be varied.  There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "original_text": "Some of those will need to take time to allow our operations to settle with that lower volume. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56540ff106d76e42309bae0760dae041a5d27e2483bc722c8ba64a8ed45ce34d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b502215-b55b-49bf-b7fb-090f91df898c", "node_type": "1", "metadata": {"window": "And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "original_text": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. "}, "hash": "cc65e92ce242400def601cdfb35ea3aa9a3608f45e2246da44de6324cba4530d", "class_name": "RelatedNodeInfo"}}, "text": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "start_char_idx": 2399, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b502215-b55b-49bf-b7fb-090f91df898c": {"__data__": {"id_": "8b502215-b55b-49bf-b7fb-090f91df898c", "embedding": null, "metadata": {"window": "And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "original_text": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5a630cf-cb88-429a-ba77-9724db53b5c8", "node_type": "1", "metadata": {"window": "There are some things we've been planning for \nthis for quite some  time.  And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "original_text": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.  ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33e9e26b6fb91ebc3c84fe9e85108e8494d2bb77efe4b106cdffe8409c969a45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ac49b4c-5ec2-49fd-b51a-a14d694013fa", "node_type": "1", "metadata": {"window": "Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n", "original_text": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. "}, "hash": "2977f241198d4aa892b2da85aad59ba4a5e551699d52187af31399ba74a38971", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "start_char_idx": 2519, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ac49b4c-5ec2-49fd-b51a-a14d694013fa": {"__data__": {"id_": "9ac49b4c-5ec2-49fd-b51a-a14d694013fa", "embedding": null, "metadata": {"window": "Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n", "original_text": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b502215-b55b-49bf-b7fb-090f91df898c", "node_type": "1", "metadata": {"window": "And so, some of those cost actions will be in place by the end of the year. \n Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "original_text": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "984774e0bf9a110123d72a2da8f427f814c6906fa79d1a13f81bb16fd30a3b67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d13e2203-8060-4e42-9417-207ec5e63456", "node_type": "1", "metadata": {"window": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir. ", "original_text": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. "}, "hash": "9315f803615eec21fa7ad95f701a08d140a26f3da1303e5ef603de72fc86d818", "class_name": "RelatedNodeInfo"}}, "text": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "start_char_idx": 2663, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d13e2203-8060-4e42-9417-207ec5e63456": {"__data__": {"id_": "d13e2203-8060-4e42-9417-207ec5e63456", "embedding": null, "metadata": {"window": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir. ", "original_text": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ac49b4c-5ec2-49fd-b51a-a14d694013fa", "node_type": "1", "metadata": {"window": "Some of those will need to take time to allow our operations to settle with that lower volume.  So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n", "original_text": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3c137a027962fb77a58cd6362841b55e0fa682ddbae245de42750dd0c77a023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd", "node_type": "1", "metadata": {"window": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America. ", "original_text": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n"}, "hash": "5b68926fb3c78534b6c16f571c1d3075b3d2fa1ec9edb9049197721c8d6b4a2c", "class_name": "RelatedNodeInfo"}}, "text": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "start_char_idx": 2788, "end_char_idx": 2972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd": {"__data__": {"id_": "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd", "embedding": null, "metadata": {"window": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America. ", "original_text": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d13e2203-8060-4e42-9417-207ec5e63456", "node_type": "1", "metadata": {"window": "So, this \nis a customer that beyond it being , it's a large and growing customer , so we definitely like that \nvolume.   At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir. ", "original_text": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07034d436665c30868a901eb840e2396ea66e7f419c693152a886a8636ee274b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2e8c589-1a27-46fe-8004-1d92bc8393fd", "node_type": "1", "metadata": {"window": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n", "original_text": "Matt Sims:  Next question, please?  \n \n"}, "hash": "5b7022de428488554217043981ddc2aa622a32cea673b59a9a2a57d87798379c", "class_name": "RelatedNodeInfo"}}, "text": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "start_char_idx": 2972, "end_char_idx": 3141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2e8c589-1a27-46fe-8004-1d92bc8393fd": {"__data__": {"id_": "a2e8c589-1a27-46fe-8004-1d92bc8393fd", "embedding": null, "metadata": {"window": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n", "original_text": "Matt Sims:  Next question, please?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd", "node_type": "1", "metadata": {"window": "At the same time, it was a customer that had a lot of non -standard and customized \nprocesses,  and the demand profile was a bit more volatile.  So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America. ", "original_text": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2131d1036b01a92a1f40b16019a4669d5f4f9f852324be36a9b60977d34981a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ff51072-aa7e-46c5-a889-5a8ef4c36081", "node_type": "1", "metadata": {"window": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question. ", "original_text": "Operator:  Thank you, sir. "}, "hash": "1f68dafcc147c25a788cf29d7e15ed01a20a2ce2c533307b82cb80b41c6040f8", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please?  \n \n", "start_char_idx": 3141, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff51072-aa7e-46c5-a889-5a8ef4c36081": {"__data__": {"id_": "4ff51072-aa7e-46c5-a889-5a8ef4c36081", "embedding": null, "metadata": {"window": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2e8c589-1a27-46fe-8004-1d92bc8393fd", "node_type": "1", "metadata": {"window": "So, we'll be able to operate more \nefficiently as this volume exits, but that w on't necessarily be a day one type of thing.  It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n", "original_text": "Matt Sims:  Next question, please?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c24fd18417b1741c57def86e0e963ec7a013ea26b154fda8d508063b28be84b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c21baf1-911a-4c0f-b435-bb5a509ee3d2", "node_type": "1", "metadata": {"window": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "original_text": "We'll now move to Allen Lutz calling from Bank of America. "}, "hash": "6faa20c6a35a0b4903c8107e5b15587818e8c07cc5dcf1e8fff68fa4275958c6", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you, sir. ", "start_char_idx": 3180, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c21baf1-911a-4c0f-b435-bb5a509ee3d2": {"__data__": {"id_": "0c21baf1-911a-4c0f-b435-bb5a509ee3d2", "embedding": null, "metadata": {"window": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "original_text": "We'll now move to Allen Lutz calling from Bank of America. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ff51072-aa7e-46c5-a889-5a8ef4c36081", "node_type": "1", "metadata": {"window": "It will take us a \nlittle bit of time to get to each of the individual sites to be flowing with the new product that is coming \nin, but also just optimizing with the existing product.  So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e9bd78505857179260029c7e76f6153f3c2da9c9a8e402efd5a0486c137faff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Please go \nahead.  \n \n"}, "hash": "08bfd3e01d162c9bc43a17c4ce35ab4fef98db8fe90f5574c9a81fdbf82992f2", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Allen Lutz calling from Bank of America. ", "start_char_idx": 3207, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7": {"__data__": {"id_": "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c21baf1-911a-4c0f-b435-bb5a509ee3d2", "node_type": "1", "metadata": {"window": "So, the puts and takes there are all items that we \nstart to see some mitigation at the very beginning of the fiscal year and then build over the course of \nthe year . \n Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "original_text": "We'll now move to Allen Lutz calling from Bank of America. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c0c0a5f252f363d6c7acfc4c832c340dc562f809a8e556da1be841a1107cd39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Allen Lutz:  Good morning and thanks for taking the question. "}, "hash": "428ac49a3944b07ba7bb5d7a814a5997bd1a700742549709515679bc561df179", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 3266, "end_char_idx": 3288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff": {"__data__": {"id_": "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff", "embedding": null, "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Allen Lutz:  Good morning and thanks for taking the question. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please?  \n \n Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Please go \nahead.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be505d857666901bc8659ce2a8bbf1fc1a12b8f56b04ab412eedc8104294c220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8768137b-7c74-44de-849e-ac9f5e755897", "node_type": "1", "metadata": {"window": "We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. "}, "hash": "8b9b3423bc0f9b040aaa83e31dfd1ed91a8211be47c08b3295a909fe92a34c9c", "class_name": "RelatedNodeInfo"}}, "text": "Allen Lutz:  Good morning and thanks for taking the question. ", "start_char_idx": 3288, "end_char_idx": 3350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8768137b-7c74-44de-849e-ac9f5e755897": {"__data__": {"id_": "8768137b-7c74-44de-849e-ac9f5e755897", "embedding": null, "metadata": {"window": "We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Allen Lutz:  Good morning and thanks for taking the question. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8650898c3fcc04831c5633f36352e112a4a8781ac74ed83d11c3699bdcc7b9c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c8931e-3928-487a-8b36-bfe2e2bccee7", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Can you talk a little bit about buy side "}, "hash": "1ba0f5fc2c67184e390c0eb99e2ded60d022943fd946c63eeb148cdde7a14023", "class_name": "RelatedNodeInfo"}}, "text": "We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "start_char_idx": 3350, "end_char_idx": 3453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c8931e-3928-487a-8b36-bfe2e2bccee7": {"__data__": {"id_": "49c8931e-3928-487a-8b36-bfe2e2bccee7", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Can you talk a little bit about buy side ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c78de647-c986-455f-8595-0c748aca612f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d4f784e6bc777ceb8136cf3dce2722911a381a818fffc4d47d9f1b8c9d51977", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8768137b-7c74-44de-849e-ac9f5e755897", "node_type": "1", "metadata": {"window": "We'll now move to Allen Lutz calling from Bank of America.  Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year. ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2b3224849b55dc7a5f72866fb6a4099678677609073c59cabfca6d4589ad3bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6557d6a2-ddb3-465b-8bfd-5a920ed901a6", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "original_text": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n"}, "hash": "ab9c671f30472e380d3ed44b395887498e5dcc0a69b8466c5c7e6632b538d02a", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk a little bit about buy side ", "start_char_idx": 3453, "end_char_idx": 3494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6557d6a2-ddb3-465b-8bfd-5a920ed901a6": {"__data__": {"id_": "6557d6a2-ddb3-465b-8bfd-5a920ed901a6", "embedding": null, "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "original_text": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c8931e-3928-487a-8b36-bfe2e2bccee7", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Allen Lutz:  Good morning and thanks for taking the question.  We've heard anecdotally that generic \nprices are a little bit firmer this time versus maybe last year.  Can you talk a little bit about buy side ", "original_text": "Can you talk a little bit about buy side ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9812bbd62035c8a0cb69fc86afd1fb870f958c17a44e83aaac153addd84538ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acfa11a9-218e-448f-9040-7f5e5482ed37", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "original_text": "Aaron Alt : Thanks for the question. "}, "hash": "26035d02a7bcb37b23591fbc130b3fc2b426f896c4c2593daf127db41b0627ed", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n", "start_char_idx": 0, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acfa11a9-218e-448f-9040-7f5e5482ed37": {"__data__": {"id_": "acfa11a9-218e-448f-9040-7f5e5482ed37", "embedding": null, "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "original_text": "Aaron Alt : Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6557d6a2-ddb3-465b-8bfd-5a920ed901a6", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "original_text": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "631495d7c0f6f6c94ac8611a79a8c37db873eeec3cc658683a2e1cad93803995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a6a4701-73b9-4dab-acba-86d9b9355e56", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you. ", "original_text": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness. "}, "hash": "b2e9bf487c396be573aac6962313890077d7e132f2ee781c2a2ee001c7a03f23", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt : Thanks for the question. ", "start_char_idx": 178, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a6a4701-73b9-4dab-acba-86d9b9355e56": {"__data__": {"id_": "7a6a4701-73b9-4dab-acba-86d9b9355e56", "embedding": null, "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you. ", "original_text": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acfa11a9-218e-448f-9040-7f5e5482ed37", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "original_text": "Aaron Alt : Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07f456a8df94fe90af24f75508729b140ffa104f389963e2c03e82f3b4d4a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce5e87cc-7528-431c-8e8b-d35270cd4676", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS. ", "original_text": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. "}, "hash": "44bb9d03cf7be6d29d0a467335e4821fe5651c28d3586720c35d2f37687649b3", "class_name": "RelatedNodeInfo"}}, "text": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness. ", "start_char_idx": 215, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce5e87cc-7528-431c-8e8b-d35270cd4676": {"__data__": {"id_": "ce5e87cc-7528-431c-8e8b-d35270cd4676", "embedding": null, "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS. ", "original_text": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a6a4701-73b9-4dab-acba-86d9b9355e56", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you. ", "original_text": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c0bdf3cd41d3e5a97bcc2bad7adf5178c15821e52a8f78ecab3b5a9ed107cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae525f6b-9489-47a1-937e-47aa4641c36c", "node_type": "1", "metadata": {"window": "Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n", "original_text": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n"}, "hash": "60d358f923353a70d164a16c106914ac63764dded7edae04f0026e2844d3665e", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "start_char_idx": 388, "end_char_idx": 640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae525f6b-9489-47a1-937e-47aa4641c36c": {"__data__": {"id_": "ae525f6b-9489-47a1-937e-47aa4641c36c", "embedding": null, "metadata": {"window": "Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n", "original_text": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce5e87cc-7528-431c-8e8b-d35270cd4676", "node_type": "1", "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS. ", "original_text": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96d3dd6f922c4e82f4a15dec616ab9b728ba48af1a1d5e1a966ff36fed9b748e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53f82d81-0026-450a-902c-979dc9f71175", "node_type": "1", "metadata": {"window": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks. ", "original_text": "Operator:  Thank you. "}, "hash": "e1379bb2c3afca164dddd9de7ddf8715f90e263985249cb545a07661d0dd56d5", "class_name": "RelatedNodeInfo"}}, "text": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "start_char_idx": 640, "end_char_idx": 820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53f82d81-0026-450a-902c-979dc9f71175": {"__data__": {"id_": "53f82d81-0026-450a-902c-979dc9f71175", "embedding": null, "metadata": {"window": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks. ", "original_text": "Operator:  Thank you. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae525f6b-9489-47a1-937e-47aa4641c36c", "node_type": "1", "metadata": {"window": "Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n", "original_text": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712a92f4bef9851ad0bd78ce024900b04713893ffaecca196856f10d26190f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aec500a7-187f-47bb-86a2-137c9ecfda2f", "node_type": "1", "metadata": {"window": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped. ", "original_text": "We'll now move to Kevin Caliendo, calling from UBS. "}, "hash": "7b475c6e42e6dc98d7b8af4ca1f09f058a83e2b64e18fb90bc8a945671448470", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 820, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aec500a7-187f-47bb-86a2-137c9ecfda2f": {"__data__": {"id_": "aec500a7-187f-47bb-86a2-137c9ecfda2f", "embedding": null, "metadata": {"window": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped. ", "original_text": "We'll now move to Kevin Caliendo, calling from UBS. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53f82d81-0026-450a-902c-979dc9f71175", "node_type": "1", "metadata": {"window": "What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks. ", "original_text": "Operator:  Thank you. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3f6f1d19388e9f6f4aed32a9f458bb2d2ec56ee33b676016bfe2a0c84ffee0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a", "node_type": "1", "metadata": {"window": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "original_text": "Please go ahead.  \n \n"}, "hash": "97938ea5cc4b8f8dbdbb59d8ced08e30722bc8cfd1b15285004351ed37c02ba3", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Kevin Caliendo, calling from UBS. ", "start_char_idx": 842, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a": {"__data__": {"id_": "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a", "embedding": null, "metadata": {"window": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aec500a7-187f-47bb-86a2-137c9ecfda2f", "node_type": "1", "metadata": {"window": "As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are.  We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped. ", "original_text": "We'll now move to Kevin Caliendo, calling from UBS. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7c539179ba0dc6f7197fa429bb1211e03b32aefe3847efb1a2a1c4d69e651d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f607d1f7-e593-4a00-9bf9-985fa858f855", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "original_text": "Kevin Caliendo:  Thanks. "}, "hash": "f51d2a74bc35bbb179a9f819af37521c93201500ff68af0bc184e865efa8ea68", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 894, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f607d1f7-e593-4a00-9bf9-985fa858f855": {"__data__": {"id_": "f607d1f7-e593-4a00-9bf9-985fa858f855", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "original_text": "Kevin Caliendo:  Thanks. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a", "node_type": "1", "metadata": {"window": "We are aware that others have made \ncomments somewhat var y from that over time, but we see consistent market dynamics and view that \nstability as a strength of our portfolio.  \n \n Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9940134ae4bf23e2a5e15fae65547f8042490666552b04e3750ee72f52d4c40b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03663870-7552-4028-aa48-fc33b31e6cb8", "node_type": "1", "metadata": {"window": "We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n", "original_text": "I'll try to ask quickly before it gets dropped. "}, "hash": "f3bdd10d8e055d776ea775f09c9d09831305b955d64acada9e6dd95f4ce98e8c", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Thanks. ", "start_char_idx": 915, "end_char_idx": 940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03663870-7552-4028-aa48-fc33b31e6cb8": {"__data__": {"id_": "03663870-7552-4028-aa48-fc33b31e6cb8", "embedding": null, "metadata": {"window": "We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n", "original_text": "I'll try to ask quickly before it gets dropped. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f607d1f7-e593-4a00-9bf9-985fa858f855", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "original_text": "Kevin Caliendo:  Thanks. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "213081614ee625d5917bf2f08e17a6b6e20b1d71b16ad8a7ee1c6bf87a8c0b25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "original_text": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? "}, "hash": "db9b2fc1ac79fbe912e6feb358ab6caee5dc5a39258932e565ff987e8994dc20", "class_name": "RelatedNodeInfo"}}, "text": "I'll try to ask quickly before it gets dropped. ", "start_char_idx": 940, "end_char_idx": 988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e": {"__data__": {"id_": "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "original_text": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03663870-7552-4028-aa48-fc33b31e6cb8", "node_type": "1", "metadata": {"window": "We'll now move to Kevin Caliendo, calling from UBS.  Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n", "original_text": "I'll try to ask quickly before it gets dropped. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa92154b2edbca1c801973d337e513c2a40116615a03797acdd5192d8250b9d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "original_text": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? "}, "hash": "ee3dcb2d1bee7d6decacec2045fa0149a3e68185c5972d1d450ac590ac726926", "class_name": "RelatedNodeInfo"}}, "text": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "start_char_idx": 988, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc": {"__data__": {"id_": "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "original_text": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "original_text": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7deba1b8556a553ea4dcf4d36dd3c9934fa1c003216ef07ac67baa0f4051dbc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8162e1fb-a175-47a2-804d-a034271a879f", "node_type": "1", "metadata": {"window": "I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n", "original_text": "And then just a quick follow -up. \n"}, "hash": "43c1e3d9f9648c2538fad3e2e6ab7a4179deffeb03f6792dd2ef08900501688f", "class_name": "RelatedNodeInfo"}}, "text": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "start_char_idx": 1129, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8162e1fb-a175-47a2-804d-a034271a879f": {"__data__": {"id_": "8162e1fb-a175-47a2-804d-a034271a879f", "embedding": null, "metadata": {"window": "I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n", "original_text": "And then just a quick follow -up. \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Thanks.  I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "original_text": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f3ee26f1e824edeeee11f5f5f33e0e5df959c5812107bb6f4f74053820e2489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6", "node_type": "1", "metadata": {"window": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "original_text": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? "}, "hash": "84e305b9195db61bbd3cfd5c8498aed2a356279329cb50fed861ae04a21dde37", "class_name": "RelatedNodeInfo"}}, "text": "And then just a quick follow -up. \n", "start_char_idx": 1295, "end_char_idx": 1330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6": {"__data__": {"id_": "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6", "embedding": null, "metadata": {"window": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "original_text": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8162e1fb-a175-47a2-804d-a034271a879f", "node_type": "1", "metadata": {"window": "I'll try to ask quickly before it gets dropped.  Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n", "original_text": "And then just a quick follow -up. \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "548d636a3787a18c447ba0578e4272159e5704ff0ba950de4cede1662836a6d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "180411d1-42cd-418f-95e0-8cfc092adf2e", "node_type": "1", "metadata": {"window": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "original_text": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. "}, "hash": "d48999d6e96d92003e3e6e3291b6a25268364618b0a82bdea80f9d26cb7a2ac9", "class_name": "RelatedNodeInfo"}}, "text": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "start_char_idx": 1330, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "180411d1-42cd-418f-95e0-8cfc092adf2e": {"__data__": {"id_": "180411d1-42cd-418f-95e0-8cfc092adf2e", "embedding": null, "metadata": {"window": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "original_text": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6", "node_type": "1", "metadata": {"window": "Can you help us bridge on the \nMedical side, sort of the inputs to get to your fiscal \u201825 operating income from sort of where we are \ntoday?  What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "original_text": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "756c20eccc7b3044fed611f960d92c9526b7fb7b000e80e7537bbfa75cec5cd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cf13663-5fda-4bd9-b922-f9151af2073a", "node_type": "1", "metadata": {"window": "And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "original_text": "Thank you.  \n"}, "hash": "0ac485cee1ba3ab831bea960c84247d525818b2dc8944f9678c38fe1f686ecc2", "class_name": "RelatedNodeInfo"}}, "text": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "start_char_idx": 1521, "end_char_idx": 1676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cf13663-5fda-4bd9-b922-f9151af2073a": {"__data__": {"id_": "3cf13663-5fda-4bd9-b922-f9151af2073a", "embedding": null, "metadata": {"window": "And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "original_text": "Thank you.  \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "180411d1-42cd-418f-95e0-8cfc092adf2e", "node_type": "1", "metadata": {"window": "What are the most important factors that will get us from , sort of , where we are with the run \nrate through fiscal 3Q of \u201824 to the expected numbers in fiscal \u201825?  And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "original_text": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "453e74f2a99dc18e064c4644bd2ac2cda056398bc19d02f6fc0074586f5d87ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d", "node_type": "1", "metadata": {"window": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "original_text": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. "}, "hash": "b2db97fe7df4515581d4156ef98e5b68e6df7a46f292c34f8e03d11dcf9ee069", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n", "start_char_idx": 1676, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d": {"__data__": {"id_": "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d", "embedding": null, "metadata": {"window": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "original_text": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cf13663-5fda-4bd9-b922-f9151af2073a", "node_type": "1", "metadata": {"window": "And then just a quick follow -up. \n Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "original_text": "Thank you.  \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "effe6a570fa200db53624b329e2cd91f31d860b0568548d2ec6d0794f63e638d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a", "node_type": "1", "metadata": {"window": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "original_text": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. "}, "hash": "edbb45513a3e2d533ea51cf507bb0c19fffbbe9f4381c7c4e7bb2edc73a760db", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "start_char_idx": 1689, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a": {"__data__": {"id_": "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a", "embedding": null, "metadata": {"window": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "original_text": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d", "node_type": "1", "metadata": {"window": "Does the loss of Optum and your partner in Red Oak also lost a large payer contract , has that \naffected Red Oak in any way, shape or form or you're purchasing power or your economics there?  I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "original_text": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9e791aee1f84c3df1789aa6909d20dd22ac60a85414f55dff3a2fabd6206c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f71fe2c-9810-40ec-8b88-8d02aa1007f3", "node_type": "1", "metadata": {"window": "Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "original_text": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . "}, "hash": "7f988aec2dba5cca105b66f30151734a4eeb03fbefe572e2bb37a42d5ad992c9", "class_name": "RelatedNodeInfo"}}, "text": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "start_char_idx": 1808, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f71fe2c-9810-40ec-8b88-8d02aa1007f3": {"__data__": {"id_": "1f71fe2c-9810-40ec-8b88-8d02aa1007f3", "embedding": null, "metadata": {"window": "Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "original_text": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a", "node_type": "1", "metadata": {"window": "I'm \njust wondering how to think about that because it's two sizable chunks  of business, but I just don't \nknow how to think about the impact on Red Oak.  Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "original_text": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a5f0d6106adc0f3c0e27f7f9d4d7b02d805ac2b550ff556623563d144868083", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d587a589-5950-4cd4-8545-b0df9041230f", "node_type": "1", "metadata": {"window": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far . ", "original_text": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n"}, "hash": "8b860e809f5faa01fd9ec4423f40f7469557e38277c014a43b71382ea0694419", "class_name": "RelatedNodeInfo"}}, "text": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "start_char_idx": 1934, "end_char_idx": 2023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d587a589-5950-4cd4-8545-b0df9041230f": {"__data__": {"id_": "d587a589-5950-4cd4-8545-b0df9041230f", "embedding": null, "metadata": {"window": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far . ", "original_text": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f71fe2c-9810-40ec-8b88-8d02aa1007f3", "node_type": "1", "metadata": {"window": "Thank you.  \n Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "original_text": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million . ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "299865cd036400b27cc1b28ca9dc2d7972ff26f1f810633af7b2e9d0f526d03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5", "node_type": "1", "metadata": {"window": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "original_text": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. "}, "hash": "c8637a7d8db8be84321431f5b5feede17d976c49735300422ad40e673c3faf25", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "start_char_idx": 2023, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5": {"__data__": {"id_": "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5", "embedding": null, "metadata": {"window": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "original_text": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d587a589-5950-4cd4-8545-b0df9041230f", "node_type": "1", "metadata": {"window": "Aaron Alt:  Why don't I start with the Med cadence and then  turn it  to over to Jason to talk further \nabout Red Oak.  Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far . ", "original_text": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "499fd983b41feb8d2c0f1b759434e832a4f7ef44e5218785f41503ad7f1738dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54dceb47-9268-4e8b-93e5-5ae9e38d59ac", "node_type": "1", "metadata": {"window": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%. ", "original_text": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  "}, "hash": "3ac6695d1b312dc89afea19c7f5816c6768fb2f9347a33f857c5f27d6a400c92", "class_name": "RelatedNodeInfo"}}, "text": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "start_char_idx": 2100, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54dceb47-9268-4e8b-93e5-5ae9e38d59ac": {"__data__": {"id_": "54dceb47-9268-4e8b-93e5-5ae9e38d59ac", "embedding": null, "metadata": {"window": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%. ", "original_text": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5", "node_type": "1", "metadata": {"window": "Look, the Med, the G MPD business, we are executing against the plan that we've \nnow been talking about for several quarters.  And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "original_text": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c719e94daa8547c93682ff05f1d6370ff446a80c540b75f53b12febddc11cf95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fdd9682-2700-412b-bc46-c9aed3f5842c", "node_type": "1", "metadata": {"window": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year. ", "original_text": "How we \nget there is how we've gotten halfway there so far . "}, "hash": "cd5bcf4268a3544c81d00c06408102ff74e6dd708e44625a9ae686f4e19bc35c", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "start_char_idx": 2199, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fdd9682-2700-412b-bc46-c9aed3f5842c": {"__data__": {"id_": "4fdd9682-2700-412b-bc46-c9aed3f5842c", "embedding": null, "metadata": {"window": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year. ", "original_text": "How we \nget there is how we've gotten halfway there so far . ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54dceb47-9268-4e8b-93e5-5ae9e38d59ac", "node_type": "1", "metadata": {"window": "And a couple of numbers on the page, fiscal year \u201823, it \nwas a negative $165  million .  In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%. ", "original_text": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.  ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b6d1aa65720e639b25a78337e272df19ed7dd67e8ac80d6b1626ce9d777d46b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "867f654d-96ea-4fae-8a39-74cf5fd52a28", "node_type": "1", "metadata": {"window": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "original_text": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. "}, "hash": "9b938db034e47754fa1520bdda0949c5097954b8ff6064d5ca91c67525b1a305", "class_name": "RelatedNodeInfo"}}, "text": "How we \nget there is how we've gotten halfway there so far . ", "start_char_idx": 2301, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "867f654d-96ea-4fae-8a39-74cf5fd52a28": {"__data__": {"id_": "867f654d-96ea-4fae-8a39-74cf5fd52a28", "embedding": null, "metadata": {"window": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "original_text": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fdd9682-2700-412b-bc46-c9aed3f5842c", "node_type": "1", "metadata": {"window": "In fiscal \u201824 today, we've confirmed we're calling a positive $65 million . \n That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year. ", "original_text": "How we \nget there is how we've gotten halfway there so far . ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b159f348d8d83a1d0be81b9f6d26fbf04d47f1da5a841ae9d1bdfa930a661593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e", "node_type": "1", "metadata": {"window": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind. ", "original_text": "We exited Q3 at about 90%. "}, "hash": "6a41e227bb62d13676bcc80e9d3a453d792feb982fe640cc4edd8c33eed37015", "class_name": "RelatedNodeInfo"}}, "text": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "start_char_idx": 2362, "end_char_idx": 2541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e": {"__data__": {"id_": "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e", "embedding": null, "metadata": {"window": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind. ", "original_text": "We exited Q3 at about 90%. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "867f654d-96ea-4fae-8a39-74cf5fd52a28", "node_type": "1", "metadata": {"window": "That's about a $230 million swing, which puts us halfway to the fiscal \u201826 target of $300 million.  Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "original_text": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9f11ecae9a38de9c79fc6abd0a6fc20b768d4be3557e8555a0e623b787cc121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6d34f7-0365-457d-af78-435b777b19e6", "node_type": "1", "metadata": {"window": "How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "original_text": "We expect to achieve full mitigation by the end of \nthe fiscal year. "}, "hash": "46569aae09c87c50449a139c1ce8c57935dcf87fdb8162c2fd1b38a3d81e1e5c", "class_name": "RelatedNodeInfo"}}, "text": "We exited Q3 at about 90%. ", "start_char_idx": 2541, "end_char_idx": 2568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6d34f7-0365-457d-af78-435b777b19e6": {"__data__": {"id_": "ba6d34f7-0365-457d-af78-435b777b19e6", "embedding": null, "metadata": {"window": "How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "original_text": "We expect to achieve full mitigation by the end of \nthe fiscal year. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e", "node_type": "1", "metadata": {"window": "Fiscal \n\u201825, we've called today will be approximately $175 million, really a midpoint between those.   How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind. ", "original_text": "We exited Q3 at about 90%. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2058f537d812f041701da06a8aef96c117d6de18fbb50217c7e127a56d39e1e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d304728e-43db-447a-a94e-2e27ea874816", "node_type": "1", "metadata": {"window": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "original_text": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. "}, "hash": "6367e00dd9dcf318c2117222873ae13dad1d77a226d481c067985aab5285ae87", "class_name": "RelatedNodeInfo"}}, "text": "We expect to achieve full mitigation by the end of \nthe fiscal year. ", "start_char_idx": 2568, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d304728e-43db-447a-a94e-2e27ea874816": {"__data__": {"id_": "d304728e-43db-447a-a94e-2e27ea874816", "embedding": null, "metadata": {"window": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "original_text": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6d34f7-0365-457d-af78-435b777b19e6", "node_type": "1", "metadata": {"window": "How we \nget there is how we've gotten halfway there so far .  The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "original_text": "We expect to achieve full mitigation by the end of \nthe fiscal year. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd972868b6d73bd7711f21812cb83437aa08fda8d750e1b9c2176decec83dd1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd7684ad-15b7-4c24-a0de-9706c8177ead", "node_type": "1", "metadata": {"window": "We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "original_text": "So th at will be a tailwind. "}, "hash": "7d6d5321b1372c2c904b4d7d2e6bca33b3a4ad4eaa1402ffe506ba97047a2ff8", "class_name": "RelatedNodeInfo"}}, "text": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "start_char_idx": 2637, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd7684ad-15b7-4c24-a0de-9706c8177ead": {"__data__": {"id_": "cd7684ad-15b7-4c24-a0de-9706c8177ead", "embedding": null, "metadata": {"window": "We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "original_text": "So th at will be a tailwind. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d304728e-43db-447a-a94e-2e27ea874816", "node_type": "1", "metadata": {"window": "The single biggest initiative , the single biggest \nimpact to those numbers is continuing to achieve the inflation mitigation that we've been talking about \nfor several quarters.  We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "original_text": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f89e959733045d7a80506d4f45d5c63069c0c266a49eb601d81a72d9f7a33f30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da", "node_type": "1", "metadata": {"window": "We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth. ", "original_text": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  "}, "hash": "baf1d30371d5181fa76b3ebb932a50b33cf87c9fd7bce309cfabbd83794d9ba5", "class_name": "RelatedNodeInfo"}}, "text": "So th at will be a tailwind. ", "start_char_idx": 2728, "end_char_idx": 2757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da": {"__data__": {"id_": "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da", "embedding": null, "metadata": {"window": "We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth. ", "original_text": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd7684ad-15b7-4c24-a0de-9706c8177ead", "node_type": "1", "metadata": {"window": "We exited Q3 at about 90%.  We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "original_text": "So th at will be a tailwind. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0ab9fdc630629afc1ae475d9050c1dbd5315b7fdcf4d0384f2b79a0e1bc82f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498", "node_type": "1", "metadata": {"window": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth. ", "original_text": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. "}, "hash": "dd7dbfa4ecb7ec718de02b911514269e9f4d6bdf9d927b54c9727059aea8c8b5", "class_name": "RelatedNodeInfo"}}, "text": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "start_char_idx": 2757, "end_char_idx": 2870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498": {"__data__": {"id_": "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498", "embedding": null, "metadata": {"window": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth. ", "original_text": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da", "node_type": "1", "metadata": {"window": "We expect to achieve full mitigation by the end of \nthe fiscal year.  But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth. ", "original_text": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.  ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72621a0906cc8e432f0fc177c19b6879c1821a40c0ec3916075c6c0b204c21e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f853292-5775-4a70-9aba-44f3d17af465", "node_type": "1", "metadata": {"window": "So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "original_text": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. "}, "hash": "5904791258373f2e8efcd0a29cc77dfd7610f691ff1490b1f6a2a75b9ddc5a5b", "class_name": "RelatedNodeInfo"}}, "text": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "start_char_idx": 2870, "end_char_idx": 3099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f853292-5775-4a70-9aba-44f3d17af465": {"__data__": {"id_": "3f853292-5775-4a70-9aba-44f3d17af465", "embedding": null, "metadata": {"window": "So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "original_text": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498", "node_type": "1", "metadata": {"window": "But as we move i nto next year, of course, we'll be lapping a lower percentage \nexecution.  So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth. ", "original_text": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "093bcbca81e95f3ed3cf30bcaf48446a485b369c315061d3eef014e510c644aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dc2bc8-760b-48a7-af4f-19e113730b1e", "node_type": "1", "metadata": {"window": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "original_text": "In Q2, we saw 2% growth. "}, "hash": "bfb7f70af598005f8a1d571c69798862dca432373007ed8a0dcc8af8ad4bbff1", "class_name": "RelatedNodeInfo"}}, "text": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "start_char_idx": 3099, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dc2bc8-760b-48a7-af4f-19e113730b1e": {"__data__": {"id_": "19dc2bc8-760b-48a7-af4f-19e113730b1e", "embedding": null, "metadata": {"window": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "original_text": "In Q2, we saw 2% growth. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f853292-5775-4a70-9aba-44f3d17af465", "node_type": "1", "metadata": {"window": "So th at will be a tailwind.  That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "original_text": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6743d06934610b044210c8ed2952d593c73d8ef846730ef712f098283504d09e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb52d000-b170-42d9-9edc-af7de86abe3e", "node_type": "1", "metadata": {"window": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Q4, we \nsaw 4% growth. "}, "hash": "efb6d085e0d579931376163ec8b614f0d794e9c20270adc5e1331f3e5c652884", "class_name": "RelatedNodeInfo"}}, "text": "In Q2, we saw 2% growth. ", "start_char_idx": 3214, "end_char_idx": 3239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb52d000-b170-42d9-9edc-af7de86abe3e": {"__data__": {"id_": "eb52d000-b170-42d9-9edc-af7de86abe3e", "embedding": null, "metadata": {"window": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Q4, we \nsaw 4% growth. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dc2bc8-760b-48a7-af4f-19e113730b1e", "node_type": "1", "metadata": {"window": "That will be a significant tailwind for us certainly in the first half, \nindeed, the first , for the full year.   It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "original_text": "In Q2, we saw 2% growth. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "181f5870c55f095ae4880d88f15a2fd68baecdce0fbc8f2a884354673cb19cf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4", "node_type": "1", "metadata": {"window": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n"}, "hash": "9c4fbb931b2da1d0865c1b2c4dfb6c1b4f87f1c174317e9455445efb0b2ba88d", "class_name": "RelatedNodeInfo"}}, "text": "Q4, we \nsaw 4% growth. ", "start_char_idx": 3239, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4": {"__data__": {"id_": "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4", "embedding": null, "metadata": {"window": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb52d000-b170-42d9-9edc-af7de86abe3e", "node_type": "1", "metadata": {"window": "It's also important that we continue to see the good revenue growth \nand in particular, the good volume and revenue growth tied to the Cardinal Health Brand is that is a \nbroader , that is a more profitable part of our business.  I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Q4, we \nsaw 4% growth. ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64ccf42e97ab789a68ae1094ede41d7f070789a7753c2cd32b1dd5ae0d1d2028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb928bbb-979c-48cc-b177-adfd6a621033", "node_type": "1", "metadata": {"window": "In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? "}, "hash": "6f4c1945aec51acbae0ac63af9e8beee413a66813326756e194169d10317e08b", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "start_char_idx": 3262, "end_char_idx": 3419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb928bbb-979c-48cc-b177-adfd6a621033": {"__data__": {"id_": "bb928bbb-979c-48cc-b177-adfd6a621033", "embedding": null, "metadata": {"window": "In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4", "node_type": "1", "metadata": {"window": "I know you noticed that in Q1, we called out a \npositive change in trend relative to the revenue in that business.  In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dbe62a2c4dcaff8a61782bdfcf58f45578f0df1062ac35b8a858c4c88e22475", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06216ec8-3d42-4088-aae9-58becd7d0b87", "node_type": "1", "metadata": {"window": "Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n "}, "hash": "3f8d9f49375f660aed75f5f5de0909985029a0c4e0bf6a03dac05aeb8beb9950", "class_name": "RelatedNodeInfo"}}, "text": "Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "start_char_idx": 3419, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06216ec8-3d42-4088-aae9-58becd7d0b87": {"__data__": {"id_": "06216ec8-3d42-4088-aae9-58becd7d0b87", "embedding": null, "metadata": {"window": "Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ffd0893022560fdc3b761baec3dd7972e9a9e4caf74674d5382fcd25df8972d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb928bbb-979c-48cc-b177-adfd6a621033", "node_type": "1", "metadata": {"window": "In Q2, we saw 2% growth.  Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right? ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9263ad09db62e5f9d8485f4ff6d8fc8267377f5bc753471bede07e5a61fb2e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b30a0b8-1f45-4142-88a4-7d5c8e793dad", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "original_text": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n"}, "hash": "42860b9534a040c8d2bec8667279e626f8d8852bcf5cdb10d561703beebaf335", "class_name": "RelatedNodeInfo"}}, "text": "It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "start_char_idx": 3561, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b30a0b8-1f45-4142-88a4-7d5c8e793dad": {"__data__": {"id_": "0b30a0b8-1f45-4142-88a4-7d5c8e793dad", "embedding": null, "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "original_text": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06216ec8-3d42-4088-aae9-58becd7d0b87", "node_type": "1", "metadata": {"window": "Q4, we \nsaw 4% growth.  And so, we're seeing signs of progress that give us reasons to believe that we can \nachieve both the $65 million this year and the $175 million next year.  \n Lastly, on the cadence and the importance of the team will continue to do what they've been doing \naround simplification and cost out, right?  It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "original_text": "It's a very complex business, and the team has been doing a \ngood job of simplifying and identifying sources of cost  this year, and that will continue into next year \nas well.  \n ", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3a683f6ce0a14c4defde1096a0a7440ff7cccb1ba9e176e97c6f25a176678de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00187220-6b4b-4bbd-a207-36a2b6ae9e4f", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "original_text": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak. "}, "hash": "2bb872563ba44b95863a44e39c051d109afdbee8a870be2c139969124b6e1e18", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n", "start_char_idx": 0, "end_char_idx": 78, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00187220-6b4b-4bbd-a207-36a2b6ae9e4f": {"__data__": {"id_": "00187220-6b4b-4bbd-a207-36a2b6ae9e4f", "embedding": null, "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "original_text": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b30a0b8-1f45-4142-88a4-7d5c8e793dad", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "original_text": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a2825b407d48547f577dbc5817762ad8e59c075de90aed2f4250ee82a92c32d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecb85199-923a-46b2-8454-3a0183f2ebcc", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space . "}, "hash": "2ca26279d6a333e7491492812a23113125641b1369bd5e2f22ae50e194a3061c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak. ", "start_char_idx": 78, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecb85199-923a-46b2-8454-3a0183f2ebcc": {"__data__": {"id_": "ecb85199-923a-46b2-8454-3a0183f2ebcc", "embedding": null, "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space . ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00187220-6b4b-4bbd-a207-36a2b6ae9e4f", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "original_text": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85107f276001aa2700c5a606b14cf351d277deaf2af4d6299e32c12b709144b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "013f3d52-788f-4db7-8a58-5cb4c79627d7", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "original_text": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. "}, "hash": "94379003353ef3eb1b93aa8ac06ad66f3e5315c4ef1536f816a8972049545118", "class_name": "RelatedNodeInfo"}}, "text": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space . ", "start_char_idx": 152, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "013f3d52-788f-4db7-8a58-5cb4c79627d7": {"__data__": {"id_": "013f3d52-788f-4db7-8a58-5cb4c79627d7", "embedding": null, "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "original_text": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecb85199-923a-46b2-8454-3a0183f2ebcc", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space . ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "711e724ccca9e4b06e15b8ef34e22ffd84cbfaadf2c11e6af9994dbdda308c41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78", "node_type": "1", "metadata": {"window": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n", "original_text": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n"}, "hash": "1d3ebca0ed8219e1683389a3bf90f077d3f2690d560439a8a600f714ebf105d5", "class_name": "RelatedNodeInfo"}}, "text": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "start_char_idx": 357, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78": {"__data__": {"id_": "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78", "embedding": null, "metadata": {"window": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n", "original_text": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "013f3d52-788f-4db7-8a58-5cb4c79627d7", "node_type": "1", "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "original_text": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dc986e069e2b36641c624d6aa1966193712dce70faad3caa3d11bbe5ff18fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb37191-9466-4086-b303-35f40d07a134", "node_type": "1", "metadata": {"window": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": "Matt Sims: Next question, please.  \n \n"}, "hash": "74b442849cc9e519f76671d31693abf4ec8490f82d5eb372c90d0b231e2a6a58", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "start_char_idx": 486, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb37191-9466-4086-b303-35f40d07a134": {"__data__": {"id_": "1bb37191-9466-4086-b303-35f40d07a134", "embedding": null, "metadata": {"window": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78", "node_type": "1", "metadata": {"window": "Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n", "original_text": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f237d622a3f0949600254d2d364b4f3a6f1f8bf78dc3fd526821ef786a49339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddd43648-22c4-4223-809b-6a5e75b7ebea", "node_type": "1", "metadata": {"window": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n", "original_text": "Operator:  We'll now go to Eric Percher calling from Nephron Research. "}, "hash": "c0b1266c5d05ed5964cb45f72c6433fd75ac71f73500219fb0bc2dcae98bc7aa", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims: Next question, please.  \n \n", "start_char_idx": 699, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddd43648-22c4-4223-809b-6a5e75b7ebea": {"__data__": {"id_": "ddd43648-22c4-4223-809b-6a5e75b7ebea", "embedding": null, "metadata": {"window": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n", "original_text": "Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb37191-9466-4086-b303-35f40d07a134", "node_type": "1", "metadata": {"window": "We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdb3b9596679092179c68e00ab040612e2927a0f8d67ea716d3bdbfaadfb1ebd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de24a9c2-1a1b-47eb-bc3b-e441ba664266", "node_type": "1", "metadata": {"window": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "original_text": "Please go ahead.  \n \n"}, "hash": "bdf06f61246a84334e01ab06e0b4d7de60fb1d5cbd6cf125deeaf8d4e8548d87", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "start_char_idx": 737, "end_char_idx": 808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de24a9c2-1a1b-47eb-bc3b-e441ba664266": {"__data__": {"id_": "de24a9c2-1a1b-47eb-bc3b-e441ba664266", "embedding": null, "metadata": {"window": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddd43648-22c4-4223-809b-6a5e75b7ebea", "node_type": "1", "metadata": {"window": "The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains.  So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n", "original_text": "Operator:  We'll now go to Eric Percher calling from Nephron Research. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5808b01f5d1edde253487f719471c1a7a34bf3e48d311b6f9775b5b9dcc3e30b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none. ", "original_text": "Eric Percher:  Thank you. "}, "hash": "86c65be449dd672f0dd637628109513b53cd9d97283b56566acd85f679142309", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 808, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0": {"__data__": {"id_": "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0", "embedding": null, "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de24a9c2-1a1b-47eb-bc3b-e441ba664266", "node_type": "1", "metadata": {"window": "So, we feel good about our , continuing our mandate of both continued value for our partners \nand ultimately our customers , and as well as the dual mandate aspect of also driving supply as much \nas possible.  \n \n Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d62053fe82ab4ea326e1580f39b0c7a67cf05bc571b2d5ba94667db15e8f00bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "670da30f-615e-4349-8263-74a962f55725", "node_type": "1", "metadata": {"window": "Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "original_text": "A couple of modest items relative to Pharma that I want to tick through. \n"}, "hash": "31ed65be4f72142986068af6c23d5eb562d23551b3f8f23a2c5930b91575d5a0", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you. ", "start_char_idx": 829, "end_char_idx": 855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "670da30f-615e-4349-8263-74a962f55725": {"__data__": {"id_": "670da30f-615e-4349-8263-74a962f55725", "embedding": null, "metadata": {"window": "Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "original_text": "A couple of modest items relative to Pharma that I want to tick through. \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a51e5c608647d44ab5ff3137e8d04c20cf83b6f82a32d2e5256de02718e78a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3cd3f1b-d322-4330-9dce-02c1f280bb8a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "original_text": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? "}, "hash": "95410e2b869f047d4a0b3874eef16aae5b2e8cb072ed62b9404fefb039eaa416", "class_name": "RelatedNodeInfo"}}, "text": "A couple of modest items relative to Pharma that I want to tick through. \n", "start_char_idx": 855, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3cd3f1b-d322-4330-9dce-02c1f280bb8a": {"__data__": {"id_": "e3cd3f1b-d322-4330-9dce-02c1f280bb8a", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "original_text": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "670da30f-615e-4349-8263-74a962f55725", "node_type": "1", "metadata": {"window": "Operator:  We'll now go to Eric Percher calling from Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "original_text": "A couple of modest items relative to Pharma that I want to tick through. \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ece3d1418734de7e7a37d4cbddc85168e2ec1cd6fb7b9cead166d08a382d1c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a04ad2e-6b4e-4344-a903-c651bcbbba81", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "original_text": "That would be \none. "}, "hash": "54eb58f1a0a303637dde490e2ce5dbdc6f4996bc503963a35fe68eea14b7ab4d", "class_name": "RelatedNodeInfo"}}, "text": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "start_char_idx": 929, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a04ad2e-6b4e-4344-a903-c651bcbbba81": {"__data__": {"id_": "4a04ad2e-6b4e-4344-a903-c651bcbbba81", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "original_text": "That would be \none. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3cd3f1b-d322-4330-9dce-02c1f280bb8a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "original_text": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07d2158e3eecd2f0f7ef49a23ed472a8b94b97a5cbef8991dc12e4e85a052109", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6326f677-992f-4a9b-89cb-0df309641953", "node_type": "1", "metadata": {"window": "A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.  ", "original_text": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? "}, "hash": "ae7d6fbe92e84cceacd17b72b713857b3d72e389ef93ff6084932f0dae96970c", "class_name": "RelatedNodeInfo"}}, "text": "That would be \none. ", "start_char_idx": 1121, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6326f677-992f-4a9b-89cb-0df309641953": {"__data__": {"id_": "6326f677-992f-4a9b-89cb-0df309641953", "embedding": null, "metadata": {"window": "A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.  ", "original_text": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a04ad2e-6b4e-4344-a903-c651bcbbba81", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "original_text": "That would be \none. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f114156b4f822a8ece4512b016ee40be31bdb3a6c53008b64737afa40a606e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc", "node_type": "1", "metadata": {"window": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n", "original_text": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. "}, "hash": "46340723401577c1ca144dbb3e0147192ff8fe28c077a7d6cf204093df0a2e2e", "class_name": "RelatedNodeInfo"}}, "text": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "start_char_idx": 1141, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc": {"__data__": {"id_": "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc", "embedding": null, "metadata": {"window": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n", "original_text": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6326f677-992f-4a9b-89cb-0df309641953", "node_type": "1", "metadata": {"window": "A couple of modest items relative to Pharma that I want to tick through. \n One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.  ", "original_text": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0baa35b042783e9b8c8cb70b8d385b546d71daba35409838b6566f00999855d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dec538d-5508-4148-9694-b56758364351", "node_type": "1", "metadata": {"window": "That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes. ", "original_text": "I believe the comment when you closed it would be accretive 12 months \nfollowing close. "}, "hash": "ad06d380e8faa582273aa536cd2fc9876f101cb9559c67aac18ccd2b0f5c4ecb", "class_name": "RelatedNodeInfo"}}, "text": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "start_char_idx": 1268, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dec538d-5508-4148-9694-b56758364351": {"__data__": {"id_": "8dec538d-5508-4148-9694-b56758364351", "embedding": null, "metadata": {"window": "That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes. ", "original_text": "I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc", "node_type": "1", "metadata": {"window": "One is in discussing the headwind penciling out to $80 million used the comments so far , once or \ntwice, is that so far reflecting that there may be more mitigation or that this is in flux ?  That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n", "original_text": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a82238f18b33bcd3f7ffaf415cf4401170e0e6185e3d7006e3378a11ef4a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dc6303a-6146-4b37-93cc-e9a8c592bb57", "node_type": "1", "metadata": {"window": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "original_text": "Any commentary on contribution there would be helpful as well.  "}, "hash": "1cccef9ff32ac585bac3b9c0a915924c7e6e84a2eff54cb2d416e333add3814d", "class_name": "RelatedNodeInfo"}}, "text": "I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "start_char_idx": 1375, "end_char_idx": 1463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dc6303a-6146-4b37-93cc-e9a8c592bb57": {"__data__": {"id_": "1dc6303a-6146-4b37-93cc-e9a8c592bb57", "embedding": null, "metadata": {"window": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "original_text": "Any commentary on contribution there would be helpful as well.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dec538d-5508-4148-9694-b56758364351", "node_type": "1", "metadata": {"window": "That would be \none.  Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes. ", "original_text": "I believe the comment when you closed it would be accretive 12 months \nfollowing close. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bda0ff4db00b69fccd407295880402fbc0d2d5553320aeacc7616376401619cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de20c1be-6d94-4069-8fac-f2de39a947e6", "node_type": "1", "metadata": {"window": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "original_text": "Thank you.  \n \n"}, "hash": "56c4897a9b6fefd664bbf49a74df3d32de6c403a8f23d1a18730d568c50c5c72", "class_name": "RelatedNodeInfo"}}, "text": "Any commentary on contribution there would be helpful as well.  ", "start_char_idx": 1463, "end_char_idx": 1527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de20c1be-6d94-4069-8fac-f2de39a947e6": {"__data__": {"id_": "de20c1be-6d94-4069-8fac-f2de39a947e6", "embedding": null, "metadata": {"window": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "original_text": "Thank you.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dc6303a-6146-4b37-93cc-e9a8c592bb57", "node_type": "1", "metadata": {"window": "Number two, is there a contemplation of any incentive comp reduction in \u201825 that would then \nreset in \u201826 in that mitigation ?  And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "original_text": "Any commentary on contribution there would be helpful as well.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aca3c6ab76be642d42aedf2d96e16a0dc5c259b04c1316e830a69e9c4979f4e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ee71592-3c87-4c08-8899-847dacb15032", "node_type": "1", "metadata": {"window": "I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "original_text": "Jason Hollar:  Yes. "}, "hash": "ad45ceef41c2191b9761613ff9038d57bb29bde6f8736f04fe02f5cdc8289174", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1527, "end_char_idx": 1542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ee71592-3c87-4c08-8899-847dacb15032": {"__data__": {"id_": "0ee71592-3c87-4c08-8899-847dacb15032", "embedding": null, "metadata": {"window": "I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "original_text": "Jason Hollar:  Yes. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de20c1be-6d94-4069-8fac-f2de39a947e6", "node_type": "1", "metadata": {"window": "And the last one is Specialty Networks, it sounds like you're expecting a \nbenefit at the op pro fit line.  I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "original_text": "Thank you.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1efb3a7242e2c9002c5903af3fe95a136a3128c8f6deb9e5c100a66c865c39b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d95e277-7f93-42f3-9cc9-b411f2f35a5d", "node_type": "1", "metadata": {"window": "Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "original_text": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. "}, "hash": "76e96677ce76b03b70fa824bb8f08e4bbe875d7470df63bf6432d709004cb214", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 1542, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d95e277-7f93-42f3-9cc9-b411f2f35a5d": {"__data__": {"id_": "4d95e277-7f93-42f3-9cc9-b411f2f35a5d", "embedding": null, "metadata": {"window": "Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "original_text": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ee71592-3c87-4c08-8899-847dacb15032", "node_type": "1", "metadata": {"window": "I believe the comment when you closed it would be accretive 12 months \nfollowing close.  Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "original_text": "Jason Hollar:  Yes. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fd8903548cf8130f1eebef560e710e2fb0250cd756ea50702945a9c34c8c75c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "original_text": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . "}, "hash": "76b61e308dab3c246e4b91f44780824a891841bf073b49c11651555b01ffb273", "class_name": "RelatedNodeInfo"}}, "text": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "start_char_idx": 1562, "end_char_idx": 1656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f": {"__data__": {"id_": "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "original_text": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d95e277-7f93-42f3-9cc9-b411f2f35a5d", "node_type": "1", "metadata": {"window": "Any commentary on contribution there would be helpful as well.   Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "original_text": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97b797598d800e2584ed30a197581e003bc6b72d36118e5ff71508b4bbd48132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9379013-aa88-424e-be1c-31d0014fa29d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "original_text": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  "}, "hash": "ec819f5ba071415c5fd70c3df016a73589164f3cc1b597c51180bf6bf3b221dc", "class_name": "RelatedNodeInfo"}}, "text": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "start_char_idx": 1656, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9379013-aa88-424e-be1c-31d0014fa29d": {"__data__": {"id_": "d9379013-aa88-424e-be1c-31d0014fa29d", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "original_text": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "original_text": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp . ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c220a5e8161a7e72f4a945e907c225ae8713cb03a47f3151197a285c35de348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5321b106-9e7a-4537-b98f-d9df20720557", "node_type": "1", "metadata": {"window": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n", "original_text": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. "}, "hash": "f99eaf599a65ac91fd1d2e24b5333bdb0f5a2da7e7817b5a0d25086c7c4ba524", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "start_char_idx": 1895, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5321b106-9e7a-4537-b98f-d9df20720557": {"__data__": {"id_": "5321b106-9e7a-4537-b98f-d9df20720557", "embedding": null, "metadata": {"window": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n", "original_text": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9379013-aa88-424e-be1c-31d0014fa29d", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "original_text": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f5c2eceb4f888abb766924007aadb4536d938749a43f1d4a408b2d0af33d523", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b3be6e8-9093-4896-a3ee-03cc63be4403", "node_type": "1", "metadata": {"window": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "original_text": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. "}, "hash": "321083271bacdb0ad770191b650f5018704117438a92451b0463d42e7b8a34b5", "class_name": "RelatedNodeInfo"}}, "text": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "start_char_idx": 2041, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b3be6e8-9093-4896-a3ee-03cc63be4403": {"__data__": {"id_": "8b3be6e8-9093-4896-a3ee-03cc63be4403", "embedding": null, "metadata": {"window": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "original_text": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5321b106-9e7a-4537-b98f-d9df20720557", "node_type": "1", "metadata": {"window": "So, the \u2018so far comment \u2019 was simply to highlight that we are guiding to at least 1% \ngrowth.  And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n", "original_text": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a02f48b2655f6dee6e4f75b51b88e2eb92fd2726941e57570070b29a462f527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c21de45a-83ff-4844-9c6c-85c539dfb286", "node_type": "1", "metadata": {"window": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "original_text": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. "}, "hash": "a0628d70de31843303153709b0c0e0ba70c8d0722c29c17ae8ac168a76b2d684", "class_name": "RelatedNodeInfo"}}, "text": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "start_char_idx": 2131, "end_char_idx": 2294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c21de45a-83ff-4844-9c6c-85c539dfb286": {"__data__": {"id_": "c21de45a-83ff-4844-9c6c-85c539dfb286", "embedding": null, "metadata": {"window": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "original_text": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b3be6e8-9093-4896-a3ee-03cc63be4403", "node_type": "1", "metadata": {"window": "And so that reference is entirely around o f course, we continue to look for other opportunities \nto mitigate further and depending upon our success with those additional actions will be the answer to \nyour question about incentive comp .  We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "original_text": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14c957e3f2d7aa487116b222145d1d2f16ef1e57eac9fc0957fcb664a808ed28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23be6511-18fa-4536-a306-19248c397685", "node_type": "1", "metadata": {"window": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, it's really just the geography of the plus and minus with that.  \n \n"}, "hash": "463cf565d775fbd5cf4a4e314f405f96c161bec330ab62f1135f6f0c50159da7", "class_name": "RelatedNodeInfo"}}, "text": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "start_char_idx": 2294, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23be6511-18fa-4536-a306-19248c397685": {"__data__": {"id_": "23be6511-18fa-4536-a306-19248c397685", "embedding": null, "metadata": {"window": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, it's really just the geography of the plus and minus with that.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c21de45a-83ff-4844-9c6c-85c539dfb286", "node_type": "1", "metadata": {"window": "We\u2019ll of course, appropriately define a target with the alignment \nwith our Board to ensure that we are motivated to drive the business forward.   And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "original_text": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7075556b75995525e196a44399ae41bab7a5ea82e4b90014942aab36fcaf139e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c80d6055-38c9-4606-b418-f7488b93ff82", "node_type": "1", "metadata": {"window": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "original_text": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. "}, "hash": "8ea234d8b8dfa59a7be51f7949779aa75f5c7db07280d0cdefcdab1e136e15b1", "class_name": "RelatedNodeInfo"}}, "text": "So, it's really just the geography of the plus and minus with that.  \n \n", "start_char_idx": 2417, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c80d6055-38c9-4606-b418-f7488b93ff82": {"__data__": {"id_": "c80d6055-38c9-4606-b418-f7488b93ff82", "embedding": null, "metadata": {"window": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "original_text": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23be6511-18fa-4536-a306-19248c397685", "node_type": "1", "metadata": {"window": "And then as it relate s to \nSpecialty Networks, our underlying assumptions are unchanged.  The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, it's really just the geography of the plus and minus with that.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "014852135b705bd91f6b34de339d8f3cbadf470a402857f3cc11d9e356c536f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38428494-7237-4416-b082-8d34991f3fbe", "node_type": "1", "metadata": {"window": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n", "original_text": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n"}, "hash": "d14b9f81bb53555e351f01a631b3efe44317b917d86de9938eff35d389e96090", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "start_char_idx": 2489, "end_char_idx": 2669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38428494-7237-4416-b082-8d34991f3fbe": {"__data__": {"id_": "38428494-7237-4416-b082-8d34991f3fbe", "embedding": null, "metadata": {"window": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n", "original_text": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c80d6055-38c9-4606-b418-f7488b93ff82", "node_type": "1", "metadata": {"window": "The accretive comment was, you're \nright, Eric, th at the reference point was a year after the close, and that was including the dilutive effect \non the interest.  So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "original_text": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "050a5d260171b5a504796970f391a492f04a16e12224e8c03bf40d8fcec9329c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b9c3042-2323-460b-98a9-3e27c113cf66", "node_type": "1", "metadata": {"window": "So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys. ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "383c6e238fcd94b131d84035401271751261111e33a75651eb816c39eddc5ef6", "class_name": "RelatedNodeInfo"}}, "text": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "start_char_idx": 2669, "end_char_idx": 2857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b9c3042-2323-460b-98a9-3e27c113cf66": {"__data__": {"id_": "6b9c3042-2323-460b-98a9-3e27c113cf66", "embedding": null, "metadata": {"window": "So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38428494-7237-4416-b082-8d34991f3fbe", "node_type": "1", "metadata": {"window": "So, the lost interest on the $1.2 billion is the offset to the operating earnings that we \nsee within the Pharma business.  So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n", "original_text": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d866431d497204d700306cc1b098bbff1e3ddeecbb0f3c293891b539fa06b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e93f35af-5b9b-4abe-94c5-1771de56ae29", "node_type": "1", "metadata": {"window": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question. ", "original_text": "Operator:  The next question will be coming from Stephanie Davis of Barclays. "}, "hash": "25dc764a5608c180094614bd04ea94fac3e928f02c069420343b56cab26d3856", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 2857, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e93f35af-5b9b-4abe-94c5-1771de56ae29": {"__data__": {"id_": "e93f35af-5b9b-4abe-94c5-1771de56ae29", "embedding": null, "metadata": {"window": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question. ", "original_text": "Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b9c3042-2323-460b-98a9-3e27c113cf66", "node_type": "1", "metadata": {"window": "So, it's really just the geography of the plus and minus with that.  \n \n Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2156f9b994486cd6ed4efb3499d2ad9c17fd8a9f5e6888cd0a2aab3dc69d10ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0d06606-5b74-4f0f-96cf-5158976b194f", "node_type": "1", "metadata": {"window": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "original_text": "Please go ahead.   \n \n"}, "hash": "e52e22471fb829c1e07d691efbe393309bb25a162e3e648bff115d68d13b95dd", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "start_char_idx": 2896, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0d06606-5b74-4f0f-96cf-5158976b194f": {"__data__": {"id_": "f0d06606-5b74-4f0f-96cf-5158976b194f", "embedding": null, "metadata": {"window": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "original_text": "Please go ahead.   \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e93f35af-5b9b-4abe-94c5-1771de56ae29", "node_type": "1", "metadata": {"window": "Aaron Alt:  Eric, you had also asked about the impact to compensation plans and the  point  I would \nmake is we set compensation plans on an annual basis for the management teams.  But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question. ", "original_text": "Operator:  The next question will be coming from Stephanie Davis of Barclays. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20852703ee39776500117bb75f7b7dbd696999e882d32349dcaa72a18198c006", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ac34a0f-521c-48dd-b756-cf5a8c817f62", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.  ", "original_text": "Stephanie Davis:   Hi guys. "}, "hash": "d307aa254543b6555dbc653c7afd6b90956c0aa4de913ab180e6216f6cfadf4c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n \n", "start_char_idx": 2974, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ac34a0f-521c-48dd-b756-cf5a8c817f62": {"__data__": {"id_": "4ac34a0f-521c-48dd-b756-cf5a8c817f62", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.  ", "original_text": "Stephanie Davis:   Hi guys. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0d06606-5b74-4f0f-96cf-5158976b194f", "node_type": "1", "metadata": {"window": "But we also have \na long -term element, which is highlighted in our proxy, the targets there and we'll continue to , the \nteams will be continu ally motivated to hit those objectives.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "original_text": "Please go ahead.   \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbac527aa61543a5d2708732a5a58a3fdd78ced5e51a63ee3686854029cec638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914", "node_type": "1", "metadata": {"window": "Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins? ", "original_text": "Thank you for taking my question. "}, "hash": "68632c5e45252d302ee26f84a2f89fec8d986d5631bb0ef425f5c63da735ccf0", "class_name": "RelatedNodeInfo"}}, "text": "Stephanie Davis:   Hi guys. ", "start_char_idx": 2996, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914": {"__data__": {"id_": "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914", "embedding": null, "metadata": {"window": "Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins? ", "original_text": "Thank you for taking my question. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ac34a0f-521c-48dd-b756-cf5a8c817f62", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.  ", "original_text": "Stephanie Davis:   Hi guys. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "920e4b382f199a16e90e881f01622060c3121e3bbe4540206f0c05f116698dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbd8594d-dc01-45fd-817d-33ddd9d51015", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core? ", "original_text": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. "}, "hash": "89a4990fe4399a384a2d04082d5cbe55b302a893905ccaf6595a65dc68cc3ada", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for taking my question. ", "start_char_idx": 3024, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbd8594d-dc01-45fd-817d-33ddd9d51015": {"__data__": {"id_": "fbd8594d-dc01-45fd-817d-33ddd9d51015", "embedding": null, "metadata": {"window": "Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core? ", "original_text": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914", "node_type": "1", "metadata": {"window": "Operator:  The next question will be coming from Stephanie Davis of Barclays.  Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins? ", "original_text": "Thank you for taking my question. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d37d49ba307e9760546dbfc7a6087c5ffe64367bf54be2175fa2dc76ad30f03b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a170972d-290e-4e2e-b708-3d5e7bbc5fa1", "node_type": "1", "metadata": {"window": "Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies. ", "original_text": "So, I was hoping we can dig in there a little bit more.  "}, "hash": "fdee2ab5924a7d65bc6cbd98076607ac1a94df9de32ec9a328eb620ac2cf001b", "class_name": "RelatedNodeInfo"}}, "text": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "start_char_idx": 3058, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a170972d-290e-4e2e-b708-3d5e7bbc5fa1": {"__data__": {"id_": "a170972d-290e-4e2e-b708-3d5e7bbc5fa1", "embedding": null, "metadata": {"window": "Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies. ", "original_text": "So, I was hoping we can dig in there a little bit more.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbd8594d-dc01-45fd-817d-33ddd9d51015", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core? ", "original_text": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c42d6bfe097300814e141544a629a75cf63983cc3c546c2f08509a8e0281ab59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7768996d-3f10-481e-8a96-68c62cb0201e", "node_type": "1", "metadata": {"window": "Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Can you tell us about the \nnature of these wins? "}, "hash": "b8d52040763fb738ee24e6d186e11d003bd71f04f17d0b51bf2980902e0e9e1b", "class_name": "RelatedNodeInfo"}}, "text": "So, I was hoping we can dig in there a little bit more.  ", "start_char_idx": 3209, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7768996d-3f10-481e-8a96-68c62cb0201e": {"__data__": {"id_": "7768996d-3f10-481e-8a96-68c62cb0201e", "embedding": null, "metadata": {"window": "Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Can you tell us about the \nnature of these wins? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a170972d-290e-4e2e-b708-3d5e7bbc5fa1", "node_type": "1", "metadata": {"window": "Stephanie Davis:   Hi guys.  Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies. ", "original_text": "So, I was hoping we can dig in there a little bit more.  ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2135d0018de282e1b517e52a2d75fbab62a1fc64609bdc449377f97193fb0df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "378ff0fc-f136-44c1-8279-416fd23d19fa", "node_type": "1", "metadata": {"window": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is this more core? "}, "hash": "d5ab17c1beaba69ee78b407879c83095abf4d7ae0b9701fc65d9e2f78f0c9e95", "class_name": "RelatedNodeInfo"}}, "text": "Can you tell us about the \nnature of these wins? ", "start_char_idx": 3266, "end_char_idx": 3315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "378ff0fc-f136-44c1-8279-416fd23d19fa": {"__data__": {"id_": "378ff0fc-f136-44c1-8279-416fd23d19fa", "embedding": null, "metadata": {"window": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is this more core? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7768996d-3f10-481e-8a96-68c62cb0201e", "node_type": "1", "metadata": {"window": "Thank you for taking my question.  You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Can you tell us about the \nnature of these wins? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb43ef1ae5c11f6cdd2f6d11f0e8d7add6bb0739480d68108f7130a328a22e8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02db101c-3494-4367-a6a9-a6dd757dc7da", "node_type": "1", "metadata": {"window": "So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is it on the Other-ologies. "}, "hash": "b795a4565a4bd17a35b4cca74ed68d54ae90326dd0b566a49abbe50385dd1b69", "class_name": "RelatedNodeInfo"}}, "text": "Is this more core? ", "start_char_idx": 3315, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02db101c-3494-4367-a6a9-a6dd757dc7da": {"__data__": {"id_": "02db101c-3494-4367-a6a9-a6dd757dc7da", "embedding": null, "metadata": {"window": "So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is it on the Other-ologies. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "378ff0fc-f136-44c1-8279-416fd23d19fa", "node_type": "1", "metadata": {"window": "You called out a few new wins and \nexpansions in the prepared remarks, and you did highlight some customer progress that offsets the \nOptum headwinds.  So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is this more core? ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaea1de10f2a02a4b7397ea26000b2d1599ce0da485c510dd3336f882c2b685c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097b89d2-254a-4467-8d11-f709c25a8bd2", "node_type": "1", "metadata": {"window": "Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "And how much the bridge from "}, "hash": "16f69c0afdffec469eaf2d37cc8ab2e245a7b7a183204249975f23edd65844ce", "class_name": "RelatedNodeInfo"}}, "text": "Is it on the Other-ologies. ", "start_char_idx": 3334, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097b89d2-254a-4467-8d11-f709c25a8bd2": {"__data__": {"id_": "097b89d2-254a-4467-8d11-f709c25a8bd2", "embedding": null, "metadata": {"window": "Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "And how much the bridge from ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4399aa77e7c0042c545f4b4c28587655780e1ec337c13aa832cdb40eb963385d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02db101c-3494-4367-a6a9-a6dd757dc7da", "node_type": "1", "metadata": {"window": "So, I was hoping we can dig in there a little bit more.   Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "Is it on the Other-ologies. ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4336071fa922dd99e1cd18ce050da78b891c5a5d825a5216c120aacc1aff11f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d60dc63-4a6d-49a4-b43c-3e066fef7faa", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived. ", "original_text": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n"}, "hash": "e926b4522a6dfd7879b542402ea8c824b8ec367c9a37b0c4c47de3d099e7b430", "class_name": "RelatedNodeInfo"}}, "text": "And how much the bridge from ", "start_char_idx": 3362, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d60dc63-4a6d-49a4-b43c-3e066fef7faa": {"__data__": {"id_": "8d60dc63-4a6d-49a4-b43c-3e066fef7faa", "embedding": null, "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived. ", "original_text": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097b89d2-254a-4467-8d11-f709c25a8bd2", "node_type": "1", "metadata": {"window": "Can you tell us about the \nnature of these wins?  Is this more core?  Is it on the Other-ologies.  And how much the bridge from ", "original_text": "And how much the bridge from ", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8194586f55cdda143b244e554db16a72b46d2934edb883a80dc23a8f34121f4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4720a1c3-f90b-46c4-8590-8733ffb3ffc5", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "original_text": "Jason Hollar:  Yeah. "}, "hash": "981f16bd8dbc10609a5e848eb86610391f15eea2be0ab49f18743b72ea8c8989", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n", "start_char_idx": 0, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4720a1c3-f90b-46c4-8590-8733ffb3ffc5": {"__data__": {"id_": "4720a1c3-f90b-46c4-8590-8733ffb3ffc5", "embedding": null, "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d60dc63-4a6d-49a4-b43c-3e066fef7faa", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived. ", "original_text": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f58f0f3ed444191aca8856f11451f6ddba24a5c47a8ce851b963c56ea8d5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c498f57b-7c7a-4e53-8850-dc658f754d28", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "original_text": "So, it's across various classes of trade. "}, "hash": "f4663f2ee9b50632d5e469c5c6ae21c9f79a24cd07cc07b302169822687caff3", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 169, "end_char_idx": 190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c498f57b-7c7a-4e53-8850-dc658f754d28": {"__data__": {"id_": "c498f57b-7c7a-4e53-8850-dc658f754d28", "embedding": null, "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "original_text": "So, it's across various classes of trade. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4720a1c3-f90b-46c4-8590-8733ffb3ffc5", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a5cdf64c4c89d43ae036dec44dc5624c06eddea1eb98ccfc41429acbe337833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "original_text": "So, its broad -based wins that we've \nreceived. "}, "hash": "490e093e39c455883911f212a78b66eec183a1a3eff195da73bfe7887c3ea29d", "class_name": "RelatedNodeInfo"}}, "text": "So, it's across various classes of trade. ", "start_char_idx": 190, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2": {"__data__": {"id_": "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2", "embedding": null, "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "original_text": "So, its broad -based wins that we've \nreceived. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c498f57b-7c7a-4e53-8850-dc658f754d28", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "original_text": "So, it's across various classes of trade. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3577466646a852b0710470c5a7a19267fa9b7cb8b7bb9bfe0e306fc01977adb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "original_text": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  "}, "hash": "b1caeceb36e5f482f80571f124c78a764c1b34fc6afc19778b64b9e831829868", "class_name": "RelatedNodeInfo"}}, "text": "So, its broad -based wins that we've \nreceived. ", "start_char_idx": 232, "end_char_idx": 280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c": {"__data__": {"id_": "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "original_text": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2", "node_type": "1", "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "original_text": "So, its broad -based wins that we've \nreceived. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78cadaf134b00207ae34629b3b7792381f8e0839e60348c1afddc709218148f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c", "node_type": "1", "metadata": {"window": "So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "original_text": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . "}, "hash": "fb20d6b868939559a48941e81089573d6fd905da061d7fb71f0687a1f2c6670d", "class_name": "RelatedNodeInfo"}}, "text": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "start_char_idx": 280, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c": {"__data__": {"id_": "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c", "embedding": null, "metadata": {"window": "So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "original_text": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "original_text": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d923a1ada63e8f6963e2adf356f8e6452be48b9b9ef50a425f7195989bee97bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee5281c3-9eb4-48ca-9594-041632a4b47f", "node_type": "1", "metadata": {"window": "So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "original_text": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  "}, "hash": "9f17745dbea5074da075bbec2436e5ef97dbd09330f7ba15f504cdbadfd72bd2", "class_name": "RelatedNodeInfo"}}, "text": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "start_char_idx": 399, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee5281c3-9eb4-48ca-9594-041632a4b47f": {"__data__": {"id_": "ee5281c3-9eb4-48ca-9594-041632a4b47f", "embedding": null, "metadata": {"window": "So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "original_text": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c", "node_type": "1", "metadata": {"window": "So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "original_text": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth . ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a48c46be82149c879b13ecfb9bbc910cf883657731803eb7ff44e9ff55707842", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3b44192-5a04-4657-b48d-f6b8833459b1", "node_type": "1", "metadata": {"window": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "original_text": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. "}, "hash": "225285dc4a6a6f98cd346b26ca2f761872bf34b217b9e941a7025f18f180e85c", "class_name": "RelatedNodeInfo"}}, "text": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "start_char_idx": 557, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3b44192-5a04-4657-b48d-f6b8833459b1": {"__data__": {"id_": "b3b44192-5a04-4657-b48d-f6b8833459b1", "embedding": null, "metadata": {"window": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "original_text": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee5281c3-9eb4-48ca-9594-041632a4b47f", "node_type": "1", "metadata": {"window": "So, its broad -based wins that we've \nreceived.  We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "original_text": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35f648daf278bd3e7cb33140c5368d8acd7468626d8e9e700c0b3d7b5754d9b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "194f93d8-01b2-495d-adad-bf4f2d2ef981", "node_type": "1", "metadata": {"window": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "original_text": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. "}, "hash": "d2165cd71aea8c634253316b200cb0ca4e0fd762cbdb692cf884e68698f5c49e", "class_name": "RelatedNodeInfo"}}, "text": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "start_char_idx": 707, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "194f93d8-01b2-495d-adad-bf4f2d2ef981": {"__data__": {"id_": "194f93d8-01b2-495d-adad-bf4f2d2ef981", "embedding": null, "metadata": {"window": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "original_text": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3b44192-5a04-4657-b48d-f6b8833459b1", "node_type": "1", "metadata": {"window": "We are not anticipating needing additional new wins beyond what we've already completed \nor in process of completing.   And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "original_text": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e2a81e228d1944afa5efbd65b2cbd28fd611576146bd007e80710e43ab0d8f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9987cd7d-a3b6-4c63-951b-ede64324f0cd", "node_type": "1", "metadata": {"window": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "original_text": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  "}, "hash": "27a1f8a1096543b61813ceea8d4c09b82b27578c1c158838fc61e2dfb9ac3d5e", "class_name": "RelatedNodeInfo"}}, "text": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "start_char_idx": 866, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9987cd7d-a3b6-4c63-951b-ede64324f0cd": {"__data__": {"id_": "9987cd7d-a3b6-4c63-951b-ede64324f0cd", "embedding": null, "metadata": {"window": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "original_text": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "194f93d8-01b2-495d-adad-bf4f2d2ef981", "node_type": "1", "metadata": {"window": "And that's why when you think about the embedded guidance that we're \ntalking about in terms of maintaining our long -term targets of that 4 % to 6% growth .  Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "original_text": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cec8ef5c26d0e83e5f46ba79be5e1b21cca047e745a4d652c315b0fc11df241e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01176827-1cf1-4ea0-b744-160cf4f8fbd7", "node_type": "1", "metadata": {"window": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that. ", "original_text": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. "}, "hash": "8ea6f5d62a1926ce2716f525bba3fbe199dba993f1cb05578c78378fe829ec4c", "class_name": "RelatedNodeInfo"}}, "text": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "start_char_idx": 1181, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01176827-1cf1-4ea0-b744-160cf4f8fbd7": {"__data__": {"id_": "01176827-1cf1-4ea0-b744-160cf4f8fbd7", "embedding": null, "metadata": {"window": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that. ", "original_text": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9987cd7d-a3b6-4c63-951b-ede64324f0cd", "node_type": "1", "metadata": {"window": "Some years, like \nthis year, we're  at above the high end and next year will be a little bit below the low end the average \nis out to that 4% to 6%.   And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "original_text": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7d6b2c0995a3108c3fa387677c30d759749dc9d79551079101f7d43bcc297f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5382931-c227-466b-b867-ead7df595e6b", "node_type": "1", "metadata": {"window": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "original_text": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode. "}, "hash": "e2a0029ac3b4fe25b5ab3d7ee8b287b60845617827402609178fd5c40cae710d", "class_name": "RelatedNodeInfo"}}, "text": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "start_char_idx": 1417, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5382931-c227-466b-b867-ead7df595e6b": {"__data__": {"id_": "f5382931-c227-466b-b867-ead7df595e6b", "embedding": null, "metadata": {"window": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "original_text": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01176827-1cf1-4ea0-b744-160cf4f8fbd7", "node_type": "1", "metadata": {"window": "And so, it implies a \u201826 and beyond type of rate , that continues to be in that \n4% to 6% range, which is kind of a normalized ongoing type of earnings level.  So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that. ", "original_text": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de612195e9a145bd927500ee9c719e207bff230e01039b59a575e289dacf01f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92", "node_type": "1", "metadata": {"window": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "original_text": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n"}, "hash": "4c8b9b0f0cd02991b099b5234f9f56257166b8ac6310b342b20ef0e9734cf919", "class_name": "RelatedNodeInfo"}}, "text": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "start_char_idx": 1688, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92": {"__data__": {"id_": "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92", "embedding": null, "metadata": {"window": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "original_text": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5382931-c227-466b-b867-ead7df595e6b", "node_type": "1", "metadata": {"window": "So, how I step back \nand think about our progress to date, it really comes down to our service levels and our customer \nservice and really listening to what is important to those customers and working with them for a \nsolution that is not necess arily customized , it is standardized, but with their needs in mind.  And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "original_text": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62343373aa6443cbf1a4604eb351dc1327bb6114918703495d341c786af6992f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87965e7b-1d6b-4390-bad6-c6744162caca", "node_type": "1", "metadata": {"window": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.  ", "original_text": "Aaron Alt:  I would add a couple of things to that. "}, "hash": "8016b61882c9354920ed261e12d25d8d00931ea97168afacf75bf6e122b808c9", "class_name": "RelatedNodeInfo"}}, "text": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "start_char_idx": 1783, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87965e7b-1d6b-4390-bad6-c6744162caca": {"__data__": {"id_": "87965e7b-1d6b-4390-bad6-c6744162caca", "embedding": null, "metadata": {"window": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.  ", "original_text": "Aaron Alt:  I would add a couple of things to that. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92", "node_type": "1", "metadata": {"window": "And we're \ngetting fantastic feedback from our current customers in terms of what that service level has been, \nthat is translating over to the desire by customers that we're not working with today to consider  using \nCardinal Health.   And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "original_text": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9924224be9b05f08d849f28c11c5c0f85cc3f90f5601a91b1a793839857055d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0aec661-4749-4fc1-aab3-b3cb15012c43", "node_type": "1", "metadata": {"window": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "original_text": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  "}, "hash": "86f62a33b7183c6938ca9a4ae8b7b3f0a8c38e436c3014a5980a3794b6318034", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  I would add a couple of things to that. ", "start_char_idx": 1876, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0aec661-4749-4fc1-aab3-b3cb15012c43": {"__data__": {"id_": "e0aec661-4749-4fc1-aab3-b3cb15012c43", "embedding": null, "metadata": {"window": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "original_text": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87965e7b-1d6b-4390-bad6-c6744162caca", "node_type": "1", "metadata": {"window": "And so, we have the time, attention and energy now that we're able to devote even \nmore to those existing customers to streamline those processes in a little bit more of a simplified \nfashion , and we'll continue to drive that value proposition with those new customers.  But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.  ", "original_text": "Aaron Alt:  I would add a couple of things to that. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66d067e85a1605964ce904fe0583a121dbdda6a32ae6e0b6a380bb004a68ff29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af3a1d2a-6cee-4b35-ba50-0aa376cda714", "node_type": "1", "metadata": {"window": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir. ", "original_text": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. "}, "hash": "391fe190ea6001802a434ef517cc04307e6f5dc7fbb700481aebe0662c79d766", "class_name": "RelatedNodeInfo"}}, "text": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "start_char_idx": 1928, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af3a1d2a-6cee-4b35-ba50-0aa376cda714": {"__data__": {"id_": "af3a1d2a-6cee-4b35-ba50-0aa376cda714", "embedding": null, "metadata": {"window": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir. ", "original_text": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0aec661-4749-4fc1-aab3-b3cb15012c43", "node_type": "1", "metadata": {"window": "But it's very \nmuch a booked -business type of perspective that we're now into execution mode.  And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "original_text": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc7d7a1c1554965ef4376e425182c4f0b5ead1dd5c4859831ffd56b0ef6d3f1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9", "node_type": "1", "metadata": {"window": "Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird. ", "original_text": "And we're not backing away from investing in our \nfuture across our enterprise.  "}, "hash": "cdcdb474830dc33fd94a58a379b2a97fc2fe41ce67dbc21a80e261a06b45e927", "class_name": "RelatedNodeInfo"}}, "text": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "start_char_idx": 2190, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9": {"__data__": {"id_": "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9", "embedding": null, "metadata": {"window": "Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird. ", "original_text": "And we're not backing away from investing in our \nfuture across our enterprise.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af3a1d2a-6cee-4b35-ba50-0aa376cda714", "node_type": "1", "metadata": {"window": "And after this year, \nfiscal \u201825, we'd expect it to be even more normalized at that point.  \n Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir. ", "original_text": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cc858666a9cac8b25f1cbd837b33d388dbe071c89c8be10b7bd256e672c725f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82fe1a87-bb34-46c5-8c3e-86cfc61bd761", "node_type": "1", "metadata": {"window": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n", "original_text": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n"}, "hash": "8556d3e5aa89895ef89fc9f3ef6c0a81808e4c693f2bed37ea53ac13e5988bab", "class_name": "RelatedNodeInfo"}}, "text": "And we're not backing away from investing in our \nfuture across our enterprise.  ", "start_char_idx": 2345, "end_char_idx": 2426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82fe1a87-bb34-46c5-8c3e-86cfc61bd761": {"__data__": {"id_": "82fe1a87-bb34-46c5-8c3e-86cfc61bd761", "embedding": null, "metadata": {"window": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n", "original_text": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9", "node_type": "1", "metadata": {"window": "Aaron Alt:  I would add a couple of things to that.  First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird. ", "original_text": "And we're not backing away from investing in our \nfuture across our enterprise.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85cd92aebca94b4c7f0ba50707874770a65dcb3f04228df2c0aae9c9eef5454a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c", "node_type": "1", "metadata": {"window": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning. ", "original_text": "Operator:  Thank you, sir. "}, "hash": "5ed0680941171fa6a6db5a0b5921df937a4b63b49129fed251e3b64096b30ef1", "class_name": "RelatedNodeInfo"}}, "text": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "start_char_idx": 2426, "end_char_idx": 2608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c": {"__data__": {"id_": "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c", "embedding": null, "metadata": {"window": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82fe1a87-bb34-46c5-8c3e-86cfc61bd761", "node_type": "1", "metadata": {"window": "First, you asked about cost out and my response , or \nour response , is that simplification has been a priority of ours for the last couple of years, and we will, \nof course, continue to go looking for ways we can simplify our operations and optimize our cost.   But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n", "original_text": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc0eb5a35d29a6ff4dc7fd9ad6d5d6def97bb68929cfaa7f3c0a4197451908dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fecd1dba-ed62-401f-8854-e96c3c9e2dc1", "node_type": "1", "metadata": {"window": "And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "original_text": "We'll now move to Eric Coldwell calling from Baird. "}, "hash": "70d306951b0d2206d3f3b6a986fe7bfa544c73f4462d68411846b8ea243d4df7", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you, sir. ", "start_char_idx": 2608, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fecd1dba-ed62-401f-8854-e96c3c9e2dc1": {"__data__": {"id_": "fecd1dba-ed62-401f-8854-e96c3c9e2dc1", "embedding": null, "metadata": {"window": "And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "original_text": "We'll now move to Eric Coldwell calling from Baird. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c", "node_type": "1", "metadata": {"window": "But \nlet me be clear, right, we are not backing away from customer support, particularly the new customers \ncoming on board so that we do that seamlessly.  And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25cc5aee939c0fc101db32c30313956c58d15ed855e77c443555b60d54f08b52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "061a6334-e238-4af2-9fb7-6d53b57c73aa", "node_type": "1", "metadata": {"window": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "original_text": "Please go ahead.  \n"}, "hash": "1430038c2c1de73d4fd1373e34e90c160d7d23eebaae468446b8c57f3949833c", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Eric Coldwell calling from Baird. ", "start_char_idx": 2635, "end_char_idx": 2687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "061a6334-e238-4af2-9fb7-6d53b57c73aa": {"__data__": {"id_": "061a6334-e238-4af2-9fb7-6d53b57c73aa", "embedding": null, "metadata": {"window": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "original_text": "Please go ahead.  \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fecd1dba-ed62-401f-8854-e96c3c9e2dc1", "node_type": "1", "metadata": {"window": "And we're not backing away from investing in our \nfuture across our enterprise.   And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "original_text": "We'll now move to Eric Coldwell calling from Baird. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab2f44d59497ee8acdb9433161491088e3d7ac6b29d1cf65883ed149b218daeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99f6fc32-d987-4d4a-8a77-fae5782675ef", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "original_text": "Eric Coldwell:   Thanks,  and good morning. "}, "hash": "5e1369a888fe4dfd8f32d4318e07431d9475cca4f738eba5ece2f2e9577b65a6", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n", "start_char_idx": 2687, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99f6fc32-d987-4d4a-8a77-fae5782675ef": {"__data__": {"id_": "99f6fc32-d987-4d4a-8a77-fae5782675ef", "embedding": null, "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "original_text": "Eric Coldwell:   Thanks,  and good morning. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "061a6334-e238-4af2-9fb7-6d53b57c73aa", "node_type": "1", "metadata": {"window": "And so , we will continue to talk about the highlights of those as we make \nthem in future earnings calls, but we will optimize as appropriate, while focused on the long -term.   \n \n Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "original_text": "Please go ahead.  \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2065734cd92c8642a83503fb7d7f02219fe044c35a9ef81f2f924b136e26363", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04", "node_type": "1", "metadata": {"window": "We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "original_text": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. "}, "hash": "6d982ca1cff46c7f96e9b108c15789ece1d7afeee577c3324e567208fe1298f0", "class_name": "RelatedNodeInfo"}}, "text": "Eric Coldwell:   Thanks,  and good morning. ", "start_char_idx": 2706, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04": {"__data__": {"id_": "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04", "embedding": null, "metadata": {"window": "We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "original_text": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99f6fc32-d987-4d4a-8a77-fae5782675ef", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "original_text": "Eric Coldwell:   Thanks,  and good morning. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "845e363cc4358fb5d95c3c9d366c7d5b4bac5d0654b722278d2602860d5d19f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39d8107d-6c38-4c38-add3-91c9e5ab800b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "original_text": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  "}, "hash": "71d07f29635af17a2cf37e1a4c676ef647eac5bb2eced109200b8858fdc8818c", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "start_char_idx": 2750, "end_char_idx": 2837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39d8107d-6c38-4c38-add3-91c9e5ab800b": {"__data__": {"id_": "39d8107d-6c38-4c38-add3-91c9e5ab800b", "embedding": null, "metadata": {"window": "Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "original_text": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04", "node_type": "1", "metadata": {"window": "We'll now move to Eric Coldwell calling from Baird.  Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "original_text": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "948d59696847acfad46f6b5b1664c48c484a91f7f6dc614e5f19da86a21dbf71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1628488-82b4-44c9-8597-d16bea481830", "node_type": "1", "metadata": {"window": "Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course. ", "original_text": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. "}, "hash": "7b4a06ec22927ef44d8645f6deb75f25cec709603d000c2b43b0cb227d3b9121", "class_name": "RelatedNodeInfo"}}, "text": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "start_char_idx": 2837, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1628488-82b4-44c9-8597-d16bea481830": {"__data__": {"id_": "d1628488-82b4-44c9-8597-d16bea481830", "embedding": null, "metadata": {"window": "Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course. ", "original_text": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39d8107d-6c38-4c38-add3-91c9e5ab800b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "original_text": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.  ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dec953aa0255e84a98703e42125b8d6b957b0e15daa883a68e6da38f05239637", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17f7f671-06f4-4f93-b9c7-989664120d25", "node_type": "1", "metadata": {"window": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "original_text": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n"}, "hash": "4b18b36fa0f728498a7c0b14ffbdaaebb3b019421ae39b0193da88d77e1599dc", "class_name": "RelatedNodeInfo"}}, "text": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "start_char_idx": 2958, "end_char_idx": 3142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17f7f671-06f4-4f93-b9c7-989664120d25": {"__data__": {"id_": "17f7f671-06f4-4f93-b9c7-989664120d25", "embedding": null, "metadata": {"window": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "original_text": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1628488-82b4-44c9-8597-d16bea481830", "node_type": "1", "metadata": {"window": "Eric Coldwell:   Thanks,  and good morning.  I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course. ", "original_text": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb5e4e73ec77fb299f6ad5ff10c493ad914e023bd21d417605d3ac026f358a55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0db902a6-535e-496b-826e-6af87431790a", "node_type": "1", "metadata": {"window": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty. ", "original_text": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. "}, "hash": "c766cfef96dbf34a1e89b1d8c884bf8c3fb26112b9ab9953711b365b46525cd2", "class_name": "RelatedNodeInfo"}}, "text": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "start_char_idx": 3142, "end_char_idx": 3278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0db902a6-535e-496b-826e-6af87431790a": {"__data__": {"id_": "0db902a6-535e-496b-826e-6af87431790a", "embedding": null, "metadata": {"window": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty. ", "original_text": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17f7f671-06f4-4f93-b9c7-989664120d25", "node_type": "1", "metadata": {"window": "I wanted to talk a bit about Specialty in general and then \ntie in Specialty Networks.  So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "original_text": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6eff0ee20095590f5d8ab471e600dbfd0f2af5834203f391be13a56062e6a8c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02", "node_type": "1", "metadata": {"window": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "original_text": "We will be providing that in the next update, of course. "}, "hash": "85276780c77e342b43e5989f6cf53dc352e6becde69ab1d9df31b14dc2c8b188", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "start_char_idx": 3278, "end_char_idx": 3424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02": {"__data__": {"id_": "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02", "embedding": null, "metadata": {"window": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "original_text": "We will be providing that in the next update, of course. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0db902a6-535e-496b-826e-6af87431790a", "node_type": "1", "metadata": {"window": "So, in the recent past, you've given a sizing of your overall Specialty \nbusiness in the low -to-mid $30 billion range.   You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty. ", "original_text": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef45afa67fc4e547bf9f64db9653fdac7c12fc678b80eaf5bdd0dce51706006c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f58689a6-80d7-48c4-944c-d48f20aac462", "node_type": "1", "metadata": {"window": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . "}, "hash": "12563e87fc60d074b065963d267111d12db06956268c5b4e7f0939b1f650e95c", "class_name": "RelatedNodeInfo"}}, "text": "We will be providing that in the next update, of course. ", "start_char_idx": 3424, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f58689a6-80d7-48c4-944c-d48f20aac462": {"__data__": {"id_": "f58689a6-80d7-48c4-944c-d48f20aac462", "embedding": null, "metadata": {"window": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02", "node_type": "1", "metadata": {"window": "You will lose some of that with the Optum roll off, \nprobably $3.5 -$4 billion, I'm guessing, you're going to add some with Specialty Networks and then \nyou have normal market growth.  So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "original_text": "We will be providing that in the next update, of course. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db15a833fb5da924111cc27118c20ed5e0d6c38162253602beee3262a54314db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cdf1534-3e52-400d-877d-bb527ee3d159", "node_type": "1", "metadata": {"window": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "That Specialty, everything else will be PD non -specialty. "}, "hash": "d0d71e2254e5ac940830c2f259aac38db0fa0a5bae2481ffb1e0e6797152d363", "class_name": "RelatedNodeInfo"}}, "text": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "start_char_idx": 3481, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cdf1534-3e52-400d-877d-bb527ee3d159": {"__data__": {"id_": "6cdf1534-3e52-400d-877d-bb527ee3d159", "embedding": null, "metadata": {"window": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "That Specialty, everything else will be PD non -specialty. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f58689a6-80d7-48c4-944c-d48f20aac462", "node_type": "1", "metadata": {"window": "So, netting this all together, what would you anticipate the baseline \nspecialty busin ess to be sized at when you start fiscal \u201825? \n \n Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business . ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c31a16220c2c2ad1c9c4e3195ee43d2395db627d76384f26d14f79e1abef98d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee969de7-ec8a-484b-9a11-7060aa6c0292", "node_type": "1", "metadata": {"window": "We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. "}, "hash": "821a17867008dd095e365d95d5d61ab85d1f0741b1d372f0aa4b7e0fa8b4a9ac", "class_name": "RelatedNodeInfo"}}, "text": "That Specialty, everything else will be PD non -specialty. ", "start_char_idx": 3628, "end_char_idx": 3687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee969de7-ec8a-484b-9a11-7060aa6c0292": {"__data__": {"id_": "ee969de7-ec8a-484b-9a11-7060aa6c0292", "embedding": null, "metadata": {"window": "We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cdf1534-3e52-400d-877d-bb527ee3d159", "node_type": "1", "metadata": {"window": "Jason Hollar:  So those are a number of puts and takes that as you noticed, I'm  sure, Eric, we did not \nprovide revenue guidance in this update.  We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "That Specialty, everything else will be PD non -specialty. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07c2186d2a7e06dbf2402d78547f1f96e241785099777375a3762454d13823ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792", "node_type": "1", "metadata": {"window": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "But don't think about that \nas something specifically related to Specialty Networks.   "}, "hash": "992693390baec6e0c99223fec1d33406599cd822967f8b5ba7bf8e4eb68a3c6f", "class_name": "RelatedNodeInfo"}}, "text": "And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "start_char_idx": 3687, "end_char_idx": 3970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792": {"__data__": {"id_": "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792", "embedding": null, "metadata": {"window": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "But don't think about that \nas something specifically related to Specialty Networks.   ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07fc017d8111abc0e7e1c9f4db5a53572684bb03125b3aa63aedee61579df61b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee969de7-ec8a-484b-9a11-7060aa6c0292", "node_type": "1", "metadata": {"window": "We will be providing that in the next update, of course.  So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that. ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7806c087e6af17930b5af74bf15313211533c62987f617f902c2432f8207b6ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ee2208d-153c-42bd-892d-234238c13ab1", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys. ", "original_text": " \nPage 17 of 20 \n \nOperator:  Thank you very much.  "}, "hash": "4a7dd567fad46d9f55069e55a56ee090f9d6a7d7526c9378b108dd867b5ab666", "class_name": "RelatedNodeInfo"}}, "text": "But don't think about that \nas something specifically related to Specialty Networks.   ", "start_char_idx": 3970, "end_char_idx": 4057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ee2208d-153c-42bd-892d-234238c13ab1": {"__data__": {"id_": "6ee2208d-153c-42bd-892d-234238c13ab1", "embedding": null, "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys. ", "original_text": " \nPage 17 of 20 \n \nOperator:  Thank you very much.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792", "node_type": "1", "metadata": {"window": "So \ncertainly, you're in the ballpark on the Optum piece because as I've highlighted before, that is about \n10% of that overall book of business .  That Specialty, everything else will be PD non -specialty.  And \nSpecialty Networks, the revenue is quite low because it's the service revenue, it's not distribution \nrevenue, so that's what I would think of independent is that we, of course, would e xpect our non -\nOptum Specialty revenue to continue to grow nicely, and we will frame that.  But don't think about that \nas something specifically related to Specialty Networks.   ", "original_text": "But don't think about that \nas something specifically related to Specialty Networks.   ", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47c19ea4881ea7954c84d6988631d0818c5c0f069f6481eb492cd879ce178227", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cad15c15-622a-4302-9b0a-01a670ccd14a", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question. ", "original_text": "Our next question is coming from Elizabeth Anderson calling from \nEvercore. "}, "hash": "e1fbb027d821090bd2f1a646f9538c104013f5098b86a4f99bfd23deb8e38162", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 20 \n \nOperator:  Thank you very much.  ", "start_char_idx": 0, "end_char_idx": 52, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cad15c15-622a-4302-9b0a-01a670ccd14a": {"__data__": {"id_": "cad15c15-622a-4302-9b0a-01a670ccd14a", "embedding": null, "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question. ", "original_text": "Our next question is coming from Elizabeth Anderson calling from \nEvercore. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ee2208d-153c-42bd-892d-234238c13ab1", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys. ", "original_text": " \nPage 17 of 20 \n \nOperator:  Thank you very much.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaedb03790e57ecd9a6798066ee856ea9851dfa4d181c91df433e5544fc49be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f232ed6-0730-4036-8f65-6e990d707d97", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD. ", "original_text": "Please go ahead.  \n \n"}, "hash": "c7591b59cfefe8943bb2d3612d146dae8636027cae167479d56824874272de9f", "class_name": "RelatedNodeInfo"}}, "text": "Our next question is coming from Elizabeth Anderson calling from \nEvercore. ", "start_char_idx": 52, "end_char_idx": 128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f232ed6-0730-4036-8f65-6e990d707d97": {"__data__": {"id_": "0f232ed6-0730-4036-8f65-6e990d707d97", "embedding": null, "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD. ", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cad15c15-622a-4302-9b0a-01a670ccd14a", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question. ", "original_text": "Our next question is coming from Elizabeth Anderson calling from \nEvercore. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76d30ecdfd31010ad76c309ddbddff590ae1184955e8dd1655c64fdea2a3525e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a1596c3-a0c3-4734-9b76-d21131e6c961", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "original_text": "Elizabeth Anderson:   Hi guys. "}, "hash": "e277d0bdd55122c052ca14bb9d89f72adde4a4ec5744bf8654c83fcab715bebc", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 128, "end_char_idx": 149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a1596c3-a0c3-4734-9b76-d21131e6c961": {"__data__": {"id_": "9a1596c3-a0c3-4734-9b76-d21131e6c961", "embedding": null, "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "original_text": "Elizabeth Anderson:   Hi guys. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f232ed6-0730-4036-8f65-6e990d707d97", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD. ", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e11b5c0678aa4e2743e25509c901215512bcc72c66989481e588d06665b5a2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b34a24fc-a79f-4dee-be09-05943ab0baf7", "node_type": "1", "metadata": {"window": "Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "original_text": "Thanks so much for the question. "}, "hash": "d20057996d75181407dd428980af7639880dbfa06c5a5612b1cc0f45c75628e2", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:   Hi guys. ", "start_char_idx": 149, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b34a24fc-a79f-4dee-be09-05943ab0baf7": {"__data__": {"id_": "b34a24fc-a79f-4dee-be09-05943ab0baf7", "embedding": null, "metadata": {"window": "Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "original_text": "Thanks so much for the question. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a1596c3-a0c3-4734-9b76-d21131e6c961", "node_type": "1", "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "original_text": "Elizabeth Anderson:   Hi guys. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55658d183ded3ac813853c10d40df2074e53def13de7653ea33b7d5ec8faafdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc5ea76b-21a9-441e-9fad-05bddd071f75", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "original_text": "I was hoping you could talk a little bit \nmore about GMPD. "}, "hash": "eb417082b0be5d47b1f4809ec61ebd420b7c979b8f257149eae675788de9344c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 180, "end_char_idx": 213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc5ea76b-21a9-441e-9fad-05bddd071f75": {"__data__": {"id_": "bc5ea76b-21a9-441e-9fad-05bddd071f75", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "original_text": "I was hoping you could talk a little bit \nmore about GMPD. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b34a24fc-a79f-4dee-be09-05943ab0baf7", "node_type": "1", "metadata": {"window": "Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "original_text": "Thanks so much for the question. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "343def5ae4178f20e1fb88495403495647b1bbfa6eb9cdddc360cf4b4a360f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39ed20f8-3299-40f2-8370-762a1a76b9e4", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically. ", "original_text": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  "}, "hash": "84062bd33c07fcd2c0f5dd3a33a0c5934717054285057808369dd0920f30eb8a", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could talk a little bit \nmore about GMPD. ", "start_char_idx": 213, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39ed20f8-3299-40f2-8370-762a1a76b9e4": {"__data__": {"id_": "39ed20f8-3299-40f2-8370-762a1a76b9e4", "embedding": null, "metadata": {"window": "Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically. ", "original_text": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc5ea76b-21a9-441e-9fad-05bddd071f75", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "original_text": "I was hoping you could talk a little bit \nmore about GMPD. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39d32b638244fca0ef2d622c94c3e28a290a301832af9d42ee71cffffb35e54e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "original_text": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n"}, "hash": "561e63367e60b9471ab763f7a2de0c07c446aa672f5109da257a20d8935eb5ec", "class_name": "RelatedNodeInfo"}}, "text": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "start_char_idx": 272, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f": {"__data__": {"id_": "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "original_text": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39ed20f8-3299-40f2-8370-762a1a76b9e4", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:   Hi guys.  Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically. ", "original_text": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccf1f4429b8020c3eebb5c2bb13e2a7c5aeb7e8cb88ae49e676cc221bb34dd88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c430302-8593-435b-91b7-83e7b2d3d7be", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable. ", "original_text": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. "}, "hash": "295746e6b5709e94affcd681fe5db3719f81213574b734df962dc679ac5742f5", "class_name": "RelatedNodeInfo"}}, "text": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "start_char_idx": 439, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c430302-8593-435b-91b7-83e7b2d3d7be": {"__data__": {"id_": "0c430302-8593-435b-91b7-83e7b2d3d7be", "embedding": null, "metadata": {"window": "I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable. ", "original_text": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "original_text": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aed1792916e2ddcb538d7b1c6f068e2aa32a9a6ce9aaddc3c41af3390cce45c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2304db73-6f1b-4ae1-a445-0a30238be03e", "node_type": "1", "metadata": {"window": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "original_text": "Our \nperformance within this industry has improved dramatically. "}, "hash": "bfb00e9f3cf1464b3fb2aa1b96c8e189c92fcdfef0aa30a663e231d177ad4168", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "start_char_idx": 680, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2304db73-6f1b-4ae1-a445-0a30238be03e": {"__data__": {"id_": "2304db73-6f1b-4ae1-a445-0a30238be03e", "embedding": null, "metadata": {"window": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "original_text": "Our \nperformance within this industry has improved dramatically. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c430302-8593-435b-91b7-83e7b2d3d7be", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit \nmore about GMPD.  It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable. ", "original_text": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebdd775847e798ca3d461e73d132d14b48e8e45782ec5785960cfb4895418418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2", "node_type": "1", "metadata": {"window": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability. ", "original_text": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  "}, "hash": "6c63e93bfcdd2bb5e8c021704c6fbf5308283ce4f12c32e57335beb4bc7c665f", "class_name": "RelatedNodeInfo"}}, "text": "Our \nperformance within this industry has improved dramatically. ", "start_char_idx": 777, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2": {"__data__": {"id_": "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2", "embedding": null, "metadata": {"window": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability. ", "original_text": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2304db73-6f1b-4ae1-a445-0a30238be03e", "node_type": "1", "metadata": {"window": "It seems like the competitive environment maybe is improving in your favor, it \nseems like maybe there's some benefit from underlying , just like utilization demand.   Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "original_text": "Our \nperformance within this industry has improved dramatically. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8606068a7129296ebd9802d0290b8d6696521c0c6743248499752c31e5523253", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20fa3057-64c1-4910-9512-af5ad40f28c6", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels. ", "original_text": "So, our performance is noticeable. "}, "hash": "d18b0063575ab2242b4d2051a2bcb3b6b9df07f5dd0d283157502c974b0a2e4a", "class_name": "RelatedNodeInfo"}}, "text": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "start_char_idx": 842, "end_char_idx": 1000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20fa3057-64c1-4910-9512-af5ad40f28c6": {"__data__": {"id_": "20fa3057-64c1-4910-9512-af5ad40f28c6", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels. ", "original_text": "So, our performance is noticeable. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2", "node_type": "1", "metadata": {"window": "Could you please \njust give us a little bit more color on sort of those underlying changing dynamics and maybe more \nconceptually and above some of the specific cost cutting and other inflation offsets that you've \nalready talked about?  \n \n Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability. ", "original_text": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9f9c03585718d196d5559dfbe00923b6e9d091a72a2a4dfabe0704f68d153a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5", "node_type": "1", "metadata": {"window": "Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective. ", "original_text": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . "}, "hash": "746142874695a46443b7fb96b83adc48f5dd86f84572783b3881498c11ed2154", "class_name": "RelatedNodeInfo"}}, "text": "So, our performance is noticeable. ", "start_char_idx": 1000, "end_char_idx": 1035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5": {"__data__": {"id_": "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5", "embedding": null, "metadata": {"window": "Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective. ", "original_text": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20fa3057-64c1-4910-9512-af5ad40f28c6", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah , I think the competitive environment, I'm  not sure I'd put much into that.  Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels. ", "original_text": "So, our performance is noticeable. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5274eead5a734bf4da3d7cdd819953e26ed20449176f61f856cf5686331842f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34d4b1fb-e669-4290-ab61-7b5046e9462c", "node_type": "1", "metadata": {"window": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "original_text": "We \nhave product availability. "}, "hash": "bceb4ae5b6014e9c62a8ea3a8a94c8b1b15657a461a0fe01c4cc3e870c1911c4", "class_name": "RelatedNodeInfo"}}, "text": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "start_char_idx": 1035, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34d4b1fb-e669-4290-ab61-7b5046e9462c": {"__data__": {"id_": "34d4b1fb-e669-4290-ab61-7b5046e9462c", "embedding": null, "metadata": {"window": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "original_text": "We \nhave product availability. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5", "node_type": "1", "metadata": {"window": "Our \nperformance within this industry has improved dramatically.  I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective. ", "original_text": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3264a84940dbd3b5b33885844115d05e06acf6d34d64d2bd2cfb1aa608001f62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fdd2f26-331e-4eb9-b594-fa3f981abce9", "node_type": "1", "metadata": {"window": "So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that. ", "original_text": "We have great service levels. "}, "hash": "d48d95919338b41d2659a34dce9986ef94d5ebd4a6cefac0856d2ebe98e26680", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave product availability. ", "start_char_idx": 1164, "end_char_idx": 1195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fdd2f26-331e-4eb9-b594-fa3f981abce9": {"__data__": {"id_": "3fdd2f26-331e-4eb9-b594-fa3f981abce9", "embedding": null, "metadata": {"window": "So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that. ", "original_text": "We have great service levels. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34d4b1fb-e669-4290-ab61-7b5046e9462c", "node_type": "1", "metadata": {"window": "I referenced in my comments the \ncustomer loyalty scores have improved consistently and dramatically from the bottom of the \npandemic a couple of years ago.   So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "original_text": "We \nhave product availability. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16e27311677f69046094d1d99fc8986e82ac15d099f81b02303a371685cb425c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc8d471-df49-4985-a6d9-c1537c6ea65a", "node_type": "1", "metadata": {"window": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates. ", "original_text": "We're very engaged from a sales force  \nperspective. "}, "hash": "ba84a74f762ff0e0e38acb7dd18049124eac5423b18e7d80a6bf23ea6691a1e0", "class_name": "RelatedNodeInfo"}}, "text": "We have great service levels. ", "start_char_idx": 1195, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc8d471-df49-4985-a6d9-c1537c6ea65a": {"__data__": {"id_": "dcc8d471-df49-4985-a6d9-c1537c6ea65a", "embedding": null, "metadata": {"window": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates. ", "original_text": "We're very engaged from a sales force  \nperspective. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fdd2f26-331e-4eb9-b594-fa3f981abce9", "node_type": "1", "metadata": {"window": "So, our performance is noticeable.  Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that. ", "original_text": "We have great service levels. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b1847a48581771605e6c96817f205425c6a294e57a9b646f47d5f5641d7876d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04b0e18e-aaae-4c83-b55b-9fc8cfead31c", "node_type": "1", "metadata": {"window": "We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now. ", "original_text": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n"}, "hash": "0cbe25aa797f4f0bb737d6e0cd44ec9a81923135632dba5da5c58d7062763a7c", "class_name": "RelatedNodeInfo"}}, "text": "We're very engaged from a sales force  \nperspective. ", "start_char_idx": 1225, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04b0e18e-aaae-4c83-b55b-9fc8cfead31c": {"__data__": {"id_": "04b0e18e-aaae-4c83-b55b-9fc8cfead31c", "embedding": null, "metadata": {"window": "We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now. ", "original_text": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc8d471-df49-4985-a6d9-c1537c6ea65a", "node_type": "1", "metadata": {"window": "Our customers are feeling it that \ncustomer loyalty index, the score is behind it improving because we have the low back order .  We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates. ", "original_text": "We're very engaged from a sales force  \nperspective. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b001498b837be5fd94f4e5bf03095559a155f626625027cabd0e35cc84fb4b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a8c698-a621-45f8-8c7e-f512a0e03202", "node_type": "1", "metadata": {"window": "We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "original_text": "So, our customers are feeling that. "}, "hash": "9dc6a413e904ce0a7640cbf9710f666bdd688d5a29d973c8d8e0a1756402716d", "class_name": "RelatedNodeInfo"}}, "text": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "start_char_idx": 1278, "end_char_idx": 1367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a8c698-a621-45f8-8c7e-f512a0e03202": {"__data__": {"id_": "e2a8c698-a621-45f8-8c7e-f512a0e03202", "embedding": null, "metadata": {"window": "We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "original_text": "So, our customers are feeling that. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04b0e18e-aaae-4c83-b55b-9fc8cfead31c", "node_type": "1", "metadata": {"window": "We \nhave product availability.  We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now. ", "original_text": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf63c9b22f910f67e29397731c78a861f3c04ede10a90261c6062b33f39a47c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a54d23-17a5-4218-afb0-6a31c3a2636a", "node_type": "1", "metadata": {"window": "We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.  ", "original_text": "We have very stable win -loss types of rates. "}, "hash": "bb254de71c15ae90cff8d4f8445ff3183f3b65c6e8e0fc5ef0f05fcd6e773408", "class_name": "RelatedNodeInfo"}}, "text": "So, our customers are feeling that. ", "start_char_idx": 1367, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a54d23-17a5-4218-afb0-6a31c3a2636a": {"__data__": {"id_": "c8a54d23-17a5-4218-afb0-6a31c3a2636a", "embedding": null, "metadata": {"window": "We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.  ", "original_text": "We have very stable win -loss types of rates. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2a8c698-a621-45f8-8c7e-f512a0e03202", "node_type": "1", "metadata": {"window": "We have great service levels.  We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "original_text": "So, our customers are feeling that. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8484f0479ae8997bc75075db049584a719c8d4801c96a0e6ab865e347c41fde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a871a1-a050-4897-8216-3b704d6bb7b1", "node_type": "1", "metadata": {"window": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "original_text": "We're growing at \nleast with the market now. "}, "hash": "1d2a5336d38bd3e07834b8f2d4c82b852bb8c9aea21b9fa3efdaf54e30b394c5", "class_name": "RelatedNodeInfo"}}, "text": "We have very stable win -loss types of rates. ", "start_char_idx": 1403, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a871a1-a050-4897-8216-3b704d6bb7b1": {"__data__": {"id_": "33a871a1-a050-4897-8216-3b704d6bb7b1", "embedding": null, "metadata": {"window": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "original_text": "We're growing at \nleast with the market now. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a54d23-17a5-4218-afb0-6a31c3a2636a", "node_type": "1", "metadata": {"window": "We're very engaged from a sales force  \nperspective.  So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.  ", "original_text": "We have very stable win -loss types of rates. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05c2723be8d196b8b17fa92da7890346222322af2d84c3be9c9a6b6911fd06f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c1eb472-da89-4e66-a145-eff9291b439e", "node_type": "1", "metadata": {"window": "So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like. ", "original_text": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . "}, "hash": "94f894d28821a395074c27a73a8af6a55de44017e9dd00fc0c67d4ffa403b714", "class_name": "RelatedNodeInfo"}}, "text": "We're growing at \nleast with the market now. ", "start_char_idx": 1449, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c1eb472-da89-4e66-a145-eff9291b439e": {"__data__": {"id_": "7c1eb472-da89-4e66-a145-eff9291b439e", "embedding": null, "metadata": {"window": "So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like. ", "original_text": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a871a1-a050-4897-8216-3b704d6bb7b1", "node_type": "1", "metadata": {"window": "So, we're out there now selling instead of reacting to the challenges of the pandemic.  \n So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "original_text": "We're growing at \nleast with the market now. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "020a7ec825c051048c426c54a791c07ee86640be98a5e4a38c13a1c988cd53dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13f4c351-5da6-451a-928b-9d682cd39ecb", "node_type": "1", "metadata": {"window": "We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "original_text": "The market utilization continues to be more and more \nnormalized.  "}, "hash": "146aee9120305db799bf6f3c522d4cc73edc5b6e95950c53e0109d5f9f197931", "class_name": "RelatedNodeInfo"}}, "text": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "start_char_idx": 1494, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13f4c351-5da6-451a-928b-9d682cd39ecb": {"__data__": {"id_": "13f4c351-5da6-451a-928b-9d682cd39ecb", "embedding": null, "metadata": {"window": "We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "original_text": "The market utilization continues to be more and more \nnormalized.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c1eb472-da89-4e66-a145-eff9291b439e", "node_type": "1", "metadata": {"window": "So, our customers are feeling that.  We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like. ", "original_text": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6ef144c52564f4f2c9934ade7fe011399966037854df09ef2cc899d70b56d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4c29888-11a2-4755-980c-26d63e3df728", "node_type": "1", "metadata": {"window": "We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "original_text": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. "}, "hash": "06d7da2f40db38a0f2451dbf7e6d60b4f230ba907264b259862fdaacdb8b56a9", "class_name": "RelatedNodeInfo"}}, "text": "The market utilization continues to be more and more \nnormalized.  ", "start_char_idx": 1610, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4c29888-11a2-4755-980c-26d63e3df728": {"__data__": {"id_": "c4c29888-11a2-4755-980c-26d63e3df728", "embedding": null, "metadata": {"window": "We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "original_text": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13f4c351-5da6-451a-928b-9d682cd39ecb", "node_type": "1", "metadata": {"window": "We have very stable win -loss types of rates.  We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "original_text": "The market utilization continues to be more and more \nnormalized.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd32f49113fafbd2f560875f8a3be38bcac1ecb77848f7bb166de5bff7d8c223", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44e4d620-bc30-4463-9940-9ca829e25d22", "node_type": "1", "metadata": {"window": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "original_text": "And that's the environment we like. "}, "hash": "c1c3a263d607924b4c130308924cb17ec78c21526d95f5eac46abde09e81697c", "class_name": "RelatedNodeInfo"}}, "text": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "start_char_idx": 1677, "end_char_idx": 1826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44e4d620-bc30-4463-9940-9ca829e25d22": {"__data__": {"id_": "44e4d620-bc30-4463-9940-9ca829e25d22", "embedding": null, "metadata": {"window": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "original_text": "And that's the environment we like. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4c29888-11a2-4755-980c-26d63e3df728", "node_type": "1", "metadata": {"window": "We're growing at \nleast with the market now.  So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "original_text": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18847283c4643a483607828822622de7767228803356732988258e2835eb7935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e451d82-39fa-4e5b-97bf-cf95cd2d304b", "node_type": "1", "metadata": {"window": "The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "original_text": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  "}, "hash": "b8f9a1c8246895b1d69654a7a66d4052f30daa356520ee6206e4fef48681a852", "class_name": "RelatedNodeInfo"}}, "text": "And that's the environment we like. ", "start_char_idx": 1826, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e451d82-39fa-4e5b-97bf-cf95cd2d304b": {"__data__": {"id_": "4e451d82-39fa-4e5b-97bf-cf95cd2d304b", "embedding": null, "metadata": {"window": "The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "original_text": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44e4d620-bc30-4463-9940-9ca829e25d22", "node_type": "1", "metadata": {"window": "So, it's more of us showing up, I think, the right way than the market being \noverly growing more or growing less .  The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "original_text": "And that's the environment we like. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a382d02fdacd065b7a62b9542dc32070f15b67cdc9848508124977ff244a00ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb9aa194-0e36-477c-ba6e-4352af432cac", "node_type": "1", "metadata": {"window": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . "}, "hash": "65c2fb908caa1a93d13f4353974e4d5164e046ca713fc2c232bb4541a6a396d4", "class_name": "RelatedNodeInfo"}}, "text": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "start_char_idx": 1862, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb9aa194-0e36-477c-ba6e-4352af432cac": {"__data__": {"id_": "cb9aa194-0e36-477c-ba6e-4352af432cac", "embedding": null, "metadata": {"window": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e451d82-39fa-4e5b-97bf-cf95cd2d304b", "node_type": "1", "metadata": {"window": "The market utilization continues to be more and more \nnormalized.   So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "original_text": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7733affeacd23c29b375863e2d79872643ad6460d4decada6c808cc6c60e459", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c7849f-cecc-4cf0-8278-9f4e23a1e836", "node_type": "1", "metadata": {"window": "And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "original_text": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  "}, "hash": "92894eff07d8bee3a86f69da8cdd6780d41376df609163f2c25dd67d2e44c6a6", "class_name": "RelatedNodeInfo"}}, "text": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "start_char_idx": 2027, "end_char_idx": 2285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77c7849f-cecc-4cf0-8278-9f4e23a1e836": {"__data__": {"id_": "77c7849f-cecc-4cf0-8278-9f4e23a1e836", "embedding": null, "metadata": {"window": "And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "original_text": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb9aa194-0e36-477c-ba6e-4352af432cac", "node_type": "1", "metadata": {"window": "So, there's maybe a little bit of volatility here and there, but it's much more normalized \ncompared to where it has been in the last several years.  And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n", "original_text": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that . ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "119e596a8b7bf4c7613f980643bc005e0d9415e687208e1a49e7fca988b02ac1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ed862f2-e305-4514-b150-eacddd8f37e6", "node_type": "1", "metadata": {"window": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n", "original_text": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n"}, "hash": "6b2acb53e6016bff9e609f9398a8a163561a72d31f3fe2bd2aaf3e99734027d5", "class_name": "RelatedNodeInfo"}}, "text": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "start_char_idx": 2285, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ed862f2-e305-4514-b150-eacddd8f37e6": {"__data__": {"id_": "0ed862f2-e305-4514-b150-eacddd8f37e6", "embedding": null, "metadata": {"window": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n", "original_text": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c7849f-cecc-4cf0-8278-9f4e23a1e836", "node_type": "1", "metadata": {"window": "And that's the environment we like.  We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "original_text": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66336bafc750e7e988118e0fa09c07db8519251065b5d62e836bada402bb5330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ab939a0-ca9b-48b0-8371-fbe217cf78e7", "node_type": "1", "metadata": {"window": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks. ", "original_text": "Matt Sims: Next question, please.  \n \n"}, "hash": "5af27a054393557973f6208557f94ec59da8344f0a307312cf9d7f4da5d38005", "class_name": "RelatedNodeInfo"}}, "text": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "start_char_idx": 2553, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab939a0-ca9b-48b0-8371-fbe217cf78e7": {"__data__": {"id_": "3ab939a0-ca9b-48b0-8371-fbe217cf78e7", "embedding": null, "metadata": {"window": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ed862f2-e305-4514-b150-eacddd8f37e6", "node_type": "1", "metadata": {"window": "We like \nto see predictab le, consistent lower single -digit type of utilization rates that we can grow a little bit \nabove that through our mix and other actions.   And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n", "original_text": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32b51177f9311d932dc5610eb9631531c284bcc52e8778c0adc67a8c680cb9e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a996eb2-828a-4038-b295-36ef7d25d28d", "node_type": "1", "metadata": {"window": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question. ", "original_text": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. "}, "hash": "606b71127266e05a19dce44cc69476612ff34b0842f156d33616e7dabef216b4", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims: Next question, please.  \n \n", "start_char_idx": 2828, "end_char_idx": 2866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a996eb2-828a-4038-b295-36ef7d25d28d": {"__data__": {"id_": "9a996eb2-828a-4038-b295-36ef7d25d28d", "embedding": null, "metadata": {"window": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question. ", "original_text": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ab939a0-ca9b-48b0-8371-fbe217cf78e7", "node_type": "1", "metadata": {"window": "And then, of course, as Aaron highlighted, the single \nbiggest driver, not only this past year, but what we expect at least in the first half of next year would \nbe the , just the lapping of the inflation impacts and everything we've done to mitigate that .  Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks. ", "original_text": "Matt Sims: Next question, please.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfe4e70f6bc496a0845b3a334c6f210b1921c67b666ce1c5eb15eb84db3797a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7", "node_type": "1", "metadata": {"window": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "bacc7a874a13a45a0edbfb0ce4c91ab4d62fa22d230e3b1f5c4ad31efb8fe746", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "start_char_idx": 2866, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7": {"__data__": {"id_": "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7", "embedding": null, "metadata": {"window": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a996eb2-828a-4038-b295-36ef7d25d28d", "node_type": "1", "metadata": {"window": "Which \nthat's another thing that's helpful for us to get that behind us so that we're focused on selling and \ntalking to our  customers what the value that we can help provide them as opposed to dealing with \ninflationary fluctuations that have occurred in the past.   So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question. ", "original_text": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "312e98545a3c2dc894e5b91133ae93c09733e783280527bc8735b7610182ee37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc4e2155-76b5-4b21-8e89-bccb99fe7f33", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "original_text": "Stephen Baxter:   Hi, thanks. "}, "hash": "7d47dd1ff8b1cde892bbb55f357633bb62571d65e9fcb963d7f9fc5d8a15d5d0", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 2961, "end_char_idx": 2983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc4e2155-76b5-4b21-8e89-bccb99fe7f33": {"__data__": {"id_": "dc4e2155-76b5-4b21-8e89-bccb99fe7f33", "embedding": null, "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "original_text": "Stephen Baxter:   Hi, thanks. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7", "node_type": "1", "metadata": {"window": "So, we're well positioned to now drive the \nother elements, the Medical , the GMPD improvement plan, which is the ongoing simplification, the \nongoing cost reductions, but just continuing to really prioritize more than anything that Cardinal Health \nBrand volume growth.  \n \n Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "346efa63769323fda744237d6fccd419753f8e9232e97a0fd9f934c0fa887377", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb12c4de-2d27-4fe3-867e-3d0092468ec2", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "original_text": "Just one quick confirmation and then the actual question. "}, "hash": "101f3ddbde12e40b5303f507048ad5d6550618965f4aedc5f5768a157d364f93", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter:   Hi, thanks. ", "start_char_idx": 2983, "end_char_idx": 3013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb12c4de-2d27-4fe3-867e-3d0092468ec2": {"__data__": {"id_": "bb12c4de-2d27-4fe3-867e-3d0092468ec2", "embedding": null, "metadata": {"window": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "original_text": "Just one quick confirmation and then the actual question. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc4e2155-76b5-4b21-8e89-bccb99fe7f33", "node_type": "1", "metadata": {"window": "Matt Sims: Next question, please.  \n \n Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "original_text": "Stephen Baxter:   Hi, thanks. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cf10d6f3192359f36646f6607cc856820205fa20bb9e2b49dda9a9cafb13578", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f7e71f7-90b7-4c11-87d7-f11665f20bde", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "original_text": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. "}, "hash": "c1a6f36ded518bdcf253a9ab64f8bbf64cd7cfc6ab2c1aa34a303eff86b2de99", "class_name": "RelatedNodeInfo"}}, "text": "Just one quick confirmation and then the actual question. ", "start_char_idx": 3013, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f7e71f7-90b7-4c11-87d7-f11665f20bde": {"__data__": {"id_": "9f7e71f7-90b7-4c11-87d7-f11665f20bde", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "original_text": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb12c4de-2d27-4fe3-867e-3d0092468ec2", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir, the next question is coming from Stephen Baxter calling from Wells Fargo.  Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "original_text": "Just one quick confirmation and then the actual question. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "351ba519b5426293a6525d4e90205e1fa7ae797c473c8d8d6a537853d3e468c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a23ec9b4-6cc3-4486-809b-3023d3f35f58", "node_type": "1", "metadata": {"window": "Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "original_text": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  "}, "hash": "a6568099965b157bb07f105e7558cb60d216f3d8483f455d0dbc2adb467c5ca4", "class_name": "RelatedNodeInfo"}}, "text": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "start_char_idx": 3071, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a23ec9b4-6cc3-4486-809b-3023d3f35f58": {"__data__": {"id_": "a23ec9b4-6cc3-4486-809b-3023d3f35f58", "embedding": null, "metadata": {"window": "Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "original_text": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f7e71f7-90b7-4c11-87d7-f11665f20bde", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "original_text": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "218c159027e50c487c8d82eb73d9531812e1001bfece739535de834414d6bf3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "592c998f-e77d-4132-8a3b-27125a022461", "node_type": "1", "metadata": {"window": "Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. "}, "hash": "494815a44f7ad39e8c7575d9fad54e4a980fce7f6799babfdaee846948660e4c", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "start_char_idx": 3214, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "592c998f-e77d-4132-8a3b-27125a022461": {"__data__": {"id_": "592c998f-e77d-4132-8a3b-27125a022461", "embedding": null, "metadata": {"window": "Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a23ec9b4-6cc3-4486-809b-3023d3f35f58", "node_type": "1", "metadata": {"window": "Stephen Baxter:   Hi, thanks.  Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "original_text": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d7310d53cf315ab0adb09911293547df59b896ae60222c3e608cd41344d7e57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "710a083f-db69-4edd-b1d9-c6b881cbf87a", "node_type": "1", "metadata": {"window": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. "}, "hash": "725dd8b24bf7686bb901fa6376ec6321f9ca24c45e654e286e53a3d02341975d", "class_name": "RelatedNodeInfo"}}, "text": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "start_char_idx": 3334, "end_char_idx": 3433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "710a083f-db69-4edd-b1d9-c6b881cbf87a": {"__data__": {"id_": "710a083f-db69-4edd-b1d9-c6b881cbf87a", "embedding": null, "metadata": {"window": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "592c998f-e77d-4132-8a3b-27125a022461", "node_type": "1", "metadata": {"window": "Just one quick confirmation and then the actual question.  I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "495d18d2d83dcef15d2a5a3bb4a488af659eccdbca70e715ed6157e234288cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4ec4598-5f60-42aa-948c-16d641e9cdd4", "node_type": "1", "metadata": {"window": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? "}, "hash": "271fe71b920e6ae46d1077b7984c43094009ccf6a136dde531cf3ff693f8ef71", "class_name": "RelatedNodeInfo"}}, "text": "It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "start_char_idx": 3433, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4ec4598-5f60-42aa-948c-16d641e9cdd4": {"__data__": {"id_": "a4ec4598-5f60-42aa-948c-16d641e9cdd4", "embedding": null, "metadata": {"window": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "710a083f-db69-4edd-b1d9-c6b881cbf87a", "node_type": "1", "metadata": {"window": "I think what \nyou're suggesting is that beyond fiscal 2025 there is no direct or indirect impact from the  Optum \ncontract loss to compensate.  Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations. ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8f57ac0c2029f48fd1b92e750447abfae074b068188dbd9f4a1c300f0aa37a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f05a2d0d-5051-4673-9e69-6449a3cb6dec", "node_type": "1", "metadata": {"window": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Thanks.  "}, "hash": "6f3c86641f5ace04d1ae9eb5346d4d78f648197cb767854b7e59183da41600b3", "class_name": "RelatedNodeInfo"}}, "text": "Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "start_char_idx": 3533, "end_char_idx": 3641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f05a2d0d-5051-4673-9e69-6449a3cb6dec": {"__data__": {"id_": "f05a2d0d-5051-4673-9e69-6449a3cb6dec", "embedding": null, "metadata": {"window": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Thanks.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16581eccf0e0040b150377b5c386202551a60753563b3a7eab99cd00fc351859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4ec4598-5f60-42aa-948c-16d641e9cdd4", "node_type": "1", "metadata": {"window": "Just wanted to  confirm that point, that there's no earnings contribution \nfrom a transitional period inside the 2025.   And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years? ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3f16f9b1210065b764302bdb08b7ea49979ea9502155ba9ccdad407eaea8b0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71ffb338-7915-414e-84fe-12488c37b2b5", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far. ", "original_text": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%. "}, "hash": "365e4a4072e7499114251dff16c8adea00ec0cfa92bb311b86b37cc58942fce1", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  ", "start_char_idx": 3641, "end_char_idx": 3650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71ffb338-7915-414e-84fe-12488c37b2b5": {"__data__": {"id_": "71ffb338-7915-414e-84fe-12488c37b2b5", "embedding": null, "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far. ", "original_text": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f05a2d0d-5051-4673-9e69-6449a3cb6dec", "node_type": "1", "metadata": {"window": "And then the actual question is from the Other segment, \nthe revenue growth has been quite strong.  It's  taken a little bit of the profit growth to kind of catch up \nto your long -term expectations.  Just remind us of the key moving parts there are to accelerate the \nprofit growth in the next couple years?  Thanks.  ", "original_text": "Thanks.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c089bcabc12041a5d7c729f416672b795bfc6464ec8e04078b3832a74864d8c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09def0ed-2db7-4b6b-9a6f-cc9668893fb2", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "original_text": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%. "}, "hash": "6ae4d66aa0ec1d3d778b00b31a2066fca900f3768746ac1e169344f6f2fd285b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%. ", "start_char_idx": 0, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09def0ed-2db7-4b6b-9a6f-cc9668893fb2": {"__data__": {"id_": "09def0ed-2db7-4b6b-9a6f-cc9668893fb2", "embedding": null, "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "original_text": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71ffb338-7915-414e-84fe-12488c37b2b5", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far. ", "original_text": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d8dbc745c4ea3a33195ef849a2fe1b7517152d67ae02e11e2e35a6b7772e80e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d919132-2602-4527-9188-dd1a5b00a6f4", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n", "original_text": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n"}, "hash": "6cb4779dbb542ed7c42a4e74c7192e0b92992db467ba6853ace3f71e6514b875", "class_name": "RelatedNodeInfo"}}, "text": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%. ", "start_char_idx": 163, "end_char_idx": 234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d919132-2602-4527-9188-dd1a5b00a6f4": {"__data__": {"id_": "1d919132-2602-4527-9188-dd1a5b00a6f4", "embedding": null, "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n", "original_text": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09def0ed-2db7-4b6b-9a6f-cc9668893fb2", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "original_text": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2a72dc87abbbee13e8d154820cf5a534bbb55865bd0838177f9afc45a226b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89d40f4d-d427-4e1b-8306-58ee14da5406", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year. ", "original_text": "With respect to the Other business, we are pleased with what we're seeing so far. "}, "hash": "e4d0ef95287a31eb2c34181978b91630ca66ef7f2b2daa682f36a81c65c2e56f", "class_name": "RelatedNodeInfo"}}, "text": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n", "start_char_idx": 234, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89d40f4d-d427-4e1b-8306-58ee14da5406": {"__data__": {"id_": "89d40f4d-d427-4e1b-8306-58ee14da5406", "embedding": null, "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year. ", "original_text": "With respect to the Other business, we are pleased with what we're seeing so far. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d919132-2602-4527-9188-dd1a5b00a6f4", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n", "original_text": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb8f610bf72153a7a8f00ecefc926c23c54faec01162c3b93ddad93d4cc5f6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da", "node_type": "1", "metadata": {"window": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "original_text": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. "}, "hash": "b52fd99bcd682d12fa7b8b1c11f55c2658fb817c51ec6f37d54706f53967107a", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the Other business, we are pleased with what we're seeing so far. ", "start_char_idx": 432, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da": {"__data__": {"id_": "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da", "embedding": null, "metadata": {"window": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "original_text": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89d40f4d-d427-4e1b-8306-58ee14da5406", "node_type": "1", "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year. ", "original_text": "With respect to the Other business, we are pleased with what we're seeing so far. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84f46000ee5a34004a0f49681b39de64fb67f0e7482b98003a9de084514fa5a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56241dea-09ca-4c9f-8917-2aecadd94f6a", "node_type": "1", "metadata": {"window": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "original_text": "The top -line resu lts are good, right?  \n"}, "hash": "30ba670f8b4a2c79316b443cab85ce6e4998b7284b013a69a447aea5858cb743", "class_name": "RelatedNodeInfo"}}, "text": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "start_char_idx": 514, "end_char_idx": 695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56241dea-09ca-4c9f-8917-2aecadd94f6a": {"__data__": {"id_": "56241dea-09ca-4c9f-8917-2aecadd94f6a", "embedding": null, "metadata": {"window": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "original_text": "The top -line resu lts are good, right?  \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da", "node_type": "1", "metadata": {"window": "It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "original_text": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3143d2721656644cc99a4deb0b0e23a1db99e337a9495a9c2527cc78e3c754fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "082bb6aa-7848-4b0a-8296-570f858c5de0", "node_type": "1", "metadata": {"window": "With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "original_text": "And we guided 6% to 8% profit growth for this year. "}, "hash": "7436ab18a9840aa77f73411f35a3eb0c2ee2ac90b7b0738d532349d4de4edaf0", "class_name": "RelatedNodeInfo"}}, "text": "The top -line resu lts are good, right?  \n", "start_char_idx": 695, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "082bb6aa-7848-4b0a-8296-570f858c5de0": {"__data__": {"id_": "082bb6aa-7848-4b0a-8296-570f858c5de0", "embedding": null, "metadata": {"window": "With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "original_text": "And we guided 6% to 8% profit growth for this year. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56241dea-09ca-4c9f-8917-2aecadd94f6a", "node_type": "1", "metadata": {"window": "We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "original_text": "The top -line resu lts are good, right?  \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f88e2bd9402672731822d84c2de292e620adf1e61ac33a328d59de13f4cde00a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "260bcc70-7931-4aa7-97f9-6699684dc93b", "node_type": "1", "metadata": {"window": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add. ", "original_text": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . "}, "hash": "3ff0258cb6209097825280c1d3dbad11e3fb1069b0ef1fa730ce55ae636a4cb8", "class_name": "RelatedNodeInfo"}}, "text": "And we guided 6% to 8% profit growth for this year. ", "start_char_idx": 737, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "260bcc70-7931-4aa7-97f9-6699684dc93b": {"__data__": {"id_": "260bcc70-7931-4aa7-97f9-6699684dc93b", "embedding": null, "metadata": {"window": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add. ", "original_text": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "082bb6aa-7848-4b0a-8296-570f858c5de0", "node_type": "1", "metadata": {"window": "With respect to the Other business, we are pleased with what we're seeing so far.  We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "original_text": "And we guided 6% to 8% profit growth for this year. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f18cb855e020d5837b9b2c3f59c780990168d021dd6e3df26a4bb4cfce097e20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd", "node_type": "1", "metadata": {"window": "The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "original_text": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. "}, "hash": "bd1efb2d797b480b54dfa7b803acf61125004f2f7c00b5edabbc08f559763823", "class_name": "RelatedNodeInfo"}}, "text": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "start_char_idx": 789, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd": {"__data__": {"id_": "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd", "embedding": null, "metadata": {"window": "The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "original_text": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "260bcc70-7931-4aa7-97f9-6699684dc93b", "node_type": "1", "metadata": {"window": "We re -segmented \nthe operation to create additional transparency focus and accountability, and I referenced in my \nprepared remarks that we are already seeing the benefit of that.  The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add. ", "original_text": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter . ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "893945b27a9c417c63ef979999723cade64b3ce87f00ffa3aa820d6e810acfc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36fecd90-07b1-49a3-b026-43cfb0ba42a3", "node_type": "1", "metadata": {"window": "And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "original_text": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n"}, "hash": "0efc2d78c69ac782cfea7b126877c1c958e2b703a55d5835bbe045c183b5bbbc", "class_name": "RelatedNodeInfo"}}, "text": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "start_char_idx": 1061, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36fecd90-07b1-49a3-b026-43cfb0ba42a3": {"__data__": {"id_": "36fecd90-07b1-49a3-b026-43cfb0ba42a3", "embedding": null, "metadata": {"window": "And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "original_text": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd", "node_type": "1", "metadata": {"window": "The top -line resu lts are good, right?  \n And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "original_text": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87590966287e488d58e087a6053b04d9df0ee2707c83974fc8acdf65ebb16258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821bae44-5d55-4c3b-8245-8a57b1e84c5d", "node_type": "1", "metadata": {"window": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "original_text": "Jason Hollar:  Yeah, just a couple things to add. "}, "hash": "169a007a849fd74f40048b6c4864d9a47e9e1b6a8922646a4fbe1c2b1bbcb6f9", "class_name": "RelatedNodeInfo"}}, "text": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "start_char_idx": 1250, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821bae44-5d55-4c3b-8245-8a57b1e84c5d": {"__data__": {"id_": "821bae44-5d55-4c3b-8245-8a57b1e84c5d", "embedding": null, "metadata": {"window": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "original_text": "Jason Hollar:  Yeah, just a couple things to add. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36fecd90-07b1-49a3-b026-43cfb0ba42a3", "node_type": "1", "metadata": {"window": "And we guided 6% to 8% profit growth for this year.  We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "original_text": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14b25081e3e9bb1a87708f46972c9c8513495c0e9b2e6963cd7f29e74f623d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99582cdb-a43a-46f8-a214-412212603db7", "node_type": "1", "metadata": {"window": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "original_text": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. "}, "hash": "261ae066a02ea647ffbe6ad682f92a7653fe545c8f7dbade7370217b76cc3780", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, just a couple things to add. ", "start_char_idx": 1427, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99582cdb-a43a-46f8-a214-412212603db7": {"__data__": {"id_": "99582cdb-a43a-46f8-a214-412212603db7", "embedding": null, "metadata": {"window": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "original_text": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821bae44-5d55-4c3b-8245-8a57b1e84c5d", "node_type": "1", "metadata": {"window": "We were a little bit lower than that in Q3 for the \nbusinesses aggregating in Other so far, and of course we had the impact of some of the non -\nrecurring adjustments that we called out in Q2 tied to the at -Home business which reports into Other \nin the second quarter .  But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "original_text": "Jason Hollar:  Yeah, just a couple things to add. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1e1f1bcc94e0b56b2d9d565a39d3dddb42738e5b8b2c7574f9df94e7b4b772d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87fba192-f67d-416c-9d58-63d5add1a175", "node_type": "1", "metadata": {"window": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted. ", "original_text": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. "}, "hash": "23a5f2f007fc8b147c00203732196b2598477fa6e133b4cbfea221addc45e485", "class_name": "RelatedNodeInfo"}}, "text": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "start_char_idx": 1477, "end_char_idx": 1795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87fba192-f67d-416c-9d58-63d5add1a175": {"__data__": {"id_": "87fba192-f67d-416c-9d58-63d5add1a175", "embedding": null, "metadata": {"window": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted. ", "original_text": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99582cdb-a43a-46f8-a214-412212603db7", "node_type": "1", "metadata": {"window": "But I want to emphasize we did confirm that we are expecting to achieve the \nhigher results, the 8% to 10%, for the fiscal \u201824, and we confirmed the high end of that range for fiscal \n\u201825.  As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "original_text": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fa98c32906db6536294e9312da05283dcd69fdfeceb129f9886c9ef2bd641aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef929eb-5041-46ec-849a-3eb4c6d96dda", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "original_text": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. "}, "hash": "93f3e54db764a856d9c9f5d5008e04408b7ed161120192096a549898711a69dc", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "start_char_idx": 1795, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef929eb-5041-46ec-849a-3eb4c6d96dda": {"__data__": {"id_": "1ef929eb-5041-46ec-849a-3eb4c6d96dda", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "original_text": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87fba192-f67d-416c-9d58-63d5add1a175", "node_type": "1", "metadata": {"window": "As Jaso n digs in with the businesses now reporting directly to them, and as we invest as an \nenterprise against setting those businesses up for a higher growth trajectory.  \n \n Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted. ", "original_text": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "434f6425e448d7d2278cb871af1f710ba7aae5f439ab97f402fc786498d7d63e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2da3809-de08-4af6-9d3d-22e6ba114c13", "node_type": "1", "metadata": {"window": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, we are well -positioned for each one of th ese three and why \nwe have confidence. "}, "hash": "9021d95a9cf83fbe69b6a176db7da7b6929e94dcb52b86842ee8097cbd7e3153", "class_name": "RelatedNodeInfo"}}, "text": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "start_char_idx": 1898, "end_char_idx": 2418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2da3809-de08-4af6-9d3d-22e6ba114c13": {"__data__": {"id_": "d2da3809-de08-4af6-9d3d-22e6ba114c13", "embedding": null, "metadata": {"window": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef929eb-5041-46ec-849a-3eb4c6d96dda", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, just a couple things to add.  First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "original_text": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ff93ca912481a9cf4d37119f899e6d4a1ea7a163e1e7fe19e4850547cb7f3cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4009632-bd71-489f-86c9-734f4427fbb4", "node_type": "1", "metadata": {"window": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "We are investing into them, as Aaron highlighted. "}, "hash": "42088e24654333ea9fae9497fbb768caf5fcd4b7009ec187833ff23323483fef", "class_name": "RelatedNodeInfo"}}, "text": "So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "start_char_idx": 2418, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4009632-bd71-489f-86c9-734f4427fbb4": {"__data__": {"id_": "d4009632-bd71-489f-86c9-734f4427fbb4", "embedding": null, "metadata": {"window": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "We are investing into them, as Aaron highlighted. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2da3809-de08-4af6-9d3d-22e6ba114c13", "node_type": "1", "metadata": {"window": "First of all, the first question, just to be real explicit, \ngiven it's a cliff event, customer transition that we are anticipating for July 1, we have anticipated that \nthat would be largely in fiscal \u201825 results and there's nothing that we're calling out or indicating at this \npoint that would carry over into \u201826.  And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "So, we are well -positioned for each one of th ese three and why \nwe have confidence. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7781a10b73295054949ea649476b5d7267df1f366e8f906ec691bfeec9d68d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34", "node_type": "1", "metadata": {"window": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen. ", "original_text": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n"}, "hash": "56a0b418f5b867c25bf83671f9fd035840c108f1499d37329bd34e32b46685ed", "class_name": "RelatedNodeInfo"}}, "text": "We are investing into them, as Aaron highlighted. ", "start_char_idx": 2504, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34": {"__data__": {"id_": "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34", "embedding": null, "metadata": {"window": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen. ", "original_text": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4009632-bd71-489f-86c9-734f4427fbb4", "node_type": "1", "metadata": {"window": "And as it relates to the other businesses, how I think about them, \nthey are each growing very nicely.  They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "We are investing into them, as Aaron highlighted. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d52674da1ae08684705067be9050958e2c8fae853bd23f37f10ff61d84e0ccc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec85a842-8d34-4d64-97bd-2f650a263bb7", "node_type": "1", "metadata": {"window": "So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "63dee01f8258a57aefb1f2554694ed2530bb7be9a5e06361d638366450a8c7ce", "class_name": "RelatedNodeInfo"}}, "text": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "start_char_idx": 2554, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec85a842-8d34-4d64-97bd-2f650a263bb7": {"__data__": {"id_": "ec85a842-8d34-4d64-97bd-2f650a263bb7", "embedding": null, "metadata": {"window": "So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34", "node_type": "1", "metadata": {"window": "They each have strong industry, strong sector s of the industry that \nare benefiting from their own individual secular tailwinds, so they each have different reasons for their \ngrowth, but ultimately it's because each of these three areas provide a real interesting value \nproposition to customers and ult imately to the patients, and each of these three we have a leadership \nposition in, so we're not only benefiting from that secular trend but we \u2019re leading and maintaining or \ngrowing our own fair share within it.  So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen. ", "original_text": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57940d3e33cb9b3f8f2109e5cd091175a9067e4c51e0dcd8fe5845193accaced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a90615c-04a0-4088-9255-4a6a3414501a", "node_type": "1", "metadata": {"window": "We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. "}, "hash": "77869d466913598df26666434592d2e91c103d6d03e2cbc8975aff54d2166aa1", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 2651, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a90615c-04a0-4088-9255-4a6a3414501a": {"__data__": {"id_": "3a90615c-04a0-4088-9255-4a6a3414501a", "embedding": null, "metadata": {"window": "We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec85a842-8d34-4d64-97bd-2f650a263bb7", "node_type": "1", "metadata": {"window": "So, we are well -positioned for each one of th ese three and why \nwe have confidence.  We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c3498afac39a070909c1297e3193f148d03e8abfd918141ee16fe64a05d0f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3116390c-c8be-4e07-a0e9-8a8ae61a61e8", "node_type": "1", "metadata": {"window": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles. ", "original_text": "Next question will be coming from Charles Rhyee of TD Cowen. "}, "hash": "21da2ca4127c722bbf2726fdcadfb6835911cd8532bf8aec521f60724ca55a57", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Yes, sir. ", "start_char_idx": 2690, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3116390c-c8be-4e07-a0e9-8a8ae61a61e8": {"__data__": {"id_": "3116390c-c8be-4e07-a0e9-8a8ae61a61e8", "embedding": null, "metadata": {"window": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles. ", "original_text": "Next question will be coming from Charles Rhyee of TD Cowen. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a90615c-04a0-4088-9255-4a6a3414501a", "node_type": "1", "metadata": {"window": "We are investing into them, as Aaron highlighted.  That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeeb822d81c3a4e622fee4c2991a0e0cb4c610c34dc0cabc1415e08cb6599362", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc67f94-0c72-48b3-bea7-43b7f10a200b", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "original_text": "Please go ahead. \n"}, "hash": "368637a7971715275d6d7b585fe184ad9232ca81f513568ae40a2aa7f0e04a7b", "class_name": "RelatedNodeInfo"}}, "text": "Next question will be coming from Charles Rhyee of TD Cowen. ", "start_char_idx": 2711, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc67f94-0c72-48b3-bea7-43b7f10a200b": {"__data__": {"id_": "dfc67f94-0c72-48b3-bea7-43b7f10a200b", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "original_text": "Please go ahead. \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3116390c-c8be-4e07-a0e9-8a8ae61a61e8", "node_type": "1", "metadata": {"window": "That's driving the growth that \nwe believe will be driving long -term profitability as well.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles. ", "original_text": "Next question will be coming from Charles Rhyee of TD Cowen. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acac5e8dda730d660016f4ddc8204294ae8207beb9408ba40d87e66c52c415ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac408b44-50d7-4e8a-bc55-e95515e098cf", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "original_text": "Your line is open.  \n \n"}, "hash": "b071ed72d71dd64bc40c743e934980cc9a59fe700dfdbe40f88ad4c184b57e7b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead. \n", "start_char_idx": 2772, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac408b44-50d7-4e8a-bc55-e95515e098cf": {"__data__": {"id_": "ac408b44-50d7-4e8a-bc55-e95515e098cf", "embedding": null, "metadata": {"window": "Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "original_text": "Your line is open.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc67f94-0c72-48b3-bea7-43b7f10a200b", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "original_text": "Please go ahead. \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aea861d194ce02b11138023350b4eba00a9429d63eb94809df7418c95fe6480a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6b3ee3d-a061-405a-a19b-613aacb52aac", "node_type": "1", "metadata": {"window": "Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "original_text": "Lucas Romanski :  Hi, this is Lucas on for Charles. "}, "hash": "3940ded2c689b957a7be752f3e03136d93eb1f9944fee89be4ca3579e7273476", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n \n", "start_char_idx": 2790, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6b3ee3d-a061-405a-a19b-613aacb52aac": {"__data__": {"id_": "c6b3ee3d-a061-405a-a19b-613aacb52aac", "embedding": null, "metadata": {"window": "Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "original_text": "Lucas Romanski :  Hi, this is Lucas on for Charles. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac408b44-50d7-4e8a-bc55-e95515e098cf", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "original_text": "Your line is open.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "901ccab1e4328823618988d938768114b619566541614f738ef1cff5f1f5088e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9768c3a2-ee93-417c-a495-b1e36cde7ee2", "node_type": "1", "metadata": {"window": "Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n", "original_text": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. "}, "hash": "b326575053a4ba9975da380fdce6f870f0fe7002878c02df77262db7f9905635", "class_name": "RelatedNodeInfo"}}, "text": "Lucas Romanski :  Hi, this is Lucas on for Charles. ", "start_char_idx": 2813, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9768c3a2-ee93-417c-a495-b1e36cde7ee2": {"__data__": {"id_": "9768c3a2-ee93-417c-a495-b1e36cde7ee2", "embedding": null, "metadata": {"window": "Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n", "original_text": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6b3ee3d-a061-405a-a19b-613aacb52aac", "node_type": "1", "metadata": {"window": "Next question will be coming from Charles Rhyee of TD Cowen.  Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "original_text": "Lucas Romanski :  Hi, this is Lucas on for Charles. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08d9039d69f04e16442bc1eb0721ecc77fade4cfe5ca3c82b0f4f80ee7f3804f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccc96798-25b8-447c-9128-d1f5b97d7963", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "original_text": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. "}, "hash": "0614ef303c9f628b029eea8e3db38de6a0c9473de6c3cbf484270dd672bc7785", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "start_char_idx": 2865, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccc96798-25b8-447c-9128-d1f5b97d7963": {"__data__": {"id_": "ccc96798-25b8-447c-9128-d1f5b97d7963", "embedding": null, "metadata": {"window": "Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "original_text": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9768c3a2-ee93-417c-a495-b1e36cde7ee2", "node_type": "1", "metadata": {"window": "Please go ahead. \n Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n", "original_text": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fafc1a9e007d98ab4d65bfa241025cd0fd817de6a8fe0874ac930a952b7ce614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43", "node_type": "1", "metadata": {"window": "Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "original_text": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? "}, "hash": "1a4f4e26d98cb12c331ab081de2cbba19248869789e8694ab2b01b8d9eb7d82b", "class_name": "RelatedNodeInfo"}}, "text": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "start_char_idx": 3015, "end_char_idx": 3169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43": {"__data__": {"id_": "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43", "embedding": null, "metadata": {"window": "Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "original_text": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccc96798-25b8-447c-9128-d1f5b97d7963", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "original_text": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6941ae8c5f704c6c750c7f82b41ea97f934f907dcc89bc61509a8c6efeaf88e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3803a396-b90e-4dce-8f94-e547a5bad305", "node_type": "1", "metadata": {"window": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "original_text": "Thanks.  \n \n"}, "hash": "910cecc85bbf2f6851842e131aaaa935bb6b19372841169ebfd93bc9611088b8", "class_name": "RelatedNodeInfo"}}, "text": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "start_char_idx": 3169, "end_char_idx": 3325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3803a396-b90e-4dce-8f94-e547a5bad305": {"__data__": {"id_": "3803a396-b90e-4dce-8f94-e547a5bad305", "embedding": null, "metadata": {"window": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "original_text": "Thanks.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43", "node_type": "1", "metadata": {"window": "Lucas Romanski :  Hi, this is Lucas on for Charles.  I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "original_text": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825? ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "368ac59f3999edf1863a3462002365d31f8615691a397423e557ce3066707545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "522f3861-bae8-45a5-841b-b383e6853c93", "node_type": "1", "metadata": {"window": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? "}, "hash": "844a2e42a970ebdc86e9416820e3f66efc8e49b665d52c12decd3ca1007ef111", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 3325, "end_char_idx": 3337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "522f3861-bae8-45a5-841b-b383e6853c93": {"__data__": {"id_": "522f3861-bae8-45a5-841b-b383e6853c93", "embedding": null, "metadata": {"window": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3803a396-b90e-4dce-8f94-e547a5bad305", "node_type": "1", "metadata": {"window": "I wanted to ask about Cardinal Health Brand and \nget a sense of where we're at to the path of realizing $50 million in targeted growth by fiscal \u201826.  I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "original_text": "Thanks.  \n \n", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "830eb91603c76936f8211a9547e37c2bbcec1d0132f72c9584195b547363504f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b249688b-b66d-491a-bada-657ad045854f", "node_type": "1", "metadata": {"window": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. "}, "hash": "5ee14f2ac41068219ebde1be320b9db68fb0cd7d67a1b955693981dd39bc8605", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "start_char_idx": 3337, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b249688b-b66d-491a-bada-657ad045854f": {"__data__": {"id_": "b249688b-b66d-491a-bada-657ad045854f", "embedding": null, "metadata": {"window": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "522f3861-bae8-45a5-841b-b383e6853c93", "node_type": "1", "metadata": {"window": "I \nunderstand that you have expanded the number of products you offer under a private label and that \nyou're starting to see momentum in growing volumes.  Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right? ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00a912fd16e4ff3989e5c2d203ca4e9385cd18bebcece0906c3d3f2f847b1f44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db553ca-b3e8-4590-b032-ed255af069d8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. "}, "hash": "3f1758201ad7589718a4ddbbcbb2562c8e63328b4ac04fd1e1b2c9393b1998e7", "class_name": "RelatedNodeInfo"}}, "text": "You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "start_char_idx": 3415, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db553ca-b3e8-4590-b032-ed255af069d8": {"__data__": {"id_": "9db553ca-b3e8-4590-b032-ed255af069d8", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b249688b-b66d-491a-bada-657ad045854f", "node_type": "1", "metadata": {"window": "Can you help us understand how much of that \n$50 million has already been realized , and then how much we should expect you guys to realize in \nfiscal \u201825?  Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e6bd9a80b073dfa14f3f9748f7b14810b7cdadb50dd80b20fe59c10beef40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9ffaabc-f76f-4305-9835-265784ffd81c", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "We are seeing that we have won some  "}, "hash": "1b4415a8ce27aebe0b50d1a942380adf3de7ca43dcc785424d41ab71df0e06d6", "class_name": "RelatedNodeInfo"}}, "text": "So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "start_char_idx": 3527, "end_char_idx": 3707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9ffaabc-f76f-4305-9835-265784ffd81c": {"__data__": {"id_": "e9ffaabc-f76f-4305-9835-265784ffd81c", "embedding": null, "metadata": {"window": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "We are seeing that we have won some  ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ada4be07-6c24-4efb-8355-bfefc662a651", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf227dbc650370a9d39013152b6ca93ab6bdc28cedd6a8af68de70789fe92e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db553ca-b3e8-4590-b032-ed255af069d8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeda2ea006753b7bee0f1d692c0379a43e99e64b4285fc3dd5b85f05835dbb82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d20b88d7-6a43-492c-afb1-1f55b385464c", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "original_text": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market. "}, "hash": "fad3aeb188a7764a3c4146deb877d8e32d4598673b7aebca66b5778c97f4b091", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing that we have won some  ", "start_char_idx": 3707, "end_char_idx": 3744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d20b88d7-6a43-492c-afb1-1f55b385464c": {"__data__": {"id_": "d20b88d7-6a43-492c-afb1-1f55b385464c", "embedding": null, "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "original_text": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9ffaabc-f76f-4305-9835-265784ffd81c", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah, so I would , we inflected a couple quarters ago, right?  You saw that with our \noverall revenue growth that is partly driven by the Cardinal Health Brand volume growth.  So, we saw, \nfor example, this quarter our revenue growth of 4% was prorated within that national brand as well as \nCardinal Health Brand, so we are seeing distribution stabilize.  We are seeing that we have won some  ", "original_text": "We are seeing that we have won some  ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0eadcb019d21ca31471d84be29b2dbc7f0598a11d310c02dfe4e5e5abc034301", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4eccf39-0e3d-45ba-ab46-1f5a2932095d", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "original_text": "We expect that to \ncontinue. "}, "hash": "bf85fba37121f196cf9aa215febb4e270a84d705cc3f1f327f58fa80fe1afd15", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market. ", "start_char_idx": 0, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4eccf39-0e3d-45ba-ab46-1f5a2932095d": {"__data__": {"id_": "e4eccf39-0e3d-45ba-ab46-1f5a2932095d", "embedding": null, "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "original_text": "We expect that to \ncontinue. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d20b88d7-6a43-492c-afb1-1f55b385464c", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "original_text": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "487c7014dc2c82e3d470dd3c92771a035bb470ac29466a22d635f48f7bee0ec6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7238e30c-d801-4a51-950b-8cd1f5069269", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "original_text": "This is something that we do have as a component of that growth. "}, "hash": "58a2eeea0f6484d2568ad7bb068c3e7ede31250e6b851146b4962e5c1bad6c61", "class_name": "RelatedNodeInfo"}}, "text": "We expect that to \ncontinue. ", "start_char_idx": 209, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7238e30c-d801-4a51-950b-8cd1f5069269": {"__data__": {"id_": "7238e30c-d801-4a51-950b-8cd1f5069269", "embedding": null, "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "original_text": "This is something that we do have as a component of that growth. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4eccf39-0e3d-45ba-ab46-1f5a2932095d", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "original_text": "We expect that to \ncontinue. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c82fdc9b1a7f7856eb2afc3539ea167e3db5cbfc88b00a2502e9aa1ae2e32f7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c26ece1-4362-4ea5-8c59-55af8fa69f32", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "original_text": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . "}, "hash": "026992391a98257cbb38ca3ae605cf87ff531577decde0cc127d25f0f3e42eb6", "class_name": "RelatedNodeInfo"}}, "text": "This is something that we do have as a component of that growth. ", "start_char_idx": 238, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c26ece1-4362-4ea5-8c59-55af8fa69f32": {"__data__": {"id_": "0c26ece1-4362-4ea5-8c59-55af8fa69f32", "embedding": null, "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "original_text": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7238e30c-d801-4a51-950b-8cd1f5069269", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "original_text": "This is something that we do have as a component of that growth. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "895495b303dcba63964b6ac59643fb85c65b5c1d8cb96c59889a94e996cfc8c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e80f016-3356-4673-929c-1c7db63dc53c", "node_type": "1", "metadata": {"window": "We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "original_text": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  "}, "hash": "3220c68cdde8d6915a429bed4a655909a9d16ddfdc20aa7e946e34996f496940", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "start_char_idx": 303, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e80f016-3356-4673-929c-1c7db63dc53c": {"__data__": {"id_": "2e80f016-3356-4673-929c-1c7db63dc53c", "embedding": null, "metadata": {"window": "We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "original_text": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c26ece1-4362-4ea5-8c59-55af8fa69f32", "node_type": "1", "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "original_text": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24cd016bc2da92742fdf752d4839d0f6aecbf24f3657b310a7786af77fc67c12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6433becf-e21b-48c0-881c-42c85f6c7bd6", "node_type": "1", "metadata": {"window": "This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. "}, "hash": "9e3feea8cac7923f8be43d829cf52cb617094ed9bb7868aca7b96747b0f51811", "class_name": "RelatedNodeInfo"}}, "text": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "start_char_idx": 458, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6433becf-e21b-48c0-881c-42c85f6c7bd6": {"__data__": {"id_": "6433becf-e21b-48c0-881c-42c85f6c7bd6", "embedding": null, "metadata": {"window": "This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e80f016-3356-4673-929c-1c7db63dc53c", "node_type": "1", "metadata": {"window": "We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "original_text": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf9a4990af43a1881f2dc61cd71a8835b0d3bea08ec37e6aac6823afd0bc3702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4132745e-0d7d-41da-ab02-797089e42493", "node_type": "1", "metadata": {"window": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. "}, "hash": "19056d26b42abbfddf1a2f899fcc392e2ee83feaa1fe9c3382c8f76c5378c53e", "class_name": "RelatedNodeInfo"}}, "text": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "start_char_idx": 570, "end_char_idx": 695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4132745e-0d7d-41da-ab02-797089e42493": {"__data__": {"id_": "4132745e-0d7d-41da-ab02-797089e42493", "embedding": null, "metadata": {"window": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6433becf-e21b-48c0-881c-42c85f6c7bd6", "node_type": "1", "metadata": {"window": "This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c740680fd22ac2b04cc9e7ed697de33c2df6b08d578868b3e34fa8e621b5efd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6541afc9-4de5-4dee-aa0f-082e9bcec2ef", "node_type": "1", "metadata": {"window": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi. ", "original_text": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n"}, "hash": "aea757d72f994aa9b81729c031fd059cde1043de5e682350c131034ff11364ef", "class_name": "RelatedNodeInfo"}}, "text": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "start_char_idx": 695, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6541afc9-4de5-4dee-aa0f-082e9bcec2ef": {"__data__": {"id_": "6541afc9-4de5-4dee-aa0f-082e9bcec2ef", "embedding": null, "metadata": {"window": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi. ", "original_text": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4132745e-0d7d-41da-ab02-797089e42493", "node_type": "1", "metadata": {"window": "As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure .  So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc77a3fba8e9e02beb65681340c39ebf65853842a415c0a08b18af388eda6ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65893e5-26eb-47e3-b728-991752550a27", "node_type": "1", "metadata": {"window": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "4a23c4e6ed848e9860cbe6d3590437d25fb192f0b4f648d2202f52fe0beb8b77", "class_name": "RelatedNodeInfo"}}, "text": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "start_char_idx": 995, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65893e5-26eb-47e3-b728-991752550a27": {"__data__": {"id_": "e65893e5-26eb-47e3-b728-991752550a27", "embedding": null, "metadata": {"window": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6541afc9-4de5-4dee-aa0f-082e9bcec2ef", "node_type": "1", "metadata": {"window": "So, that\u2019s  the biggest item of that implied $100 million to $110 million year -over-\nyear profit improvement.   Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi. ", "original_text": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b4e016aab5d64337381e627d2e98e26d423ee404b33280b4f56f3dbe12d64a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "132b1ccb-4913-4579-b5c5-b4dbdb4fd292", "node_type": "1", "metadata": {"window": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. "}, "hash": "10bceacaccad624fb86ed3baee88f43bb73a91aacbe5c1f1e3f37cf490a511e8", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 1129, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "132b1ccb-4913-4579-b5c5-b4dbdb4fd292": {"__data__": {"id_": "132b1ccb-4913-4579-b5c5-b4dbdb4fd292", "embedding": null, "metadata": {"window": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e65893e5-26eb-47e3-b728-991752550a27", "node_type": "1", "metadata": {"window": "Then beyond that you have Cardinal Health Brand volume growth, cost \nreductions and other actions, and so it is a component.  It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fdb948c2a3cd775d230639efb699f5a1ad67ad95bae6f262b337230a74aa2bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c3df0bf-762d-4977-b57e-50a650616fdd", "node_type": "1", "metadata": {"window": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys. ", "original_text": "Our last question today will be coming from Daniel Grosslight of Citi. "}, "hash": "b85f912b8b738cd2e7b3ebb78c486afc4ba1c52c52bbe70feb5680bc75a91f18", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Yes, sir. ", "start_char_idx": 1168, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c3df0bf-762d-4977-b57e-50a650616fdd": {"__data__": {"id_": "1c3df0bf-762d-4977-b57e-50a650616fdd", "embedding": null, "metadata": {"window": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys. ", "original_text": "Our last question today will be coming from Daniel Grosslight of Citi. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "132b1ccb-4913-4579-b5c5-b4dbdb4fd292", "node_type": "1", "metadata": {"window": "It's not the biggest component, and then it \nwould be from \u201825 to \u201826 the primary components that then drive that growth would be Cardinal Health \nBrand volume as well as further cost reductions as we continue to look to streamline and optimize our \nfootprint, as well as our other supporting costs.  So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n", "original_text": "Operator:  Yes, sir. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c9aa32c6aa0b7a40ca5d77df321d2b79761c6fe6c384a3de7d370b60e0dd85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72af4a75-9e99-4970-b5bb-57d0b56a0916", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "original_text": "Please go \nahead. "}, "hash": "73f7e799b8046c365197caff1b07685b58639cb59e7f0db5574da820b0ca148d", "class_name": "RelatedNodeInfo"}}, "text": "Our last question today will be coming from Daniel Grosslight of Citi. ", "start_char_idx": 1189, "end_char_idx": 1260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72af4a75-9e99-4970-b5bb-57d0b56a0916": {"__data__": {"id_": "72af4a75-9e99-4970-b5bb-57d0b56a0916", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "original_text": "Please go \nahead. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c3df0bf-762d-4977-b57e-50a650616fdd", "node_type": "1", "metadata": {"window": "So, we're  not going to break out the individual pieces \nthere, but those are the biggest pieces then when you go from \u201825 to \u201826. \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys. ", "original_text": "Our last question today will be coming from Daniel Grosslight of Citi. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a93b10dd15eb0614fd7919fc091d6785116d3c0198d95b88ceb7af103790d15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d508d23b-6647-4b3b-b119-410b12970819", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "original_text": "Your line is open.  \n \n"}, "hash": "bd185ffaec157fb50d6f069bd1d85c784d158b3c9e55b0af7be56333420c2daa", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead. ", "start_char_idx": 1260, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d508d23b-6647-4b3b-b119-410b12970819": {"__data__": {"id_": "d508d23b-6647-4b3b-b119-410b12970819", "embedding": null, "metadata": {"window": "Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "original_text": "Your line is open.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72af4a75-9e99-4970-b5bb-57d0b56a0916", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "original_text": "Please go \nahead. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e31ca66802030c1069b318f285487c03078d2f62e81cfe29320887347e19381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2963d30f-bb87-454c-be90-78e3e5ca52a7", "node_type": "1", "metadata": {"window": "Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "original_text": "Daniel Grosslight:   Hey, guys. "}, "hash": "d1fd4a746962e29157719c80f7368a3620363604ff69abe145a7e1a88f0aca22", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n \n", "start_char_idx": 1278, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2963d30f-bb87-454c-be90-78e3e5ca52a7": {"__data__": {"id_": "2963d30f-bb87-454c-be90-78e3e5ca52a7", "embedding": null, "metadata": {"window": "Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "original_text": "Daniel Grosslight:   Hey, guys. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d508d23b-6647-4b3b-b119-410b12970819", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "original_text": "Your line is open.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d09db11defe30f0affbf3ae66012f500e86b371dea268dc171c0fb8761c3b59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49782242-abe7-4b8e-9263-dc393eaaac52", "node_type": "1", "metadata": {"window": "Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n", "original_text": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. "}, "hash": "d13bc8490eba6fb9c7c844f9da2d6991a29a82bb753795017297fa805777f1be", "class_name": "RelatedNodeInfo"}}, "text": "Daniel Grosslight:   Hey, guys. ", "start_char_idx": 1301, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49782242-abe7-4b8e-9263-dc393eaaac52": {"__data__": {"id_": "49782242-abe7-4b8e-9263-dc393eaaac52", "embedding": null, "metadata": {"window": "Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n", "original_text": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2963d30f-bb87-454c-be90-78e3e5ca52a7", "node_type": "1", "metadata": {"window": "Our last question today will be coming from Daniel Grosslight of Citi.  Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "original_text": "Daniel Grosslight:   Hey, guys. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0db10d57b114376058e544dfc0a8ac2aa05225d887c1b781401c568dea3a9ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ba058f5-3d40-4a8b-837d-9388c33f1959", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel . ", "original_text": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. "}, "hash": "0572ea913bc606311b1be7a73dad447b8db698a980a0315e409775127f97afc0", "class_name": "RelatedNodeInfo"}}, "text": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "start_char_idx": 1333, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ba058f5-3d40-4a8b-837d-9388c33f1959": {"__data__": {"id_": "7ba058f5-3d40-4a8b-837d-9388c33f1959", "embedding": null, "metadata": {"window": "Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel . ", "original_text": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49782242-abe7-4b8e-9263-dc393eaaac52", "node_type": "1", "metadata": {"window": "Please go \nahead.  Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n", "original_text": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa08bcd186c677ca45d2d3e81e99bcd83396e05be2e60fc6fd9dd7c3642a012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "956ab472-b0d8-45c1-ba2d-320601397715", "node_type": "1", "metadata": {"window": "Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "original_text": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. "}, "hash": "2a491d13a47d9048d8b3cc3286185f94edb720d5de28f1d7b3868a31171d1d11", "class_name": "RelatedNodeInfo"}}, "text": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "start_char_idx": 1552, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "956ab472-b0d8-45c1-ba2d-320601397715": {"__data__": {"id_": "956ab472-b0d8-45c1-ba2d-320601397715", "embedding": null, "metadata": {"window": "Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "original_text": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba058f5-3d40-4a8b-837d-9388c33f1959", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel . ", "original_text": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b366f69673340445f91bd4be200f9c38612c55ad076e7ad805a7d163679748e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ea26de7-c6a1-4a2a-871e-5daa07bea223", "node_type": "1", "metadata": {"window": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets. ", "original_text": "Thank you.  \n \n"}, "hash": "8d43b10b8968da4270d3d5edb2eebdc5961289d2bd26110ec1109026e46c81b1", "class_name": "RelatedNodeInfo"}}, "text": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "start_char_idx": 1751, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ea26de7-c6a1-4a2a-871e-5daa07bea223": {"__data__": {"id_": "4ea26de7-c6a1-4a2a-871e-5daa07bea223", "embedding": null, "metadata": {"window": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets. ", "original_text": "Thank you.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "956ab472-b0d8-45c1-ba2d-320601397715", "node_type": "1", "metadata": {"window": "Daniel Grosslight:   Hey, guys.  Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "original_text": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23c1127519f25c6f9b83051a65be5fe8ead2236df1c4d8c458b1dde6bf9690cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0faf230-6995-4b96-a3a4-a565a47a010d", "node_type": "1", "metadata": {"window": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "original_text": "Jason Hollar:  Yeah, thanks for the question, Daniel . "}, "hash": "da13bbd924d9afcd7cffb8df66e54065560dc03420bf0d15952d496df9d717ca", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1901, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0faf230-6995-4b96-a3a4-a565a47a010d": {"__data__": {"id_": "b0faf230-6995-4b96-a3a4-a565a47a010d", "embedding": null, "metadata": {"window": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "original_text": "Jason Hollar:  Yeah, thanks for the question, Daniel . ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ea26de7-c6a1-4a2a-871e-5daa07bea223", "node_type": "1", "metadata": {"window": "Most of my questions have been asked, but I was hoping to just get an \nupdate on Navista \u2122 and any metrics you're able to share on the market adoption you're seeing there, \nnumber of providers aligned to it, et cetera.  And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets. ", "original_text": "Thank you.  \n \n", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4741bcedc41421bb291429d880e7c12d0bb38e5e8165ccd189888fe1fb53a55a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c83fd002-c650-49bc-8a4c-5dfbbea4c561", "node_type": "1", "metadata": {"window": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "original_text": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. "}, "hash": "05540f4a6f0e0d49eb900152bc4bb27130f905983ca873bee7d7861b78d9475e", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, thanks for the question, Daniel . ", "start_char_idx": 1916, "end_char_idx": 1971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c83fd002-c650-49bc-8a4c-5dfbbea4c561": {"__data__": {"id_": "c83fd002-c650-49bc-8a4c-5dfbbea4c561", "embedding": null, "metadata": {"window": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "original_text": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0faf230-6995-4b96-a3a4-a565a47a010d", "node_type": "1", "metadata": {"window": "And I know one of the key strategic objectives of the \nSpecialty Networks acquisition was to kind of integrate some of their techn ology, [indiscernible]  into \nNavista \u2122 and other specialty assets.  I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "original_text": "Jason Hollar:  Yeah, thanks for the question, Daniel . ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "117a2eaece6771220a7366f95b3b2ad61a6eabbc87d31f8376429daea62e6df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0f8080c-19e2-44ab-9834-6cc21655ce49", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "original_text": "As I think about the progress that we \nhave made, I break it into a few key buckets. "}, "hash": "46defae96f0b9c71a08e2ff18d73b5d8e648f9fdb46e7983ad79671458347bea", "class_name": "RelatedNodeInfo"}}, "text": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "start_char_idx": 1971, "end_char_idx": 2080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0f8080c-19e2-44ab-9834-6cc21655ce49": {"__data__": {"id_": "d0f8080c-19e2-44ab-9834-6cc21655ce49", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "original_text": "As I think about the progress that we \nhave made, I break it into a few key buckets. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c83fd002-c650-49bc-8a4c-5dfbbea4c561", "node_type": "1", "metadata": {"window": "I'm also curious if you can provide an update on how quickly \nyou can in tegrate that technology or if you have already kind of started on that path.  Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "original_text": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8606b72965b88e9ec6b0e0b347f47cf1df6f9777e55c0e7ddd655698340c311d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73d0475a-4aff-4991-8de9-ab610f971357", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it. ", "original_text": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. "}, "hash": "d1710d9d2431a15c6f51e04daad3d4f3ccfec3415c27aa1bd59e57d34345eecb", "class_name": "RelatedNodeInfo"}}, "text": "As I think about the progress that we \nhave made, I break it into a few key buckets. ", "start_char_idx": 2080, "end_char_idx": 2165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73d0475a-4aff-4991-8de9-ab610f971357": {"__data__": {"id_": "73d0475a-4aff-4991-8de9-ab610f971357", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it. ", "original_text": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0f8080c-19e2-44ab-9834-6cc21655ce49", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "original_text": "As I think about the progress that we \nhave made, I break it into a few key buckets. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cb326969b211293fa340528600bdb00cdf504f8921264729e46bcb89d069ad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd9e123d-f892-482f-80bd-6ccc29a90954", "node_type": "1", "metadata": {"window": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "original_text": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. "}, "hash": "b5602143b0a052dfa5689360c902add95700eb3b830b0d698d20ef0eac68dff6", "class_name": "RelatedNodeInfo"}}, "text": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "start_char_idx": 2165, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd9e123d-f892-482f-80bd-6ccc29a90954": {"__data__": {"id_": "bd9e123d-f892-482f-80bd-6ccc29a90954", "embedding": null, "metadata": {"window": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "original_text": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73d0475a-4aff-4991-8de9-ab610f971357", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks for the question, Daniel .  And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it. ", "original_text": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3769fcd1834291b3142f608ef57d49785ba88bc77eb5398b88b8efd707e4cad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "568f543d-3fd2-453b-84f5-d15e91f8bbed", "node_type": "1", "metadata": {"window": "As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "original_text": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. "}, "hash": "77007410e44e8671bea6644720cd12ef303fea9765e6e2fc8848118c3c7a92fa", "class_name": "RelatedNodeInfo"}}, "text": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "start_char_idx": 2525, "end_char_idx": 2773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "568f543d-3fd2-453b-84f5-d15e91f8bbed": {"__data__": {"id_": "568f543d-3fd2-453b-84f5-d15e91f8bbed", "embedding": null, "metadata": {"window": "As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "original_text": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd9e123d-f892-482f-80bd-6ccc29a90954", "node_type": "1", "metadata": {"window": "And so, with Navista \u2122, we are on track to \neverything that we laid out first raising this about a year ago.  As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "original_text": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59afdcd0279f2e39fa99ebfef2c43aa0a7f5fa820756a73d1e8028d90a660679", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e156613b-2d55-4a51-8ac7-c75a226d2f8d", "node_type": "1", "metadata": {"window": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "original_text": "So, we \ndidn't just go off and build it. "}, "hash": "3286105b11b422b11f9ff53e6b1ed7c2f1969ee8a1b24a00c6aeb7f69d7e9000", "class_name": "RelatedNodeInfo"}}, "text": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "start_char_idx": 2773, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e156613b-2d55-4a51-8ac7-c75a226d2f8d": {"__data__": {"id_": "e156613b-2d55-4a51-8ac7-c75a226d2f8d", "embedding": null, "metadata": {"window": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "original_text": "So, we \ndidn't just go off and build it. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "568f543d-3fd2-453b-84f5-d15e91f8bbed", "node_type": "1", "metadata": {"window": "As I think about the progress that we \nhave made, I break it into a few key buckets.  First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "original_text": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b523b92b1144b750c74d801a786c143fe9958db95d9c5b8c3bca9ee836e32a3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b617f6f-e03d-495a-9a01-0bb58f5581ec", "node_type": "1", "metadata": {"window": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "original_text": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  "}, "hash": "2a32be6b5aa6eeadeab5bf7b4b558934cc68dc155b5329dba2941b03958a3f8a", "class_name": "RelatedNodeInfo"}}, "text": "So, we \ndidn't just go off and build it. ", "start_char_idx": 2928, "end_char_idx": 2969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b617f6f-e03d-495a-9a01-0bb58f5581ec": {"__data__": {"id_": "8b617f6f-e03d-495a-9a01-0bb58f5581ec", "embedding": null, "metadata": {"window": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "original_text": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e156613b-2d55-4a51-8ac7-c75a226d2f8d", "node_type": "1", "metadata": {"window": "First of all, first and foremost, we have hired and \nbrought in a fantastic team, a great  mixture of internal and external talent, really drawing from industry \nthose that have done this before and understand what that looks like, but also using our own \nexpertise that have been more focused on other therapeutic areas, but a nice augmentation of  the \ntwo.  And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "original_text": "So, we \ndidn't just go off and build it. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed93d7f2d3b4daaf3202249055106b7bd2274aedc53b835aab49a6d4579e4bd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a74a0db4-0f52-4996-98bb-8b40b9c37012", "node_type": "1", "metadata": {"window": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "original_text": "So, that is the work that's been done, and we are \nevery day building out more elements of this. "}, "hash": "81c0d1416a505b62f0084d0fdf580b5c6f345120cc081758e262a744eb0020eb", "class_name": "RelatedNodeInfo"}}, "text": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "start_char_idx": 2969, "end_char_idx": 3294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a74a0db4-0f52-4996-98bb-8b40b9c37012": {"__data__": {"id_": "a74a0db4-0f52-4996-98bb-8b40b9c37012", "embedding": null, "metadata": {"window": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "original_text": "So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b617f6f-e03d-495a-9a01-0bb58f5581ec", "node_type": "1", "metadata": {"window": "And then that new team quickly went to work and defined, well, went in front of our customers \nand perspective customers and really listened as to what is it that they need to run their practice, their \nbusiness more efficiently, more effectively.  And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "original_text": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41af5b36ace0cf40dc7f3659e09bbb43713f85cb4a089e5670d57c08b599652f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea", "node_type": "1", "metadata": {"window": "So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "original_text": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. "}, "hash": "2ec687c7aad6be744732b9958df62d1322853e479203219f7921637c1336da3c", "class_name": "RelatedNodeInfo"}}, "text": "So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "start_char_idx": 3294, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea": {"__data__": {"id_": "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea", "embedding": null, "metadata": {"window": "So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "original_text": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a74a0db4-0f52-4996-98bb-8b40b9c37012", "node_type": "1", "metadata": {"window": "And it was  through that work that we then came to the \nfinal point,  which is defining the tools, the capabilities that we are building within Navista \u2122.  So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "original_text": "So, that is the work that's been done, and we are \nevery day building out more elements of this. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1208f34a43455fa867f2c4c0dc82f31674dbfa08cef08024f802e707ca6a8eb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8079d03f-bf5d-49c7-8523-db42a7131cd8", "node_type": "1", "metadata": {"window": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. "}, "hash": "44f647d4cefc11ae93b58c01f4033563a35c742951f8ede8dc3056ef64407d24", "class_name": "RelatedNodeInfo"}}, "text": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "start_char_idx": 3391, "end_char_idx": 3514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8079d03f-bf5d-49c7-8523-db42a7131cd8": {"__data__": {"id_": "8079d03f-bf5d-49c7-8523-db42a7131cd8", "embedding": null, "metadata": {"window": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea", "node_type": "1", "metadata": {"window": "So, we \ndidn't just go off and build it.  We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "original_text": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62a092eb6df782362dd7f8e5d2eca14ada029faff9afbd01410890bba80e6a44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b92b13e6-56ba-4f56-b9f8-07073126902c", "node_type": "1", "metadata": {"window": "So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. "}, "hash": "43af045770cd7a97eeb54b6e0697d6adffa6486e5577da1c4da80c81be6ab74c", "class_name": "RelatedNodeInfo"}}, "text": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "start_char_idx": 3514, "end_char_idx": 3770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b92b13e6-56ba-4f56-b9f8-07073126902c": {"__data__": {"id_": "b92b13e6-56ba-4f56-b9f8-07073126902c", "embedding": null, "metadata": {"window": "So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8079d03f-bf5d-49c7-8523-db42a7131cd8", "node_type": "1", "metadata": {"window": "We are building it around what the customers are demanding that t hey \nneed, those community oncologists, those independent community oncologists, really looking at \ndifferentiating for what they need to run their business, both again efficiently , but also effectively to \nfurther improve upon the lives of their patients.   So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efab23c73eaaae2f2d04160196ce075664a40a94b04f52f6456f27556f86a2bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcb96b36-0d52-42c7-9490-65720ec75b22", "node_type": "1", "metadata": {"window": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  "}, "hash": "03d46115fbfcc8650a98b83294b545d57d0ed8646d7a51cfdfbf2b3782b91ac6", "class_name": "RelatedNodeInfo"}}, "text": "So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "start_char_idx": 3770, "end_char_idx": 3946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcb96b36-0d52-42c7-9490-65720ec75b22": {"__data__": {"id_": "bcb96b36-0d52-42c7-9490-65720ec75b22", "embedding": null, "metadata": {"window": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b92b13e6-56ba-4f56-b9f8-07073126902c", "node_type": "1", "metadata": {"window": "So, that is the work that's been done, and we are \nevery day building out more elements of this.  So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bda675bdac14c9a04b64c7e0dcaba65074479eab4b2d3ce43b1a05f9f774f8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4befb49f-11f7-4265-a4c9-6c03914844bb", "node_type": "1", "metadata": {"window": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "Using what we "}, "hash": "f95be2f76b718d53b8dec726dd72babdff74f42aae5f0cc58ecb8a92be779aac", "class_name": "RelatedNodeInfo"}}, "text": "But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "start_char_idx": 3946, "end_char_idx": 4035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4befb49f-11f7-4265-a4c9-6c03914844bb": {"__data__": {"id_": "4befb49f-11f7-4265-a4c9-6c03914844bb", "embedding": null, "metadata": {"window": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "Using what we ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48a211a7-0710-436c-83be-eb1304ce9c4b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d00ae994587c3b5a3202e437e499e24ac77b510b022c6d12e6188604e94ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcb96b36-0d52-42c7-9490-65720ec75b22", "node_type": "1", "metadata": {"window": "So, I wouldn't think about it as a particular date that \neverything goes live, and we suddenly have this influx of volume.  This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.  ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "172fa5fc19b19481adfcd73e2b1b0af4fe80d7082bbd1d8676ec9c332ef52500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec5ed44-d3ab-4869-9a13-c1a08d87e4ea", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "original_text": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat. "}, "hash": "1e09d425deeb1aa8e6c0bff7ec61ff79186a17e702985eb75fb7c11b641a5e34", "class_name": "RelatedNodeInfo"}}, "text": "Using what we ", "start_char_idx": 4035, "end_char_idx": 4049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec5ed44-d3ab-4869-9a13-c1a08d87e4ea": {"__data__": {"id_": "bec5ed44-d3ab-4869-9a13-c1a08d87e4ea", "embedding": null, "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "original_text": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4befb49f-11f7-4265-a4c9-6c03914844bb", "node_type": "1", "metadata": {"window": "This is the type of thing that builds \nout our capability over time in different ways and working with our current customers as well as the \nprospective ones to layer in when they come into this network and which services they utilize within \nthe network.  So that leads you to the Specialty Networks piece, which I would think about it as we \nnow have an internal technology and capability set that's augmenting what we had before.  But \nNavista\u2019s \u2122 always approached us in terms of the best of the best in the industry.   Using what we ", "original_text": "Using what we ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d88bf5185bddb4d06f086b6b4d28659f119ac42cac82000a989ed934a9d48d93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3ea3a56-e6c4-49b8-ba54-35162edc599a", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "original_text": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform. "}, "hash": "d151161ed2889b01bd93fa211826476f9cfbacc577f9011ccb8e08e4582074b6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat. ", "start_char_idx": 0, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3ea3a56-e6c4-49b8-ba54-35162edc599a": {"__data__": {"id_": "a3ea3a56-e6c4-49b8-ba54-35162edc599a", "embedding": null, "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "original_text": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec5ed44-d3ab-4869-9a13-c1a08d87e4ea", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "original_text": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5dbd680e5a0590059b3c013451d0f467afab9c861216ebcaa0e9331f624236e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d786f56-9d30-485f-a7e3-19dc9a9e904c", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "original_text": "But \nwe're not going to make that the priority. "}, "hash": "0e20bd30a55c11c3d144406f3d698ec1ac7ee2213ec596edf0f0ae0a14bd6fa8", "class_name": "RelatedNodeInfo"}}, "text": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform. ", "start_char_idx": 240, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d786f56-9d30-485f-a7e3-19dc9a9e904c": {"__data__": {"id_": "9d786f56-9d30-485f-a7e3-19dc9a9e904c", "embedding": null, "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "original_text": "But \nwe're not going to make that the priority. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3ea3a56-e6c4-49b8-ba54-35162edc599a", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "original_text": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c22d922bf27ff8f39796b960c4d3b0bd3e706ecc649d3781461de8b05d9363d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b22c3f1d-0812-4039-92b9-98b4dedf118d", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "original_text": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. "}, "hash": "bc56204b2472df55a996c30f7c1e1dcb4e164001a03c9d3468e8c306242792bd", "class_name": "RelatedNodeInfo"}}, "text": "But \nwe're not going to make that the priority. ", "start_char_idx": 331, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b22c3f1d-0812-4039-92b9-98b4dedf118d": {"__data__": {"id_": "b22c3f1d-0812-4039-92b9-98b4dedf118d", "embedding": null, "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "original_text": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d786f56-9d30-485f-a7e3-19dc9a9e904c", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "original_text": "But \nwe're not going to make that the priority. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b252853cc9c0d8c57dc6f98a6e898f890215a57785fbfa4b1146d1681be52845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244", "node_type": "1", "metadata": {"window": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "original_text": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. "}, "hash": "132a3de78df5bac7c9e4eb6819e7f28ba5652184488132f63f0ecf30157ed6ac", "class_name": "RelatedNodeInfo"}}, "text": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "start_char_idx": 379, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244": {"__data__": {"id_": "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244", "embedding": null, "metadata": {"window": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "original_text": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b22c3f1d-0812-4039-92b9-98b4dedf118d", "node_type": "1", "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "original_text": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ec400d8bc14d3316aa94fabd707cb266861472a38e96e16dfdc6b0eaa4c72b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c36240ea-2c42-4629-a941-cddad47b8303", "node_type": "1", "metadata": {"window": "But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen. ", "original_text": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  "}, "hash": "a1e42f9a1ef3fee096539c828e0070a27e1994d30d578d26194de07df09f81f4", "class_name": "RelatedNodeInfo"}}, "text": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "start_char_idx": 487, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c36240ea-2c42-4629-a941-cddad47b8303": {"__data__": {"id_": "c36240ea-2c42-4629-a941-cddad47b8303", "embedding": null, "metadata": {"window": "But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen. ", "original_text": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244", "node_type": "1", "metadata": {"window": "So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "original_text": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d88477b7bdf4a63830c96b5850938299e6f0dc776a01c303587816b9a9d15e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71affd72-18dd-4f97-b680-fd1044274ecb", "node_type": "1", "metadata": {"window": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "original_text": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. "}, "hash": "5a121377534d4bfb7c39d82d3b9e5332a2f0cda1ae3a2d29ba9915369293d15f", "class_name": "RelatedNodeInfo"}}, "text": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "start_char_idx": 567, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71affd72-18dd-4f97-b680-fd1044274ecb": {"__data__": {"id_": "71affd72-18dd-4f97-b680-fd1044274ecb", "embedding": null, "metadata": {"window": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "original_text": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c36240ea-2c42-4629-a941-cddad47b8303", "node_type": "1", "metadata": {"window": "But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen. ", "original_text": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.  ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb1daa61aee2e48cc5333b5204262e73d4d1bc2c6230fc9ccff1df4160fb7378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b78f5fb-608d-45b3-a946-316d7512b429", "node_type": "1", "metadata": {"window": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr. ", "original_text": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n"}, "hash": "563b96b50fc8a198838f3850f291aac68855652fbbec86d58af07de440b392b2", "class_name": "RelatedNodeInfo"}}, "text": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "start_char_idx": 706, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b78f5fb-608d-45b3-a946-316d7512b429": {"__data__": {"id_": "1b78f5fb-608d-45b3-a946-316d7512b429", "embedding": null, "metadata": {"window": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr. ", "original_text": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71affd72-18dd-4f97-b680-fd1044274ecb", "node_type": "1", "metadata": {"window": "We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network.  So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "original_text": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59f2bf8703a6b91af651b99e10e2e686db7fb39079e30189ad387134cfcc3b89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c30c8d8-5211-43e1-aaaa-06f7ac871661", "node_type": "1", "metadata": {"window": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks. ", "original_text": "Operator:   Thank you, very much gentlemen. "}, "hash": "a746c74ae649dc73aec23553d47d770532ed23cc348bf1fbd69ff7789dddd75b", "class_name": "RelatedNodeInfo"}}, "text": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "start_char_idx": 816, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c30c8d8-5211-43e1-aaaa-06f7ac871661": {"__data__": {"id_": "7c30c8d8-5211-43e1-aaaa-06f7ac871661", "embedding": null, "metadata": {"window": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks. ", "original_text": "Operator:   Thank you, very much gentlemen. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b78f5fb-608d-45b3-a946-316d7512b429", "node_type": "1", "metadata": {"window": "So, we haven't finalized those decisions as it re lates to \nSpecialty Networks.  But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr. ", "original_text": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfae7096b900418113b580ae4fddadfaeb0665be8668a4b4f64ad0721707fab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98", "node_type": "1", "metadata": {"window": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's \nquestion -answer session. "}, "hash": "5d6b284e1f6e8f257b33bf24aec65b746e97ed95e2efa925efb0fe571e35ab6c", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   Thank you, very much gentlemen. ", "start_char_idx": 1238, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98": {"__data__": {"id_": "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98", "embedding": null, "metadata": {"window": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c30c8d8-5211-43e1-aaaa-06f7ac871661", "node_type": "1", "metadata": {"window": "But what I will tell you, on day one, just having that team's insights and expertise \nhas been very beneficial to our own Navista \u2122 team.   And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks. ", "original_text": "Operator:   Thank you, very much gentlemen. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a0052ab526f12e2f3e691dabd9434036955ec2c69801565acc28ca4c9cb21cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd31015-552a-42d3-a7ef-2f3dc28ca331", "node_type": "1", "metadata": {"window": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you. ", "original_text": "I'd like to turn the call back over to Mr. "}, "hash": "4d5f987422411b8d84240b7faceee52a6f7367c13c5827ca03caab74d9b58b8b", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "start_char_idx": 1282, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd31015-552a-42d3-a7ef-2f3dc28ca331": {"__data__": {"id_": "bbd31015-552a-42d3-a7ef-2f3dc28ca331", "embedding": null, "metadata": {"window": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you. ", "original_text": "I'd like to turn the call back over to Mr. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98", "node_type": "1", "metadata": {"window": "And I mentioned this when we announced the \nacquisition of Specialty Networks, yes, the assets are fantastic.  The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's \nquestion -answer session. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f63b6f2d3f5ee52d317b5bd13024be6a78b78fdc6a62004a4119fdefe2029de8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1ee0c78-8a68-4895-9960-d0ee6ded0c70", "node_type": "1", "metadata": {"window": "Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning. ", "original_text": "Jason Hollar for any additional or \nclosing remarks. "}, "hash": "b85754b4e333487cced1fabbac7ddde8b37411d72bafe68e4145cf3a8471299a", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to turn the call back over to Mr. ", "start_char_idx": 1358, "end_char_idx": 1401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1ee0c78-8a68-4895-9960-d0ee6ded0c70": {"__data__": {"id_": "f1ee0c78-8a68-4895-9960-d0ee6ded0c70", "embedding": null, "metadata": {"window": "Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning. ", "original_text": "Jason Hollar for any additional or \nclosing remarks. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd31015-552a-42d3-a7ef-2f3dc28ca331", "node_type": "1", "metadata": {"window": "The business is fantastic, but the \nmost important thing for us was the leadership team and the capabilities that they're bringing along \nwith it is ever y bit as great as what we thought it was when we made the announcement, and we're \nseein g that with boots on the ground now as we work , not just with Navista \u2122, but with the broader \nbusiness to further improve our capabilities across all the therapeutic areas.  \n \n Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you. ", "original_text": "I'd like to turn the call back over to Mr. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec61f0638c2ff092882cf7694a88d764940f3323616fcdb65ed8fbf3906447b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "055d14dd-dafb-45cd-bfb4-23ddf2259224", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "original_text": "Thank you.  \n \n"}, "hash": "5bf6a5ef3266c29e7a7ab490dc87dc7e22596d992a085622a7e14b9e0d9e05a5", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar for any additional or \nclosing remarks. ", "start_char_idx": 1401, "end_char_idx": 1454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "055d14dd-dafb-45cd-bfb4-23ddf2259224": {"__data__": {"id_": "055d14dd-dafb-45cd-bfb4-23ddf2259224", "embedding": null, "metadata": {"window": "Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "original_text": "Thank you.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1ee0c78-8a68-4895-9960-d0ee6ded0c70", "node_type": "1", "metadata": {"window": "Operator:   Thank you, very much gentlemen.  Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning. ", "original_text": "Jason Hollar for any additional or \nclosing remarks. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "087ce08632070e20c151387f25078b84436cf4fd7a6c37cc0b52166123e38893", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8494f39-e18a-4a9a-bb3c-a8bd33c83995", "node_type": "1", "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n", "original_text": "Jason Hollar:   Yes, thank you. "}, "hash": "8e84591a489a60990eccbe9bc020ec441b6ab7b6ae742ee5bd47372331234b3e", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1454, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8494f39-e18a-4a9a-bb3c-a8bd33c83995": {"__data__": {"id_": "c8494f39-e18a-4a9a-bb3c-a8bd33c83995", "embedding": null, "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n", "original_text": "Jason Hollar:   Yes, thank you. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "055d14dd-dafb-45cd-bfb4-23ddf2259224", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that will conclude today's \nquestion -answer session.  I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "original_text": "Thank you.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbbbdb9e7881768bca3ce320c69392d1a180ab5270bf47fc383db6d9ad4c6a5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86d80b57-c411-4fdd-a10c-cd68782c292d", "node_type": "1", "metadata": {"window": "Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much. ", "original_text": "Just to close, I appreciate everyone spending some time with us this \nmorning. "}, "hash": "a9125d2c0ac77530b07cb1cc9e06bd1d578fff4d283ade6ac99612fa252b3155", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yes, thank you. ", "start_char_idx": 1469, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86d80b57-c411-4fdd-a10c-cd68782c292d": {"__data__": {"id_": "86d80b57-c411-4fdd-a10c-cd68782c292d", "embedding": null, "metadata": {"window": "Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much. ", "original_text": "Just to close, I appreciate everyone spending some time with us this \nmorning. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8494f39-e18a-4a9a-bb3c-a8bd33c83995", "node_type": "1", "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n", "original_text": "Jason Hollar:   Yes, thank you. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e8a825e38093e3ed73fa4fe089d50e564ecc7a52798651fb17f7f649ba59a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4564ddf4-3c2f-42be-8b41-8e031bd5b42a", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation. ", "original_text": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. "}, "hash": "a27a04ede4a1835a6945d240b76184b091f2d812fa074aee375283554fb22649", "class_name": "RelatedNodeInfo"}}, "text": "Just to close, I appreciate everyone spending some time with us this \nmorning. ", "start_char_idx": 1501, "end_char_idx": 1580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4564ddf4-3c2f-42be-8b41-8e031bd5b42a": {"__data__": {"id_": "4564ddf4-3c2f-42be-8b41-8e031bd5b42a", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation. ", "original_text": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86d80b57-c411-4fdd-a10c-cd68782c292d", "node_type": "1", "metadata": {"window": "Jason Hollar for any additional or \nclosing remarks.  Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much. ", "original_text": "Just to close, I appreciate everyone spending some time with us this \nmorning. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dec8c0b405ecfbc2ec78cde53b683a3fd8530da6274e6e128f34ba4dd8996680", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d5fe44f-a10e-4ac0-b99f-6da0117192d5", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance. ", "original_text": "So, \nthanks again for joining us today, and have a great day.  \n \n"}, "hash": "0c460d320f2fbc6b46e6916061707adf9700ccd37b8846085e06af619ac410c0", "class_name": "RelatedNodeInfo"}}, "text": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "start_char_idx": 1580, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d5fe44f-a10e-4ac0-b99f-6da0117192d5": {"__data__": {"id_": "7d5fe44f-a10e-4ac0-b99f-6da0117192d5", "embedding": null, "metadata": {"window": "Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance. ", "original_text": "So, \nthanks again for joining us today, and have a great day.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4564ddf4-3c2f-42be-8b41-8e031bd5b42a", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation. ", "original_text": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f795ed8363c1cd0edc2326fd664b10e32ec4fd9a14410c60e472a1fe031e2576", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5ee1771-500a-44f5-9edf-45ac8d62bc95", "node_type": "1", "metadata": {"window": "Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much. "}, "hash": "2521683800200e885a8e7c684971e20ab4a0bf3a461052b0f2e4b0ad541d17bf", "class_name": "RelatedNodeInfo"}}, "text": "So, \nthanks again for joining us today, and have a great day.  \n \n", "start_char_idx": 1872, "end_char_idx": 1938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5ee1771-500a-44f5-9edf-45ac8d62bc95": {"__data__": {"id_": "a5ee1771-500a-44f5-9edf-45ac8d62bc95", "embedding": null, "metadata": {"window": "Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d5fe44f-a10e-4ac0-b99f-6da0117192d5", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yes, thank you.  Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance. ", "original_text": "So, \nthanks again for joining us today, and have a great day.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167caa6a50390c4b5f753b7a271a3263c417821a5e3f32da0ed2ebc65e42fab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb78f962-d2d8-4106-bde4-d937639f1fc0", "node_type": "1", "metadata": {"window": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Ladies and gentlemen, that concludes today's presentation. "}, "hash": "dd8cf5abd7a5a3f15d9815578a2b4886f0b05ca3770a287c16f089815f892671", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much. ", "start_char_idx": 1938, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb78f962-d2d8-4106-bde4-d937639f1fc0": {"__data__": {"id_": "fb78f962-d2d8-4106-bde4-d937639f1fc0", "embedding": null, "metadata": {"window": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Ladies and gentlemen, that concludes today's presentation. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5ee1771-500a-44f5-9edf-45ac8d62bc95", "node_type": "1", "metadata": {"window": "Just to close, I appreciate everyone spending some time with us this \nmorning.  We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db45dfdbe054b2eb8697d09e3a3729e50ae9b0d5c424ee63e0cb69eb3855a845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11a64742-5ebd-4492-a0b7-d0d1b79891fa", "node_type": "1", "metadata": {"window": "So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Thank \nyou for your attendance. "}, "hash": "a4578e2ad42717f3a94bd464e7d15092be4c8b8823645e814767577de210d3ef", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, that concludes today's presentation. ", "start_char_idx": 1970, "end_char_idx": 2029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11a64742-5ebd-4492-a0b7-d0d1b79891fa": {"__data__": {"id_": "11a64742-5ebd-4492-a0b7-d0d1b79891fa", "embedding": null, "metadata": {"window": "So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Thank \nyou for your attendance. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb78f962-d2d8-4106-bde4-d937639f1fc0", "node_type": "1", "metadata": {"window": "We hope the overall message that you took away from the call today is that we have a \nstrong and resilient business and a very clear plan for us for '25 and '26, and we' re excited about the \nopportunities and ensuring that our customers and their patients continue to get fantastic service.  So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Ladies and gentlemen, that concludes today's presentation. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae39f8e2b05fd1237a8052baaf2b9acf5f6fd246cf761ef08e5dca1c462ea977", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f43a280d-f417-456b-b73c-76c1c787630b", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "You may now disconnect. "}, "hash": "96f4d4d3b63f7614e7c36cdbbf9fa164ce033466836619342890e0c56b75baaa", "class_name": "RelatedNodeInfo"}}, "text": "Thank \nyou for your attendance. ", "start_char_idx": 2029, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f43a280d-f417-456b-b73c-76c1c787630b": {"__data__": {"id_": "f43a280d-f417-456b-b73c-76c1c787630b", "embedding": null, "metadata": {"window": "Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "You may now disconnect. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11a64742-5ebd-4492-a0b7-d0d1b79891fa", "node_type": "1", "metadata": {"window": "So, \nthanks again for joining us today, and have a great day.  \n \n Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Thank \nyou for your attendance. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "502855b956a647570f3b74ed6e3dfbe5fc46089d86dfa891caad84aaa46a6dbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "054ac121-b1f5-4972-9cab-72ee9f90fea2", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Have a good day, and goodbye.  \n "}, "hash": "6a95813c44f3c4509fcbb2d6727f701d4d8d16777d2af23d44fa012e2b80cbcf", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect. ", "start_char_idx": 2061, "end_char_idx": 2085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "054ac121-b1f5-4972-9cab-72ee9f90fea2": {"__data__": {"id_": "054ac121-b1f5-4972-9cab-72ee9f90fea2", "embedding": null, "metadata": {"window": "Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "Have a good day, and goodbye.  \n ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353f317abc969552dc33b406c5afc66af63572a348f0d3fc15edc241eb880edf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f43a280d-f417-456b-b73c-76c1c787630b", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much.  Ladies and gentlemen, that concludes today's presentation.  Thank \nyou for your attendance.  You may now disconnect.  Have a good day, and goodbye.  \n ", "original_text": "You may now disconnect. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc21218e96c584a3f76930d21a38b577526b82ae1b50f5d0d8f4af87c1c65f55", "class_name": "RelatedNodeInfo"}}, "text": "Have a good day, and goodbye.  \n ", "start_char_idx": 2085, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"9a5bfc13-a550-4f45-94fe-773f02876989": {"doc_hash": "b73ef69f341afc64f4a5c7da6f08df34129bfab217d576fdbf84438e8380c722", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "b1c42720-5ab7-423d-a8af-06ebf80c6e56": {"doc_hash": "3e1e5e32b31c4246bbea476463903220e3733feef749143cf4d93709a1c27ef0", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "ef3b19a9-af26-4e0e-81e2-f7913d636b31": {"doc_hash": "4af52ccbb42ef7394d6d9b68a49a75f57603931128a49eef9cc1ea8e38c01b8a", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "9d2e4d8c-fd83-4481-bc99-e7b505394daf": {"doc_hash": "194407c69db189dee1aa0718bb610a2f2e4f95262658384a1703c4fb1f5ab791", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9": {"doc_hash": "1bd1300196d27b284a9889d775c46fcd65b05d0763d96dbbe5d5183df9eb12d8", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "38a67711-a796-45bb-bad7-2e0fe0bf214b": {"doc_hash": "5c6c993817b30245e8f0a4ed9a22c4dfae3bc0bfdc1b604d91cd700a86323c8f", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "a677db83-a6bd-403d-8149-a5a453bc09c9": {"doc_hash": "eb16fee5a356e1e5de5cd9278ce841af841dbc54d43c6f193cb9290dfee5b6cd", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "3f6380c1-31cf-4593-87ba-1d552394c1ff": {"doc_hash": "d21b378868237597df1c96a7bb884ce84a36dbf8e291782517554ec70413c00f", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "30e55fa5-bc77-4078-943e-4bd3f005261a": {"doc_hash": "e25503774b58adee226715b628eb14bd405a9112365533049ce2abc33f0f2ea8", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "23797e91-34df-4149-a806-090d1b7be757": {"doc_hash": "62140c6459132cfde655e4d6852768848ca74511c82f3f2c05362046ffaa5ddb", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "23a5a8b6-900c-4f56-9bc6-0860ac2ee545": {"doc_hash": "28089f856cf7c25507276f0ee4e3982c5f919f5a8d02bb0ebf3fc9ee834a4a04", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "bb7e4d90-0130-484f-b826-e25b6120bf8b": {"doc_hash": "45ba26464a2c280b1dae4c5547d21efd0eb34b6f45b6d393faca55ae83a23f6e", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "e45ccb65-d227-46bb-ab43-9079195f1ad6": {"doc_hash": "7fc0b32f31d345aec16a494edccb31c3a4d2df023093b3d882dacf7f052d5aea", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "c62db472-466d-4e68-9d18-f394660aa2bd": {"doc_hash": "a64b63a66d378b42719e3a6d5381d85fbc37b5ea805f3b51fc2fca52bf39f878", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "1fb961db-2a53-4816-9f4d-54527b404e9f": {"doc_hash": "9e9d70d4ba1c59ca6776eaad42cc4c70fc24d86bcd8b5ac1c7da49fd39cafe6c", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "37e904f9-8569-4646-9f3d-645b139ee6bf": {"doc_hash": "2e2dcaa7bfa807908fa57a34f704a9ec2c906c48687ccffc5a41a26cd82545fd", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "6647f02c-e1ae-4569-bb13-ef8f2a43622b": {"doc_hash": "cdd9876514b438947288dfc5a5cb6cfd4e94cd024ad17c054847fdfbcef857ec", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "d794dc99-5299-48bc-8d5d-38fb8fe1409b": {"doc_hash": "f68fa4984ba9fa4c922ab2fb5abf46868d8e28fbc940e1441d4faec5e471342e", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "71af6e9c-190c-4b87-bc77-7ca43a60a978": {"doc_hash": "bfc24b4a483bee400bb83a4ae2f49410d31f8e19958dfb7cb13abb4bc829b866", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e": {"doc_hash": "da95a152e0506ca585762d62a7ff5541c4d15437601e0fcfee0026cb1c838fc8", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "df258f3c-bc80-4255-a215-e1d642d788f4": {"doc_hash": "299259250265926f033d2d11c9ffaf9dbab27f4d82f6c220a6c7c8453ed2c87a", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "94709e04-121b-495f-9794-cf5ce3f86b4d": {"doc_hash": "9665099acc8ff5885d8aa8ed4ca4465b8932a7d42e197590cf3d5a83cfad1613", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "af1ef664-7954-41e5-b314-cc0d8d737da7": {"doc_hash": "7bf64993c4a5d7be4f83654f5fdd8a3559fd4183b63d5e81b9688087e6a6a195", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "b22ec311-a27c-420f-89d9-a970dc85faa9": {"doc_hash": "f63e863bbf38b5abd4eeafc163d8ce622fdaa13655a0bd7901c6af511daafb27", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "b107d7e3-f80f-4401-81c9-9dff1914b365": {"doc_hash": "600ebf6dd2e7b74d4a81ceebef55807870fd6b8bdf4e538916e439768521b7ec", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "c9d64cee-3a4e-4f42-885f-6526f8cdb280": {"doc_hash": "787c6652a72cc9327ce8bc46202e951be134de09f420769341e9b421d4eed584", "ref_doc_id": "5a12502e-cc47-4649-8477-68f012a15051"}, "dbc645c6-d232-4967-b743-525e9dd02342": {"doc_hash": "7ad42e342b96c206a58f392f08932a83a9897fdcf7158e937b370337480e7f3a", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "6b8ab74d-be62-4525-86cb-a573e2454337": {"doc_hash": "843823e101c03c31c2d1938f0913e8dde34a6f35122ca8d2be08d1a82e5b718a", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "3630c16b-8855-42d3-878a-df76f95ba4d0": {"doc_hash": "1ba43106fbab061df7758b74330016ad7a87bb04f2b7e9659407ab23c3b79c1e", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "5c4cad97-1dd8-4d67-984f-5df263df8a59": {"doc_hash": "79cbc53afdef5596f3ecfd91a5ff12afeacb339e8ca57edac77b3f4aa5e10a63", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "6cf63221-b039-478e-9cd2-e5ba5c95b976": {"doc_hash": "7b7f72fe71df8b64c180e6deeb7396da536117823c6ef11674d1b97b9adc8d68", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "4129cfad-1e8b-4d36-823a-bed84ce33343": {"doc_hash": "f1e076781089d43808f38f6438decf0f9391544dd8fe7f7bb2b7d431ed3d3c2b", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "c5e4076c-c571-461c-9063-2f707a014b09": {"doc_hash": "089111b662c0cefe99c2e17be98f7c2fcd56bf25521f5ab040921392135278d2", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "5d007017-a8bc-474d-bff6-2ec97cc70709": {"doc_hash": "bc2791e364619ae069e142a4af8771c6866cbfe51e07dd824b066347f047fcb2", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "68125a42-6bfd-4e71-9c03-282526ed937d": {"doc_hash": "b5da2843041da75c00d4a34bd9a6ee9e05222b7231a1372a0185e330eea8fbd8", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "416ccc70-010a-462a-9dc7-7d1495172504": {"doc_hash": "d19285274e3f4dfd1042caa1d94de33c174449a4fa0abd15a3944c752c1a423a", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "c6da3b17-0111-4d18-a7bc-7f838010b43a": {"doc_hash": "3115ecc9631a452a08364ddef848c14f8037e9bd975b3157ef292ea6a29f5185", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "1590b2e6-4b37-4f17-a382-be5c4021c75d": {"doc_hash": "ae9a90d25ce5180829f6d1ce7f556b65347bb9db642abe93c178e835394da46e", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "586d942d-e8b0-491d-b61d-667e3768f538": {"doc_hash": "5d606adad09f46ebf556a12ae1b6fdf089f07e5274c35c10e8b0366cf381b250", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "2b08638b-ae2d-412b-9de3-5b33af7fa8a8": {"doc_hash": "a78cdb8d9ad0aa3242e232cc801d95d15b6a3921100ea078f2ca0aca2dbc4d3e", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "ac05931b-808a-4641-808d-fcd241bb84a4": {"doc_hash": "f70dd59db50e21d18bb632464905aad3300f69fe55b39332212a774a0c9fa46b", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73": {"doc_hash": "1c99b6bae5d69e4e0cbd70a064cf795c2070e210a06b0f7b17e8c62715453a9a", "ref_doc_id": "2fc7bfc8-3b15-436c-b294-ef7c2ac54327"}, "732a36ea-b175-46c0-b755-cf756e7957a6": {"doc_hash": "9b0ab46512bd333b297d02034f2ee7c766cb534eec599ccc3d618a44adf8b41e", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "7bc0a095-c41e-4d15-8295-dac9975f7ff0": {"doc_hash": "e371f0c7169a0dbce758bda1e5f8e68e094ea0fe3c3057b2d313fbc009810548", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "3aa50260-fc64-4d96-98ca-c1f4a200e312": {"doc_hash": "c49295eb586f7a2d3385c9187d17ba493bc0207743451f2d429376a79ffd5ee8", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "ca2a1648-dbbb-4f72-9953-47569d4d981f": {"doc_hash": "a4bde111191f2a2d8016bb2f03301c8eaa26892481f884cc6bb1a39979ed50d9", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "7b12b0de-4e64-4238-919c-9d1cc9c3b172": {"doc_hash": "8882aa2a6449136f361814f1aeef8af25a5bda2f9ba7d12777653555708e2a2d", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "6ec884c6-7679-422c-9ed2-5848759cde4e": {"doc_hash": "88d6822ac23a8a110185f6bcd861118ae3eada528e73fd9ac481811ce04ed170", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "8ee78718-3392-4f37-9030-71988e4249e3": {"doc_hash": "bb67a5e896b186edf9b03e63b069d5883d0fde7bb9a98e54bc525fbe806aed59", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "6a615a80-733d-4a7a-87c7-2da5f0f681a1": {"doc_hash": "583453bab9a6985a4019a92d76e9f27492c055b133d48f9ed9b838e05d15eb1f", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "f4577259-debc-4fd9-be21-95f0fba06b4d": {"doc_hash": "6707231d20d6ca8129ab7a345e3b9dc9de243ee471cc5482376e52d5425e06a5", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "17853fb0-d9f1-4025-967a-5480290e20c9": {"doc_hash": "c022f5465fd69ec73f726ab7d91571707727c78f67b4fdddfb43245ce11df032", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "78ee45c5-567e-410e-86a1-608fbda190a2": {"doc_hash": "62058005ac731ab2759ae8ba137ab7734b4c330901936038b7474d6bb90ae3a9", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "4a3e131b-1d2e-4ad7-92b1-870b443ea672": {"doc_hash": "50e537f1d7c29e5cc7f1f7ba8e42faa8c7224260c04bd18547165b761b015c9b", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "b11fb997-d842-43e8-be43-032f11098eaf": {"doc_hash": "ef6253e59d68f158e710c583bb54ae7b2c6b4e3ea3ecf36fcefef65eab14161a", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1": {"doc_hash": "7a6bcb76043d79acb12f9a3d886b8ea605a906943c09ab997680d62d6ea5ec5c", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "41125bc1-47ef-4b32-8517-7f435580b3ce": {"doc_hash": "a13ebd73cc7b3505ec12af4ea68b7cec31e87c8e30d6a19928929a47de375003", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "e654f313-60a6-4acc-a0d7-a603329ac594": {"doc_hash": "80c84d87bde1a6a5b3288b46f9fb62d9d520312bb0bc8ef1edb9699bfdd039d7", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "0aa7d385-d3eb-41f2-830a-cffd9f9970a7": {"doc_hash": "2b5bf23fcca928f4d7b58c70a804a4eb3a295bf4fdd4a5c0df4b058ae7096087", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "71db3aec-bd16-4901-b566-ab567c47b3a8": {"doc_hash": "e24394ac8891fb4e1457f1453e6d41d72d6a1ba65051514cd83614a2fbcc1949", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "207ede5a-f11a-4ee5-ae30-1b01a8681552": {"doc_hash": "e53f2fb017c458fa4a61dec60b32bb5fd593c7c1304cad6bca7ead914589f688", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "b8c2e92d-e61a-4789-a95a-29d7c9b48b03": {"doc_hash": "ee8d0eb04e1008a910f16922cf4f47a9ef9d8c80e7425edb44b8dbc44c65cf3e", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "1cca9215-b782-4af3-a3b0-f4cac7779d1a": {"doc_hash": "b0069560114ad411902ebb48de60a85267abb4e2d8b2b2564299eba13433ef9b", "ref_doc_id": "58273310-5952-4a1f-8284-f79597ed94b9"}, "feabcdc9-7aa2-446f-a541-13eff393462d": {"doc_hash": "74fe1533e1b8ab0ff79dd116a9b08c3e9dc747733b21a8b48017dcb3bffafc4b", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "4cc18428-b404-43d8-8133-28b68bf067c3": {"doc_hash": "2e132a5bd4d7bc9c9cdcc98b03ee30678eddf40bbfca0b68ccb5fb73e9c97e2a", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "5c35a8e5-f257-40d3-9f48-a495814fd852": {"doc_hash": "6e7863f950c382a002a957f55d71ed7f5e9b54c249f4ff1e706e1223643f518e", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "a868d88f-e667-485a-b3f4-6ef3d428779a": {"doc_hash": "7a63b53d1aafa52d580392e41feb512fb545a451fc119030a99834a52df67d86", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "315bd1e5-6a04-425c-b169-52344da8166c": {"doc_hash": "52a40d5a4eb06c16064c3d0792035ac295354060a24ed272de6a9c7864bc61a6", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "d0199404-c498-4b4b-8047-991601f3a5fd": {"doc_hash": "9f6e4b773154eb72ad676bbe34c54e55725d5b27f17f80cb3c125941dbb91ba4", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "db39e1b3-e5b7-460c-bc60-4ace0800ad17": {"doc_hash": "57196ba21025cf5ae2a51e03179236881de41c86f9eec3b6401ecb9ef086d3fb", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "c5059cf2-793d-48cd-886e-e099f189cad6": {"doc_hash": "948daf5b692f5e8767595a2f34af76e16872e0d0b48864401c902f6673ca3e87", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "58324abb-c5fd-4ddc-a526-3c4b7019c6a1": {"doc_hash": "1144d29b62012bfa309f46696f3bb410103a2a26715993bd10c01637ece6e8c5", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "ea17d7b7-4479-47a7-8719-cd6bdab65604": {"doc_hash": "bb7ffda8e443dd8d24ac102d275739e4054aa41abe6b802c62e638194349cb4a", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "4105315b-17fa-4a78-b3a8-ad523dc12fbd": {"doc_hash": "8fb3516c88938f7212144964833d1e88bb6f719dd6a36631603d032ddb219715", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "ff4ac06c-bba4-456f-9d64-f1dae9dda735": {"doc_hash": "642a884472b7e5d1a393970f43c128156c495cf47e5619618dbdac0541a78ff0", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "fe209236-5956-4ef9-b26d-aa5cda78f348": {"doc_hash": "423d5a07d78193f25dc7426388366166bd325e797bf5e05376084531925c0e3a", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "92b1fdb2-3924-4245-b8ab-4569101d835c": {"doc_hash": "9e02de53afd7a04b9f786ed59629e206a56db416508e637ed0c31b68e9da238b", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "8c015cdb-bc48-4df7-8418-e8e1dc77b42f": {"doc_hash": "06dc0c47da48f80b9efc35aa658823d96dad71ce8df2b53b38f93463b1edc499", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "ae99f1b9-2674-43c4-b1cd-6dfef15105c3": {"doc_hash": "fdfb27502dec188f0807db9e29e91c8f8c5e4d6eb76682a84adbd6fe5f0a2de9", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "78ae7708-1b7c-4cce-9ffd-417bf99502e4": {"doc_hash": "ced975a7f6e392767cf09f3926dad6cd4d027fac6ab0687868517649f18ec42e", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc": {"doc_hash": "c8a8fcbb32510d303ad41f38c0f19aad5712acbd9e61dd7b58f995f7408e3379", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "66769955-cca4-4289-9a29-fa0915d0f675": {"doc_hash": "cd346187faf0c9b2db1d95897ba24c7d7d537b058878b9fc01ff9dd707dc5372", "ref_doc_id": "c674e0a7-0778-4c7f-af6f-4708cbfa59d9"}, "db135c83-7f9b-423b-9fb7-138511825223": {"doc_hash": "8328525023b971218386f8a2104096159eb64e3346b6f919c67587d6626e3daf", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "74f77c13-898f-40ed-b198-d4fe87f76551": {"doc_hash": "6edfee08a901ed464f84040d76c3e7ba458454cf3c52515c99088d92c9d1b140", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "8fff023f-8974-43cf-8ddf-e62d98034246": {"doc_hash": "556617bc82b9d389f818ca660a9b4ab95bf5e64388aa389ffe12ba2163cd9a3c", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "db89ec8e-3e39-4614-8fbf-9ce1b11a081c": {"doc_hash": "117812c6082f757293cd62fcaca27f808bc5c1052e45fcfcddb1df7d2cb0af56", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "42f85b46-fac7-4771-9110-299a31136a97": {"doc_hash": "ab2561105ddf671f00df5daf9ba58fe526742db304aac824591437d4d1681afa", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "408dd544-ec4b-499e-9ce5-c8ba914627b6": {"doc_hash": "653e6eac1834560011bc16ff28dc2157793f75abb68941b8d62e424bd5ddb2d9", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "419f8d0a-ca0d-445c-957f-40fee49e7835": {"doc_hash": "2d292eb0ddc61d75625e0d94b478fdb8eceb75b23b6a4e50ecd981eb27b3b475", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "6404f772-0a1b-429c-987e-4d6905f0e222": {"doc_hash": "f684b196e82913b32a6ffb282e3a15fa75468d6ba1e03fda9b066d1beb028632", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "17b627d9-f0e9-4360-81f4-4bb360292dab": {"doc_hash": "0616d9fe027f33edac8a1084fcd9b14eec1a4d4632b87284887fc2e2c9855c19", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "6add21ee-14d5-4c87-8cb5-7cb5172f89c8": {"doc_hash": "abb3540addc045ae798c4b7078c72fd7402e06e05bfc513d69d64d11708c8489", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "df744f32-4e83-420b-8170-b89488717cf5": {"doc_hash": "b8ad386aedf9aa51d71132749c06fad929cf8db88ec53fbf998a803edc99bb42", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "f92f51c1-c27c-4e56-ab11-df020c1a0326": {"doc_hash": "06d75c842ff0387c9797f42c53b0bc75a466b75abab3dcc3006939eeb7c112e7", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "f0faef01-7b6e-418a-8c11-e18d7db5a6f6": {"doc_hash": "b5c6d2af99e18257769002e84da1463d7b87851c0b96bd165337d67eaab7c0ba", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "46be63d5-483c-48a9-8460-de1f0bd369f6": {"doc_hash": "ff661eb6ead942a82f18ae2ee103a6a0193fbc703306540a7cebc30493a94956", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "271a596f-37c9-42ab-ac2a-6d998ebcdf46": {"doc_hash": "666e71bc50f0f234eccf9dff7a34c2c2c7edc9ef79367e6368a5bea0d49db959", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "bf8cac38-0cb6-472f-9305-8f77fbf906d9": {"doc_hash": "26df6552e9002a42b3283c2871925c29fa22aaf90fa2dc86241d9392ce4192a4", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "9cec9cbb-9345-4dd8-a656-097d02496f7d": {"doc_hash": "14e76272e7fd14f4141f94f1fac2ba605476e95a6aa89091032d03444c037cbb", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "23d4785d-4ff2-48fb-889a-59d88272f011": {"doc_hash": "3a0082f4a2c7ab0ea9512891a107a97c2d795af73a5cb52b2e7e33bb157f2da6", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "791555bf-732f-4b82-b0b6-1adf7cc3b53d": {"doc_hash": "c6882866aa45c4b25266e4d64f789a0aa879c08d6619b7bab9c21d08c8c6943f", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "a6a4c211-3152-4f87-b004-3ae882fb9542": {"doc_hash": "3a5925ba2505bd3d6dbd79a1a1c7026986d14514f8a2e86b5d21167f6ab11f1f", "ref_doc_id": "67435a7d-4b18-4711-a325-95e98b72f911"}, "8c7d40d7-1a2b-413c-9515-74362c3bffbf": {"doc_hash": "94edbd56392c48b430887fc99cfe165550e6fd2307fa22a8aaf55bb070cf95d8", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "1a2bd04e-d428-4d1f-a28d-0e025da74204": {"doc_hash": "63ae2d89859f5f9748414138229de5b121c3f2c0f019ae3f2dd111ca1af92184", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "c9772a33-98de-44c0-ad55-65c065a4bdbc": {"doc_hash": "854aecd76877d3357e27a90db00dbb1ea26bdcacec3e0d5b71444e152db89a2b", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "084bfaae-5b24-4a50-914e-dfa2fa11dabf": {"doc_hash": "f955edbe415bde7982b1c6fd3f22c85af4e4b9a7a48e483a652dc3f58544ab1a", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d": {"doc_hash": "84ca2c5070367489235b2854c6aeee010d1c893807bbee7d70ddb37613d6b043", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "3240e164-cdca-455a-a089-19d5f6cbf1b9": {"doc_hash": "6ee65be28bff0df433fb21f2a617c89084ea3ddfb4776a390b79053b9f4c9f2e", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "b038af58-0867-46ac-b97f-1dfd61547b10": {"doc_hash": "635b6d9f8161619e2c18239c4163859d5d067b30628b3b71ec2ce73f47d94232", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "def7626f-0dbd-402e-8c76-7d30a40f674e": {"doc_hash": "4239b22b10330dd117054c0ef6a1e728a1b1c9219701c31d7912f26ca296ebfe", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "cefd68e2-7155-4206-b898-26e8ed9ad6dc": {"doc_hash": "3521fe539553984e8dbb58a880787efea5db67ed634e433761e8e091052c8db8", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "a8811e18-2fda-44c6-b485-594c9749364a": {"doc_hash": "9223e32a0a9ffa4bde78e30879c14c94be50cd6f3f080f5e31dd7341596fc134", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "5a1c9c04-3591-41e1-9eff-003674591109": {"doc_hash": "82edbbed4be0d257a0b53a2db53e96bec2d79179732c3ae352b1a912fc12e01a", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "241e7537-60a3-465d-8e87-d60cb98adbaf": {"doc_hash": "cd53a3904038caeb5b706ca0b692cc40c72ff1c8e867da1cd3713e90cb4efdc0", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3": {"doc_hash": "fecf132601776b1f973371e0cc99dd399a0ac09383bab4969fb51173a71fe9c4", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "e93f2485-46cf-45e9-8a20-f30a1b10c68b": {"doc_hash": "7d2877a2d42b0e9cdf16b2d1e48ef78472f6123592f9a57d4bc6ae59b5394b93", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "5e2041e1-3fe2-4688-846d-d03c7b6d7980": {"doc_hash": "f968daa187da10b352efd169b683ea22128e5d5b9ac7912e7464f25f6a0a58da", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "77315319-49a3-4973-8f1d-5ec011a81e04": {"doc_hash": "7e601d06f1409c0c72767982be91f8492240f8dc3c66b12db940600202edf501", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a": {"doc_hash": "aacad4f0a7c056360e91e0dd788aeb0464a0622c60cb8608e8e77904c9e6d5da", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "a29e9b8b-c45b-4902-9060-2faccf130b6a": {"doc_hash": "ecb0ff6551c9d0a95dce6737c214c57e54680b03ece532d8a3d1b6ae433f99ec", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "616c81aa-9826-4299-a6d3-71bb514f5931": {"doc_hash": "787ec0f88b065a55d03b6d7829bc05002c61d02b7455ca527d93100dc4093392", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "9471167b-282c-4ef8-b001-9dd0c4112a2e": {"doc_hash": "6e40ff7cb179b4b36d2608bdf82b84965f5009449494423ccdcb186fe944144e", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "473c2869-bbcf-4f0a-96e2-ad1270a03ccf": {"doc_hash": "e6d5579896c0f27160afdc8d38e41a64c4a73f915550e6c6c8641f71c43129b1", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "89818386-719a-48a4-8951-c83b941d7617": {"doc_hash": "16e1fbe29507c9795a582c5b50c87fdeaf12aa9eb5617bd9f82834de2916a640", "ref_doc_id": "f1695c05-c36e-480f-b39b-a2911516c999"}, "54ea95ee-6290-4a41-b763-018eae909936": {"doc_hash": "094a9b947ab6da05d477a2fdfd3e3c25fe95c4f4bfab655b8bb25f2d9c9b2014", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "b3d5e5fc-565c-4601-b7c7-c0b9d536c215": {"doc_hash": "e0ea8feed1645ca700bc249fc5fe38385707178963016148b275adb0b90d54b5", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "300e5319-f677-44d5-a173-d40e3876a86a": {"doc_hash": "b2648ed35924eddaac27942adafe87efc3c915ae15e88e3446b4d2b91a6b1efe", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a": {"doc_hash": "cee188c2ad137e06636200dec3b9cf21aac3dfd830b063cffbc9effb561a8000", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "c58840f8-6c70-4dae-880a-05ec218c719b": {"doc_hash": "f5569ca716b8718e809107228b5c397dfe2a355f5e15477f90dfae5a3488e354", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "7e2e12bf-d2d2-48a8-b001-da9bb3af1631": {"doc_hash": "3154b07c5403d4e54c02d5be6028a3b08d3e55f723260910ab2f50de58ad36a3", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f": {"doc_hash": "4f47ff6a88ece989e2b476a705ac5e73b1cd691a160463d0795902e5a37f0806", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "c8be3412-25c8-466d-ac5d-c3b16e7650dd": {"doc_hash": "dde943e27ec61f607fe9b05c712bd75dd06551e210a9f5dbc3a658e6c8ab03d2", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "34ad6423-7260-47a2-b9fa-d0211b809ef0": {"doc_hash": "96749af0fedfa81885f65d8cda9650522c681143ee884b27a0edba5b95c3542a", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "850afa52-2d1e-480a-893c-0b4732779109": {"doc_hash": "8a07d33d651b6032a15bff9e740f95f10f9990bbede06a66fb0983f5ebe0c012", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "1d597be4-aad0-4258-9258-55c5780cd3a5": {"doc_hash": "bc8dc0f887ec58938467874e492dbce27d29211620795126986e023566aa3375", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "d03e3a09-b941-46f6-97c6-9a72e68279cf": {"doc_hash": "897b040e05e5c17eee364314698bc50bf10976b4a2d81d45ffa12a1f5645f571", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "35501589-1cbc-4b5a-96f8-627d66653f11": {"doc_hash": "9d73dbbf1e03a83d12a8d351962837164eca4583ec9b39fdfd1a7c5627883ffd", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "f547df87-f536-41e3-9f53-eb2532f90c35": {"doc_hash": "6b251864fa45ca9b592f4b8f83cf885d5b27536207ca1db0de6b391257d89c4f", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "b1b1324f-25cd-4510-a722-8181b0625359": {"doc_hash": "f44c1c760d67977a9934d0d40dcf70fb38f6ae758676f531c7e5c11396b72659", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "7ab7ad1a-73ff-4f18-8554-c4c276062e0a": {"doc_hash": "50239e054d57117489a1362a2115605a3004924871f6d2a77070255e0fcd1e7a", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "6a2f9760-9bca-437e-8fdc-6e9dca3f4066": {"doc_hash": "41ba46001ac0566e75e9e58e62702667b9a8cf06fe1b3a441d52de7ab99ef048", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "b6607325-9e23-4aad-96a4-9f0df0437758": {"doc_hash": "32b1878b0f7ea2897c4fd1da181ab232dea15425ba9d225b9775e56d2f2305da", "ref_doc_id": "3133095d-d419-4f68-b29a-47abc408b487"}, "95f7c4eb-c377-492c-9a39-ed3e439a8bf2": {"doc_hash": "4d33e810fa86d3fc68bddf2c6096ca65c86a09d503a4a6de481585b7a65a7aa9", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "222e43de-71ae-4ba3-ab72-ccf1ae192a45": {"doc_hash": "9fe042e0362fbd4178606a70f22d5051466d31559102c742ee14e1384b8d3c30", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "2376659f-44d4-47b6-a167-00819593aacf": {"doc_hash": "a121320efa4ad771902f013b191420e3c54ba5a479cf63cc2b500ec8def251c6", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "6a3bc2a9-6473-4755-a9f0-a41f84fa9083": {"doc_hash": "df4ca51fcddf62f21f7af9dcacaeba36a5160bc723f2885b72d3a5017e395025", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "fc347c1e-2d9a-486a-b1f1-9a22676e13b8": {"doc_hash": "026ea0aa9bd19d04e16d232ab218804a5782a0e30ff077f1a9273d699ad072b5", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "9e956fdb-8f3c-41aa-b5b0-6de59385d869": {"doc_hash": "6de241ac654fc39a8e74b5cece2ba07f7a0aa1bbe7750fe033a599887163bced", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "27c55c3d-6c7f-457b-896a-9447d2f25ae5": {"doc_hash": "86793d651f631facc29bcad23c0a952a66887d18a09722c5b32088d6455030d8", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "794437ce-a716-47de-b591-e1c0364dd82d": {"doc_hash": "1a61ae274a79e58f4dbc214bd56f1e42cdc5b0679d00706fb20dd9f079a07e8f", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "1ea50913-7025-4840-8cb8-871c82d05377": {"doc_hash": "b09d4abde0c0fb16c5dcda698c85966a7cee7dabec388cd313b3a04f933afa5a", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "df8b3c92-af93-4945-9839-f41198116245": {"doc_hash": "31c5a515571bd7ae378821982bb8009b47de9ffbee1c185145bb72aef3251c7e", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "bee5fb38-c077-41b3-a62b-7ae517a51e9d": {"doc_hash": "d4847cecb1e9d29d3ed676d692223c9ffb5d4a4ac94ebf562d535d66704ee119", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "6d0ba463-4f0b-424d-87b5-f65942ce447e": {"doc_hash": "a5561cb9db7665e73b50c828a377dd1854675f6e6ae6ace517ebe480a98c749b", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "fa048122-b246-4b02-8a57-9f6a5f06cbba": {"doc_hash": "2a49d941ab0bfaf017c142ad170a134bb5017f7d768691a1566f8a1d5d875467", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "6a3341b5-cc37-4011-886d-422b31a2e354": {"doc_hash": "f63135acf0a72bfdc0ef79dd27c73c6f05f5a7feeb98df18fb8ae3987a1c2055", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5": {"doc_hash": "2d2abf686be5d57f199666658c0b89fb9577f692d80c8472911bb735ddb58661", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "3d3751aa-e286-446d-a10e-b6794921fd72": {"doc_hash": "500dd8c93173b05add4732017c158fe8ac040d3a296de5c06c9f91cf35cd18de", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "86af24c0-9854-4dc5-b1b4-61893da9ee2c": {"doc_hash": "fcb7cd13f3a7b66ec7cae97e5475b1277917fe7db99ee9d5ff666b0cf77fb45a", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "c76fe5e1-151f-4467-b207-cf5c83d4301b": {"doc_hash": "9aca7d0322b4fe7e6cee13b1514fadea80ee5ec1ca23f95b957e72c25d0b6638", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "b5f20e95-c79b-4d43-91f0-ad6108697057": {"doc_hash": "0264d739b86a7021b2c774ba56c059085cdda664c876a2bbfe59eea1d19e817d", "ref_doc_id": "2eceacca-2085-4efc-a7eb-cc403164e1cb"}, "0c9aeddd-72ac-4580-9924-6a539e7fecc5": {"doc_hash": "d5cebfd4b1d6230fb9b718012470c9148f61ea692418550daa17e3e91abdf92b", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "f8331b69-13ef-43ab-90d5-627b4dafac56": {"doc_hash": "6b20f2db9aaa4b495d858ac6e8e7ef38c21c86e812890db8da06e8a9895c1bd3", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "85953dc3-664e-4b9e-a034-b43e66645a0a": {"doc_hash": "83455e6371d9a2e077cfc92f4851e64a6cfcce46d9d8b9328b5c4b3d251939f9", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "009295a0-dc92-477d-bcd7-9ee08765c687": {"doc_hash": "253d3a8f06ab2e30db747466062bb45845185718f05980a61afd10648ebcd731", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "617bb2d2-a0f2-4519-97d7-363f6c59b18d": {"doc_hash": "98a7c228edbc876b1420d6d86a92d5b34a36f8af41c6691d8aa5b2a20fb1791e", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "5ec864a2-8d76-4657-a6c2-e11a77359a7f": {"doc_hash": "6c9e804a6670b3b6b39e9db569b0e2044ca27375665f76d8dfd964cf3810f64c", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "dd5bd418-d396-460c-833c-4659020ac4d0": {"doc_hash": "1550ef2c006432859a87053f4545c5721b3e8e5c77d228e46443d5d945cd6e49", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e": {"doc_hash": "f2c95a43c739ac5f8ef511e41a2084f642bb899ee3157a3c4865aad3bfc5c249", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "94beb6dd-f233-4c08-9b88-790fe46726bb": {"doc_hash": "d441f7563b0fa482a8d163dae4822fc821475c09a6d3aa014133370eda74c7c2", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "1e5753f3-3888-4bcf-affa-95ebdb229e8a": {"doc_hash": "e3caefb457b0dbe8710bd7a0381fb88456fe0634fe5d64c98f17e94d1f82a666", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30": {"doc_hash": "049cb5e7b1c9eec73178b85c3853fa16aaf3bb7c5ac8b56f5c8ca988d550248e", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "ba511882-e2a3-46e4-b338-f5cbf3a98396": {"doc_hash": "62189cbb3b122c68acbf3f0391d35175ab84836567b2daf0ddcc5d26fb985371", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "5f00f3da-fc11-43d3-9395-dd90e2419e12": {"doc_hash": "b55b6e44835d022e956d46502fd85cf83dabd2eabf2c4df87404298af676a71f", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "9c712732-ce3e-468c-9bcc-051f3efa0188": {"doc_hash": "12e6676cef69aa1cbeba8809a4dbfdab4e486c4e13d9ea5cbb096e8f8c011c4d", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "a1c2c702-ce00-4234-9edf-627e0ac96958": {"doc_hash": "c5ea9c8cc2a0481a31938b303b17bf1e3c0000593d98da92f847e86b777926d3", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "79e100d9-95e5-45ed-9c09-c1908740d54f": {"doc_hash": "e20f6117b2f098545fe4eb40f37d487e0a1726de88f7f966be6bcf8cd946d940", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "182ebc49-b649-433a-9aed-0a8c3d633331": {"doc_hash": "00fa25c2c947d94d267c3b44664cb58bb74664bd06f214873b3a2d180cb4fb9d", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "6735cac7-d542-48ea-b2ea-534afcfd718e": {"doc_hash": "8b2c17c9f58c65340d552775b164b1b870b4c409647237339e2002a7f4e94abd", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "f073d2d0-09e0-4c39-b761-38cf89681956": {"doc_hash": "b3daec311133b5c07ca6f248db475cabf3d62d3246c21390cae3a07d7c077881", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "cee9ad58-e9d8-46b5-a9cc-ee89112cd301": {"doc_hash": "f7e473f2bf69198302bd4509d3f58c44511baba7b5e5cea99cac032f70a66af1", "ref_doc_id": "a38790da-1e71-46b2-8df9-35eacbb9ce1a"}, "27deab52-26cc-42bf-912e-e4bffcff5d31": {"doc_hash": "ddcf1b7334b7c07fa4208162372d43efbaac5207f8f287697b987b8d683d98fd", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "7106b6a3-4404-4375-91b0-953321878261": {"doc_hash": "caca3097ceed48c795af4bc3043da2667c73651b52ad948d8f463f716f94576c", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "d593740d-98ae-4539-afab-f6ed36a05a9d": {"doc_hash": "ea237872ada753e7bb366004b715b52ca0d69cbe7b4ac758241ea930dc072b22", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "1a0e986d-b9a9-4810-87f6-67d1830017bc": {"doc_hash": "dd2d2a1b572e2c5bd9368bcf5769b3b6014d60c03be2be86751cc48eb92d3d3f", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "ed5457ff-ab0c-4a34-846b-6a5739473b55": {"doc_hash": "40384d66a382de500055a298910ccb46d5abe283511e7131e457b838cbc53fe2", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "a470aee8-fb88-49e7-b5b0-13ac32088639": {"doc_hash": "50e66f6b068460b59582ba7b0d733f3c4189fc443cd73604df56ba32c0f85685", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "bbd98777-422a-4102-8336-d023acaeef87": {"doc_hash": "235c8666dd300128c5ec1b8d3c5de8e54f218b18a7a8736e9ade3bc45ee10805", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982": {"doc_hash": "bc5cbd457450ebffb8213404657c5654f4242c8e257551e1643a4c844250042f", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "6f2961c8-df8a-40ce-91ee-a790d20f7199": {"doc_hash": "0d780aac498acc201db34f92550cddc9d02f75acac804f8ae1f2f40fed7bd163", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "3046171a-cae0-4f38-8577-70d15dc747ec": {"doc_hash": "77e81a24efbc888ce6817900d2bd46c4ff0eb09cbbd85a0ed47ac9143fc2292d", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "dc036459-de3b-4e1a-83dd-d300a7cb9b7c": {"doc_hash": "7ab612ffa6a97f029ea48a4facf25d59690eeb5fcc08e84c554250d8bf3a5f41", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "2fe8d05e-364c-432c-ac5f-d72147fc9ccb": {"doc_hash": "384ef4151bcc8750d586fef20fe5bd56bb2367aa31400a8b529eefc32b71f8e2", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "e0388045-3752-4621-81d8-326efe251625": {"doc_hash": "6fb0139a845f9ded073e3ae2b3f49ec6fee67dfab0dba6d68566b56e20c6456e", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "4730ecc1-2271-44f5-85b4-5e221e1aeb78": {"doc_hash": "4ebf2054114e1831b6ca66a30d295534c4e4369a04bdd10fa28d8b95bc5ef00f", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "1edf9823-401e-433b-990b-695bbfcf92e8": {"doc_hash": "acfe42901af9d2a34cbb2b5eaf381ebc69e585f93f109cac4e2d0b2d235cd2d6", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "08437907-3f20-4bba-b9db-d366264380ac": {"doc_hash": "547b10e91d5d621477822450f45a6753e7d742cb5657dd710a07a69d565cbd4e", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "383e2741-3615-4522-8986-0935295cef03": {"doc_hash": "9293e42ed286117059728fb217a0c051eb94f7c1e159f74136da8c335b107e57", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1": {"doc_hash": "aaf6cafbded725d6b71035903585f080d12d3d109e0bbefcf7e7e3be941e99b2", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "1e790cd7-3cbc-4854-bdb4-6da8030ff200": {"doc_hash": "a28795d8c516802332ca9907fb48f7bb38eee27f4cf50f95fd0267c81670d0a5", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "8fc49eee-38ae-464a-b1da-cda2e861acf9": {"doc_hash": "2d1d86b8c1cab39d92970bd7244f0af66e4c72aec1c73404646481b3cf51cc66", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "997b7368-b697-4809-950a-3ee34b4ed5e1": {"doc_hash": "19e3fb71d217674fdeb0f5a873b5aba3947a408ed7a8c8e62f93a1576a0c599b", "ref_doc_id": "81578dac-a6e0-4796-96ef-8c76c3202e6b"}, "5470e70c-642c-4cb1-88ca-5943c32d0f29": {"doc_hash": "0d2b14cb984c270a3ae75f86fb843f3a7313745daa088bd3962ac5098ed54d89", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "921a49cd-35b0-4bca-8cf9-d37c94c413e7": {"doc_hash": "101014af8084c97a2a3ed5fbcf7d8439ecc61b384856a4d8bf8e75ca79eb2a74", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "f8efd33c-cb68-4112-9c5e-25356959428d": {"doc_hash": "c25935bb804010165544de278b748e7cde9db2c5cc727638862fc34b4ea616fd", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "fbab93c6-d465-48f5-bc9f-b99e2c29e50b": {"doc_hash": "ee07b59d50d054e5740851912191be4c83c035bd4b7278ec478e08a910d8d83a", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "20aa6438-f6bc-49c2-8999-c2072cd80a11": {"doc_hash": "1053dbad19ebaad7e0b7a74ca211c092d72957b301e6b1ed93e6706669ca093b", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "e8ee40fa-9851-4f44-bba4-be5365547431": {"doc_hash": "1d0640e7136056ff98aa19106e52886168529e7f8955425f20f913b50594e8dd", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "d77b58b5-998d-4e7e-8638-88a4ecbd77bf": {"doc_hash": "35c0f91ca4e3edcade8846231ce284426183a73629cbcc9a6e02d088fd7b1320", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "de0577c8-d770-450c-9dac-3b7fbe5a248c": {"doc_hash": "3d0a6c3f0e6b5c7d18cfe29d360b2d038a875d666cea8766773e5ef6b41a542d", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "a60ccbe1-14a1-4178-a042-4fab7c71d269": {"doc_hash": "1daf4bab67e9b52d22f50b8b5d591bad7f381a16f0fa0827112196b6baa925c1", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "5d517919-cecb-43ff-b9d7-9aee444c3859": {"doc_hash": "f4196f7852d41413f214498d4049e99966b30bf8fed3407afb2de99b1f677503", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "03fe5b46-34ac-43b0-b875-e5a8a6c2493d": {"doc_hash": "c23d079fff7014c5865d7997f46fc4ce6542cf96dbc2395cf4204e4c78ba03fa", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "50eba34b-a560-4f86-97f9-6800ac39d603": {"doc_hash": "249fae8ec944239d26485fea660406ae7f32c0981c0d90fd0dc0efa11e96df5f", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "a5d42be9-6c6e-4650-8f23-3043129490b6": {"doc_hash": "7df1e4dbf80f97220f731817d3f070da06afe99f50e40304b95e365b356e9db2", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "f3e40de8-2635-4c94-977a-d7dd640e7aed": {"doc_hash": "59183e6efe0296093ab5a240f51c837d014fded29c291d5e3a054459f660960b", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "437f1f7d-060e-4492-998a-9d63dadf3c77": {"doc_hash": "8a71c84a190191c1e3b20cc372fa46a73f9e4f23d698568c33610873615c9b14", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7": {"doc_hash": "8ac341759acad14b622980949a572db39317ade06e7d27ace8188120b449d9f1", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "bdb14811-9660-4649-8f8e-7d9975b9a207": {"doc_hash": "f8363d3cd449e8c331677cb1d1422adfb9ab16c081a0c6fa821ceb53ac0bc25b", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "99df7daf-a983-4282-8a92-11fe17841adb": {"doc_hash": "10e105f0cdd3f4c4f4ed25e8cb50cf3216dfcd02983f6bc188228903fbd95b30", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "25f592ec-eca8-4e9b-8f26-7092439a7341": {"doc_hash": "f51bbeaad614fea67e8555ac6e7376dd2815cd77f8dfaa94c9f49404941ecb2b", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "64a744de-b972-47da-81ae-83b11540136c": {"doc_hash": "139148bf0ae8912b03d2309ae8abe01a6b2479c2b867e396d913df9cbb6e1f1d", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "1c513df0-bfc0-4850-bec7-9618ebcaf723": {"doc_hash": "dc6f15c5ac8b41ae98ea8266c20a91a34f0c271f0c5519aae8dc2a46320c0e65", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2": {"doc_hash": "687d6128ce924df989861026f95ebe47117adbf902ddab8d1ebc3cb42498aedd", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "c117f52c-e778-4774-bc1d-f1ef617c34cc": {"doc_hash": "2e8078a6193956e116cf257814199d58161c1e864c44e437e7c00999c94845ff", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "da625ffa-b093-4a04-9570-071f8bfc45d3": {"doc_hash": "0c4654c3f929f8406731bbe76b613b11536ed0dbc72e7dea131b7eeeb109ddc5", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942": {"doc_hash": "6415615e54990e3b16ae3c9f522e6daaac809451b6ab963bb153681b88c69eb3", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "e1d27382-74b7-4a24-b3aa-b42acc5aa150": {"doc_hash": "11a8d7ed41943450425e2f84306200e69b51c7736753d6c52d8ed87ef5a832bf", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "33c37d34-8624-43d4-9cca-16fe0062bb45": {"doc_hash": "bb585c1692a09451c6e232d8b58460dfa4bdbaba0cebcf3688c3eca5f9b46bb8", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "d0effd95-6959-4d11-8f36-956cea4b4ade": {"doc_hash": "c08f7534e7d994fc7475d11c2e44fef8ea1bea05210442762d97a40d8e263b61", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "9aea0186-6c3b-4956-8ba9-27c259bf900b": {"doc_hash": "4c72bc96a9ed0fb9a92909f7bb3ce62efae2c12be015cb18bb416ea1f5df044d", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "022840a3-6e70-4365-9bab-ec26d957a20d": {"doc_hash": "eb3059517a5cd4dca7fc1d8dfb65e8b4fc513590ddd7c5e671b494224ccbcb7c", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0": {"doc_hash": "58d6942925de7fc37a94c2c6d48be97107e04be8e0d573bb08e0d26daa9eb154", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "c04543e4-0815-4668-970f-0f82adfa7e4a": {"doc_hash": "9cd1981847db44dadc56d12f38f68bbc6eaf3052e48d20cf0e21a3bfa3b6c347", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "d8596fd5-1e35-450c-8d85-e566d4370911": {"doc_hash": "3b410915d2b734c74a303b9072a10726e359d3d9f43438b35c7a2899391f556c", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "e7251315-be09-41bd-a4df-ac8b79c02bd5": {"doc_hash": "08af49191d428e3b836adfc5792a78b412cd2ee9cf5b3f19fcb515a224dcd75d", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "e1f3cd1e-d36e-4777-aae4-f83b403a21e4": {"doc_hash": "872a0b9e5e28fdfa58715871d5acc08ef5e03d23fda5b74a66f9e69ef20a25e2", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "1c88ca13-86f6-4c68-9773-a9d2a9987f10": {"doc_hash": "46f00d688e8293f3a3aca6fdd5bb6ae1780b81f2da9dfe6ebfeb28808ac768a5", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "8b17baed-9cac-4079-bb6e-156e6d6ebec4": {"doc_hash": "96d95b0543b62371c240c22266884ff287b63d0571a9460bf5d6ffd671440e51", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71": {"doc_hash": "76619d3b00e00a5d674be384b01d5601122a05cf300f6d591b3ef46d4195485c", "ref_doc_id": "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190"}, "b8826952-e754-4120-9038-d0076b11008a": {"doc_hash": "b440a65bfe681f904392da1be0566ec787fbc4902fdee59c7fc54fe6bdd41209", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "78baffd8-025f-4008-9774-74ff783d9cf0": {"doc_hash": "0ad59c586bb9aa3b55094d0dde26a0e188f2af9c2096833eb88c0eb0f8ee7649", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "bf4c0caf-2f53-4f87-826e-da650d00e0e9": {"doc_hash": "09308b90f203591b6df620794764312d3609d6aa31accd5518e5d0896cae047a", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "768deaeb-3435-4bfc-9c90-15883b95acf8": {"doc_hash": "67e72084e08fa38cb873078a7affb1ccebd959ff94276e3299b4f213861d9a69", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "9df38c7e-48cc-48b8-9d2c-ce022106c713": {"doc_hash": "c2bf0392a66eecd7fbd941ff2761267fe526ec68d864c45e0e617b12bee0716d", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "eb974195-4233-4808-8153-bb1e16f2fc85": {"doc_hash": "0b88874f86481e9dfa9a5549e5c14dd619af41c9a4763cdf49a9cc73eecb33ae", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "dce6cf34-b013-4449-a8a0-e2a994ae47b5": {"doc_hash": "90ab18a473d550c776dad30569035f1ad2d0d428f2899618238b5d5dd75a0e64", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "dc5b596e-8213-43eb-8f25-fcc152f991b7": {"doc_hash": "cc3e944c5ce5a5a60d1e0375731b407b9457d319212ca9a23e5919c8799ef2c5", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "55d1f3cd-77a7-4ea9-9ccf-de430eac2005": {"doc_hash": "6b59658ae25f86179dfc36a8477beb7373693ec2fb467ef7ff8795246befe8ba", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "d25143b7-f86c-47c3-8b8d-671a5b2a1b76": {"doc_hash": "f3c9556f3ba564505580ed264d13ec156593725c0e59a51fe0eff59b7a9757b2", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "d22f1f4b-b412-4719-9e02-ba4becc7a7b0": {"doc_hash": "66bfc8b9e447d7040612c1b0bba845f78b2895b2153461dad80f406d47296767", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "6b4ebcee-2f56-49fd-bf7d-93a77925b711": {"doc_hash": "61d47de2fff5498646444570763456502f966fd5da3cd8b1b583c4024edb2f7b", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "8c4bd27d-506a-48c7-9f71-6ed5e1d67626": {"doc_hash": "611708bb182316ae5f2cc659c6e61ab0c18324045d9b61b258da1e100976a55d", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "097e9b38-c952-4afd-8669-283707661457": {"doc_hash": "7bc56d04f06d8dd1fa6013a4b078a363885e37cc74437410315e628cf0861fef", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "beb68fbd-1116-45a2-90f8-8aac0fe4d227": {"doc_hash": "200ced68d3a606dc854d51ddb5737af0138fd59f1e6f32a4aca46e50d4a985f4", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "05142a04-edb6-48b1-9600-7342a31d43e7": {"doc_hash": "556654f902f86239835077e717a9becbe515e278716736ea5144d2daa35cd799", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "e44ffaef-8585-4360-af94-9493be5ad3ca": {"doc_hash": "0d03103ba8f460c3b8dbe97fd648a58cf8c1c7d2a42294e1eeaeaf2cb9eb5c15", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "ef760c53-017e-4061-b9ab-a07c50602b4b": {"doc_hash": "b90bca6f3ed6bffb19bc95be69a46a52368e680b52fdb731f0a9b5577956e102", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8": {"doc_hash": "faa4a8bd7e43cc149d27bf67e6e8c8ff01af828032b0721f45da1d15e24782fb", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "6164f303-6034-468e-8c3d-9985f85ccb91": {"doc_hash": "7d7da5d9a36a5a766c7af12021f7da384cd95d6ae4a128f7ed47e0a1a65ca89a", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "cca79382-7d43-4f82-b774-5d2ac106a84d": {"doc_hash": "7131f5105f4eb9c132a3043a53bc43c0624b75b2a7e7cd20292040779e595034", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "90be1458-674b-4b7b-8808-9350e5983248": {"doc_hash": "b050a81d70aff3f3225f54bba93d7a76f989a6eed9a066799c57e3bc392bd014", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "a348348c-b27a-4d68-8265-1af4a1f29674": {"doc_hash": "8446afd9f4889cbc6ef3555f8e32eb47ac08b941b344fc782f809461c9b4e740", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "1e14055a-0394-4da2-8502-e824f196a682": {"doc_hash": "be00a05bf9a2135a96bd1374ba9aad9e57a6ea8009e9dfff01e637f18aebaaad", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "6d0014ee-2613-47a0-ac36-669a5157b2de": {"doc_hash": "4dd067ac6ad320a056c2b7b07aca666905715c1c4f01817d6f118eddf3ded43f", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "d8b40063-df13-4df1-942a-325f659153b1": {"doc_hash": "ae8267148cb721ee7e18402df2ab169cc0a298d5b9d6765b7ff0eb7485c8fd3a", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd": {"doc_hash": "b2daff8ce9023006ce7d3448c2f0fcf99dceb3d71c7cbe1eb6b4f07f192149c5", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b": {"doc_hash": "b8c23e9e7940c694fec667a748aee29d8d275446d5700739721dd46f9215c798", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "e5b599d2-f238-4eca-9005-78dc165575d7": {"doc_hash": "f4f03616d6509f75d4dc7895b5c470146f00fc04a5c9524399e61da402e3fb23", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "a2db330d-df36-46db-bf87-75ee0a5b8818": {"doc_hash": "3d19d6b10e9cd777a05682b640bafce4d232334dea5accb12453c67378075190", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "913230bc-7001-4cd0-979f-f2e28fc13c6c": {"doc_hash": "503a38d92568ce8bb04852fe5811035d20c14c4eaa9d981a09f31fcbeff7b573", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "54d58bbc-186e-4ca7-87e8-69d46a882ce1": {"doc_hash": "eab4d7d4ae42c75bb630b9934423e47e799d788b6c87c58669226427806648d7", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb": {"doc_hash": "a864206ee215938f7bee3f03c1cdd702f65be7727f9a3d639a8130f0502a3cce", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "266eb1d3-7163-4e0a-b2c9-f7c99322c833": {"doc_hash": "fa243a11fce1a5b8cfa6c23a6690ab1b92cadb95c265e3fbe11798ee89b25238", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "792fb1bd-bed7-483f-b0fc-ff21ae2accfb": {"doc_hash": "653eb5461ab0108ca967d07d9b51416cf5bf9fd62784c837e3e863be20981622", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "f8ab1445-7e03-45de-b72e-be2b8a93b3c1": {"doc_hash": "bc2af32fd0e6e345952dd6fce4fda7499a71f5b5db1db2ca07e5ddf424aa0ca4", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "7b50939a-147e-4501-869a-f2d229e020b6": {"doc_hash": "5c0382e3a7bf857735449a033ed847c8ea79a3f7cd7b2342db5e646b76e7f82e", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "20a477e8-e235-42cd-8288-57711b64738a": {"doc_hash": "6e7f2a3c1f16bb2c9eff18d913a25bcac332ee40e14542b11fea746e4abf1eb2", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "f8663a03-caa7-4683-b01e-1a836bf3675a": {"doc_hash": "a514da8afc5fc8ff74ca92a5c794577357f508ed75ad9cb1abc3599fe1ea76e8", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "0f5c1589-07b8-4f17-802d-eaa8b931507d": {"doc_hash": "283f26677b112ae808a4d4ee9577b65e2e657ebae77e06b11ad5d7bfb5e41029", "ref_doc_id": "6631bf36-f58b-4c34-8639-475bbd65e2ac"}, "6bfc3cd9-7962-4efa-bd9b-7a7e07c18046": {"doc_hash": "884176f7e17ac0b6e2b1fa2c4983529b623ee543e7e60f82d9b3f6248331c12a", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "27fe7f73-2202-4bcc-b948-a93339f65b53": {"doc_hash": "e97177c45df803c9f5d9e0e81df6676700d39781db25502fe43535fcfd6f1291", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "a090a661-572b-4de5-8c75-91151545025c": {"doc_hash": "e9f76acb1f066e75d29393730c39054ec6f8cde9900db3208866dd9dd7316925", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "e3500c88-ba41-4663-b711-ec92ade04afe": {"doc_hash": "7d50dffdd1132cd018e6c5f675dc13acf6af4ea53c2c7425cdd33328be21121b", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "c7812593-0215-496e-af1c-be6aa35503fe": {"doc_hash": "e1acc9325a49d6eb6e2bd443bd4e0233d6aec766176d5f5b262ac3d0f5898a51", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "14c7607d-1b06-4d3f-aef6-ae304138d057": {"doc_hash": "f26f1f8f73664aceb63dd0cda6f66e4f34e431d878a8fa9bafaad6023d9b9e68", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "aa4ddced-2236-4a44-9666-def27c5c5966": {"doc_hash": "6e83080d26dfea39ba4cf18f73514ec186e3524bb5d80a5528776299984c30ac", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "ec6cfd84-18d4-40ec-9cba-aafd702c6053": {"doc_hash": "887bfa9182e1c72d82723f8906cd2c6e5b4c6dc8f1c5b3ba1bcd268fa0a9a7f2", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7": {"doc_hash": "dd6c72941b7e6f3319e6463c99d87593e8925e14f7f6590a4b25d38a6e67e732", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "fc9dc170-2e15-4dd6-9385-b3a7b21782c3": {"doc_hash": "b6ea92309f434336c27c8a635a092368d7f62064d85393957318c8c899a4ff21", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "41f20d92-95c4-4237-8884-051e2034775a": {"doc_hash": "3563c4ff8739d99cba7339a00a3716625a241e7bc460811fe3b35517c7baadc0", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4": {"doc_hash": "0cb5e654cb0fbbc64c8e0c18672b21f831c2dcc1903c130e8455b119fd9ad931", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "8de2a458-2ffe-4827-b952-43c42d8272a9": {"doc_hash": "a2e0f1375bd456f251b448be23e378ee2f3fa193923694de35725276883d3476", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "b49f8c2e-1991-4705-8d06-5c8b74bbb151": {"doc_hash": "e0827a8168af7fd931878805505cbb1253713ee68c4334380c1c08065bfd1d34", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "bb785eeb-7989-4c58-8aa8-67ff22696e5b": {"doc_hash": "5aa9357f195f64f93f1ab719c9e3a914818cf5ccf9bb580fcbd056c15b1329fe", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "893ef4ad-12c6-4ae9-8945-28af4836b472": {"doc_hash": "0f72aa17216aa96dd9e60539f614b1c2fe934e911cf2b22e459ba527def965b1", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "78568140-0523-47ae-b948-d5cfdee20109": {"doc_hash": "d0c3cfc44d75c21ec4028ad9c53136f6ca18e249f4ae93af94d6c596e407ac88", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "3920b587-72af-4337-b0e9-c6b19cdbbc85": {"doc_hash": "970eda905382b152feaf237b7e1bebd2a517c579e55433814c1d0bfda4d627bf", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "b55c6268-43cd-4784-8063-93d0208951e1": {"doc_hash": "5c5a5258ebc71ba4a38a061fe3d260a8088375c166db27336cd67e7338f0f954", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "4189cc94-0d19-4b0b-97a5-bbb6c4a88020": {"doc_hash": "1d9f705e9d409e91e38ea2212daa0b31dc7bb01d60752ddf42f81556f3f843eb", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd": {"doc_hash": "3b902f5417aa640150fbe91bbeea07da909332a3f95996ad384ae44ab15d3692", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "735aa3a4-bb8c-45b0-a18b-1664970d188d": {"doc_hash": "f0aaf5209b48c548acca98ea3c8bce3f3f926b2e927c234a382e61b2ee5d5b34", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "c7a5db69-170c-4c81-9dc0-dbab01869369": {"doc_hash": "2fc4234cddd318110d7d44794d84bfe92a2efd35bd5e926085fb9ab7cc383adc", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "f98e191e-cef7-4710-832b-56bd8aeedff0": {"doc_hash": "b28ed483a39dcf136c93aef1e7ae54cfc41abb9c05aac7318f406f1762afed0b", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "eea1d7ba-fd18-4e03-aaaf-a43b7de23042": {"doc_hash": "80bbe2b19b5141a48f5fa89bcf5007c07ce9b4aa950bed8b50209ba4ffb0549d", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d": {"doc_hash": "12c9ad8806f4d6d150ef2749838bb8e613acb821b936c751e99093a189da98ae", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "7a8a019f-f6a6-4e94-86d6-6603492afc02": {"doc_hash": "0a04b30f5ca2ad7b0a0df2fb3129f875545983b58d87cf0b4428cc58dde22952", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "d24dfe06-220f-4805-9f3c-fe4c07f41de4": {"doc_hash": "3389ca86912982d0ddeb8cc0b3979c352e4f4bf3c6eec8b9a0d652d7c8b0623c", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "805d523d-5610-460b-846a-3e1b4600863e": {"doc_hash": "56540ff106d76e42309bae0760dae041a5d27e2483bc722c8ba64a8ed45ce34d", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "d5a630cf-cb88-429a-ba77-9724db53b5c8": {"doc_hash": "33e9e26b6fb91ebc3c84fe9e85108e8494d2bb77efe4b106cdffe8409c969a45", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "8b502215-b55b-49bf-b7fb-090f91df898c": {"doc_hash": "984774e0bf9a110123d72a2da8f427f814c6906fa79d1a13f81bb16fd30a3b67", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "9ac49b4c-5ec2-49fd-b51a-a14d694013fa": {"doc_hash": "c3c137a027962fb77a58cd6362841b55e0fa682ddbae245de42750dd0c77a023", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "d13e2203-8060-4e42-9417-207ec5e63456": {"doc_hash": "07034d436665c30868a901eb840e2396ea66e7f419c693152a886a8636ee274b", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd": {"doc_hash": "b2131d1036b01a92a1f40b16019a4669d5f4f9f852324be36a9b60977d34981a", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "a2e8c589-1a27-46fe-8004-1d92bc8393fd": {"doc_hash": "c24fd18417b1741c57def86e0e963ec7a013ea26b154fda8d508063b28be84b5", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "4ff51072-aa7e-46c5-a889-5a8ef4c36081": {"doc_hash": "8e9bd78505857179260029c7e76f6153f3c2da9c9a8e402efd5a0486c137faff", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "0c21baf1-911a-4c0f-b435-bb5a509ee3d2": {"doc_hash": "5c0c0a5f252f363d6c7acfc4c832c340dc562f809a8e556da1be841a1107cd39", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7": {"doc_hash": "be505d857666901bc8659ce2a8bbf1fc1a12b8f56b04ab412eedc8104294c220", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff": {"doc_hash": "8650898c3fcc04831c5633f36352e112a4a8781ac74ed83d11c3699bdcc7b9c4", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "8768137b-7c74-44de-849e-ac9f5e755897": {"doc_hash": "d2b3224849b55dc7a5f72866fb6a4099678677609073c59cabfca6d4589ad3bc", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "49c8931e-3928-487a-8b36-bfe2e2bccee7": {"doc_hash": "9812bbd62035c8a0cb69fc86afd1fb870f958c17a44e83aaac153addd84538ba", "ref_doc_id": "c78de647-c986-455f-8595-0c748aca612f"}, "6557d6a2-ddb3-465b-8bfd-5a920ed901a6": {"doc_hash": "631495d7c0f6f6c94ac8611a79a8c37db873eeec3cc658683a2e1cad93803995", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "acfa11a9-218e-448f-9040-7f5e5482ed37": {"doc_hash": "9e07f456a8df94fe90af24f75508729b140ffa104f389963e2c03e82f3b4d4a6", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "7a6a4701-73b9-4dab-acba-86d9b9355e56": {"doc_hash": "0c0bdf3cd41d3e5a97bcc2bad7adf5178c15821e52a8f78ecab3b5a9ed107cd5", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "ce5e87cc-7528-431c-8e8b-d35270cd4676": {"doc_hash": "96d3dd6f922c4e82f4a15dec616ab9b728ba48af1a1d5e1a966ff36fed9b748e", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "ae525f6b-9489-47a1-937e-47aa4641c36c": {"doc_hash": "712a92f4bef9851ad0bd78ce024900b04713893ffaecca196856f10d26190f06", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "53f82d81-0026-450a-902c-979dc9f71175": {"doc_hash": "c3f6f1d19388e9f6f4aed32a9f458bb2d2ec56ee33b676016bfe2a0c84ffee0d", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "aec500a7-187f-47bb-86a2-137c9ecfda2f": {"doc_hash": "3c7c539179ba0dc6f7197fa429bb1211e03b32aefe3847efb1a2a1c4d69e651d", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a": {"doc_hash": "9940134ae4bf23e2a5e15fae65547f8042490666552b04e3750ee72f52d4c40b", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "f607d1f7-e593-4a00-9bf9-985fa858f855": {"doc_hash": "213081614ee625d5917bf2f08e17a6b6e20b1d71b16ad8a7ee1c6bf87a8c0b25", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "03663870-7552-4028-aa48-fc33b31e6cb8": {"doc_hash": "aa92154b2edbca1c801973d337e513c2a40116615a03797acdd5192d8250b9d0", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e": {"doc_hash": "7deba1b8556a553ea4dcf4d36dd3c9934fa1c003216ef07ac67baa0f4051dbc3", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc": {"doc_hash": "5f3ee26f1e824edeeee11f5f5f33e0e5df959c5812107bb6f4f74053820e2489", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "8162e1fb-a175-47a2-804d-a034271a879f": {"doc_hash": "548d636a3787a18c447ba0578e4272159e5704ff0ba950de4cede1662836a6d7", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6": {"doc_hash": "756c20eccc7b3044fed611f960d92c9526b7fb7b000e80e7537bbfa75cec5cd1", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "180411d1-42cd-418f-95e0-8cfc092adf2e": {"doc_hash": "453e74f2a99dc18e064c4644bd2ac2cda056398bc19d02f6fc0074586f5d87ba", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "3cf13663-5fda-4bd9-b922-f9151af2073a": {"doc_hash": "effe6a570fa200db53624b329e2cd91f31d860b0568548d2ec6d0794f63e638d", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d": {"doc_hash": "f9e791aee1f84c3df1789aa6909d20dd22ac60a85414f55dff3a2fabd6206c61", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a": {"doc_hash": "0a5f0d6106adc0f3c0e27f7f9d4d7b02d805ac2b550ff556623563d144868083", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "1f71fe2c-9810-40ec-8b88-8d02aa1007f3": {"doc_hash": "299865cd036400b27cc1b28ca9dc2d7972ff26f1f810633af7b2e9d0f526d03d", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "d587a589-5950-4cd4-8545-b0df9041230f": {"doc_hash": "499fd983b41feb8d2c0f1b759434e832a4f7ef44e5218785f41503ad7f1738dc", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5": {"doc_hash": "c719e94daa8547c93682ff05f1d6370ff446a80c540b75f53b12febddc11cf95", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "54dceb47-9268-4e8b-93e5-5ae9e38d59ac": {"doc_hash": "2b6d1aa65720e639b25a78337e272df19ed7dd67e8ac80d6b1626ce9d777d46b", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "4fdd9682-2700-412b-bc46-c9aed3f5842c": {"doc_hash": "b159f348d8d83a1d0be81b9f6d26fbf04d47f1da5a841ae9d1bdfa930a661593", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "867f654d-96ea-4fae-8a39-74cf5fd52a28": {"doc_hash": "f9f11ecae9a38de9c79fc6abd0a6fc20b768d4be3557e8555a0e623b787cc121", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e": {"doc_hash": "2058f537d812f041701da06a8aef96c117d6de18fbb50217c7e127a56d39e1e1", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "ba6d34f7-0365-457d-af78-435b777b19e6": {"doc_hash": "fd972868b6d73bd7711f21812cb83437aa08fda8d750e1b9c2176decec83dd1c", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "d304728e-43db-447a-a94e-2e27ea874816": {"doc_hash": "f89e959733045d7a80506d4f45d5c63069c0c266a49eb601d81a72d9f7a33f30", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "cd7684ad-15b7-4c24-a0de-9706c8177ead": {"doc_hash": "d0ab9fdc630629afc1ae475d9050c1dbd5315b7fdcf4d0384f2b79a0e1bc82f8", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da": {"doc_hash": "72621a0906cc8e432f0fc177c19b6879c1821a40c0ec3916075c6c0b204c21e6", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498": {"doc_hash": "093bcbca81e95f3ed3cf30bcaf48446a485b369c315061d3eef014e510c644aa", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "3f853292-5775-4a70-9aba-44f3d17af465": {"doc_hash": "6743d06934610b044210c8ed2952d593c73d8ef846730ef712f098283504d09e", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "19dc2bc8-760b-48a7-af4f-19e113730b1e": {"doc_hash": "181f5870c55f095ae4880d88f15a2fd68baecdce0fbc8f2a884354673cb19cf8", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "eb52d000-b170-42d9-9edc-af7de86abe3e": {"doc_hash": "64ccf42e97ab789a68ae1094ede41d7f070789a7753c2cd32b1dd5ae0d1d2028", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4": {"doc_hash": "3dbe62a2c4dcaff8a61782bdfcf58f45578f0df1062ac35b8a858c4c88e22475", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "bb928bbb-979c-48cc-b177-adfd6a621033": {"doc_hash": "9263ad09db62e5f9d8485f4ff6d8fc8267377f5bc753471bede07e5a61fb2e81", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "06216ec8-3d42-4088-aae9-58becd7d0b87": {"doc_hash": "d3a683f6ce0a14c4defde1096a0a7440ff7cccb1ba9e176e97c6f25a176678de", "ref_doc_id": "05614b9b-e43a-44c9-b1e9-2b817c3bbf13"}, "0b30a0b8-1f45-4142-88a4-7d5c8e793dad": {"doc_hash": "2a2825b407d48547f577dbc5817762ad8e59c075de90aed2f4250ee82a92c32d", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "00187220-6b4b-4bbd-a207-36a2b6ae9e4f": {"doc_hash": "85107f276001aa2700c5a606b14cf351d277deaf2af4d6299e32c12b709144b1", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "ecb85199-923a-46b2-8454-3a0183f2ebcc": {"doc_hash": "711e724ccca9e4b06e15b8ef34e22ffd84cbfaadf2c11e6af9994dbdda308c41", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "013f3d52-788f-4db7-8a58-5cb4c79627d7": {"doc_hash": "6dc986e069e2b36641c624d6aa1966193712dce70faad3caa3d11bbe5ff18fba", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78": {"doc_hash": "9f237d622a3f0949600254d2d364b4f3a6f1f8bf78dc3fd526821ef786a49339", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "1bb37191-9466-4086-b303-35f40d07a134": {"doc_hash": "bdb3b9596679092179c68e00ab040612e2927a0f8d67ea716d3bdbfaadfb1ebd", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "ddd43648-22c4-4223-809b-6a5e75b7ebea": {"doc_hash": "5808b01f5d1edde253487f719471c1a7a34bf3e48d311b6f9775b5b9dcc3e30b", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "de24a9c2-1a1b-47eb-bc3b-e441ba664266": {"doc_hash": "d62053fe82ab4ea326e1580f39b0c7a67cf05bc571b2d5ba94667db15e8f00bb", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0": {"doc_hash": "a51e5c608647d44ab5ff3137e8d04c20cf83b6f82a32d2e5256de02718e78a6b", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "670da30f-615e-4349-8263-74a962f55725": {"doc_hash": "2ece3d1418734de7e7a37d4cbddc85168e2ec1cd6fb7b9cead166d08a382d1c9", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "e3cd3f1b-d322-4330-9dce-02c1f280bb8a": {"doc_hash": "07d2158e3eecd2f0f7ef49a23ed472a8b94b97a5cbef8991dc12e4e85a052109", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "4a04ad2e-6b4e-4344-a903-c651bcbbba81": {"doc_hash": "f114156b4f822a8ece4512b016ee40be31bdb3a6c53008b64737afa40a606e5b", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "6326f677-992f-4a9b-89cb-0df309641953": {"doc_hash": "b0baa35b042783e9b8c8cb70b8d385b546d71daba35409838b6566f00999855d", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc": {"doc_hash": "f6a82238f18b33bcd3f7ffaf415cf4401170e0e6185e3d7006e3378a11ef4a22", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "8dec538d-5508-4148-9694-b56758364351": {"doc_hash": "bda0ff4db00b69fccd407295880402fbc0d2d5553320aeacc7616376401619cc", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "1dc6303a-6146-4b37-93cc-e9a8c592bb57": {"doc_hash": "aca3c6ab76be642d42aedf2d96e16a0dc5c259b04c1316e830a69e9c4979f4e7", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "de20c1be-6d94-4069-8fac-f2de39a947e6": {"doc_hash": "1efb3a7242e2c9002c5903af3fe95a136a3128c8f6deb9e5c100a66c865c39b7", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "0ee71592-3c87-4c08-8899-847dacb15032": {"doc_hash": "0fd8903548cf8130f1eebef560e710e2fb0250cd756ea50702945a9c34c8c75c", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "4d95e277-7f93-42f3-9cc9-b411f2f35a5d": {"doc_hash": "97b797598d800e2584ed30a197581e003bc6b72d36118e5ff71508b4bbd48132", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f": {"doc_hash": "4c220a5e8161a7e72f4a945e907c225ae8713cb03a47f3151197a285c35de348", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "d9379013-aa88-424e-be1c-31d0014fa29d": {"doc_hash": "5f5c2eceb4f888abb766924007aadb4536d938749a43f1d4a408b2d0af33d523", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "5321b106-9e7a-4537-b98f-d9df20720557": {"doc_hash": "8a02f48b2655f6dee6e4f75b51b88e2eb92fd2726941e57570070b29a462f527", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "8b3be6e8-9093-4896-a3ee-03cc63be4403": {"doc_hash": "14c957e3f2d7aa487116b222145d1d2f16ef1e57eac9fc0957fcb664a808ed28", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "c21de45a-83ff-4844-9c6c-85c539dfb286": {"doc_hash": "7075556b75995525e196a44399ae41bab7a5ea82e4b90014942aab36fcaf139e", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "23be6511-18fa-4536-a306-19248c397685": {"doc_hash": "014852135b705bd91f6b34de339d8f3cbadf470a402857f3cc11d9e356c536f2", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "c80d6055-38c9-4606-b418-f7488b93ff82": {"doc_hash": "050a5d260171b5a504796970f391a492f04a16e12224e8c03bf40d8fcec9329c", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "38428494-7237-4416-b082-8d34991f3fbe": {"doc_hash": "3d866431d497204d700306cc1b098bbff1e3ddeecbb0f3c293891b539fa06b01", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "6b9c3042-2323-460b-98a9-3e27c113cf66": {"doc_hash": "2156f9b994486cd6ed4efb3499d2ad9c17fd8a9f5e6888cd0a2aab3dc69d10ef", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "e93f35af-5b9b-4abe-94c5-1771de56ae29": {"doc_hash": "20852703ee39776500117bb75f7b7dbd696999e882d32349dcaa72a18198c006", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "f0d06606-5b74-4f0f-96cf-5158976b194f": {"doc_hash": "fbac527aa61543a5d2708732a5a58a3fdd78ced5e51a63ee3686854029cec638", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "4ac34a0f-521c-48dd-b756-cf5a8c817f62": {"doc_hash": "920e4b382f199a16e90e881f01622060c3121e3bbe4540206f0c05f116698dec", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914": {"doc_hash": "d37d49ba307e9760546dbfc7a6087c5ffe64367bf54be2175fa2dc76ad30f03b", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "fbd8594d-dc01-45fd-817d-33ddd9d51015": {"doc_hash": "c42d6bfe097300814e141544a629a75cf63983cc3c546c2f08509a8e0281ab59", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "a170972d-290e-4e2e-b708-3d5e7bbc5fa1": {"doc_hash": "2135d0018de282e1b517e52a2d75fbab62a1fc64609bdc449377f97193fb0df0", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "7768996d-3f10-481e-8a96-68c62cb0201e": {"doc_hash": "cb43ef1ae5c11f6cdd2f6d11f0e8d7add6bb0739480d68108f7130a328a22e8b", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "378ff0fc-f136-44c1-8279-416fd23d19fa": {"doc_hash": "aaea1de10f2a02a4b7397ea26000b2d1599ce0da485c510dd3336f882c2b685c", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "02db101c-3494-4367-a6a9-a6dd757dc7da": {"doc_hash": "4336071fa922dd99e1cd18ce050da78b891c5a5d825a5216c120aacc1aff11f7", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "097b89d2-254a-4467-8d11-f709c25a8bd2": {"doc_hash": "8194586f55cdda143b244e554db16a72b46d2934edb883a80dc23a8f34121f4f", "ref_doc_id": "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d"}, "8d60dc63-4a6d-49a4-b43c-3e066fef7faa": {"doc_hash": "f8f58f0f3ed444191aca8856f11451f6ddba24a5c47a8ce851b963c56ea8d5fa", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "4720a1c3-f90b-46c4-8590-8733ffb3ffc5": {"doc_hash": "4a5cdf64c4c89d43ae036dec44dc5624c06eddea1eb98ccfc41429acbe337833", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "c498f57b-7c7a-4e53-8850-dc658f754d28": {"doc_hash": "3577466646a852b0710470c5a7a19267fa9b7cb8b7bb9bfe0e306fc01977adb3", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2": {"doc_hash": "78cadaf134b00207ae34629b3b7792381f8e0839e60348c1afddc709218148f1", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c": {"doc_hash": "d923a1ada63e8f6963e2adf356f8e6452be48b9b9ef50a425f7195989bee97bd", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c": {"doc_hash": "a48c46be82149c879b13ecfb9bbc910cf883657731803eb7ff44e9ff55707842", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "ee5281c3-9eb4-48ca-9594-041632a4b47f": {"doc_hash": "35f648daf278bd3e7cb33140c5368d8acd7468626d8e9e700c0b3d7b5754d9b5", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "b3b44192-5a04-4657-b48d-f6b8833459b1": {"doc_hash": "4e2a81e228d1944afa5efbd65b2cbd28fd611576146bd007e80710e43ab0d8f5", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "194f93d8-01b2-495d-adad-bf4f2d2ef981": {"doc_hash": "cec8ef5c26d0e83e5f46ba79be5e1b21cca047e745a4d652c315b0fc11df241e", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "9987cd7d-a3b6-4c63-951b-ede64324f0cd": {"doc_hash": "a7d6b2c0995a3108c3fa387677c30d759749dc9d79551079101f7d43bcc297f9", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "01176827-1cf1-4ea0-b744-160cf4f8fbd7": {"doc_hash": "de612195e9a145bd927500ee9c719e207bff230e01039b59a575e289dacf01f0", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "f5382931-c227-466b-b867-ead7df595e6b": {"doc_hash": "62343373aa6443cbf1a4604eb351dc1327bb6114918703495d341c786af6992f", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92": {"doc_hash": "9924224be9b05f08d849f28c11c5c0f85cc3f90f5601a91b1a793839857055d2", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "87965e7b-1d6b-4390-bad6-c6744162caca": {"doc_hash": "66d067e85a1605964ce904fe0583a121dbdda6a32ae6e0b6a380bb004a68ff29", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "e0aec661-4749-4fc1-aab3-b3cb15012c43": {"doc_hash": "dc7d7a1c1554965ef4376e425182c4f0b5ead1dd5c4859831ffd56b0ef6d3f1a", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "af3a1d2a-6cee-4b35-ba50-0aa376cda714": {"doc_hash": "4cc858666a9cac8b25f1cbd837b33d388dbe071c89c8be10b7bd256e672c725f", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9": {"doc_hash": "85cd92aebca94b4c7f0ba50707874770a65dcb3f04228df2c0aae9c9eef5454a", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "82fe1a87-bb34-46c5-8c3e-86cfc61bd761": {"doc_hash": "cc0eb5a35d29a6ff4dc7fd9ad6d5d6def97bb68929cfaa7f3c0a4197451908dc", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c": {"doc_hash": "25cc5aee939c0fc101db32c30313956c58d15ed855e77c443555b60d54f08b52", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "fecd1dba-ed62-401f-8854-e96c3c9e2dc1": {"doc_hash": "ab2f44d59497ee8acdb9433161491088e3d7ac6b29d1cf65883ed149b218daeb", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "061a6334-e238-4af2-9fb7-6d53b57c73aa": {"doc_hash": "b2065734cd92c8642a83503fb7d7f02219fe044c35a9ef81f2f924b136e26363", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "99f6fc32-d987-4d4a-8a77-fae5782675ef": {"doc_hash": "845e363cc4358fb5d95c3c9d366c7d5b4bac5d0654b722278d2602860d5d19f1", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04": {"doc_hash": "948d59696847acfad46f6b5b1664c48c484a91f7f6dc614e5f19da86a21dbf71", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "39d8107d-6c38-4c38-add3-91c9e5ab800b": {"doc_hash": "dec953aa0255e84a98703e42125b8d6b957b0e15daa883a68e6da38f05239637", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "d1628488-82b4-44c9-8597-d16bea481830": {"doc_hash": "eb5e4e73ec77fb299f6ad5ff10c493ad914e023bd21d417605d3ac026f358a55", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "17f7f671-06f4-4f93-b9c7-989664120d25": {"doc_hash": "6eff0ee20095590f5d8ab471e600dbfd0f2af5834203f391be13a56062e6a8c8", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "0db902a6-535e-496b-826e-6af87431790a": {"doc_hash": "ef45afa67fc4e547bf9f64db9653fdac7c12fc678b80eaf5bdd0dce51706006c", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02": {"doc_hash": "db15a833fb5da924111cc27118c20ed5e0d6c38162253602beee3262a54314db", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "f58689a6-80d7-48c4-944c-d48f20aac462": {"doc_hash": "0c31a16220c2c2ad1c9c4e3195ee43d2395db627d76384f26d14f79e1abef98d", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "6cdf1534-3e52-400d-877d-bb527ee3d159": {"doc_hash": "07c2186d2a7e06dbf2402d78547f1f96e241785099777375a3762454d13823ed", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "ee969de7-ec8a-484b-9a11-7060aa6c0292": {"doc_hash": "7806c087e6af17930b5af74bf15313211533c62987f617f902c2432f8207b6ed", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792": {"doc_hash": "47c19ea4881ea7954c84d6988631d0818c5c0f069f6481eb492cd879ce178227", "ref_doc_id": "d4e1bcef-9f5f-410f-8a0b-5de669c9120e"}, "6ee2208d-153c-42bd-892d-234238c13ab1": {"doc_hash": "aaedb03790e57ecd9a6798066ee856ea9851dfa4d181c91df433e5544fc49be8", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "cad15c15-622a-4302-9b0a-01a670ccd14a": {"doc_hash": "76d30ecdfd31010ad76c309ddbddff590ae1184955e8dd1655c64fdea2a3525e", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "0f232ed6-0730-4036-8f65-6e990d707d97": {"doc_hash": "3e11b5c0678aa4e2743e25509c901215512bcc72c66989481e588d06665b5a2c", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "9a1596c3-a0c3-4734-9b76-d21131e6c961": {"doc_hash": "55658d183ded3ac813853c10d40df2074e53def13de7653ea33b7d5ec8faafdf", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "b34a24fc-a79f-4dee-be09-05943ab0baf7": {"doc_hash": "343def5ae4178f20e1fb88495403495647b1bbfa6eb9cdddc360cf4b4a360f09", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "bc5ea76b-21a9-441e-9fad-05bddd071f75": {"doc_hash": "39d32b638244fca0ef2d622c94c3e28a290a301832af9d42ee71cffffb35e54e", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "39ed20f8-3299-40f2-8370-762a1a76b9e4": {"doc_hash": "ccf1f4429b8020c3eebb5c2bb13e2a7c5aeb7e8cb88ae49e676cc221bb34dd88", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f": {"doc_hash": "5aed1792916e2ddcb538d7b1c6f068e2aa32a9a6ce9aaddc3c41af3390cce45c", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "0c430302-8593-435b-91b7-83e7b2d3d7be": {"doc_hash": "ebdd775847e798ca3d461e73d132d14b48e8e45782ec5785960cfb4895418418", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "2304db73-6f1b-4ae1-a445-0a30238be03e": {"doc_hash": "8606068a7129296ebd9802d0290b8d6696521c0c6743248499752c31e5523253", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2": {"doc_hash": "e9f9c03585718d196d5559dfbe00923b6e9d091a72a2a4dfabe0704f68d153a0", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "20fa3057-64c1-4910-9512-af5ad40f28c6": {"doc_hash": "d5274eead5a734bf4da3d7cdd819953e26ed20449176f61f856cf5686331842f", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5": {"doc_hash": "3264a84940dbd3b5b33885844115d05e06acf6d34d64d2bd2cfb1aa608001f62", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "34d4b1fb-e669-4290-ab61-7b5046e9462c": {"doc_hash": "16e27311677f69046094d1d99fc8986e82ac15d099f81b02303a371685cb425c", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "3fdd2f26-331e-4eb9-b594-fa3f981abce9": {"doc_hash": "5b1847a48581771605e6c96817f205425c6a294e57a9b646f47d5f5641d7876d", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "dcc8d471-df49-4985-a6d9-c1537c6ea65a": {"doc_hash": "b001498b837be5fd94f4e5bf03095559a155f626625027cabd0e35cc84fb4b30", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "04b0e18e-aaae-4c83-b55b-9fc8cfead31c": {"doc_hash": "cf63c9b22f910f67e29397731c78a861f3c04ede10a90261c6062b33f39a47c2", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "e2a8c698-a621-45f8-8c7e-f512a0e03202": {"doc_hash": "b8484f0479ae8997bc75075db049584a719c8d4801c96a0e6ab865e347c41fde", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "c8a54d23-17a5-4218-afb0-6a31c3a2636a": {"doc_hash": "05c2723be8d196b8b17fa92da7890346222322af2d84c3be9c9a6b6911fd06f0", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "33a871a1-a050-4897-8216-3b704d6bb7b1": {"doc_hash": "020a7ec825c051048c426c54a791c07ee86640be98a5e4a38c13a1c988cd53dd", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "7c1eb472-da89-4e66-a145-eff9291b439e": {"doc_hash": "cd6ef144c52564f4f2c9934ade7fe011399966037854df09ef2cc899d70b56d3", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "13f4c351-5da6-451a-928b-9d682cd39ecb": {"doc_hash": "bd32f49113fafbd2f560875f8a3be38bcac1ecb77848f7bb166de5bff7d8c223", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "c4c29888-11a2-4755-980c-26d63e3df728": {"doc_hash": "18847283c4643a483607828822622de7767228803356732988258e2835eb7935", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "44e4d620-bc30-4463-9940-9ca829e25d22": {"doc_hash": "a382d02fdacd065b7a62b9542dc32070f15b67cdc9848508124977ff244a00ac", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "4e451d82-39fa-4e5b-97bf-cf95cd2d304b": {"doc_hash": "a7733affeacd23c29b375863e2d79872643ad6460d4decada6c808cc6c60e459", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "cb9aa194-0e36-477c-ba6e-4352af432cac": {"doc_hash": "119e596a8b7bf4c7613f980643bc005e0d9415e687208e1a49e7fca988b02ac1", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "77c7849f-cecc-4cf0-8278-9f4e23a1e836": {"doc_hash": "66336bafc750e7e988118e0fa09c07db8519251065b5d62e836bada402bb5330", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "0ed862f2-e305-4514-b150-eacddd8f37e6": {"doc_hash": "32b51177f9311d932dc5610eb9631531c284bcc52e8778c0adc67a8c680cb9e4", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "3ab939a0-ca9b-48b0-8371-fbe217cf78e7": {"doc_hash": "cfe4e70f6bc496a0845b3a334c6f210b1921c67b666ce1c5eb15eb84db3797a3", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "9a996eb2-828a-4038-b295-36ef7d25d28d": {"doc_hash": "312e98545a3c2dc894e5b91133ae93c09733e783280527bc8735b7610182ee37", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7": {"doc_hash": "346efa63769323fda744237d6fccd419753f8e9232e97a0fd9f934c0fa887377", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "dc4e2155-76b5-4b21-8e89-bccb99fe7f33": {"doc_hash": "9cf10d6f3192359f36646f6607cc856820205fa20bb9e2b49dda9a9cafb13578", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "bb12c4de-2d27-4fe3-867e-3d0092468ec2": {"doc_hash": "351ba519b5426293a6525d4e90205e1fa7ae797c473c8d8d6a537853d3e468c7", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "9f7e71f7-90b7-4c11-87d7-f11665f20bde": {"doc_hash": "218c159027e50c487c8d82eb73d9531812e1001bfece739535de834414d6bf3b", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "a23ec9b4-6cc3-4486-809b-3023d3f35f58": {"doc_hash": "6d7310d53cf315ab0adb09911293547df59b896ae60222c3e608cd41344d7e57", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "592c998f-e77d-4132-8a3b-27125a022461": {"doc_hash": "495d18d2d83dcef15d2a5a3bb4a488af659eccdbca70e715ed6157e234288cec", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "710a083f-db69-4edd-b1d9-c6b881cbf87a": {"doc_hash": "c8f57ac0c2029f48fd1b92e750447abfae074b068188dbd9f4a1c300f0aa37a3", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "a4ec4598-5f60-42aa-948c-16d641e9cdd4": {"doc_hash": "b3f16f9b1210065b764302bdb08b7ea49979ea9502155ba9ccdad407eaea8b0d", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "f05a2d0d-5051-4673-9e69-6449a3cb6dec": {"doc_hash": "c089bcabc12041a5d7c729f416672b795bfc6464ec8e04078b3832a74864d8c5", "ref_doc_id": "6dee7745-f40f-4dc4-89ca-df57faec75fb"}, "71ffb338-7915-414e-84fe-12488c37b2b5": {"doc_hash": "3d8dbc745c4ea3a33195ef849a2fe1b7517152d67ae02e11e2e35a6b7772e80e", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "09def0ed-2db7-4b6b-9a6f-cc9668893fb2": {"doc_hash": "e2a72dc87abbbee13e8d154820cf5a534bbb55865bd0838177f9afc45a226b24", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "1d919132-2602-4527-9188-dd1a5b00a6f4": {"doc_hash": "fcb8f610bf72153a7a8f00ecefc926c23c54faec01162c3b93ddad93d4cc5f6b", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "89d40f4d-d427-4e1b-8306-58ee14da5406": {"doc_hash": "84f46000ee5a34004a0f49681b39de64fb67f0e7482b98003a9de084514fa5a6", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da": {"doc_hash": "3143d2721656644cc99a4deb0b0e23a1db99e337a9495a9c2527cc78e3c754fe", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "56241dea-09ca-4c9f-8917-2aecadd94f6a": {"doc_hash": "f88e2bd9402672731822d84c2de292e620adf1e61ac33a328d59de13f4cde00a", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "082bb6aa-7848-4b0a-8296-570f858c5de0": {"doc_hash": "f18cb855e020d5837b9b2c3f59c780990168d021dd6e3df26a4bb4cfce097e20", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "260bcc70-7931-4aa7-97f9-6699684dc93b": {"doc_hash": "893945b27a9c417c63ef979999723cade64b3ce87f00ffa3aa820d6e810acfc1", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd": {"doc_hash": "87590966287e488d58e087a6053b04d9df0ee2707c83974fc8acdf65ebb16258", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "36fecd90-07b1-49a3-b026-43cfb0ba42a3": {"doc_hash": "14b25081e3e9bb1a87708f46972c9c8513495c0e9b2e6963cd7f29e74f623d01", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "821bae44-5d55-4c3b-8245-8a57b1e84c5d": {"doc_hash": "a1e1f1bcc94e0b56b2d9d565a39d3dddb42738e5b8b2c7574f9df94e7b4b772d", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "99582cdb-a43a-46f8-a214-412212603db7": {"doc_hash": "1fa98c32906db6536294e9312da05283dcd69fdfeceb129f9886c9ef2bd641aa", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "87fba192-f67d-416c-9d58-63d5add1a175": {"doc_hash": "434f6425e448d7d2278cb871af1f710ba7aae5f439ab97f402fc786498d7d63e", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "1ef929eb-5041-46ec-849a-3eb4c6d96dda": {"doc_hash": "5ff93ca912481a9cf4d37119f899e6d4a1ea7a163e1e7fe19e4850547cb7f3cb", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "d2da3809-de08-4af6-9d3d-22e6ba114c13": {"doc_hash": "d7781a10b73295054949ea649476b5d7267df1f366e8f906ec691bfeec9d68d4", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "d4009632-bd71-489f-86c9-734f4427fbb4": {"doc_hash": "d52674da1ae08684705067be9050958e2c8fae853bd23f37f10ff61d84e0ccc8", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34": {"doc_hash": "57940d3e33cb9b3f8f2109e5cd091175a9067e4c51e0dcd8fe5845193accaced", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "ec85a842-8d34-4d64-97bd-2f650a263bb7": {"doc_hash": "9c3498afac39a070909c1297e3193f148d03e8abfd918141ee16fe64a05d0f4c", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "3a90615c-04a0-4088-9255-4a6a3414501a": {"doc_hash": "aeeb822d81c3a4e622fee4c2991a0e0cb4c610c34dc0cabc1415e08cb6599362", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "3116390c-c8be-4e07-a0e9-8a8ae61a61e8": {"doc_hash": "acac5e8dda730d660016f4ddc8204294ae8207beb9408ba40d87e66c52c415ab", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "dfc67f94-0c72-48b3-bea7-43b7f10a200b": {"doc_hash": "aea861d194ce02b11138023350b4eba00a9429d63eb94809df7418c95fe6480a", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "ac408b44-50d7-4e8a-bc55-e95515e098cf": {"doc_hash": "901ccab1e4328823618988d938768114b619566541614f738ef1cff5f1f5088e", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "c6b3ee3d-a061-405a-a19b-613aacb52aac": {"doc_hash": "08d9039d69f04e16442bc1eb0721ecc77fade4cfe5ca3c82b0f4f80ee7f3804f", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "9768c3a2-ee93-417c-a495-b1e36cde7ee2": {"doc_hash": "fafc1a9e007d98ab4d65bfa241025cd0fd817de6a8fe0874ac930a952b7ce614", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "ccc96798-25b8-447c-9128-d1f5b97d7963": {"doc_hash": "f6941ae8c5f704c6c750c7f82b41ea97f934f907dcc89bc61509a8c6efeaf88e", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43": {"doc_hash": "368ac59f3999edf1863a3462002365d31f8615691a397423e557ce3066707545", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "3803a396-b90e-4dce-8f94-e547a5bad305": {"doc_hash": "830eb91603c76936f8211a9547e37c2bbcec1d0132f72c9584195b547363504f", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "522f3861-bae8-45a5-841b-b383e6853c93": {"doc_hash": "00a912fd16e4ff3989e5c2d203ca4e9385cd18bebcece0906c3d3f2f847b1f44", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "b249688b-b66d-491a-bada-657ad045854f": {"doc_hash": "cc6e6bd9a80b073dfa14f3f9748f7b14810b7cdadb50dd80b20fe59c10beef40", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "9db553ca-b3e8-4590-b032-ed255af069d8": {"doc_hash": "aeda2ea006753b7bee0f1d692c0379a43e99e64b4285fc3dd5b85f05835dbb82", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "e9ffaabc-f76f-4305-9835-265784ffd81c": {"doc_hash": "0eadcb019d21ca31471d84be29b2dbc7f0598a11d310c02dfe4e5e5abc034301", "ref_doc_id": "ada4be07-6c24-4efb-8355-bfefc662a651"}, "d20b88d7-6a43-492c-afb1-1f55b385464c": {"doc_hash": "487c7014dc2c82e3d470dd3c92771a035bb470ac29466a22d635f48f7bee0ec6", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "e4eccf39-0e3d-45ba-ab46-1f5a2932095d": {"doc_hash": "c82fdc9b1a7f7856eb2afc3539ea167e3db5cbfc88b00a2502e9aa1ae2e32f7c", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "7238e30c-d801-4a51-950b-8cd1f5069269": {"doc_hash": "895495b303dcba63964b6ac59643fb85c65b5c1d8cb96c59889a94e996cfc8c6", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "0c26ece1-4362-4ea5-8c59-55af8fa69f32": {"doc_hash": "24cd016bc2da92742fdf752d4839d0f6aecbf24f3657b310a7786af77fc67c12", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "2e80f016-3356-4673-929c-1c7db63dc53c": {"doc_hash": "bf9a4990af43a1881f2dc61cd71a8835b0d3bea08ec37e6aac6823afd0bc3702", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "6433becf-e21b-48c0-881c-42c85f6c7bd6": {"doc_hash": "7c740680fd22ac2b04cc9e7ed697de33c2df6b08d578868b3e34fa8e621b5efd", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "4132745e-0d7d-41da-ab02-797089e42493": {"doc_hash": "7dc77a3fba8e9e02beb65681340c39ebf65853842a415c0a08b18af388eda6ea", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "6541afc9-4de5-4dee-aa0f-082e9bcec2ef": {"doc_hash": "5b4e016aab5d64337381e627d2e98e26d423ee404b33280b4f56f3dbe12d64a9", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "e65893e5-26eb-47e3-b728-991752550a27": {"doc_hash": "8fdb948c2a3cd775d230639efb699f5a1ad67ad95bae6f262b337230a74aa2bc", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "132b1ccb-4913-4579-b5c5-b4dbdb4fd292": {"doc_hash": "b5c9aa32c6aa0b7a40ca5d77df321d2b79761c6fe6c384a3de7d370b60e0dd85", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "1c3df0bf-762d-4977-b57e-50a650616fdd": {"doc_hash": "8a93b10dd15eb0614fd7919fc091d6785116d3c0198d95b88ceb7af103790d15", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "72af4a75-9e99-4970-b5bb-57d0b56a0916": {"doc_hash": "8e31ca66802030c1069b318f285487c03078d2f62e81cfe29320887347e19381", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "d508d23b-6647-4b3b-b119-410b12970819": {"doc_hash": "6d09db11defe30f0affbf3ae66012f500e86b371dea268dc171c0fb8761c3b59", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "2963d30f-bb87-454c-be90-78e3e5ca52a7": {"doc_hash": "a0db10d57b114376058e544dfc0a8ac2aa05225d887c1b781401c568dea3a9ff", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "49782242-abe7-4b8e-9263-dc393eaaac52": {"doc_hash": "faa08bcd186c677ca45d2d3e81e99bcd83396e05be2e60fc6fd9dd7c3642a012", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "7ba058f5-3d40-4a8b-837d-9388c33f1959": {"doc_hash": "3b366f69673340445f91bd4be200f9c38612c55ad076e7ad805a7d163679748e", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "956ab472-b0d8-45c1-ba2d-320601397715": {"doc_hash": "23c1127519f25c6f9b83051a65be5fe8ead2236df1c4d8c458b1dde6bf9690cb", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "4ea26de7-c6a1-4a2a-871e-5daa07bea223": {"doc_hash": "4741bcedc41421bb291429d880e7c12d0bb38e5e8165ccd189888fe1fb53a55a", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "b0faf230-6995-4b96-a3a4-a565a47a010d": {"doc_hash": "117a2eaece6771220a7366f95b3b2ad61a6eabbc87d31f8376429daea62e6df3", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "c83fd002-c650-49bc-8a4c-5dfbbea4c561": {"doc_hash": "8606b72965b88e9ec6b0e0b347f47cf1df6f9777e55c0e7ddd655698340c311d", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "d0f8080c-19e2-44ab-9834-6cc21655ce49": {"doc_hash": "3cb326969b211293fa340528600bdb00cdf504f8921264729e46bcb89d069ad7", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "73d0475a-4aff-4991-8de9-ab610f971357": {"doc_hash": "3769fcd1834291b3142f608ef57d49785ba88bc77eb5398b88b8efd707e4cad3", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "bd9e123d-f892-482f-80bd-6ccc29a90954": {"doc_hash": "59afdcd0279f2e39fa99ebfef2c43aa0a7f5fa820756a73d1e8028d90a660679", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "568f543d-3fd2-453b-84f5-d15e91f8bbed": {"doc_hash": "b523b92b1144b750c74d801a786c143fe9958db95d9c5b8c3bca9ee836e32a3e", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "e156613b-2d55-4a51-8ac7-c75a226d2f8d": {"doc_hash": "ed93d7f2d3b4daaf3202249055106b7bd2274aedc53b835aab49a6d4579e4bd7", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "8b617f6f-e03d-495a-9a01-0bb58f5581ec": {"doc_hash": "41af5b36ace0cf40dc7f3659e09bbb43713f85cb4a089e5670d57c08b599652f", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "a74a0db4-0f52-4996-98bb-8b40b9c37012": {"doc_hash": "1208f34a43455fa867f2c4c0dc82f31674dbfa08cef08024f802e707ca6a8eb7", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea": {"doc_hash": "62a092eb6df782362dd7f8e5d2eca14ada029faff9afbd01410890bba80e6a44", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "8079d03f-bf5d-49c7-8523-db42a7131cd8": {"doc_hash": "efab23c73eaaae2f2d04160196ce075664a40a94b04f52f6456f27556f86a2bd", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "b92b13e6-56ba-4f56-b9f8-07073126902c": {"doc_hash": "3bda675bdac14c9a04b64c7e0dcaba65074479eab4b2d3ce43b1a05f9f774f8b", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "bcb96b36-0d52-42c7-9490-65720ec75b22": {"doc_hash": "172fa5fc19b19481adfcd73e2b1b0af4fe80d7082bbd1d8676ec9c332ef52500", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "4befb49f-11f7-4265-a4c9-6c03914844bb": {"doc_hash": "d88bf5185bddb4d06f086b6b4d28659f119ac42cac82000a989ed934a9d48d93", "ref_doc_id": "48a211a7-0710-436c-83be-eb1304ce9c4b"}, "bec5ed44-d3ab-4869-9a13-c1a08d87e4ea": {"doc_hash": "c5dbd680e5a0590059b3c013451d0f467afab9c861216ebcaa0e9331f624236e", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "a3ea3a56-e6c4-49b8-ba54-35162edc599a": {"doc_hash": "7c22d922bf27ff8f39796b960c4d3b0bd3e706ecc649d3781461de8b05d9363d", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "9d786f56-9d30-485f-a7e3-19dc9a9e904c": {"doc_hash": "b252853cc9c0d8c57dc6f98a6e898f890215a57785fbfa4b1146d1681be52845", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "b22c3f1d-0812-4039-92b9-98b4dedf118d": {"doc_hash": "9ec400d8bc14d3316aa94fabd707cb266861472a38e96e16dfdc6b0eaa4c72b4", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244": {"doc_hash": "f3d88477b7bdf4a63830c96b5850938299e6f0dc776a01c303587816b9a9d15e", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "c36240ea-2c42-4629-a941-cddad47b8303": {"doc_hash": "cb1daa61aee2e48cc5333b5204262e73d4d1bc2c6230fc9ccff1df4160fb7378", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "71affd72-18dd-4f97-b680-fd1044274ecb": {"doc_hash": "59f2bf8703a6b91af651b99e10e2e686db7fb39079e30189ad387134cfcc3b89", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "1b78f5fb-608d-45b3-a946-316d7512b429": {"doc_hash": "dfae7096b900418113b580ae4fddadfaeb0665be8668a4b4f64ad0721707fab5", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "7c30c8d8-5211-43e1-aaaa-06f7ac871661": {"doc_hash": "4a0052ab526f12e2f3e691dabd9434036955ec2c69801565acc28ca4c9cb21cc", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98": {"doc_hash": "f63b6f2d3f5ee52d317b5bd13024be6a78b78fdc6a62004a4119fdefe2029de8", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "bbd31015-552a-42d3-a7ef-2f3dc28ca331": {"doc_hash": "ec61f0638c2ff092882cf7694a88d764940f3323616fcdb65ed8fbf3906447b7", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "f1ee0c78-8a68-4895-9960-d0ee6ded0c70": {"doc_hash": "087ce08632070e20c151387f25078b84436cf4fd7a6c37cc0b52166123e38893", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "055d14dd-dafb-45cd-bfb4-23ddf2259224": {"doc_hash": "dbbbdb9e7881768bca3ce320c69392d1a180ab5270bf47fc383db6d9ad4c6a5a", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "c8494f39-e18a-4a9a-bb3c-a8bd33c83995": {"doc_hash": "29e8a825e38093e3ed73fa4fe089d50e564ecc7a52798651fb17f7f649ba59a6", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "86d80b57-c411-4fdd-a10c-cd68782c292d": {"doc_hash": "dec8c0b405ecfbc2ec78cde53b683a3fd8530da6274e6e128f34ba4dd8996680", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "4564ddf4-3c2f-42be-8b41-8e031bd5b42a": {"doc_hash": "f795ed8363c1cd0edc2326fd664b10e32ec4fd9a14410c60e472a1fe031e2576", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "7d5fe44f-a10e-4ac0-b99f-6da0117192d5": {"doc_hash": "167caa6a50390c4b5f753b7a271a3263c417821a5e3f32da0ed2ebc65e42fab0", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "a5ee1771-500a-44f5-9edf-45ac8d62bc95": {"doc_hash": "db45dfdbe054b2eb8697d09e3a3729e50ae9b0d5c424ee63e0cb69eb3855a845", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "fb78f962-d2d8-4106-bde4-d937639f1fc0": {"doc_hash": "ae39f8e2b05fd1237a8052baaf2b9acf5f6fd246cf761ef08e5dca1c462ea977", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "11a64742-5ebd-4492-a0b7-d0d1b79891fa": {"doc_hash": "502855b956a647570f3b74ed6e3dfbe5fc46089d86dfa891caad84aaa46a6dbc", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "f43a280d-f417-456b-b73c-76c1c787630b": {"doc_hash": "dc21218e96c584a3f76930d21a38b577526b82ae1b50f5d0d8f4af87c1c65f55", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}, "054ac121-b1f5-4972-9cab-72ee9f90fea2": {"doc_hash": "b74748ecb056e10d4ec5aa816df47f261074aa73eb2ecbad84c18743711bcddc", "ref_doc_id": "8f7fb6c0-b826-4daf-a22e-a0cb87854a22"}}, "docstore/ref_doc_info": {"5a12502e-cc47-4649-8477-68f012a15051": {"node_ids": ["9a5bfc13-a550-4f45-94fe-773f02876989", "b1c42720-5ab7-423d-a8af-06ebf80c6e56", "ef3b19a9-af26-4e0e-81e2-f7913d636b31", "9d2e4d8c-fd83-4481-bc99-e7b505394daf", "6d154e04-6ee5-4bc0-9ec0-16957e9bd7e9", "38a67711-a796-45bb-bad7-2e0fe0bf214b", "a677db83-a6bd-403d-8149-a5a453bc09c9", "3f6380c1-31cf-4593-87ba-1d552394c1ff", "30e55fa5-bc77-4078-943e-4bd3f005261a", "23797e91-34df-4149-a806-090d1b7be757", "23a5a8b6-900c-4f56-9bc6-0860ac2ee545", "bb7e4d90-0130-484f-b826-e25b6120bf8b", "e45ccb65-d227-46bb-ab43-9079195f1ad6", "c62db472-466d-4e68-9d18-f394660aa2bd", "1fb961db-2a53-4816-9f4d-54527b404e9f", "37e904f9-8569-4646-9f3d-645b139ee6bf", "6647f02c-e1ae-4569-bb13-ef8f2a43622b", "d794dc99-5299-48bc-8d5d-38fb8fe1409b", "71af6e9c-190c-4b87-bc77-7ca43a60a978", "31a8eae3-3f6e-4440-bbe6-637ab46f7a6e", "df258f3c-bc80-4255-a215-e1d642d788f4", "94709e04-121b-495f-9794-cf5ce3f86b4d", "af1ef664-7954-41e5-b314-cc0d8d737da7", "b22ec311-a27c-420f-89d9-a970dc85faa9", "b107d7e3-f80f-4401-81c9-9dff1914b365", "c9d64cee-3a4e-4f42-885f-6526f8cdb280"], "metadata": {"window": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 2 , 2024 , 8:30AM Eastern  \n \nOperator :  Hello and welcome to Third Quarter Fiscal Year 2024 Cardinal Health Inc.  Earnings \nConference Call.  My name is George, and I will be your coordinator for today's event. ", "original_text": " \nPage 1 of 20 \n \nQ3 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2fc7bfc8-3b15-436c-b294-ef7c2ac54327": {"node_ids": ["dbc645c6-d232-4967-b743-525e9dd02342", "6b8ab74d-be62-4525-86cb-a573e2454337", "3630c16b-8855-42d3-878a-df76f95ba4d0", "5c4cad97-1dd8-4d67-984f-5df263df8a59", "6cf63221-b039-478e-9cd2-e5ba5c95b976", "4129cfad-1e8b-4d36-823a-bed84ce33343", "c5e4076c-c571-461c-9063-2f707a014b09", "5d007017-a8bc-474d-bff6-2ec97cc70709", "68125a42-6bfd-4e71-9c03-282526ed937d", "416ccc70-010a-462a-9dc7-7d1495172504", "c6da3b17-0111-4d18-a7bc-7f838010b43a", "1590b2e6-4b37-4f17-a382-be5c4021c75d", "586d942d-e8b0-491d-b61d-667e3768f538", "2b08638b-ae2d-412b-9de3-5b33af7fa8a8", "ac05931b-808a-4641-808d-fcd241bb84a4", "59e260d1-b16f-4d4d-b4ff-4133a9ed1f73"], "metadata": {"window": " \nPage 2 of 20 \n \nAnd we have a recent proof point.   Over the last several months, we deeply focused on preparing for a \nvariety of alternatives regarding a particular large, low -margin customer contract, which has allowed \nus to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings \nin fiscal  \u201825.  By driving improvements in our core operations, investing to expand our offerings in key \nareas like Specialty and evolving our commercial approach in ways which have resonated elsewhere \nin the m arketplace, we demonstrated that we have made progress on positioning our business for \nsustained success and growth.  \n \n As we look ahead, the current quarter\u2019s results reinforce our confidence. ", "original_text": " \nPage 2 of 20 \n \nAnd we have a recent proof point.  ", "page_label": "2", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "58273310-5952-4a1f-8284-f79597ed94b9": {"node_ids": ["732a36ea-b175-46c0-b755-cf756e7957a6", "7bc0a095-c41e-4d15-8295-dac9975f7ff0", "3aa50260-fc64-4d96-98ca-c1f4a200e312", "ca2a1648-dbbb-4f72-9953-47569d4d981f", "7b12b0de-4e64-4238-919c-9d1cc9c3b172", "6ec884c6-7679-422c-9ed2-5848759cde4e", "8ee78718-3392-4f37-9030-71988e4249e3", "6a615a80-733d-4a7a-87c7-2da5f0f681a1", "f4577259-debc-4fd9-be21-95f0fba06b4d", "17853fb0-d9f1-4025-967a-5480290e20c9", "78ee45c5-567e-410e-86a1-608fbda190a2", "4a3e131b-1d2e-4ad7-92b1-870b443ea672", "b11fb997-d842-43e8-be43-032f11098eaf", "84d08130-c1b4-44b8-bab2-0c8b2ec2cea1", "41125bc1-47ef-4b32-8517-7f435580b3ce", "e654f313-60a6-4acc-a0d7-a603329ac594", "0aa7d385-d3eb-41f2-830a-cffd9f9970a7", "71db3aec-bd16-4901-b566-ab567c47b3a8", "207ede5a-f11a-4ee5-ae30-1b01a8681552", "b8c2e92d-e61a-4789-a95a-29d7c9b48b03", "1cca9215-b782-4af3-a3b0-f4cac7779d1a"], "metadata": {"window": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n This morning, we are reporting our financial results on the new financial reporting segment structure \nwe implemented at the beginning of Q3.  To that end, we released an 8K on April 23rd which provided \nthe recast historical quarterly results for fiscal year  \u201822, fiscal year  \u201823 and fiscal year  \u201824 through Q2, \nreflective of the new segmentation  for Pharmaceutical and Specialty Solutions, GMPD and Other.  As \nwe called out at the time, the new segmentation is designed to provide greater transparency, focus \nand accountability across our businesses, and we are already seeing those benefits.  \n \n", "original_text": " \nPage 3 of 20 \n \nAaron Alt:   Thank you, Jason.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c674e0a7-0778-4c7f-af6f-4708cbfa59d9": {"node_ids": ["feabcdc9-7aa2-446f-a541-13eff393462d", "4cc18428-b404-43d8-8133-28b68bf067c3", "5c35a8e5-f257-40d3-9f48-a495814fd852", "a868d88f-e667-485a-b3f4-6ef3d428779a", "315bd1e5-6a04-425c-b169-52344da8166c", "d0199404-c498-4b4b-8047-991601f3a5fd", "db39e1b3-e5b7-460c-bc60-4ace0800ad17", "c5059cf2-793d-48cd-886e-e099f189cad6", "58324abb-c5fd-4ddc-a526-3c4b7019c6a1", "ea17d7b7-4479-47a7-8719-cd6bdab65604", "4105315b-17fa-4a78-b3a8-ad523dc12fbd", "ff4ac06c-bba4-456f-9d64-f1dae9dda735", "fe209236-5956-4ef9-b26d-aa5cda78f348", "92b1fdb2-3924-4245-b8ab-4569101d835c", "8c015cdb-bc48-4df7-8418-e8e1dc77b42f", "ae99f1b9-2674-43c4-b1cd-6dfef15105c3", "78ae7708-1b7c-4cce-9ffd-417bf99502e4", "b6bf990c-ffa1-4287-92e4-f344e0b1bfdc", "66769955-cca4-4289-9a29-fa0915d0f675"], "metadata": {"window": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.   As we\u2019ve previously noted, \nthese sales did not meaningfully contribute to the bottom line.  \n \n Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program \nperformance.  Our generics program continued to see both volume growth and consistent market \ndynamics.  \n \n", "original_text": " \nPage 4 of 20 \n \nExcluding GLP-1 sales , the segment\u2019s Q3 revenue growth would be 7%.  ", "page_label": "4", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "67435a7d-4b18-4711-a325-95e98b72f911": {"node_ids": ["db135c83-7f9b-423b-9fb7-138511825223", "74f77c13-898f-40ed-b198-d4fe87f76551", "8fff023f-8974-43cf-8ddf-e62d98034246", "db89ec8e-3e39-4614-8fbf-9ce1b11a081c", "42f85b46-fac7-4771-9110-299a31136a97", "408dd544-ec4b-499e-9ce5-c8ba914627b6", "419f8d0a-ca0d-445c-957f-40fee49e7835", "6404f772-0a1b-429c-987e-4d6905f0e222", "17b627d9-f0e9-4360-81f4-4bb360292dab", "6add21ee-14d5-4c87-8cb5-7cb5172f89c8", "df744f32-4e83-420b-8170-b89488717cf5", "f92f51c1-c27c-4e56-ab11-df020c1a0326", "f0faef01-7b6e-418a-8c11-e18d7db5a6f6", "46be63d5-483c-48a9-8460-de1f0bd369f6", "271a596f-37c9-42ab-ac2a-6d998ebcdf46", "bf8cac38-0cb6-472f-9305-8f77fbf906d9", "9cec9cbb-9345-4dd8-a656-097d02496f7d", "23d4785d-4ff2-48fb-889a-59d88272f011", "791555bf-732f-4b82-b0b6-1adf7cc3b53d", "a6a4c211-3152-4f87-b004-3ae882fb9542"], "metadata": {"window": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n We ended the quarter with a strong cash position, with $3.7  billion  of cash and equivalents on the \nbalance sheet.  \n \n Year to date, we\u2019ve  generated $2.1 billion of adjusted free cash flow and have continued to deploy \ncapital according to our disciplined capital allocation framework, including investing approximately \n$320 million in capex back into the businesses to drive organic growth, and  funding the $1.2  billion  \nacquisition of Specialty Networks.  \n \n Over the past several years we\u2019ve made tremendous progress with our balance sheet. ", "original_text": " \nPage 5 of 20 \n \nNow, turning to the balance sheet . \n \n", "page_label": "5", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f1695c05-c36e-480f-b39b-a2911516c999": {"node_ids": ["8c7d40d7-1a2b-413c-9515-74362c3bffbf", "1a2bd04e-d428-4d1f-a28d-0e025da74204", "c9772a33-98de-44c0-ad55-65c065a4bdbc", "084bfaae-5b24-4a50-914e-dfa2fa11dabf", "66e3fe8f-9c5c-4241-a622-b4a5d593cf6d", "3240e164-cdca-455a-a089-19d5f6cbf1b9", "b038af58-0867-46ac-b97f-1dfd61547b10", "def7626f-0dbd-402e-8c76-7d30a40f674e", "cefd68e2-7155-4206-b898-26e8ed9ad6dc", "a8811e18-2fda-44c6-b485-594c9749364a", "5a1c9c04-3591-41e1-9eff-003674591109", "241e7537-60a3-465d-8e87-d60cb98adbaf", "5d6d56c3-1a52-4a0a-816f-6e6dde1040c3", "e93f2485-46cf-45e9-8a20-f30a1b10c68b", "5e2041e1-3fe2-4688-846d-d03c7b6d7980", "77315319-49a3-4973-8f1d-5ec011a81e04", "e8dcd30d-4730-4ac8-8ee2-3efa8ffd9f4a", "a29e9b8b-c45b-4902-9060-2faccf130b6a", "616c81aa-9826-4299-a6d3-71bb514f5931", "9471167b-282c-4ef8-b001-9dd0c4112a2e", "473c2869-bbcf-4f0a-96e2-ad1270a03ccf", "89818386-719a-48a4-8951-c83b941d7617"], "metadata": {"window": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3.  \n \n We are also reiterating our segment profit guide for the Other businesses , 6% to 8% segment profit \ngrowth for the full year, given that we expect a strong Q4 for those businesses.  On the top line, we \nnow expect Other full year revenue growth of approximately 12%.  \n \n", "original_text": " \nPage 6 of 20 \n \nCardinal Health Brand volume growth and benefits from our continued cost savings initiatives. \n", "page_label": "6", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3133095d-d419-4f68-b29a-47abc408b487": {"node_ids": ["54ea95ee-6290-4a41-b763-018eae909936", "b3d5e5fc-565c-4601-b7c7-c0b9d536c215", "300e5319-f677-44d5-a173-d40e3876a86a", "8f8e09db-1dde-465a-a4b8-45bbf2f9fa0a", "c58840f8-6c70-4dae-880a-05ec218c719b", "7e2e12bf-d2d2-48a8-b001-da9bb3af1631", "a87d9287-6122-4c03-9fc3-5b1eef6fdd3f", "c8be3412-25c8-466d-ac5d-c3b16e7650dd", "34ad6423-7260-47a2-b9fa-d0211b809ef0", "850afa52-2d1e-480a-893c-0b4732779109", "1d597be4-aad0-4258-9258-55c5780cd3a5", "d03e3a09-b941-46f6-97c6-9a72e68279cf", "35501589-1cbc-4b5a-96f8-627d66653f11", "f547df87-f536-41e3-9f53-eb2532f90c35", "b1b1324f-25cd-4510-a722-8181b0625359", "7ab7ad1a-73ff-4f18-8554-c4c276062e0a", "6a2f9760-9bca-437e-8fdc-6e9dca3f4066", "b6607325-9e23-4aad-96a4-9f0df0437758"], "metadata": {"window": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n We anticipate a significant step -up in Interest and Other next year, primarily due to much lower \naverage cash balances, due to cash already deployed for specialty networks and due to the one -time \nunwinding of negative net working capital from the large contract nonrenewal.  We also expect lower \nshort -term investment rates on cash and  higher interest rates on debt resulting from the refinancing of \nour calendar 2024 maturities, leading to an interest and other range of $160  million  to $190  million  in \nfiscal year \u20182 5. \n \n We expect our fiscal year \u2018 25 effective tax rate to be in the range of 23% to 24%, slightly higher year -\nover-year due to the discrete favorability seen this year.  \n \n", "original_text": " \nPage 7 of 20 \n \nNow, a few callouts  below the line and with the balance sheet . \n \n", "page_label": "7", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2eceacca-2085-4efc-a7eb-cc403164e1cb": {"node_ids": ["95f7c4eb-c377-492c-9a39-ed3e439a8bf2", "222e43de-71ae-4ba3-ab72-ccf1ae192a45", "2376659f-44d4-47b6-a167-00819593aacf", "6a3bc2a9-6473-4755-a9f0-a41f84fa9083", "fc347c1e-2d9a-486a-b1f1-9a22676e13b8", "9e956fdb-8f3c-41aa-b5b0-6de59385d869", "27c55c3d-6c7f-457b-896a-9447d2f25ae5", "794437ce-a716-47de-b591-e1c0364dd82d", "1ea50913-7025-4840-8cb8-871c82d05377", "df8b3c92-af93-4945-9839-f41198116245", "bee5fb38-c077-41b3-a62b-7ae517a51e9d", "6d0ba463-4f0b-424d-87b5-f65942ce447e", "fa048122-b246-4b02-8a57-9f6a5f06cbba", "6a3341b5-cc37-4011-886d-422b31a2e354", "fc4e75bd-3972-4d58-8ae7-0bca3d0624c5", "3d3751aa-e286-446d-a10e-b6794921fd72", "86af24c0-9854-4dc5-b1b4-61893da9ee2c", "c76fe5e1-151f-4467-b207-cf5c83d4301b", "b5f20e95-c79b-4d43-91f0-ad6108697057"], "metadata": {"window": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace.  Over the past several years, we\u2019ve \nexperienced growing demand for over -the-counter consumer health products, which are an important \npart of our offering for retail pharmacy customers, particularly among our valued retail independent \ncommunity pharmacies.  With the innovative technology and automation solutions powering the new \nfacility, which will serve as a centralized replenishment center, we anticipate improved inventory \nefficiency across our network and providing unparalleled supply chain responsiveness for our \ncustomers.  \n \n We see the rapid development of advanced automation technologies as an ongoing opportunity for \nour business. ", "original_text": " \nPage 8 of 20 \n \nWe recently broke ground on our new 350,000 square foot Consumer Health Logistics Center in \nCentral Ohio that we see as a differentiator in the marketplace. ", "page_label": "8", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a38790da-1e71-46b2-8df9-35eacbb9ce1a": {"node_ids": ["0c9aeddd-72ac-4580-9924-6a539e7fecc5", "f8331b69-13ef-43ab-90d5-627b4dafac56", "85953dc3-664e-4b9e-a034-b43e66645a0a", "009295a0-dc92-477d-bcd7-9ee08765c687", "617bb2d2-a0f2-4519-97d7-363f6c59b18d", "5ec864a2-8d76-4657-a6c2-e11a77359a7f", "dd5bd418-d396-460c-833c-4659020ac4d0", "8001ec6e-b8c1-42a4-b8d2-e759aac30a5e", "94beb6dd-f233-4c08-9b88-790fe46726bb", "1e5753f3-3888-4bcf-affa-95ebdb229e8a", "1d8d4ba7-4ebd-4889-9c2b-6dcf46323b30", "ba511882-e2a3-46e4-b338-f5cbf3a98396", "5f00f3da-fc11-43d3-9395-dd90e2419e12", "9c712732-ce3e-468c-9bcc-051f3efa0188", "a1c2c702-ce00-4234-9edf-627e0ac96958", "79e100d9-95e5-45ed-9c09-c1908740d54f", "182ebc49-b649-433a-9aed-0a8c3d633331", "6735cac7-d542-48ea-b2ea-534afcfd718e", "f073d2d0-09e0-4c39-b761-38cf89681956", "cee9ad58-e9d8-46b5-a9cc-ee89112cd301"], "metadata": {"window": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n Turning to the GMPD business, where we\u2019re executing our GMPD Improvement Plan , we continued \nto drive momentum across the business in Q3, with strong sequential segment profit growth and \nsignificant improvement versus prior year.  \n \n During the quarter we offset approximately 90% of the gross inflation impact on our business. \n Through the execution of our mitigation initiatives, commercial contracting efforts and the continued \nrealization of reduced costs for international freight, we\u2019r e on track with our target to address these \nimpacts by the time we exit fiscal \u201824.  \n \n", "original_text": " \nPage 9 of 20 \n \nAdvanced Therapy Solutions and Nuclear and Precision Health Solutions businesses successfully \ncollaborating in support of cell and gene manufacturers.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "81578dac-a6e0-4796-96ef-8c76c3202e6b": {"node_ids": ["27deab52-26cc-42bf-912e-e4bffcff5d31", "7106b6a3-4404-4375-91b0-953321878261", "d593740d-98ae-4539-afab-f6ed36a05a9d", "1a0e986d-b9a9-4810-87f6-67d1830017bc", "ed5457ff-ab0c-4a34-846b-6a5739473b55", "a470aee8-fb88-49e7-b5b0-13ac32088639", "bbd98777-422a-4102-8336-d023acaeef87", "7e83a9d6-c7c7-4409-a5e0-b6c3539ab982", "6f2961c8-df8a-40ce-91ee-a790d20f7199", "3046171a-cae0-4f38-8577-70d15dc747ec", "dc036459-de3b-4e1a-83dd-d300a7cb9b7c", "2fe8d05e-364c-432c-ac5f-d72147fc9ccb", "e0388045-3752-4621-81d8-326efe251625", "4730ecc1-2271-44f5-85b4-5e221e1aeb78", "1edf9823-401e-433b-990b-695bbfcf92e8", "08437907-3f20-4bba-b9db-d366264380ac", "383e2741-3615-4522-8986-0935295cef03", "cc1e7f6f-edf1-47d6-8938-9f1984d4fda1", "1e790cd7-3cbc-4854-bdb4-6da8030ff200", "8fc49eee-38ae-464a-b1da-cda2e861acf9", "997b7368-b697-4809-950a-3ee34b4ed5e1"], "metadata": {"window": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n Our at -Home Solutions business plays an instrumental role in providing patients and caregivers the \ncritical products and services they need for care in the home.  We continue to see strong demand for \nhome healthcare, and over the past decade, we\u2019ve grown fr om servicing about 1 million customers \nannually to around 5 million today.  Our business is positioned to accelerate in the coming years as \nwe invest to expand the capacity of our network, the breadth of our offering, and deploy new \nautomation technology. ", "original_text": " \nPage 10 of 20 \n \ntheranostics pipeline, only a handful of successful products are needed to deliver the strong growth \noutlined in our long -term targets.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2b2c6f8e-1e17-47cc-9d9e-ccd3f0916190": {"node_ids": ["5470e70c-642c-4cb1-88ca-5943c32d0f29", "921a49cd-35b0-4bca-8cf9-d37c94c413e7", "f8efd33c-cb68-4112-9c5e-25356959428d", "fbab93c6-d465-48f5-bc9f-b99e2c29e50b", "20aa6438-f6bc-49c2-8999-c2072cd80a11", "e8ee40fa-9851-4f44-bba4-be5365547431", "d77b58b5-998d-4e7e-8638-88a4ecbd77bf", "de0577c8-d770-450c-9dac-3b7fbe5a248c", "a60ccbe1-14a1-4178-a042-4fab7c71d269", "5d517919-cecb-43ff-b9d7-9aee444c3859", "03fe5b46-34ac-43b0-b875-e5a8a6c2493d", "50eba34b-a560-4f86-97f9-6800ac39d603", "a5d42be9-6c6e-4650-8f23-3043129490b6", "f3e40de8-2635-4c94-977a-d7dd640e7aed", "437f1f7d-060e-4492-998a-9d63dadf3c77", "3d3c0c6b-0b81-40d0-98d2-dd476f5828b7", "bdb14811-9660-4649-8f8e-7d9975b9a207", "99df7daf-a983-4282-8a92-11fe17841adb", "25f592ec-eca8-4e9b-8f26-7092439a7341", "64a744de-b972-47da-81ae-83b11540136c", "1c513df0-bfc0-4850-bec7-9618ebcaf723", "f406181e-77e1-47a2-8f8e-7c9ad3c45bb2", "c117f52c-e778-4774-bc1d-f1ef617c34cc", "da625ffa-b093-4a04-9570-071f8bfc45d3", "30c1f7be-c1ed-4aa6-b5c7-ce7cec65c942", "e1d27382-74b7-4a24-b3aa-b42acc5aa150", "33c37d34-8624-43d4-9cca-16fe0062bb45", "d0effd95-6959-4d11-8f36-956cea4b4ade", "9aea0186-6c3b-4956-8ba9-27c259bf900b", "022840a3-6e70-4365-9bab-ec26d957a20d", "0332ac63-39b7-4a66-bee1-e6ff4ab0a7e0", "c04543e4-0815-4668-970f-0f82adfa7e4a", "d8596fd5-1e35-450c-8d85-e566d4370911", "e7251315-be09-41bd-a4df-ac8b79c02bd5", "e1f3cd1e-d36e-4777-aae4-f83b403a21e4", "1c88ca13-86f6-4c68-9773-a9d2a9987f10", "8b17baed-9cac-4079-bb6e-156e6d6ebec4", "0f9c1dc5-e7f7-4030-b8ba-a34b0a087d71"], "metadata": {"window": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen  as a reminder, if you  wish to ask  any \nquestions,  please press star one on your telephone keypad.   Please also  [indiscernible] . ", "original_text": " \nPage 11 of 20 \n \nWith that, we will take your questions.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6631bf36-f58b-4c34-8639-475bbd65e2ac": {"node_ids": ["b8826952-e754-4120-9038-d0076b11008a", "78baffd8-025f-4008-9774-74ff783d9cf0", "bf4c0caf-2f53-4f87-826e-da650d00e0e9", "768deaeb-3435-4bfc-9c90-15883b95acf8", "9df38c7e-48cc-48b8-9d2c-ce022106c713", "eb974195-4233-4808-8153-bb1e16f2fc85", "dce6cf34-b013-4449-a8a0-e2a994ae47b5", "dc5b596e-8213-43eb-8f25-fcc152f991b7", "55d1f3cd-77a7-4ea9-9ccf-de430eac2005", "d25143b7-f86c-47c3-8b8d-671a5b2a1b76", "d22f1f4b-b412-4719-9e02-ba4becc7a7b0", "6b4ebcee-2f56-49fd-bf7d-93a77925b711", "8c4bd27d-506a-48c7-9f71-6ed5e1d67626", "097e9b38-c952-4afd-8669-283707661457", "beb68fbd-1116-45a2-90f8-8aac0fe4d227", "05142a04-edb6-48b1-9600-7342a31d43e7", "e44ffaef-8585-4360-af94-9493be5ad3ca", "ef760c53-017e-4061-b9ab-a07c50602b4b", "015c7f47-bb2a-45ce-9dfc-d10ce3b7f9e8", "6164f303-6034-468e-8c3d-9985f85ccb91", "cca79382-7d43-4f82-b774-5d2ac106a84d", "90be1458-674b-4b7b-8808-9350e5983248", "a348348c-b27a-4d68-8265-1af4a1f29674", "1e14055a-0394-4da2-8502-e824f196a682", "6d0014ee-2613-47a0-ac36-669a5157b2de", "d8b40063-df13-4df1-942a-325f659153b1", "ca18b35e-b9bf-4b94-9c52-b3e9ddfbc7dd", "16fdfc0c-6ff6-4da3-a5de-1fec98a6138b", "e5b599d2-f238-4eca-9005-78dc165575d7", "a2db330d-df36-46db-bf87-75ee0a5b8818", "913230bc-7001-4cd0-979f-f2e28fc13c6c", "54d58bbc-186e-4ca7-87e8-69d46a882ce1", "e64f0b6e-922b-4c60-b4e3-d553e1cb9ddb", "266eb1d3-7163-4e0a-b2c9-f7c99322c833", "792fb1bd-bed7-483f-b0fc-ff21ae2accfb", "f8ab1445-7e03-45de-b72e-be2b8a93b3c1", "7b50939a-147e-4501-869a-f2d229e020b6", "20a477e8-e235-42cd-8288-57711b64738a", "f8663a03-caa7-4683-b01e-1a836bf3675a", "0f5c1589-07b8-4f17-802d-eaa8b931507d"], "metadata": {"window": " \nPage 12 of 20 \n \nJason Hollar:  Yes.  Just I'll build out a little bit further the puts and takes for \u201825.  As Aaron highlighted \nand scoped it, the delta is a net approximately $80 million when you look at those different reference \npoints.  So , that obviously implies an Optum impact of something greater than that. ", "original_text": " \nPage 12 of 20 \n \nJason Hollar:  Yes. ", "page_label": "12", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c78de647-c986-455f-8595-0c748aca612f": {"node_ids": ["6bfc3cd9-7962-4efa-bd9b-7a7e07c18046", "27fe7f73-2202-4bcc-b948-a93339f65b53", "a090a661-572b-4de5-8c75-91151545025c", "e3500c88-ba41-4663-b711-ec92ade04afe", "c7812593-0215-496e-af1c-be6aa35503fe", "14c7607d-1b06-4d3f-aef6-ae304138d057", "aa4ddced-2236-4a44-9666-def27c5c5966", "ec6cfd84-18d4-40ec-9cba-aafd702c6053", "1adcd55f-d37a-4fd2-9d7f-9ce2dfc6c4e7", "fc9dc170-2e15-4dd6-9385-b3a7b21782c3", "41f20d92-95c4-4237-8884-051e2034775a", "fbaab1ec-31e2-4baa-a73c-f5bd6fc6bcf4", "8de2a458-2ffe-4827-b952-43c42d8272a9", "b49f8c2e-1991-4705-8d06-5c8b74bbb151", "bb785eeb-7989-4c58-8aa8-67ff22696e5b", "893ef4ad-12c6-4ae9-8945-28af4836b472", "78568140-0523-47ae-b948-d5cfdee20109", "3920b587-72af-4337-b0e9-c6b19cdbbc85", "b55c6268-43cd-4784-8063-93d0208951e1", "4189cc94-0d19-4b0b-97a5-bbb6c4a88020", "cb25d1ae-bb2e-4c0a-8bd6-cb4218ea2ffd", "735aa3a4-bb8c-45b0-a18b-1664970d188d", "c7a5db69-170c-4c81-9dc0-dbab01869369", "f98e191e-cef7-4710-832b-56bd8aeedff0", "eea1d7ba-fd18-4e03-aaaf-a43b7de23042", "b44bab43-6ca8-4a8e-b99b-376d8cf1bb3d", "7a8a019f-f6a6-4e94-86d6-6603492afc02", "d24dfe06-220f-4805-9f3c-fe4c07f41de4", "805d523d-5610-460b-846a-3e1b4600863e", "d5a630cf-cb88-429a-ba77-9724db53b5c8", "8b502215-b55b-49bf-b7fb-090f91df898c", "9ac49b4c-5ec2-49fd-b51a-a14d694013fa", "d13e2203-8060-4e42-9417-207ec5e63456", "1c305349-79e4-4ecc-bbfe-3ec7cceaa7fd", "a2e8c589-1a27-46fe-8004-1d92bc8393fd", "4ff51072-aa7e-46c5-a889-5a8ef4c36081", "0c21baf1-911a-4c0f-b435-bb5a509ee3d2", "2e36674a-ed31-4f0f-a2bf-3ea56cbba4b7", "dcd8f691-5bb6-4254-b5b2-4d2dc2e2bfff", "8768137b-7c74-44de-849e-ac9f5e755897", "49c8931e-3928-487a-8b36-bfe2e2bccee7"], "metadata": {"window": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks .  Of course, we continue to work to get closer to the ultimate \npractitioner so that we are prepared to offer the incremental services that the industry is demanding.  \n \n Operator:  Thank you.  We now move to Lisa Gill of JP  Morgan. ", "original_text": " \nPage 13 of 20 \n \nAaron Alt:   George, I  would add one further thought, which is, as you see from examples like our \nacquisition of Specialty Networks . ", "page_label": "13", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "05614b9b-e43a-44c9-b1e9-2b817c3bbf13": {"node_ids": ["6557d6a2-ddb3-465b-8bfd-5a920ed901a6", "acfa11a9-218e-448f-9040-7f5e5482ed37", "7a6a4701-73b9-4dab-acba-86d9b9355e56", "ce5e87cc-7528-431c-8e8b-d35270cd4676", "ae525f6b-9489-47a1-937e-47aa4641c36c", "53f82d81-0026-450a-902c-979dc9f71175", "aec500a7-187f-47bb-86a2-137c9ecfda2f", "fddc9f97-3e3a-4f22-aeec-eb6d1292ab7a", "f607d1f7-e593-4a00-9bf9-985fa858f855", "03663870-7552-4028-aa48-fc33b31e6cb8", "b1a08b76-cd60-4c3f-8b7d-02d54d304a3e", "ea63840e-6dfc-46fd-bb8e-00cdfbb155cc", "8162e1fb-a175-47a2-804d-a034271a879f", "3dc91d57-3c19-4ed7-a6a3-67491a62e7d6", "180411d1-42cd-418f-95e0-8cfc092adf2e", "3cf13663-5fda-4bd9-b922-f9151af2073a", "9b7a6c5c-1908-4fe9-b9c8-d9984fe5803d", "22efcda3-0e8b-4a2a-a49a-74f7265a6b3a", "1f71fe2c-9810-40ec-8b88-8d02aa1007f3", "d587a589-5950-4cd4-8545-b0df9041230f", "e13eea77-7b42-470c-aa7a-1ecfbcf1d5f5", "54dceb47-9268-4e8b-93e5-5ae9e38d59ac", "4fdd9682-2700-412b-bc46-c9aed3f5842c", "867f654d-96ea-4fae-8a39-74cf5fd52a28", "dafc1acc-069b-4cb8-9d2a-6ffab1a0899e", "ba6d34f7-0365-457d-af78-435b777b19e6", "d304728e-43db-447a-a94e-2e27ea874816", "cd7684ad-15b7-4c24-a0de-9706c8177ead", "cbf28d64-fcc7-4b0f-b5f8-7e1977df36da", "a41b4d76-ce5f-4f4d-9ccd-6469fdc76498", "3f853292-5775-4a70-9aba-44f3d17af465", "19dc2bc8-760b-48a7-af4f-19e113730b1e", "eb52d000-b170-42d9-9edc-af7de86abe3e", "9aedc8ba-36b7-4df1-83e2-5e14ee33f3b4", "bb928bbb-979c-48cc-b177-adfd6a621033", "06216ec8-3d42-4088-aae9-58becd7d0b87"], "metadata": {"window": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n Aaron Alt : Thanks for the question.  What we would tell you is as we continue to be in an environment \nof consistent market dynamics where we see stability on the buy and the sell within our generic \nbusiness.  As we've talked about in the past, the stability that come s with that is when we see a rising \ntide of volume and a strong prescription demand environment, which we have, we continue to see \nstrength in the generics portfolio and that's where we are. ", "original_text": " \nPage 14 of 20 \n \nand sell side pricing here of generics and maybe how gross profit dollars in that part of the business \nand generics are trending versus  [indiscernible].  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cda3dbcc-503a-462d-aa84-e97b7fa6cc7d": {"node_ids": ["0b30a0b8-1f45-4142-88a4-7d5c8e793dad", "00187220-6b4b-4bbd-a207-36a2b6ae9e4f", "ecb85199-923a-46b2-8454-3a0183f2ebcc", "013f3d52-788f-4db7-8a58-5cb4c79627d7", "e6a6f555-7e5c-4a3d-a597-e61a6ee9fd78", "1bb37191-9466-4086-b303-35f40d07a134", "ddd43648-22c4-4223-809b-6a5e75b7ebea", "de24a9c2-1a1b-47eb-bc3b-e441ba664266", "1f238f5b-8e66-49bd-b5bc-5d5f3e34d9b0", "670da30f-615e-4349-8263-74a962f55725", "e3cd3f1b-d322-4330-9dce-02c1f280bb8a", "4a04ad2e-6b4e-4344-a903-c651bcbbba81", "6326f677-992f-4a9b-89cb-0df309641953", "d8b28b62-a302-45fd-b883-8f7dd9cc4ccc", "8dec538d-5508-4148-9694-b56758364351", "1dc6303a-6146-4b37-93cc-e9a8c592bb57", "de20c1be-6d94-4069-8fac-f2de39a947e6", "0ee71592-3c87-4c08-8899-847dacb15032", "4d95e277-7f93-42f3-9cc9-b411f2f35a5d", "7c81df37-2187-4c9a-ab31-3a5d0ff9cf8f", "d9379013-aa88-424e-be1c-31d0014fa29d", "5321b106-9e7a-4537-b98f-d9df20720557", "8b3be6e8-9093-4896-a3ee-03cc63be4403", "c21de45a-83ff-4844-9c6c-85c539dfb286", "23be6511-18fa-4536-a306-19248c397685", "c80d6055-38c9-4606-b418-f7488b93ff82", "38428494-7237-4416-b082-8d34991f3fbe", "6b9c3042-2323-460b-98a9-3e27c113cf66", "e93f35af-5b9b-4abe-94c5-1771de56ae29", "f0d06606-5b74-4f0f-96cf-5158976b194f", "4ac34a0f-521c-48dd-b756-cf5a8c817f62", "7ec5e1dc-07d8-4e49-aab0-9ac5d2a0f914", "fbd8594d-dc01-45fd-817d-33ddd9d51015", "a170972d-290e-4e2e-b708-3d5e7bbc5fa1", "7768996d-3f10-481e-8a96-68c62cb0201e", "378ff0fc-f136-44c1-8279-416fd23d19fa", "02db101c-3494-4367-a6a9-a6dd757dc7da", "097b89d2-254a-4467-8d11-f709c25a8bd2"], "metadata": {"window": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n Jason Hollar:  Nothing to add on that component as it relates to Red Oak.  We feel very good about \nthe scale and competitiveness of that venture , joint venture that we have with CVS, the combined \nvolume that we both bring is sufficient to have significant scale in the space .  The percentage of \nvolume that was related to the lost customer is quite small relative to the total that we have that \nremains. ", "original_text": " \nPage 15 of 20 \n \nJason, anything you want to add or talk about Red Oak?  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d4e1bcef-9f5f-410f-8a0b-5de669c9120e": {"node_ids": ["8d60dc63-4a6d-49a4-b43c-3e066fef7faa", "4720a1c3-f90b-46c4-8590-8733ffb3ffc5", "c498f57b-7c7a-4e53-8850-dc658f754d28", "44aab8f8-65ec-46a3-b61d-ef0131f4b4b2", "8b02af7f-30d0-4694-9ab6-9c5ff5302d3c", "a0a71c4c-ab4d-477c-9d12-6835fd5bb70c", "ee5281c3-9eb4-48ca-9594-041632a4b47f", "b3b44192-5a04-4657-b48d-f6b8833459b1", "194f93d8-01b2-495d-adad-bf4f2d2ef981", "9987cd7d-a3b6-4c63-951b-ede64324f0cd", "01176827-1cf1-4ea0-b744-160cf4f8fbd7", "f5382931-c227-466b-b867-ead7df595e6b", "ba1c70eb-f7d3-43f5-a0a4-8edf23b49d92", "87965e7b-1d6b-4390-bad6-c6744162caca", "e0aec661-4749-4fc1-aab3-b3cb15012c43", "af3a1d2a-6cee-4b35-ba50-0aa376cda714", "f7cc87ca-cb7c-453c-8118-e2ba0ab6c8d9", "82fe1a87-bb34-46c5-8c3e-86cfc61bd761", "ad72a8ae-0dd0-4e3d-9e4c-9b14ad6f416c", "fecd1dba-ed62-401f-8854-e96c3c9e2dc1", "061a6334-e238-4af2-9fb7-6d53b57c73aa", "99f6fc32-d987-4d4a-8a77-fae5782675ef", "73c77748-e23c-4ea6-9e0a-d5a7eb8afb04", "39d8107d-6c38-4c38-add3-91c9e5ab800b", "d1628488-82b4-44c9-8597-d16bea481830", "17f7f671-06f4-4f93-b9c7-989664120d25", "0db902a6-535e-496b-826e-6af87431790a", "5672c47c-d43e-4ee6-a8b1-0e5ea4db0e02", "f58689a6-80d7-48c4-944c-d48f20aac462", "6cdf1534-3e52-400d-877d-bb527ee3d159", "ee969de7-ec8a-484b-9a11-7060aa6c0292", "0f1f62ae-d8a8-475c-b93d-e9aa3b5c2792"], "metadata": {"window": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n Jason Hollar:  Yeah.  So, it's across various classes of trade.  So, its broad -based wins that we've \nreceived. ", "original_text": " \nPage 16 of 20 \n \nFY25 to the three -year guidance relies on further progress with these wins versus more of the \nstreamlining and cost out that you've called out.  \n \n", "page_label": "16", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6dee7745-f40f-4dc4-89ca-df57faec75fb": {"node_ids": ["6ee2208d-153c-42bd-892d-234238c13ab1", "cad15c15-622a-4302-9b0a-01a670ccd14a", "0f232ed6-0730-4036-8f65-6e990d707d97", "9a1596c3-a0c3-4734-9b76-d21131e6c961", "b34a24fc-a79f-4dee-be09-05943ab0baf7", "bc5ea76b-21a9-441e-9fad-05bddd071f75", "39ed20f8-3299-40f2-8370-762a1a76b9e4", "7ec8f86a-37b5-4a87-a2ac-3a3d7637076f", "0c430302-8593-435b-91b7-83e7b2d3d7be", "2304db73-6f1b-4ae1-a445-0a30238be03e", "4161b6a6-362f-45f5-a5d4-c8e43b6ff0a2", "20fa3057-64c1-4910-9512-af5ad40f28c6", "ea1a6e2e-d19d-4004-9784-98b5bd9e16f5", "34d4b1fb-e669-4290-ab61-7b5046e9462c", "3fdd2f26-331e-4eb9-b594-fa3f981abce9", "dcc8d471-df49-4985-a6d9-c1537c6ea65a", "04b0e18e-aaae-4c83-b55b-9fc8cfead31c", "e2a8c698-a621-45f8-8c7e-f512a0e03202", "c8a54d23-17a5-4218-afb0-6a31c3a2636a", "33a871a1-a050-4897-8216-3b704d6bb7b1", "7c1eb472-da89-4e66-a145-eff9291b439e", "13f4c351-5da6-451a-928b-9d682cd39ecb", "c4c29888-11a2-4755-980c-26d63e3df728", "44e4d620-bc30-4463-9940-9ca829e25d22", "4e451d82-39fa-4e5b-97bf-cf95cd2d304b", "cb9aa194-0e36-477c-ba6e-4352af432cac", "77c7849f-cecc-4cf0-8278-9f4e23a1e836", "0ed862f2-e305-4514-b150-eacddd8f37e6", "3ab939a0-ca9b-48b0-8371-fbe217cf78e7", "9a996eb2-828a-4038-b295-36ef7d25d28d", "7df90b40-c52e-4e54-9c2c-8c0b8345eeb7", "dc4e2155-76b5-4b21-8e89-bccb99fe7f33", "bb12c4de-2d27-4fe3-867e-3d0092468ec2", "9f7e71f7-90b7-4c11-87d7-f11665f20bde", "a23ec9b4-6cc3-4486-809b-3023d3f35f58", "592c998f-e77d-4132-8a3b-27125a022461", "710a083f-db69-4edd-b1d9-c6b881cbf87a", "a4ec4598-5f60-42aa-948c-16d641e9cdd4", "f05a2d0d-5051-4673-9e69-6449a3cb6dec"], "metadata": {"window": " \nPage 17 of 20 \n \nOperator:  Thank you very much.   Our next question is coming from Elizabeth Anderson calling from \nEvercore.  Please go ahead.  \n \n Elizabeth Anderson:   Hi guys. ", "original_text": " \nPage 17 of 20 \n \nOperator:  Thank you very much.  ", "page_label": "17", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ada4be07-6c24-4efb-8355-bfefc662a651": {"node_ids": ["71ffb338-7915-414e-84fe-12488c37b2b5", "09def0ed-2db7-4b6b-9a6f-cc9668893fb2", "1d919132-2602-4527-9188-dd1a5b00a6f4", "89d40f4d-d427-4e1b-8306-58ee14da5406", "ff69b9c3-bbb8-40d2-89bd-6af86b7ef9da", "56241dea-09ca-4c9f-8917-2aecadd94f6a", "082bb6aa-7848-4b0a-8296-570f858c5de0", "260bcc70-7931-4aa7-97f9-6699684dc93b", "f5f6ab25-ed7b-47b6-bc7f-b5bf11931abd", "36fecd90-07b1-49a3-b026-43cfb0ba42a3", "821bae44-5d55-4c3b-8245-8a57b1e84c5d", "99582cdb-a43a-46f8-a214-412212603db7", "87fba192-f67d-416c-9d58-63d5add1a175", "1ef929eb-5041-46ec-849a-3eb4c6d96dda", "d2da3809-de08-4af6-9d3d-22e6ba114c13", "d4009632-bd71-489f-86c9-734f4427fbb4", "5118ba6c-a075-4aeb-89d3-8d8cc30d3f34", "ec85a842-8d34-4d64-97bd-2f650a263bb7", "3a90615c-04a0-4088-9255-4a6a3414501a", "3116390c-c8be-4e07-a0e9-8a8ae61a61e8", "dfc67f94-0c72-48b3-bea7-43b7f10a200b", "ac408b44-50d7-4e8a-bc55-e95515e098cf", "c6b3ee3d-a061-405a-a19b-613aacb52aac", "9768c3a2-ee93-417c-a495-b1e36cde7ee2", "ccc96798-25b8-447c-9128-d1f5b97d7963", "b4e17d7b-d2f7-44d7-90a3-79b2cff84c43", "3803a396-b90e-4dce-8f94-e547a5bad305", "522f3861-bae8-45a5-841b-b383e6853c93", "b249688b-b66d-491a-bada-657ad045854f", "9db553ca-b3e8-4590-b032-ed255af069d8", "e9ffaabc-f76f-4305-9835-265784ffd81c"], "metadata": {"window": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%.  It will be off a lower base in fiscal \u201825 as we grow at least \nthe 1%.  We have not commented on absolute dollar basis, but we will provide more context on that \nwhen we get to our year end results and final guidance for fiscal \u201825 during our August earnings call.   \n \n With respect to the Other business, we are pleased with what we're seeing so far. ", "original_text": " \nPage 18 of 20 \n \nAaron Alt:  Sure, in answer to your first question, our guide today does confirm the long -term growth \nwithin the Pharma business of 4% to 6%. ", "page_label": "18", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "48a211a7-0710-436c-83be-eb1304ce9c4b": {"node_ids": ["d20b88d7-6a43-492c-afb1-1f55b385464c", "e4eccf39-0e3d-45ba-ab46-1f5a2932095d", "7238e30c-d801-4a51-950b-8cd1f5069269", "0c26ece1-4362-4ea5-8c59-55af8fa69f32", "2e80f016-3356-4673-929c-1c7db63dc53c", "6433becf-e21b-48c0-881c-42c85f6c7bd6", "4132745e-0d7d-41da-ab02-797089e42493", "6541afc9-4de5-4dee-aa0f-082e9bcec2ef", "e65893e5-26eb-47e3-b728-991752550a27", "132b1ccb-4913-4579-b5c5-b4dbdb4fd292", "1c3df0bf-762d-4977-b57e-50a650616fdd", "72af4a75-9e99-4970-b5bb-57d0b56a0916", "d508d23b-6647-4b3b-b119-410b12970819", "2963d30f-bb87-454c-be90-78e3e5ca52a7", "49782242-abe7-4b8e-9263-dc393eaaac52", "7ba058f5-3d40-4a8b-837d-9388c33f1959", "956ab472-b0d8-45c1-ba2d-320601397715", "4ea26de7-c6a1-4a2a-871e-5daa07bea223", "b0faf230-6995-4b96-a3a4-a565a47a010d", "c83fd002-c650-49bc-8a4c-5dfbbea4c561", "d0f8080c-19e2-44ab-9834-6cc21655ce49", "73d0475a-4aff-4991-8de9-ab610f971357", "bd9e123d-f892-482f-80bd-6ccc29a90954", "568f543d-3fd2-453b-84f5-d15e91f8bbed", "e156613b-2d55-4a51-8ac7-c75a226d2f8d", "8b617f6f-e03d-495a-9a01-0bb58f5581ec", "a74a0db4-0f52-4996-98bb-8b40b9c37012", "22fc0d1e-6f9e-4168-b367-069c5cbbe1ea", "8079d03f-bf5d-49c7-8523-db42a7131cd8", "b92b13e6-56ba-4f56-b9f8-07073126902c", "bcb96b36-0d52-42c7-9490-65720ec75b22", "4befb49f-11f7-4265-a4c9-6c03914844bb"], "metadata": {"window": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market.  We expect that to \ncontinue.  This is something that we do have as a component of that growth.  As Aaron highlighted, the \nsingle biggest driver of profit performance from \u201824 to \u201825 is the annualization, the carryover of the \ninflationary pressure . ", "original_text": " \nPage 19 of 20 \n \nbusiness there that has allowed us to grow at or a little bit better than the market, so overall we are \nseeing that this business has now stabilized at a growth consistent with the market. ", "page_label": "19", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8f7fb6c0-b826-4daf-a22e-a0cb87854a22": {"node_ids": ["bec5ed44-d3ab-4869-9a13-c1a08d87e4ea", "a3ea3a56-e6c4-49b8-ba54-35162edc599a", "9d786f56-9d30-485f-a7e3-19dc9a9e904c", "b22c3f1d-0812-4039-92b9-98b4dedf118d", "3f235fa5-5c82-4bc6-a864-cd3cdb9a0244", "c36240ea-2c42-4629-a941-cddad47b8303", "71affd72-18dd-4f97-b680-fd1044274ecb", "1b78f5fb-608d-45b3-a946-316d7512b429", "7c30c8d8-5211-43e1-aaaa-06f7ac871661", "ad2ceb19-43d5-46dc-bc14-10a0c31c5c98", "bbd31015-552a-42d3-a7ef-2f3dc28ca331", "f1ee0c78-8a68-4895-9960-d0ee6ded0c70", "055d14dd-dafb-45cd-bfb4-23ddf2259224", "c8494f39-e18a-4a9a-bb3c-a8bd33c83995", "86d80b57-c411-4fdd-a10c-cd68782c292d", "4564ddf4-3c2f-42be-8b41-8e031bd5b42a", "7d5fe44f-a10e-4ac0-b99f-6da0117192d5", "a5ee1771-500a-44f5-9edf-45ac8d62bc95", "fb78f962-d2d8-4106-bde4-d937639f1fc0", "11a64742-5ebd-4492-a0b7-d0d1b79891fa", "f43a280d-f417-456b-b73c-76c1c787630b", "054ac121-b1f5-4972-9cab-72ee9f90fea2"], "metadata": {"window": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat.  So, we do see that there's a role for Specialty Networks and their PPS analytics platform.  But \nwe're not going to make that the priority.  We're going to listen to the customers and then determine \nwhich pieces of that to bring into that network. ", "original_text": " \nPage 20 of 20 \n \nhave is great, but we also are using a lot of third -party partners to bring in their tools and capabilities \nbecause we're going to put the customers' needs first, the providers' needs first and then build around \nthat. ", "page_label": "20", "file_name": "CAH-Q3-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 219503, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}